OA19876A - 2-Amino-Pyridine or 2-Amino-Pyrimidine derivatives as cyclin dependent kinase inhibitors. - Google Patents
2-Amino-Pyridine or 2-Amino-Pyrimidine derivatives as cyclin dependent kinase inhibitors. Download PDFInfo
- Publication number
- OA19876A OA19876A OA1202000383 OA19876A OA 19876 A OA19876 A OA 19876A OA 1202000383 OA1202000383 OA 1202000383 OA 19876 A OA19876 A OA 19876A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- fluoroalkyl
- optionally substituted
- formula
- alkoxy
- Prior art date
Links
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-Aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 title 1
- 150000005006 2-aminopyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 527
- 201000011510 cancer Diseases 0.000 claims abstract description 77
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 30
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 513
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 463
- 125000000217 alkyl group Chemical group 0.000 claims description 290
- 125000000623 heterocyclic group Chemical group 0.000 claims description 186
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 183
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 158
- 229910052731 fluorine Inorganic materials 0.000 claims description 128
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 126
- 125000003545 alkoxy group Chemical group 0.000 claims description 113
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 95
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 94
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 90
- 229910052801 chlorine Inorganic materials 0.000 claims description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims description 77
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 61
- 229910052757 nitrogen Inorganic materials 0.000 claims description 55
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 48
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 43
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 40
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 26
- 125000002393 azetidinyl group Chemical group 0.000 claims description 23
- 239000003937 drug carrier Substances 0.000 claims description 13
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 claims description 12
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 11
- 239000000546 pharmaceutic aid Substances 0.000 claims description 11
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000080590 Niso Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 139
- 239000011780 sodium chloride Substances 0.000 abstract description 60
- 150000003839 salts Chemical class 0.000 abstract description 58
- 230000002159 abnormal effect Effects 0.000 abstract description 28
- 230000010261 cell growth Effects 0.000 abstract description 27
- 229910052720 vanadium Inorganic materials 0.000 abstract description 2
- 239000000460 chlorine Substances 0.000 description 142
- -1 aliphatic hydrocarbon radical Chemical class 0.000 description 115
- 125000004432 carbon atoms Chemical group C* 0.000 description 95
- 230000002401 inhibitory effect Effects 0.000 description 67
- 239000002585 base Substances 0.000 description 63
- 125000005842 heteroatoms Chemical group 0.000 description 60
- 125000001424 substituent group Chemical group 0.000 description 59
- 125000001072 heteroaryl group Chemical group 0.000 description 53
- 239000003112 inhibitor Substances 0.000 description 51
- 230000035492 administration Effects 0.000 description 48
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 46
- 239000002904 solvent Substances 0.000 description 45
- 239000003795 chemical substances by application Substances 0.000 description 40
- 229910052760 oxygen Inorganic materials 0.000 description 39
- 206010028980 Neoplasm Diseases 0.000 description 38
- 239000002246 antineoplastic agent Substances 0.000 description 35
- 125000003118 aryl group Chemical group 0.000 description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 31
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 28
- 239000003814 drug Substances 0.000 description 28
- 101700008359 CDK4 Proteins 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 239000002253 acid Substances 0.000 description 24
- 229910052717 sulfur Inorganic materials 0.000 description 23
- 210000004027 cells Anatomy 0.000 description 22
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 22
- 102100004109 HEY1 Human genes 0.000 description 21
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 21
- 125000002947 alkylene group Chemical group 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 102100019398 CDK4 Human genes 0.000 description 19
- 125000004429 atoms Chemical group 0.000 description 19
- 150000002829 nitrogen Chemical group 0.000 description 19
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- 150000001412 amines Chemical class 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 239000003054 catalyst Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 230000001225 therapeutic Effects 0.000 description 15
- 206010006187 Breast cancer Diseases 0.000 description 14
- 229940079593 drugs Drugs 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 13
- 238000007792 addition Methods 0.000 description 13
- 125000005418 aryl aryl group Chemical group 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 13
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 12
- 229910020008 S(O) Inorganic materials 0.000 description 12
- 125000004093 cyano group Chemical group *C#N 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229910001868 water Inorganic materials 0.000 description 12
- 102100006130 CDK6 Human genes 0.000 description 11
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 11
- 230000005712 crystallization Effects 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 102000016736 Cyclins Human genes 0.000 description 10
- 108050006400 Cyclins Proteins 0.000 description 10
- 238000006069 Suzuki reaction reaction Methods 0.000 description 10
- 125000002252 acyl group Chemical group 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 10
- 125000005647 linker group Chemical group 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrugs Drugs 0.000 description 10
- 102000003903 Cyclin-Dependent Kinases Human genes 0.000 description 9
- 108090000266 Cyclin-Dependent Kinases Proteins 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000004037 angiogenesis inhibitor Substances 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- RFONJRMUUALMBA-UHFFFAOYSA-N 2-methanidylpropane Chemical compound CC(C)[CH2-] RFONJRMUUALMBA-UHFFFAOYSA-N 0.000 description 8
- 108091007476 CDKs Proteins 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- HXCOCQWMKNUQSA-UHFFFAOYSA-N caesium hydride Inorganic materials [H-].[Cs+] HXCOCQWMKNUQSA-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 8
- 230000002829 reduced Effects 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 230000002195 synergetic Effects 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 230000000875 corresponding Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 6
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000001965 increased Effects 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 125000004430 oxygen atoms Chemical group O* 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229910052727 yttrium Inorganic materials 0.000 description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 5
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 5
- IPWKHHSGDUIRAH-UHFFFAOYSA-N Bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 5
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 5
- 102000033243 CDKN2A Human genes 0.000 description 5
- 229960005069 Calcium Drugs 0.000 description 5
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 5
- 206010027476 Metastasis Diseases 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000003042 antagnostic Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 230000001404 mediated Effects 0.000 description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
- 229940113083 morpholine Drugs 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- 230000001105 regulatory Effects 0.000 description 5
- 125000004434 sulfur atoms Chemical group 0.000 description 5
- 230000004083 survival Effects 0.000 description 5
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 4
- 206010059512 Apoptosis Diseases 0.000 description 4
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N Azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 4
- MUALRAIOVNYAIW-UHFFFAOYSA-N BINAP Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
- 101710022338 CDKN2A Proteins 0.000 description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 4
- 229960004117 Capecitabine Drugs 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- 229940034984 ENDOCRINE THERAPY ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS Drugs 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229960001592 Paclitaxel Drugs 0.000 description 4
- 229960004390 Palbociclib Drugs 0.000 description 4
- AHJRHEGDXFFMBM-UHFFFAOYSA-N Palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229940032147 Starch Drugs 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229910052770 Uranium Inorganic materials 0.000 description 4
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating Effects 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 150000001500 aryl chlorides Chemical class 0.000 description 4
- 150000005347 biaryls Chemical group 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 125000006001 difluoroethyl group Chemical group 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000009261 endocrine therapy Methods 0.000 description 4
- 230000002708 enhancing Effects 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000003000 nontoxic Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229960001756 oxaliplatin Drugs 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- HPXNTHKXCYMIJL-UHFFFAOYSA-N 1,1'-bis(diphenylphosphanyl)ferrocene Chemical compound C12C3C4C5[Fe]4322346(C7(C2C6C4C37)P(C=2C=CC=CC=2)C=2C=CC=CC=2)C15P(C=1C=CC=CC=1)C1=CC=CC=C1 HPXNTHKXCYMIJL-UHFFFAOYSA-N 0.000 description 3
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 3
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 210000001185 Bone Marrow Anatomy 0.000 description 3
- 102100007290 CD274 Human genes 0.000 description 3
- 101710012053 CD274 Proteins 0.000 description 3
- 229960004562 Carboplatin Drugs 0.000 description 3
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 3
- 229960001031 Glucose Drugs 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 3
- 229960002913 Goserelin Drugs 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- NUJOXMJBOLGQSY-UHFFFAOYSA-N Manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 3
- 208000004235 Neutropenia Diseases 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 229920000272 Oligonucleotide Polymers 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 101700036247 PARP1 Proteins 0.000 description 3
- 102100014579 PARP1 Human genes 0.000 description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 102100013504 RPL17 Human genes 0.000 description 3
- 229950003687 Ribociclib Drugs 0.000 description 3
- 108060007796 SPATA2 Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229960004793 Sucrose Drugs 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 3
- 108010010691 Trastuzumab Proteins 0.000 description 3
- 206010046766 Uterine cancer Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 3
- 229960002184 abarelix Drugs 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000000340 anti-metabolite Effects 0.000 description 3
- 230000000259 anti-tumor Effects 0.000 description 3
- 239000002256 antimetabolite Substances 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 229960000255 exemestane Drugs 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 3
- 239000008079 hexane Substances 0.000 description 3
- 230000003054 hormonal Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 230000003211 malignant Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001590 oxidative Effects 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 239000003638 reducing agent Substances 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 229960001796 sunitinib Drugs 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-(1R,3R,4S)-menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 2
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- QMVPQBFHUJZJCS-NTKFZFFISA-N 1V8X590XDP Chemical compound O=C1N(NC(CO)CO)C(=O)C(C2=C3[CH]C=C(O)C=C3NC2=C23)=C1C2=C1C=CC(O)=C[C]1N3[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QMVPQBFHUJZJCS-NTKFZFFISA-N 0.000 description 2
- NFIXBCVWIPOYCD-UHFFFAOYSA-N 2-(4-benzylphenoxy)-N,N-diethylethanamine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 NFIXBCVWIPOYCD-UHFFFAOYSA-N 0.000 description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N 283173-50-2 Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
- QFCXANHHBCGMAS-UHFFFAOYSA-N 4-[[4-(4-chloroanilino)furo[2,3-d]pyridazin-7-yl]oxymethyl]-N-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(COC=2C=3OC=CC=3C(NC=3C=CC(Cl)=CC=3)=NN=2)=C1 QFCXANHHBCGMAS-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 2
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 2
- 229950001573 Abemaciclib Drugs 0.000 description 2
- 229940028652 Abraxane Drugs 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 229950002916 Avelumab Drugs 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- IUEWAGVJRJORLA-HZPDHXFCSA-N BMN-673 Chemical compound CN1N=CN=C1[C@H]1C(NNC(=O)C2=CC(F)=C3)=C2C3=N[C@@H]1C1=CC=C(F)C=C1 IUEWAGVJRJORLA-HZPDHXFCSA-N 0.000 description 2
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 2
- UBPYILGKFZZVDX-UHFFFAOYSA-N Bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 102100016486 CCND3 Human genes 0.000 description 2
- 229940088954 Camptosar Drugs 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- 108010058545 Cyclin D3 Proteins 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N Cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N Cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 2
- 229960000605 Dexrazoxane Drugs 0.000 description 2
- 229960004679 Doxorubicin Drugs 0.000 description 2
- 229950001287 Edotecarin Drugs 0.000 description 2
- 229940120655 Eloxatin Drugs 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N Enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 2
- 229960001433 Erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960002949 Fluorouracil Drugs 0.000 description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N Fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 229960002258 Fulvestrant Drugs 0.000 description 2
- 206010017758 Gastric cancer Diseases 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229940049906 Glutamate Drugs 0.000 description 2
- XLXSAKCOAKORKW-UHFFFAOYSA-N Gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylases Human genes 0.000 description 2
- 108090000353 Histone deacetylases Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229950002133 Iniparib Drugs 0.000 description 2
- MDOJTZQKHMAPBK-UHFFFAOYSA-N Iniparib Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- 229960004873 LEVOMENTHOL Drugs 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 229960004338 Leuprorelin Drugs 0.000 description 2
- 229940002661 Lipitor Drugs 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 102000001776 Matrix Metalloproteinase 9 Human genes 0.000 description 2
- 108010015302 Matrix Metalloproteinase 9 Proteins 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 229950010895 Midostaurin Drugs 0.000 description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- 229910000949 MnO2 Inorganic materials 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- ZTFBIUXIQYRUNT-MDWZMJQESA-N Mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- DUYJMQONPNNFPI-UHFFFAOYSA-N N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 2
- UZWDCWONPYILKI-UHFFFAOYSA-N N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 2
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 2
- 229950007221 Nedaplatin Drugs 0.000 description 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 2
- 229950011068 Niraparib Drugs 0.000 description 2
- 108010019706 Nivolumab Proteins 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 101710027499 Os03g0268000 Proteins 0.000 description 2
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical class N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 108010061219 Panitumumab Proteins 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N Pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
- SZFPYBIJACMNJV-UHFFFAOYSA-N Perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 2
- 108091000081 Phosphotransferases Proteins 0.000 description 2
- 241000243142 Porifera Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102000001253 Protein Kinases Human genes 0.000 description 2
- VHXNKPBCCMUMSW-FQEVSTJZSA-N Rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 2
- 229950009213 Rubitecan Drugs 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 2
- 229950004550 Talazoparib Drugs 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- 229940063683 Taxotere Drugs 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229950007967 Tesmilifene Drugs 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N Tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 2
- 229960004824 Triptorelin Drugs 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N Vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- YCOYDOIWSSHVCK-UHFFFAOYSA-N Vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 Xylitol Drugs 0.000 description 2
- 108010023617 abarelix Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 230000002730 additional Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 2
- 108010010826 avelumab Proteins 0.000 description 2
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960003736 bosutinib Drugs 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 201000009030 carcinoma Diseases 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940009662 edetate Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229960004671 enzalutamide Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 2
- 229960003765 fluvastatin Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229940044170 formate Drugs 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 229940097042 glucuronate Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 150000005363 heterobiaryls Chemical group 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000010902 jet-milling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000001613 neoplastic Effects 0.000 description 2
- 229960002653 nilutamide Drugs 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 229960003278 osimertinib Drugs 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 229940014662 pantothenate Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 2
- 108010026276 pembrolizumab Proteins 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 108010042024 pertuzumab Proteins 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- 229960000672 rosuvastatin Drugs 0.000 description 2
- 229950004707 rucaparib Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 230000001743 silencing Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 229940086735 succinate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- 239000004066 vascular targeting agent Substances 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- QXRSDHAAWVKZLJ-PVYNADRNSA-N (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- AKJHMTWEGVYYSE-FXILSDISSA-N (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N (2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- QXOPTIPQEVJERB-JQWIXIFHSA-N (2S)-2-[[5-[2-[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid Chemical compound C1=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)SC(CC[C@H]2CC=3C(=O)N=C(N)NC=3NC2)=C1C QXOPTIPQEVJERB-JQWIXIFHSA-N 0.000 description 1
- OJLHWPALWODJPQ-QNWVGRARSA-N (2S)-2-amino-5-[[(2R)-3-[2-[bis[bis(2-chloroethyl)amino]phosphoryloxy]ethylsulfonyl]-1-[[(R)-carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound ClCCN(CCCl)P(=O)(N(CCCl)CCCl)OCCS(=O)(=O)C[C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](C(O)=O)C1=CC=CC=C1 OJLHWPALWODJPQ-QNWVGRARSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- GTXSRFUZSLTDFX-HRCADAONSA-N (2S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O GTXSRFUZSLTDFX-HRCADAONSA-N 0.000 description 1
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- OLCWFLWEHWLBTO-HSZRJFAPSA-N (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile Chemical compound C=1C=CSC=1S(=O)(=O)N([C@@H](C1)CC=2C=CC=CC=2)CC2=CC(C#N)=CC=C2N1CC1=CN=CN1 OLCWFLWEHWLBTO-HSZRJFAPSA-N 0.000 description 1
- MAVDNGWEBZTACC-HNNXBMFYSA-N (3S)-N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C1=CC=C(OCC#CCO)C=C1 MAVDNGWEBZTACC-HNNXBMFYSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 1
- 125000006736 (C6-C20) aryl group Chemical group 0.000 description 1
- BSPLGGCPNTZPIH-IPZCTEOASA-N (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide;hydrate Chemical compound O.C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 BSPLGGCPNTZPIH-IPZCTEOASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- CRPTXKKKIGGDBX-UHFFFAOYSA-N (Z)-but-2-ene Chemical compound [CH2]C=CC CRPTXKKKIGGDBX-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- UDGKZGLPXCRRAM-UHFFFAOYSA-N 1,2,5-thiadiazole Chemical compound C=1C=NSN=1 UDGKZGLPXCRRAM-UHFFFAOYSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-Bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- BQNSMXRVZSCWJZ-UHFFFAOYSA-N 1,2-oxazole;1,3-oxazole;1,2-thiazole;2-(2H-triazol-4-yl)-1,3-thiazole Chemical compound C=1C=NOC=1.C=1C=NSC=1.C1=COC=N1.C1=CSC(C2=NNN=C2)=N1 BQNSMXRVZSCWJZ-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MGNZXYYWBUKAII-UHFFFAOYSA-N 1,3-Cyclohexadiene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 1
- JYUXDXWXTPSAEL-UHFFFAOYSA-N 1,4-dioxane;oxolane Chemical compound C1CCOC1.C1COCCO1 JYUXDXWXTPSAEL-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- LMTDPKYREUZYAO-UHFFFAOYSA-N 1,4-dioxepane Chemical compound C1COCCOC1 LMTDPKYREUZYAO-UHFFFAOYSA-N 0.000 description 1
- DNWRQNQDWZNZEB-UHFFFAOYSA-N 1,4-dithiepane Chemical compound C1CSCCSC1 DNWRQNQDWZNZEB-UHFFFAOYSA-N 0.000 description 1
- FUHYSHCCRTWZAY-UHFFFAOYSA-N 1,4-oxathiepane Chemical compound C1COCCSC1 FUHYSHCCRTWZAY-UHFFFAOYSA-N 0.000 description 1
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 1
- MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical compound C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-Butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- SFNSLLSYNZWZQG-VQIMIIECSA-N 1-[(2R,4R)-2-(1H-benzimidazol-2-yl)-1-methylpiperidin-4-yl]-3-(4-cyanophenyl)urea Chemical compound N([C@@H]1CCN([C@H](C1)C=1NC2=CC=CC=C2N=1)C)C(=O)NC1=CC=C(C#N)C=C1 SFNSLLSYNZWZQG-VQIMIIECSA-N 0.000 description 1
- MUCYRGGMVNGLNP-UHFFFAOYSA-N 1-benzofuran;1-benzothiophene Chemical compound C1=CC=C2OC=CC2=C1.C1=CC=C2SC=CC2=C1 MUCYRGGMVNGLNP-UHFFFAOYSA-N 0.000 description 1
- ZRWNGUJVDUBGFQ-UHFFFAOYSA-N 1-methylsulfonylpiperidin-3-ol Chemical compound CS(=O)(=O)N1CCCC(O)C1 ZRWNGUJVDUBGFQ-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 1H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1H-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 description 1
- ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-M 2,3-dinitrobenzoate Chemical compound [O-]C(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-M 0.000 description 1
- IZKATSCDUREBRD-UHFFFAOYSA-N 2,5,6,7,8,8a-hexahydro-1H-indolizin-3-one Chemical compound C1CCCN2C(=O)CCC21 IZKATSCDUREBRD-UHFFFAOYSA-N 0.000 description 1
- SSNMISUJOQAFRR-UHFFFAOYSA-N 2,6-naphthyridine Chemical compound N1=CC=C2C=NC=CC2=C1 SSNMISUJOQAFRR-UHFFFAOYSA-N 0.000 description 1
- HCMMECMKVPHMDE-UHFFFAOYSA-N 2,7-naphthyridine Chemical compound C1=NC=C2C=NC=CC2=C1 HCMMECMKVPHMDE-UHFFFAOYSA-N 0.000 description 1
- ZWRMSOMIVOVMQX-UHFFFAOYSA-M 2-(2-aminoethyldisulfanyl)ethanamine;palladium(2+);chloride Chemical compound [Cl-].[Pd+2].NCCSSCCN ZWRMSOMIVOVMQX-UHFFFAOYSA-M 0.000 description 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-Methoxyestradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- NKZTZAQIKKGTDB-QPLCGJKRSA-N 2-[2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethoxy]ethanol Chemical compound C1=CC(OCCOCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-QPLCGJKRSA-N 0.000 description 1
- PJKVJJYMWOCLIJ-UHFFFAOYSA-N 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-1H-quinazolin-4-one;hydron;dichloride Chemical compound Cl.Cl.CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 PJKVJJYMWOCLIJ-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-M 2-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-M 0.000 description 1
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical class ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- DIQOUXNTSMWQSA-UHFFFAOYSA-N 2-oxa-5-azabicyclo[2.2.1]heptane Chemical compound C1OC2CNC1C2 DIQOUXNTSMWQSA-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- HQHCLFUZLHPXNT-UHFFFAOYSA-N 3,4-dihydro-2H-pyran;3,6-dihydro-2H-pyran;2H-pyran Chemical compound C1COC=CC1.C1CC=CCO1.C1OC=CC=C1 HQHCLFUZLHPXNT-UHFFFAOYSA-N 0.000 description 1
- ZUDXUNPSRMREOJ-UHFFFAOYSA-N 3-(4-methoxyphenyl)-4-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2H-chromen-7-ol Chemical compound C1=CC(OC)=CC=C1C(COC1=CC(O)=CC=C11)=C1CC(C=C1)=CC=C1OCCN1CCCCC1 ZUDXUNPSRMREOJ-UHFFFAOYSA-N 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-Aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- AQIXEPGDORPWBJ-UHFFFAOYSA-N 3-Pentanol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 1
- GYLMCBOAXJVARF-UHFFFAOYSA-N 3-azabicyclo[2.2.1]heptane Chemical compound C1C2CCC1NC2 GYLMCBOAXJVARF-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical class ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- SETFNECMODOHTO-UHFFFAOYSA-N 4-N-(3-chloro-1H-indol-7-yl)benzene-1,4-disulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 description 1
- JFIWEPHGRUDAJN-DYUFWOLASA-N 4-amino-1-[(2R,3R,4S,5R)-4-ethynyl-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@](O)(C#C)[C@@H](CO)O1 JFIWEPHGRUDAJN-DYUFWOLASA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2R)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical class O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N 5-chloro-4-hydroxy-1H-pyridin-2-one Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- NKGPJODWTZCHGF-KQYNXXCUSA-N 6-Thioinosinic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(S)=C2N=C1 NKGPJODWTZCHGF-KQYNXXCUSA-N 0.000 description 1
- 101710025088 66 Proteins 0.000 description 1
- PBCZSGKMGDDXIJ-HQCWYSJUSA-N 7-Hydroxystaurosporine Chemical compound N([C@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@H]1C[C@@H](NC)[C@@H](OC)[C@]3(C)O1 PBCZSGKMGDDXIJ-HQCWYSJUSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 102100011882 ARID1A Human genes 0.000 description 1
- 101710037383 ARID1A Proteins 0.000 description 1
- 102100011883 ARID1B Human genes 0.000 description 1
- 101710037380 ARID1B Proteins 0.000 description 1
- 101700066925 ARID2 Proteins 0.000 description 1
- 102100001854 ARID2 Human genes 0.000 description 1
- 229950004810 ATAMESTANE Drugs 0.000 description 1
- 229960004176 Aclarubicin Drugs 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 108010026410 Ado-Trastuzumab Emtansine Proteins 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 229940034653 Advicor Drugs 0.000 description 1
- TXUZVZSFRXZGTL-QPLCGJKRSA-N Afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 1
- 229950003105 Afimoxifene Drugs 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N Alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 229940110282 Alimta Drugs 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229950010817 Alvocidib Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- UPALIKSFLSVKIS-UHFFFAOYSA-N Amonafide Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 description 1
- 229960004701 Amonafide Drugs 0.000 description 1
- CIDNKDMVSINJCG-GKXONYSUSA-N Annamycin Chemical compound I[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(=O)CO)C1 CIDNKDMVSINJCG-GKXONYSUSA-N 0.000 description 1
- MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 description 1
- 229950002465 Apaziquone Drugs 0.000 description 1
- UUSZLLQJYRSZIS-LXNNNBEUSA-N Aplidine Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 1
- 229950002842 Apratastat Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940087620 Aromasin Drugs 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N Arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229950005529 Arzoxifene Drugs 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N Atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- PEZPMAYDXJQYRV-UHFFFAOYSA-N BBR-2778 Chemical compound O=C1C2=CN=CC=C2C(=O)C2=C1C(NCCN)=CC=C2NCCN PEZPMAYDXJQYRV-UHFFFAOYSA-N 0.000 description 1
- 101700024247 BCL6 Proteins 0.000 description 1
- 102100011377 BCL6 Human genes 0.000 description 1
- 101700009767 BRD4 Proteins 0.000 description 1
- 102100015500 BRD4 Human genes 0.000 description 1
- 229950001429 Batabulin Drugs 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N Bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N Belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 Belotecan Drugs 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N Bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N Bicalutamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 229940083476 Bosulif Drugs 0.000 description 1
- 229950004271 Brostallicin Drugs 0.000 description 1
- RXOVOXFAAGIKDQ-UHFFFAOYSA-N Brostallicin Chemical compound C1=C(C(=O)NCCN=C(N)N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3N(C=C(NC(=O)C(Br)=C)C=3)C)C=2)C)=CN1C RXOVOXFAAGIKDQ-UHFFFAOYSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 1
- PKCRUPNVGJBRRJ-UYAOXDASSA-N C(C)C=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=C(C2=C(N(C(=N2)C)C(C)C)C=1)F Chemical compound C(C)C=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=C(C2=C(N(C(=N2)C)C(C)C)C=1)F PKCRUPNVGJBRRJ-UYAOXDASSA-N 0.000 description 1
- AWWXDZBVBKKKHZ-UHFFFAOYSA-N C1CCC1.C1CCCC1 Chemical compound C1CCC1.C1CCCC1 AWWXDZBVBKKKHZ-UHFFFAOYSA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 229910014585 C2-Ce Inorganic materials 0.000 description 1
- 101710040446 CD40 Proteins 0.000 description 1
- 102100013137 CD40 Human genes 0.000 description 1
- 101700051654 CDK1 Proteins 0.000 description 1
- 102100013105 CDK1 Human genes 0.000 description 1
- 101700024634 CDK16 Proteins 0.000 description 1
- 102100019396 CDK2 Human genes 0.000 description 1
- 101700005178 CDK6 Proteins 0.000 description 1
- 102100003972 CDK9 Human genes 0.000 description 1
- 101700049227 CDK9 Proteins 0.000 description 1
- ZXFCRFYULUUSDW-OWXODZSWSA-N CHEMBL2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
- 101710014631 CHURC1 Proteins 0.000 description 1
- 101710025159 CMPK1 Proteins 0.000 description 1
- 102100006435 CSF3 Human genes 0.000 description 1
- 102100005310 CTLA4 Human genes 0.000 description 1
- 101700054183 CTLA4 Proteins 0.000 description 1
- 229940022418 Caduet Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000005461 Canertinib Substances 0.000 description 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N Canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
- 229950002826 Canertinib Drugs 0.000 description 1
- 229950000772 Canfosfamide Drugs 0.000 description 1
- 229940077731 Carbohydrate nutrients Drugs 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 229940112822 Chewing Gum Drugs 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N Cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N Cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- WXDKXMNLPNNYSW-SJLPKXTDSA-N ClC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=C(C2=C(N(C(=N2)C)C(C)C)C=1)F Chemical compound ClC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=C(C2=C(N(C(=N2)C)C(C)C)C=1)F WXDKXMNLPNNYSW-SJLPKXTDSA-N 0.000 description 1
- CQHXNOKDYKBAMH-SJLPKXTDSA-N ClC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=C(C2=C(N(C(=N2)C)C2COC2)C=1)F Chemical compound ClC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=C(C2=C(N(C(=N2)C)C2COC2)C=1)F CQHXNOKDYKBAMH-SJLPKXTDSA-N 0.000 description 1
- LPNUTFAGTQJSOJ-NVXWUHKLSA-N ClC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=CC2=C(N(N=N2)C(C)C)C=1 Chemical compound ClC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=CC2=C(N(N=N2)C(C)C)C=1 LPNUTFAGTQJSOJ-NVXWUHKLSA-N 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 229940090805 Clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229940103380 Clolar Drugs 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- DYNHJHQFHQTFTP-UHFFFAOYSA-N Crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 description 1
- 229940066901 Crestor Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229960000913 Crospovidone Drugs 0.000 description 1
- 208000002416 Cutaneous Malignant Melanoma Diseases 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N Cycloheptatriene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N Cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- LRCZQSDQZJBHAF-PUBGEWHCSA-N DHA-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 101710038368 DNMT3A Proteins 0.000 description 1
- 102100006402 DNMT3A Human genes 0.000 description 1
- 101700067544 DOT1L Proteins 0.000 description 1
- 102100018143 DOT1L Human genes 0.000 description 1
- 229950002205 Dacomitinib Drugs 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N Deforolimus Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N Deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N Dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 102000005135 EC 1.3.3.4 Human genes 0.000 description 1
- 108020001991 EC 1.3.3.4 Proteins 0.000 description 1
- 102000008807 EC 2.7.11.- Human genes 0.000 description 1
- 108030004416 EC 2.7.11.- Proteins 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 101700039191 EGFR Proteins 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 102000027760 ERBB2 Human genes 0.000 description 1
- 102100016655 ERN1 Human genes 0.000 description 1
- 101700036757 ERN1 Proteins 0.000 description 1
- 101700014948 ERN2 Proteins 0.000 description 1
- 102100016692 ESR1 Human genes 0.000 description 1
- 101700041849 EZH2 Proteins 0.000 description 1
- 102100016041 EZH2 Human genes 0.000 description 1
- BNFRJXLZYUTIII-UHFFFAOYSA-N Efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N Elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 Elsamitrucin Drugs 0.000 description 1
- 229950005627 Embonate Drugs 0.000 description 1
- 229940095399 Enema Drugs 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 229950011487 Enocitabine Drugs 0.000 description 1
- AXRCEOKUDYDWLF-UHFFFAOYSA-N Enzastaurin Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 description 1
- 229950002189 Enzastaurin Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229950009537 Epristeride Drugs 0.000 description 1
- 229950006835 Eptaplatin Drugs 0.000 description 1
- 229940082789 Erbitux Drugs 0.000 description 1
- 229950000206 Estolate Drugs 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N Etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-WDSGEKFTSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-WDSGEKFTSA-N 0.000 description 1
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N Exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 1
- MVGSNCBCUWPVDA-MFOYZWKCSA-N Exisulind Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)(=O)=O)C=C1 MVGSNCBCUWPVDA-MFOYZWKCSA-N 0.000 description 1
- 229950011548 FADROZOLE Drugs 0.000 description 1
- RZEUNDJPFIMBNB-IEBWSBKVSA-N FC1=CC(=CC=2N(C(=NC=21)C)C(C)C)C1=NC(=NC=C1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O Chemical compound FC1=CC(=CC=2N(C(=NC=21)C)C(C)C)C1=NC(=NC=C1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O RZEUNDJPFIMBNB-IEBWSBKVSA-N 0.000 description 1
- UKVZKVRVVNTCMR-SJLPKXTDSA-N FC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=C(C2=C(N(C(=N2)C)C(C)C)C=1)F Chemical compound FC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=C(C2=C(N(C(=N2)C)C(C)C)C=1)F UKVZKVRVVNTCMR-SJLPKXTDSA-N 0.000 description 1
- IIWJISYNHGWLAF-IEBWSBKVSA-N FC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=CC2=C(N(C(=N2)C)C(C)C)C=1 Chemical compound FC=1C(=NC(=NC=1)N[C@H]1[C@@H](CN(CC1)S(=O)(=O)C)O)C=1C=CC2=C(N(C(=N2)C)C(C)C)C=1 IIWJISYNHGWLAF-IEBWSBKVSA-N 0.000 description 1
- KLGBKBIJEJBONV-NVXWUHKLSA-N FC=1C(=NC(=NC=1)N[C@H]1[C@@H](CNCC1)O)C=1C=C(C2=C(N(C(=N2)C)C(C)C)C=1)F Chemical compound FC=1C(=NC(=NC=1)N[C@H]1[C@@H](CNCC1)O)C=1C=C(C2=C(N(C(=N2)C)C(C)C)C=1)F KLGBKBIJEJBONV-NVXWUHKLSA-N 0.000 description 1
- 101710009074 FLT3 Proteins 0.000 description 1
- 102100004573 FLT3 Human genes 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- 229940087476 Femara Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical group C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229950004684 Fispemifene Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229960002737 Fructose Drugs 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N Furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 229960001731 GLUCEPTATE Drugs 0.000 description 1
- 229950011325 Galarubicin Drugs 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- UIVFUQKYVFCEKJ-OPTOVBNMSA-N Gimatecan Chemical compound C1=CC=C2C(\C=N\OC(C)(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UIVFUQKYVFCEKJ-OPTOVBNMSA-N 0.000 description 1
- 229950009073 Gimatecan Drugs 0.000 description 1
- 229950003566 Glasdegib Drugs 0.000 description 1
- 229940080856 Gleevec Drugs 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 229950011595 Glufosfamide Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 101710004393 HAVCR2 Proteins 0.000 description 1
- 102100016384 HAVCR2 Human genes 0.000 description 1
- 206010065430 HER-2 positive breast cancer Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- LVASCWIMLIKXLA-LSDHHAIUSA-N Halofuginone Chemical compound O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 LVASCWIMLIKXLA-LSDHHAIUSA-N 0.000 description 1
- 229950010152 Halofuginone Drugs 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 229940022353 Herceptin Drugs 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102100004121 IDH1 Human genes 0.000 description 1
- 101700024037 IDH1 Proteins 0.000 description 1
- 101700066748 IDH3B Proteins 0.000 description 1
- 102100014263 IGF1R Human genes 0.000 description 1
- 101700025802 IGF1R Proteins 0.000 description 1
- 101700085586 IRE1A Proteins 0.000 description 1
- 101700019719 IRE1B Proteins 0.000 description 1
- 229940061301 Ibrance Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 description 1
- 229950003909 Iguratimod Drugs 0.000 description 1
- 229940054126 Imbruvica Drugs 0.000 description 1
- 229950004983 Incyclinide Drugs 0.000 description 1
- 229950009881 Indisulam Drugs 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 1
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 1
- 229940084651 Iressa Drugs 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 229940089787 KADCYLA Drugs 0.000 description 1
- 101700018814 KDM1A Proteins 0.000 description 1
- 102100000513 KDM1A Human genes 0.000 description 1
- 102100013867 KDM6A Human genes 0.000 description 1
- 101700004928 KDM6A Proteins 0.000 description 1
- 102100013180 KDR Human genes 0.000 description 1
- 101700000155 KMT2A Proteins 0.000 description 1
- 102100004455 KMT2A Human genes 0.000 description 1
- 101710033922 KRAS Proteins 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229940022039 Keytruda Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 108060004270 LAG3 Proteins 0.000 description 1
- 102100017213 LAG3 Human genes 0.000 description 1
- 101700047494 LDL1 Proteins 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N Lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229940095570 Lescol Drugs 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229950008991 Lobaplatin Drugs 0.000 description 1
- 229950001290 Lorlatinib Drugs 0.000 description 1
- 229940087857 Lupron Drugs 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N Lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 Lurtotecan Drugs 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 210000004324 Lymphatic System Anatomy 0.000 description 1
- 101710007526 MAP3K14 Proteins 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- PBUUPFTVAPUWDE-HSLMEMBISA-N Mafosfamide Chemical compound OS(=O)(=O)CCS[C@@H]1CCOP(=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-HSLMEMBISA-N 0.000 description 1
- 229950000547 Mafosfamide Drugs 0.000 description 1
- 206010025650 Malignant melanoma Diseases 0.000 description 1
- 229960002160 Maltose Drugs 0.000 description 1
- 229950008001 Matuzumab Drugs 0.000 description 1
- 230000036676 Maximum tolerable dose Effects 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N Medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229940090004 Megace Drugs 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- RAHBGWKEPAQNFF-UHFFFAOYSA-N Motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 1
- VAZLWPAHMORDGR-UHFFFAOYSA-L Motexafin gadolinium Chemical compound C1=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=C1[N]1=CC3=[N]4[Gd]11(N56)(OC(=O)C)(OC(=O)C)[N]2=CC(C(C)=C2CCCO)=[N]1C2=CC6=C(CC)C(CC)=C5C=C4C(CCCO)=C3C VAZLWPAHMORDGR-UHFFFAOYSA-L 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 239000005462 Mubritinib Substances 0.000 description 1
- 229950002212 Mubritinib Drugs 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- URCVCIZFVQDVPM-UHFFFAOYSA-N N-[2-(4-hydroxyanilino)pyridin-3-yl]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=CN=C1NC1=CC=C(O)C=C1 URCVCIZFVQDVPM-UHFFFAOYSA-N 0.000 description 1
- MAVDNGWEBZTACC-UHFFFAOYSA-N N-hydroxy-4-[4-(4-hydroxybut-2-ynoxy)phenyl]sulfonyl-2,2-dimethylthiomorpholine-3-carboxamide Chemical compound ONC(=O)C1C(C)(C)SCCN1S(=O)(=O)C1=CC=C(OCC#CCO)C=C1 MAVDNGWEBZTACC-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M N-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 101700056580 NSD1 Proteins 0.000 description 1
- 102100020123 NSD1 Human genes 0.000 description 1
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N Nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229950010159 Nemorubicin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N Neocarzinostatin Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 210000001178 Neural Stem Cells Anatomy 0.000 description 1
- 229940063708 Neutrexin Drugs 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 229940053207 Niacin Drugs 0.000 description 1
- 229940099637 Nilandron Drugs 0.000 description 1
- 229950010203 Nimotuzumab Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N Nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- AFLXUQUGROGEFA-UHFFFAOYSA-N Nitrogen mustard N-oxide Chemical compound ClCC[N+]([O-])(C)CCCl AFLXUQUGROGEFA-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N Nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229950000891 Nolatrexed Drugs 0.000 description 1
- SBUOERUWDGLPAL-UHFFFAOYSA-N O=S1(=O)CC2(C1)CCCCC2 Chemical compound O=S1(=O)CC2(C1)CCCCC2 SBUOERUWDGLPAL-UHFFFAOYSA-N 0.000 description 1
- DECPWVARNFVFKY-UHFFFAOYSA-N O=S1(=O)COCC2CCCCN12 Chemical compound O=S1(=O)COCC2CCCCN12 DECPWVARNFVFKY-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N OC(=O)C(N)CCCNC(N)=N Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- IIXWYSCJSQVBQM-LLVKDONJSA-N OSP71S83EU Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N Olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- IXWNTLSTOZFSCM-YVACAVLKSA-N Ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 description 1
- XZEUAXYWNKYKPL-URLMMPGGSA-N Ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N Ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 229950001094 Ortataxel Drugs 0.000 description 1
- ZLLOIFNEEWYATC-XMUHMHRVSA-N Osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 description 1
- 229950006466 Osaterone Drugs 0.000 description 1
- LUMKNAVTFCDUIE-VHXPQNKSSA-N Ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N Oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- 101710027500 PBRM1 Proteins 0.000 description 1
- 102100017777 PBRM1 Human genes 0.000 description 1
- LXCWYTUKZXZSAJ-AUHBJGJSSA-N PCK 3145 Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=C(O)C=C1 LXCWYTUKZXZSAJ-AUHBJGJSSA-N 0.000 description 1
- 102100004939 PDGFRB Human genes 0.000 description 1
- 101710018346 PDGFRB Proteins 0.000 description 1
- 101710040930 PTGS2 Proteins 0.000 description 1
- 102100015381 PTGS2 Human genes 0.000 description 1
- 101700044505 PUB33 Proteins 0.000 description 1
- 101700045570 PUB34 Proteins 0.000 description 1
- 101700046887 PUB35 Proteins 0.000 description 1
- 101700066160 PUB51 Proteins 0.000 description 1
- 101700067511 PUB52 Proteins 0.000 description 1
- 101700068819 PUB53 Proteins 0.000 description 1
- 101700086326 PUB70 Proteins 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 229950006299 Pelitinib Drugs 0.000 description 1
- 229950003819 Pelitrexol Drugs 0.000 description 1
- 229950010632 Perifosine Drugs 0.000 description 1
- 229940039551 Perjeta Drugs 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N Peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N Phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L Picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960004403 Pixantrone Drugs 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229950008499 Plitidepsin Drugs 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M Potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 229940089484 Pravachol Drugs 0.000 description 1
- 229960002965 Pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 241000282335 Procyon Species 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 101700007719 RAF1 Proteins 0.000 description 1
- 101700016196 RNP30 Proteins 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- 108010062724 Ranibizumab Proteins 0.000 description 1
- 229960003876 Ranibizumab Drugs 0.000 description 1
- 229950007649 Ranpirnase Drugs 0.000 description 1
- INSACQSBHKIWNS-QZQSLCQPSA-N Rebeccamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](OC)[C@@H](CO)O[C@H]1N1C2=C3N=C4[C](Cl)C=CC=C4C3=C3C(=O)NC(=O)C3=C2C2=CC=CC(Cl)=C21 INSACQSBHKIWNS-QZQSLCQPSA-N 0.000 description 1
- 229950005950 Rebimastat Drugs 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N Roxithromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- GWJPKYHYBJPXPX-UHFFFAOYSA-N S1C(CCCCC1)N1CCCCCC1 Chemical compound S1C(CCCCC1)N1CCCCCC1 GWJPKYHYBJPXPX-UHFFFAOYSA-N 0.000 description 1
- 101700071021 SETD2 Proteins 0.000 description 1
- 102100000940 SETD2 Human genes 0.000 description 1
- 101710025703 SMARCA4 Proteins 0.000 description 1
- 102100019447 SMARCA4 Human genes 0.000 description 1
- 101700032951 SWM1 Proteins 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940085605 Saccharin Sodium Drugs 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N Seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 229950000055 Seliciclib Drugs 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- DZMVCVHATYROOS-ZBFGKEHZSA-N Soblidotin Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)NCCC1=CC=CC=C1 DZMVCVHATYROOS-ZBFGKEHZSA-N 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L Sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- 229960000391 Sorbitan trioleate Drugs 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- 229950001248 Squalamine Drugs 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101710006827 Su(var)3-3 Proteins 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 Sulindac Drugs 0.000 description 1
- 229940034785 Sutent Drugs 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 102100016327 TEK Human genes 0.000 description 1
- 101710037124 TEK Proteins 0.000 description 1
- 101700048164 TET2 Proteins 0.000 description 1
- 102100003998 TET2 Human genes 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 102100006047 TIGIT Human genes 0.000 description 1
- 101700052319 TIGIT Proteins 0.000 description 1
- 101710038603 TNFRSF18 Proteins 0.000 description 1
- 102100003096 TNFRSF18 Human genes 0.000 description 1
- 101710040448 TNFRSF4 Proteins 0.000 description 1
- 102100013135 TNFRSF4 Human genes 0.000 description 1
- 102100009537 TNFRSF9 Human genes 0.000 description 1
- 101710040535 TNFRSF9 Proteins 0.000 description 1
- 229950003999 Tafluposide Drugs 0.000 description 1
- 229940092753 Tagrisso Drugs 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229940120982 Tarceva Drugs 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 229950004186 Telatinib Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229950002757 Teoclate Drugs 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 108010091299 TheraCIM Proteins 0.000 description 1
- JWCVYQRPINPYQJ-UHFFFAOYSA-N Thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 229950002376 Tirapazamine Drugs 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- CMSGWTNRGKRWGS-NQIIRXRSSA-N Torcetrapib Chemical compound COC(=O)N([C@H]1C[C@@H](CC)N(C2=CC=C(C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CMSGWTNRGKRWGS-NQIIRXRSSA-N 0.000 description 1
- 229950004514 Torcetrapib Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940074410 Trehalose Drugs 0.000 description 1
- 229940032510 Trelstar Drugs 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 108091007928 VEGF receptors Proteins 0.000 description 1
- XGOYIMQSIKSOBS-UHFFFAOYSA-N Vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229950000578 Vatalanib Drugs 0.000 description 1
- 229950011257 Veliparib Drugs 0.000 description 1
- 229940065658 Vidaza Drugs 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N Vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- RLQVKDVIBJCQGE-WDUCDQOOSA-N Win-25540 Chemical compound O=C1C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 RLQVKDVIBJCQGE-WDUCDQOOSA-N 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 229940053867 Xeloda Drugs 0.000 description 1
- 229940085728 Xtandi Drugs 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Yamafur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 101700069422 ZHX2 Proteins 0.000 description 1
- 229940099232 Zinecard Drugs 0.000 description 1
- 229940072168 Zocor Drugs 0.000 description 1
- 229940033942 Zoladex Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N Zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 Zotarolimus Drugs 0.000 description 1
- ULZLFKCWRWQURL-HHYUVNRKSA-M [(1R,4S)-3-bicyclo[2.2.1]heptanyl]-[(1S,4R)-3-bicyclo[2.2.1]heptanyl]phosphane;chloropalladium(1+);cyclopentane;1-cyclopentyl-N,N-dimethylmethanamine;iron Chemical compound [Fe].[Pd+]Cl.[CH]1[CH][CH][CH][CH]1.CN(C)C[C]1[CH][CH][CH][C-]1.C([C@H](C1)C2)C[C@@H]1C2PC1C[C@@H]2C[C@H]1CC2 ULZLFKCWRWQURL-HHYUVNRKSA-M 0.000 description 1
- GXJABQQUPOEUTA-NVXWUHKLSA-N [(1S)-3-methyl-1-[[(2R)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-NVXWUHKLSA-N 0.000 description 1
- RTJVUHUGTUDWRK-CSLCKUBZSA-N [(2R,4aR,6R,7R,8S,8aR)-6-[[(5S,5aR,8aR,9R)-9-(3,5-dimethoxy-4-phosphonooxyphenyl)-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-5-yl]oxy]-2-methyl-7-[2-(2,3,4,5,6-pentafluorophenoxy)acetyl]oxy-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]d Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](OC(=O)COC=4C(=C(F)C(F)=C(F)C=4F)F)[C@@H]4O[C@H](C)OC[C@H]4O3)OC(=O)COC=3C(=C(F)C(F)=C(F)C=3F)F)[C@@H]3[C@@H]2C(OC3)=O)=C1 RTJVUHUGTUDWRK-CSLCKUBZSA-N 0.000 description 1
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3S)-morpholin-3-yl]methyl N-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 1
- LPTCUYGPZMAHMM-GPJOBVNKSA-L [(4R,5R)-5-(azanidylmethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methylazanide;platinum(4+);propanedioate Chemical compound [Pt+4].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](C[NH-])[C@@H](C[NH-])O1 LPTCUYGPZMAHMM-GPJOBVNKSA-L 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(E)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 1
- CKXIPXAIFMTQCS-LRDUUELOSA-N [2-[(2S,4S)-4-[(2R,3R,4R,5S,6S)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 3-aminopropanoate Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCN)[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@H]1F CKXIPXAIFMTQCS-LRDUUELOSA-N 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 1
- 229960004103 abiraterone acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 229940089792 ado-trastuzumab emtansine Drugs 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000002152 alkylating Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000003388 anti-hormone Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 150000001501 aryl fluorides Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 108010072668 atezolizumab Proteins 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960000817 bazedoxifene Drugs 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- MXQOYLRVSVOCQT-UHFFFAOYSA-N bis(tri-t-butylphosphine)palladium (0) Substances [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- JUPMBRMEHSUGLE-UHFFFAOYSA-N butenyl Chemical compound CCC=[CH] JUPMBRMEHSUGLE-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M caprate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 108090000758 catumaxomab Proteins 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002281 colonystimulating Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 101710021213 crc-2 Proteins 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- CYKDRLQDTUXOBO-UHFFFAOYSA-N cyclopropan-1,1-diyl Chemical group [C]1CC1 CYKDRLQDTUXOBO-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N diethyl butanedioate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960000925 efaproxiral Drugs 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 150000002081 enamines Chemical group 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000001973 epigenetic Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N ethanone Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- HZNQVAOLVRFZBE-UHFFFAOYSA-N ethenylcyclohexane Chemical group C=C[C]1CCCCC1 HZNQVAOLVRFZBE-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229950009429 exatecan Drugs 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 229950000484 exisulind Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000000497 familial melanoma Diseases 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- CMTVYONOFRUKSQ-UHFFFAOYSA-N furan;1H-imidazole;1H-pyrazole;1H-pyrrole;thiophene Chemical compound C=1C=CNC=1.C=1C=COC=1.C=1C=NNC=1.C=1C=CSC=1.C1=CNC=N1 CMTVYONOFRUKSQ-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-L galactarate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O DSLZVSRJTYRBFB-DUHBMQHGSA-L 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 229940044168 geranylgeranylacetone Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229950009822 gimeracil Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-L hex-2-ynedioate Chemical compound [O-]C(=O)CCC#CC([O-])=O KKLGDUSGQMHBPB-UHFFFAOYSA-L 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 101500002601 human Epidermal growth factor Proteins 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- PQWQQQGKMHENOC-UHFFFAOYSA-N imidazo[1,2-c]pyrimidine Chemical compound C1=NC=CC2=NC=CN21 PQWQQQGKMHENOC-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000002519 immonomodulatory Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 101700052395 ire-1 Proteins 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-M isobutyrate Chemical compound CC(C)C([O-])=O KQNPFQTWMSNSAP-UHFFFAOYSA-M 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960002367 lasofoxifene Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 101710030209 lin-45 Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 1
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010029633 matuzumab Proteins 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- URXWVWVPMJSAJD-KOORYGTMSA-N megestrol acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 URXWVWVPMJSAJD-KOORYGTMSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 238000003328 mesylation reaction Methods 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000003232 mucoadhesive Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 108010043585 nimotuzumab Proteins 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 230000000269 nucleophilic Effects 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 229960000435 oblimersen Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229960000572 olaparib Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003327 ormeloxifene Drugs 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 229960003969 ospemifene Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960002502 paclitaxel protein-bound Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 229960004723 phenylbutyrate Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L phosphate Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- KMCHWHGTFVQFOO-UHFFFAOYSA-N piperazine;thiomorpholine Chemical compound C1CNCCN1.C1CSCCN1 KMCHWHGTFVQFOO-UHFFFAOYSA-N 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-M propane-1-sulfonate Chemical compound CCCS([O-])(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 239000003197 protein kinase b inhibitor Substances 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- LAWCSURIBCQREM-UHFFFAOYSA-N pyrazolo[4,3-c]pyridine Chemical compound C1=CN=C[C]2C=NN=C21 LAWCSURIBCQREM-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 1
- TYLGVQVJCVFREB-UHFFFAOYSA-N pyrido[3,4-b]pyrazine Chemical compound C1=NC=CC2=NC=CN=C21 TYLGVQVJCVFREB-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- GQIXFHWAAHPMSO-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=C=C[N]1 GQIXFHWAAHPMSO-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 108010061338 ranpirnase Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 1
- CKNPWBAXEKSCRG-UHFFFAOYSA-J satraplatin Chemical compound CC(=O)O[Pt-2]([NH3+])(Cl)(Cl)(OC(C)=O)[NH2+]C1CCCCC1 CKNPWBAXEKSCRG-UHFFFAOYSA-J 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000001483 serenoa repens Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(E)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960001663 sulfanilamide Drugs 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tBuOOH Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- HUCXKZBETONXFO-AJDZVAQLSA-N teprenone Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)=CCCC(C)=O HUCXKZBETONXFO-AJDZVAQLSA-N 0.000 description 1
- 229950006156 teprenone Drugs 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- ORYDPOVDJJZGHQ-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=CC2=[N+]([O-])C(N)=N[N+]([O-])=C21 ORYDPOVDJJZGHQ-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- BSUNTQCMCCQSQH-UHFFFAOYSA-N triazine Chemical compound C1=CN=NN=C1.C1=CN=NN=C1 BSUNTQCMCCQSQH-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical class CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Abstract
This invention relates to compounds of Formula (I)
Description
CYCLIN DEPENDENT KINASE INHIBITORS
BACKGROUND OF THE INVENTION
Field ofthe Invention
The présent invention relates to compounds of Formula (l)-(XII), and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds, salts and compositions ofthe présent invention may be useful for the treatment of abnormal cell growth, such as cancer, in a subject.
Description of the Related Art
Cyclin-dependent kinases (CDKs) and related serine/threonine protein kinases are important cellular enzymes that perform essential functions in regulating cell division and prolifération. The CDK catalytic units are activated by regulatory subunits known as cyclins. At 15 least sixteen mammalian cyclins hâve been identified (Johnson DG, Walker CL. Cyclins and Cell
Cycle Checkpoints. Annu. Rev. Pharmacol. Toxicol. (1999) 39:295-312). Additional functions of Cyclin/CDK hétérodynes include régulation of transcription, DNA repair, différentiation and apoptosis (Morgan DO. Cyclin-dependent kinases: engines, docks, and microprocessors. Annu. Rev. Cell. Dev. Biol. (1997) 13:261-291).
CDK inhibitors hâve been demonstrated to be useful in treating cancer. Increased activity or temporally abnormal activation of CDKs has been shown to resuit in the development of human tumors, and human tumor development is commonly associated with alterations in either the CDK proteins themselves or their regulators (Cordon-Cardo C. Mutations of cell cycle regulators: biological and clinical implications for human neoplasia. Am. J. Pathol. (1995) 147:545-560; Karp 25 JE, Broder S. Molecular foundations of cancer: new targets for intervention. Nat. Med. (1995) 1:309-320; Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in| human cancer. Adv. Cancer Res. (1996) 68:67-108). |
CDK4 and CDK6 are important regulators of cell cycle progression at the G1-S checkpoint, which are controlled by D-type cyclins and INK4 endogenous CDK inhibitors, such 30 as p16,NK4a (CDKN2A). Dysrégulation ofthe cyclin D-CDK4/6-INK4---retinoblastoma (Rb) pathway has been reported to be associated with development of endocrine therapy résistance.
Mutations of CDK4 and CDK6 hâve been described in subgroups of melanoma and other tumors (Zuo L, et al., Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet. (1996) 12, 97-99; Ortega S, et al. Cyclin D-dependent kinases, INK4 35 inhibitors and cancer. Biochim. Biophys. Acta (2002) 1602:73-87; Smalley KSM et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 ~ overexpression. Cancer Res (2008) 68: 5743-52). Amplifications of the regulatory subunits of
CDKs and cyclins, and mutation, gene délétion, or transcriptional silencing of endogenous INK4
CDK inhibitors hâve also been reported as mechanism by which the pathway can be activated (Smalley KSM (2008)).
The development of CDK inhibitors has been reviewed in the literature. For example, see
Sanchez-Martinez et al. Cyclin dépendent kinase (CDK) inhibitors as anticancer drugs, Bioorg. Med. Chem. Lett. (2015) 25: 3420-3435 (and référencés cited therein). The use of CDK4/6 inhibitors in combination with endocrine therapy has demonstrated significant efficacy in the treatment of hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative 10 advanced or metastatic breast cancers, and CDK4/6 inhibitors, including palbociclib, ribociclib and abemaciclib, hâve been approved in combination with endocrine therapy in a first-or secondline setting.
However, treatment with CDK4/6 inhibitors may resuit in adverse effects, such as gastrointestinal and/or hématologie toxicities, and acquired résistance may develop over time. 15 Emerging data suggest that cyclin D3-CDK6 may be linked to the observed hématologie toxicity.
(Malumbres et al., Mammalian Cells Cycle without the D-type Cyclin-Dependent Kinases Cdk4 and Cdk6, (2004) Cell 118(4):493-504; Sicinska et al. Essential Rôle for Cyclin D3 in Granulocyte Colony-Stimulating Factor-Driven Expansion of Neutrophil Granulocytes (2006), Mol. Cell Biol 26(21): 8052-8060; Cooper et al. A unique function for cyclin D3 in early B cell development, 20 (2006), Nat. Immunol. 5(7):489-497). CDK4 has been identified as the singular oncogenic driver in many breast cancers. Accordingly, a CDK4 sélective inhibitor may provide an improved safety profile or enhanced overall efficacy due to the potential of higher and/or continuous dosing compared to dual CDK4/6 inhibitors.
Accordingly, there remains a need for improved thérapies for the treatment of cancers. 25 The compounds, compositions and methods ofthe présent invention are believed to hâve one or more advantages, such as greater efficacy; potential to reduce side effects; potential to reduce drug-drug interactior|is; potential to enable an improved dosing schedule; or potential to overcome résistance mechanisms, and the like.
BRIEF SUMMARY OF THE INVENTION !
The présent invention provides, in part, compounds of Formula (l)-(XII) and pharmaceutically acceptable salts thereof. Such compounds can inhibit the activity of CDKs, including CDK4 and/or CDK6, thereby effecting biological functions. In some embodiments, the invention provides compounds that are sélective for CDK4. Also provided are pharmaceutical 35 compositions and médicaments comprising the compounds or salts of the invention, alone or in combination with additional anticancer therapeutic agents.
The présent invention also provides, in part, methods for preparing the compounds, pharmaceutically acceptable salts and compositions of the invention, and methods of using the foregoing alone or in combination with additional anticancer therapeutic agents.
In one aspect, the invention provides a compound of Formula (I):
or a pharmaceutically acceptable sait thereof, wherein:
A is N or CH;
R1 is H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl or C1-C2 alkoxy, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
UisNR2orCR3;
V is N or CR4 when U is NR2; and
V is NR5 when U is CR3;
X is CR6 or N;
Y is CR7 or N;
Z is CR8 or N;
R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, C(O)Ra, C(O)NRb 2, 20 C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C4 alkyl, Ci-C^ fluoroalkyl,
C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20, each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21, Ra is C1-C2 alkyl, and each Rb is independently H or C1-C2 alkyl; and I
R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl 25 is optionally substituted by R20; or
R2 can be taken together with R4, or R3 can be taken together with R5, to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(0)m as a ring member, which ring is optionally substituted by R21;
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3;
R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or
C1-C2 fluoroalkoxy, where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 fluoroalkoxy is optionally substituted by R20;
R9 is H, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
Q is NR11 or O; or
Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 or O as a ring member, which 10 ring is optionally further substituted by R10;
R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19;
R14 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R15 and R16 is independently H or CH3;
R17is C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said 20 C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NR22R23, C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C3-Ce cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
each R21 is independently F, OH, CN, NR22R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy 25 or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2;
each R22 and R23 is independently H, CrC3 alkyl, CrC3 fluoroalkyl, C3-Ce cycloalkyl or ^-6 membered heterocyclyl, where each said C1-C3 alkyl and C1-C3 fluoroalkyl is optionally further substituted by OH, C1-C2 alkoxy or C1-C2 fluoroalkoxy and each said C3-C8 cycloalkyl and 3-6 30 membered heterocyclyl is optionally further substituted by F, OH, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy; or I
R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, where said ring is optionally substituted by F, OH, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy;
R24 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R25, SO2NR26R27, COR28, COOR28 or
CONR29R30;
R15 * * * * * * * * * 25 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R26 and R27 is independently H or CH3;
R28 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2;
each R29 and R30 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said
C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2;
m is 0,1 or 2;
n is 0,1,2, 3 or 4;
p is 1, 2 or 3; and q is 0,1, 2 or 3;
wherein the sum of p and q is an integer from 1 to 4.
In another aspect, the invention provides a compound of Formula (II):
or a pharmaceutically acceptable sait thereof, wherein:
R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
U is NR2 or CR3;
V is N or CR4 when U is NR2; and | 20 V is NR5 when U is CR3; |
X is CR6 or N;
Y is CR7 or N;
j Z is CR8 or N; j i R2 and R3 are H, C1-C5 alkyl, C1-C5' fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said
C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20;
R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3;
R7 and R8 are independently H, F, Cl, CN, Ci-C2 alkyl, Ci-C2 fluoroalkyl, Ci-C2 alkoxy or Ci-C2 fluoroalkoxy, where each said Ci-C2 alkyl, Ci-C2 fluoroalkyl, Ci-C2 alkoxy and Ci-C2 fluoroalkoxy is optionally substituted by R20;
R9is H, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, Ci-C2 alkyl or Ci-C2 fluoroalkyl, where each said Ci-C2 alkyl and CrC2 fluoroalkyl is optionally substituted by R20;
Q is NR11 or O; or
Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 or O as a ring member, which ring is optionally further substituted by R10;
R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19;
R14 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R15 and R16 is independently H or CH3;
R17 is C1-C4 alkyl, C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, CrC2 alkoxy, Ci-C2 fluoroalkoxy, CN or NR22R23;
each R21 is independently F, OH, CN, NR^R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2;
each R22 and R23 is independently H, Ci-C2 alkyl or Ci-C2 fluoroalkyl; or | R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH;
n is 0,1, 2, 3 or 4;
i p is 1, 2 or3; and j ! qisO, 1,2or3; i wherein the sum of p and q is an integer from 1 to 4.
In another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention, according to any of the formulae described herein, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient.
In some embodiments, the pharmaceutical composition comprises two or more pharmaceutically acceptable carriers and/or excipients.
The invention also provides therapeutic methods and uses comprising administering a compound ofthe invention, or a pharmaceutically acceptable sait thereof.
In one aspect, the invention provides a method for the treatment of abnormal cell growth, in particular cancer, in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable sait thereof. Compounds of the invention may be administered as single agents or may be administered in combination with other anti-cancer therapeutic agents, including standard of care agents appropriate for the particular form of cancer.
In a further aspect, the invention provides a method for the treatment of abnormal cell growth, in particular cancer, in a subject in need thereof, comprising administering to the subject an amount of a compound of the invention, or a pharmaceutically acceptable sait thereof, in combination with an amount of an additional anti-cancer therapeutic agent, which amounts are together effective in treating said abnormal cell growth.
In another aspect, the invention provides a compound of the invention, or a pharmaceutically acceptable sait thereof, for use in the treatment of abnormal cell growth, in particular, cancer, in a subject.
In a further aspect, the invention provides the use of a compound of the invention, or a 20 pharmaceutically acceptable sait thereof, for the treatment of abnormal cell growth, in particular, cancer, in a subject.
In another aspect, the invention provides a pharmaceutical composition for use in the treatment of abnormal cell growth, in particular cancer, in a subject in need thereof, which pharmaceutical composition comprises a compound of the invention, or a pharmaceutically 25 acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient.
In another aspect, the invention provides a compound of the invention, or a pharmaceutically acceptable sait thereof, for use as a médicament, in particular a médicament for the treatment of abnormal cell growth, such as cancer.
In yet another aspect, the invention provides the use of a compound of the invention, or a pharmaceutically acceptable sait thereof, for the manufacture of a médicament for the treatment of abnormal cell growth, such as cancer, in a subject. I
In another aspect, the invention provides a method for the treatment of a disorder mediated by CDK4 in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount that is effective for treating said disorder, 35 in particular, cancer.
In another aspect, the invention provides a pharmaceutical composition comprising a compound of the invention, according to any of the formulae described herein, and a second pharmaceutically active agent.
In another aspect, the invention provides a compound of the invention, according to any 5 of the formulae described herein, for use in the treatment of cancer, wherein said treatment comprises the administration of a second pharmaceutically active agent.
Each of the aspects and embodiments of the compounds of the présent invention described below can be combined with one or more other embodiments of the compounds of the présent invention described herein not inconsistent with the embodiment(s) with which it is 10 combined.
In addition, each of the embodiments below describing the invention envisions within its scope the pharmaceutically acceptable salts of the compounds of the invention. Accordingly, the phrase “or a pharmaceutically acceptable sait thereof is implicit in the description of ail compounds described herein unless explicitly indicated to the contrary.
DETAILED DESCRIPTION OF THE INVENTION
The présent invention may be understood more readily by reference to the following detailed description of the preferred embodiments of the invention and the Examples included herein. It is to be understood that the terminology used herein is provided for the purpose of 20 describing spécifie embodiments only and is not intended to be limiting. It is further to be understood that unless specifically defined herein, the terminology used herein is to be given its traditional meaning as known in the relevant art.
As used herein, the singular form a, an, and the include plural référencés unless indicated otherwise. For example, a substituent includes one or more substituents. The term 25 about means having a value falling within an accepted standard of error of the mean, when considered by one of ordinary skill in the art.
The invention described herein suitably may be practiced in the absence of any element(s) not specifically disclosed herein. Thus, for example, in each instance herein any of the terms comprising, consisting essentially of, and consisting of' may be replaced with either of the 30 other two terms. ! !
Alkyl refers to a saturated, monovalent aliphatic hydrocarbon radical including straight chain and branched chain groups having the specified number of carbon atoms. Alkyl substituents typically contain 1 to 12 carbon atoms (“C1-C12 alkyl”), frequently 1 to 8 carbon atoms (“CrCe alkyl”), or more frequently 1 to 6 carbon atoms (“Ci-Ce alkyl”), 1 to 5 carbon atoms (“C1-C5 35 alkyl”), 1 to 4 carbon atoms (“C1-C4 alkyl”) or 1 to 2 carbon atoms (“C1-C2 alkyl”). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl and the like.
Alkyl groups described herein as optionally substituted may be substituted by one or more substituent groups, as further defined by the claims, which substituent groups are selected 5 independently unless otherwise indicated. The total number of substituent groups may equal the total number of hydrogen atoms on the alkyl moiety, to the extent such substitution makes Chemical sense. Optionally substituted alkyl groups typically contain from 1 to 6 optional substituents, sometimes 1 to 5 optional substituents, 1 to 4 optional substituents, or preferably 1 to 3 optional substituents.
Optional substituent that are suitable for alkyl include, but are not limited to, Ca-Ce cycloalkyl, 3-12 membered heterocyclyl, Ce-Ci2 aryl and 5-12 membered heteroaryl, halo, =0 (oxo), =S (thiono), =N-CN, =N-ORX, =NRX, -CN, -C(0)Rx, -CO2RX, -C(0)NRxRy, SRX, -SORX, -SO2Rx, -S02NRxRy, -NO2, -NRxRy, -NRxC(O)Ry, -NRxC(0)NRxRy, NRXC(O)ORX, -NRxS02Ry, -NRxS02NRxRy, -ORX, -0C(0)Rx and -0C(0)NRxRy; wherein each Rx 15 and Ry is independently H, CrCe alkyl, Ci-Ce acyl, C2-Cs alkenyl, C^Ce alkynyl, Ca-Ce cycloalkyl,
3-12 membered heterocyclyl, C6-Ci2 aryl, or 5-12 membered heteroaryl, or Rx and Ry may be taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S(0)q where q is 0-2; each Rx and Ry is optionally substituted with 1 to 3 20 substituents independently selected from the group consisting of halo, =0, =S, =N-CN, =N-OR', =NR', -CN, -C(0)R', -C02R', -C(O)NR'2i -SOR', -SO2R', -SO2NR'2i NO2, -NR'2i -NR'C(O)R', -NR'C(O)NR'2, -NR'C(0)0R', -NR'SO2R', -NR'SO2NR'2i -OR', -OC(O)R' and -OC(O)NR'2i wherein each R' is independently H, Ci-Ce alkyl, Ci-Ce acyl, C^Ce alkenyl, C2-Ce alkynyl, Ca-Ce cycloalkyl, 3-12 membered heterocyclyl, Ce-Ci2 aryl, or Cs-Ci2 heteroaryl; and wherein each said Ca-Ce cycloalkyl, 3-12 membered heterocyclyl, Ce-Ci2 aryl and 5-12 membered heteroaryl is optionally substituted as further defined herein.
Typical substituent|groups on alkyl include halo, -OH, C1-C4 alkoxy, -O-Ce(-Ci2 aryl, -CN, =0, -C00Rx, -OC(O)RX, -C(O)NRxRy, -NRxC(O)Ry, -NRxRy, C3-C8 cycloalkyl, C6-C12 aryl, 5-12 membered heteroaryl and 3-12 membered heterocyclyl; where each Rx and Ry is independently 30 H or C1-C4 alkyl, or Rx and Ry may be taken togetherwith the N to which they are'attached form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S(O)q where q is 0-2; wherein each said C3-C8 cycloalkyl, Ce-Ci2 aryl, 5-12 membered heteroaryl and 3-12 membered heterocyclyl is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, -OH, 35 =0, C1-C4 alkyl, C1-C4 alkoxy, Ci-Ce haloalkyl, CrCe hydroxyalkyl, C1-C4 alkoxy-Ci-Ce alkyl, -CN, -NH2, -NH(Ci-C4 alkyl) and -N(Ci-C4 alkyl)2.
• 10
In some instances, substituted alkyl groups are specifically named by reference to the substituent group. For example, “haloalkyl” refers to an alkyl group having the specified number of carbon atoms that is substituted by one or more halo substituents, up to the available valence number. Typically, haloalkyl groups contain 1-6 carbon atoms, 1-5 carbon atoms, 1-4 carbon 5 atoms or 1-2 carbon atoms and 1,2,3,4 or 5 halo atoms (i.e., “C1-C5 haloalkyl”, “C1-C4 haloalkyl” or “C1-C2 haloalkyl”).
More specifically, fiuorinated alkyl groups may be specifically referred to as “fluoroaikyl” groups, (e.g., C1-C5, Ci-C4or C1-C2 fluoroaikyl groups), which are typically substituted by 1, 2, 3, 4 or 5 fluoro atoms. Thus, a C1-C4 fluoroaikyl includes trifluoromethyl (-CF3), difluoromethyl 10 (-CF2H), fluoromethyl (-CFH2), difluoroethyi (-CH2CF2H), and the like. Such groups may be further substituted by groups suitable for alkyl groups, as further described herein.
In some embodiments of the présent invention, alkyl and fluoroaikyl groups are optionally substituted by one or more optional substituents, and preferably by 1 to 3 optional substituents, which are independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN or NR’2, where each R’ is 15 independently H, C1-C2 alkyl or C1-C2 fluoroaikyl.
Similarly, “alkoxyalkyl” refers to an alkyl group having the specified number of carbon atoms that is substituted by one or more alkoxy substituents. Alkoxyalkyl groups typically contain 1-4 carbon atoms in the alkyl portion and are substituted by 1, 2 or 3 C1-C4 alkyoxy substituents. Such groups are sometimes described herein as C1-C4 alkyoxy-Ci-C4 alkyl.
“Aminoalkyl” refers to alkyl group having the specified number of carbon atoms that is substituted by one or more substituted or unsubstituted amino groups, as such groups are further defined herein. Aminoalkyl groups typically contain 1-6 carbon atoms in the alkyl portion and are substituted by 1, 2 or 3 amino substituents. Thus, a Ci-Ce aminoalkyl includes, for example, aminomethyl (-CH2NH2), /V,/V-dimethylaminoethyl (-CH2CH2N(CH3)2), 3-(/V-cyclopropylamino)25 propyl (-CH2CH2CH2NH-cPr) and Af-pyrrolidinylethyl (-CH2CH2-N-pyrrolidinyl).
“Hydroxyalkyl” refers to an alkyl group having the specified number of carbon atoms that is substituted by one or more hy(|roxy substituents, and typically contain 1-6 carbon a^oms, preferably 1-4 carbon atoms, and 1, 2 or 3 hydroxy (i.e., “CrCs hydroxyalkyl”). Thus, Ci-Ce hydroxyalkyl includes hydroxymethyl (-CH2OH) and 2-hydroxyethyl (-CH2CH2OH).
Alkenyl refers to an alkyl (group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon double bond. Typically, alkenyl groups hâve 2 to 20 carbon atoms (“C2-C20 alkenyl”), preferably 2 to 12 carbon atoms (“C2-C12 alkenyl”), more preferably 2 to 8 carbon atoms (“C2-C8 alkenyl”), or 2 to 6 carbon atoms (“C2-C6 alkenyl”), or 2 to 4 carbon atoms (“C2-C4 alkenyl”). Représentative examples include, but are not limited to, ethenyl, 1-propenyl, 35 2-properiÿl, 1-, 2-, or 3-butenyl, and the like. Alkenyl groups are unsubstituted or substituted by the same groups that are described herein as suitable for alkyl.
11
Alkynyl refers to an alkyl group, as defined herein, consisting of at least two carbon atoms and at least one carbon-carbon triple bond. Alkynyl groups hâve 2 to 20 carbon atoms (“C2-C20 alkynyl”), preferably 2 to 12 carbon atoms (“C2-C12 alkynyl”), more preferably 2 to 8 carbon atoms (“C2-C8 alkynyl”), or 2 to 6 carbon atoms (“C2-C6 alkynyl”), or 2 to 4 carbon atoms (“C2-C4 alkynyl”). Représentative examples include, but are not limited to, ethynyl, 1-propynyl,
2-propynyl, 1-, 2-, or 3-butynyI, and the like. Alkynyl groups are unsubstituted or substituted by the same groups that are described herein as suitable for alkyl.
Alkylene as used herein refers to a divalent hydrocarbyl group having the specified number of carbon atoms which can link two other groups together. Sometimes it refers to a group
-(CH2)t- where t is 1-8, and preferably t is 1-6, t is 1-4 or t is 1-2. Such groups may be referred to as a Ci-C8 alkylene, Ci-C6 alkylene, C1-C4 alkylene, etc. Where specified, an alkylene can also be substituted by other groups and may include one or more degrees of unsaturation (i.e., an alkenylene or alkynlene moiety) or rings. The open valences of an alkylene need not be at opposite ends of the chain. Thus branched alkylene groups such as -CH(Me)-, -CH2CH(Me)15 and -C(Me)2- are also included within the scope of the term 'alkylenes', as are cyclic groups such as cyclopropan-1,1-diyl and unsaturated groups such as ethylene (-CH=CH-) or propylene (-CH2-CH=CH-). Where an alkylene group is described as optionally substituted, the substituents include those typically présent on alkyl groups as described herein.
Heteroalkylene refers to an alkylene group as described above, wherein one or more non-contiguous carbon atoms of the alkylene chain are replaced by -N(R)-, -O- or -S(O)x-, where R is H or a substituent group suitable for a secondary amino moiety and x is 0-2. For example, the group -Ο-(ΟΗ2)ι-3- is a ‘C2-C4’-heteroalkylene group, where one of the carbon atoms of the corresponding alkylene is replaced by O.
“Alkoxy” refers to a monovalent -O-alkyl group, wherein the alkyl portion has the specified number of carbon atoms. Alkoxy groups typically contain 1 to 8 carbon atoms (“CrCe alkoxy”), or 1 to 6 carbon atoms (“Ci-Ce alkoxy”), or 1 to 4 carbon atoms (“C1-C4 alkoxy”). For example, C1-C4 alkoxy includes methoxy, |ethoxy, isopropoxy, tert-butyloxy (i.e., - |
OCH3, -OCH2CH3, -OCH(CH3)2, -OC(CH3)3), and the like. Alkoxy groups are unsubstituted or substituted on the alkyl portion by the same groups that are described herein as suitable for alkyl.
In particular, alkoxy groups may be optionally substituted by one or more halo atoms, and in I particular one or more fluoro atoms, up to ihe total number of hydrogen atoms présent on the I alkyl portion. Such groups are referred to as “haloalkoxy” (or, where fluorinated, more specifically as “fluoroalkoxy”) groups having the specified number of carbon atoms and substituted by one or more halo substituents, Typically such groups contain from 1-6 carbon atoms, preferably 1-4 carbon atoms, and sometimes 1-2 carbon atoms, and 1, 2 or 3 halo atoms (i.e., “CrCe haloalkoxy”, “C1-C4 haloalkoxy” or “C1-C2 haloalkoxy”). More specifically, fluorinated alkoxy _ 12 groups may be specifically referred to as “fluoroalkoxy” groups, e.g., Ci-C6, C1-C4 or C1-C2 fluoroalkoxy groups, which are typically substituted by 1, 2 or 3 fluoro atoms. Thus, a C1-C4 fluoroalkoxy includes trifluoromethyloxy (-OCF3), difluoromethyloxy (-OCF2H), fluoromethyloxy (-OCFH2), difluoroethyloxy (-OCH2CF2H), and the like.
Similarly, “thioalkoxy” refers to a monovalent-S-alkyl group, wherein the alkyl portion has the specified number of carbon atoms and is optionally substituted on the alkyl portion by the same groups that are described herein as suitable for alkyl. For example, a C1-C4 thioalkoxy includes -SCH3 and -SCH2CH3.
Cycloalkyl refers to a non-aromatic, saturated carbocyclic ring system containing the 10 specified number of carbon atoms, which may be a monocyclic, spirocyclic, bridged or fused bicyclic or polycyclic ring system that is connected to the base molécule through a carbon atom of the cycloalkyl ring. Typically, the cycloalkyl groups of the invention contain 3 to 12 carbon atoms (“C3-C12 cycloalkyl”), preferably 3 to 8 carbon atoms (“C3-C8 cycloalkyl”). Partially unsaturated carbocyclic rings may be referred to as “cycloalkenyl” rings. Représentative examples of cycloalkyl and cycloalkenyl rings include, e.g., cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptatriene, adamantane, and the like. Cycloalkyl groups are unsubstituted or substituted by the same groups that are described herein as suitable for alkyl, except that cycloalkyl rings may also be substituted by alkyl groups having the specified number of carbon atoms, which may 20 be further optionally substituted as described herein.
Illustrative examples of cycloalkyl and cycloalkenyl rings include, but are not limited to, the following:
cydopropane cyclobutane cyclopentane (cyclopropanyl) (cydobutanyf) (cydopentanyl)
cyclopentene cydohexane cydohexene (cydopentenyl) (cydohexanyl) (cydohexanyl)
cycloheptane (cydoheptanyt) octahydrolndane (octahydroîndanyl) octahydropentalene (octahydropentalenyl)
I decahydronaphthafene (decahydronapthalenyl) cydoheptene (cycloheptenyl)
adamantane bicydo[1.1.1]pentane bicydo[2J.1]heptane · —bicyclo[2.2.2]octane (adamantyt) (bicydo[1.1.1]pentanyl) (blcyclo[2.2.1]heptanyl) (bicydo[2.2.2]octanyl)
Cycloàlkylalkyl is used to describe a cycloalkyl ring, typically â C3-C8 cycloalkyl, which is connected to the base molécule through an alkylene linker, typically a C1-C4 alkylene.
Cycloalkylalkyl groups are sometimes described by the total number of carbon atoms in the — 13 carbocyclic ring and linker, and typically contain from 4-12 carbon atoms (“C4-C12 cycloalkylalkyl”). Thus a cyclopropylmethyl group is a C4-cycloalkylalkyl group and a cyclohexylethyl is a Ce-cycloalkylalkyl. Cycloalkylalkyl groups are unsubstituted or substituted on the cycloalkyl and/or alkylene portions by the same groups that are described herein as suitable for alkyl groups.
The terms heterocyclyl or heterocyclic may be used interchangeably to refer to a non-aromatic, saturated ring system containing the specified number of ring atoms, including at least one heteroatom selected from N, O and S as a ring member, where ring S atoms are optionally substituted by one or two oxo groups (i.e., S(O)X, where x is 0, 1 or 2) and where the heterocyclic ring is connected to the base molécule via a ring atom, which may be C or N. Where 10 specifically indicated, such heterocyclic rings may be partially unsaturated. Heterocyclic rings include rings which are spirocyclic, bridged, or fused to one or more other heterocyclic or carbocyclic rings, where such spirocyclic, bridged, or fused rings may themselves be saturated, partially unsaturated or aromatic to the extent unsaturation or aromaticity makes Chemical sense, provided the point of attachment to the base molécule is an atom of the heterocyclic portion of 15 the ring system. Preferably, heterocyclic rings contain 1 to 4 heteroatoms selected from N, O, and S(O)q as ring members, and more preferably 1 to 2 ring heteroatoms, provided that such heterocyclic rings do not contain two contiguous oxygen atoms.
Heterocyclyl groups are unsubstituted or substituted by suitable substituent groups, for example the same groups that are described herein as suitable for alkyl, except that heterocycyl 20 rings may also be substituted by alkyl groups having the specified number of carbon atoms, which may be further optionally substituted as described herein. Such substituents may be présent on the heterocycylic ring attached to the base molécule, or on a spirocyclic, bridged or fused ring attached thereto. In addition, ring N atoms are optionally substituted by groups suitable for an amine, e.g., alkyl, acyl, carbamoyl, sulfonyl, and the like.
Heterocycles typically include 3-12 membered heterocyclyl groups, 3-10 membered heterocyclyl groups, 3-8 membered heterocyclyl groups, and more preferably 3-6 membered heterc|cyclyl groups, in accordance with the définition herein. | i i
Illustrative examples of saturated heterocycles include, but are not limited to:
oxirane thiarane aziridine (oxiranyl) (thiaranyl) (aziridinyl) oxetane thiatane (oxetanyl) (thiatanyl) azetidine (azetidinyl) tetrahydrofuran (tetrahydrofuranyl)
tetrahydrothiophene pyrrolidine tetrahydropyran tetrahydrothiopyran piperidine (tetrahydrothiophenyl) (pyrrolidinyl) (tetrahydropyranyl) (tetrahydrothiopyranyl) (piperidinyl)
piperazine thiomorpholine (piperazinyl) (thiomorpholinyl)
1,4-dioxane 1,4-oxathiarane (1,4-dioxanyl) (1,4-oxathiaranyl) morpholine 1,4-dithiane (morpholinyl) (1,4-dithianyl)
oxepane (oxepanyl) thiepane (thiepanyl) azepane (azepanyl)
1,4-dioxepane (1,4-dioxepanyl)
1,4-oxathiepane (1,4-oxathiepanyl)
1,4-oxaazepane (1,4-oxaazepanyl)
1,4-thieazepane (1,4-thieazapanyl)
1,4-diazepane (1,-diazepanyl)
1,4-dithiepane (1,4-dithiepanyl)
Illustrative examples of partially unsaturated heterocycles include, but are not limited to:
2H-pyran 3,4-dihydro-2H-pyran 5,6-dihydro-2H-pyran (2H-pyranyi) (3,4-dihydro-2H-pryanyl) (5,6-dihydro-2H-pyranyl)
1,2,3,4-tetrahydropyridine · 1,2,5,6-tetrahydropyridine (1,2,3,4-tetrahydropyridinyl) (1,2,5,6-tetrahyrodpyridinyl)
Illustrative examples of bridged, fused and spiro heterocycles include, but are not limited to:
2-azabicyclo- 8-azabicycIo[3.1.0]hexane [2.2.1]octane
2-azabicyclo[2.2.1 ]heptane
2-oxa-5-azabicyclo[2.2.1]heptane
3-oxa-8-azabicyclo- 3-azabicyclo[3.2.1]octane [3.1.0]hexane
3-oxooctahydroindolizine
1,1 -dioxidohexahydropyrido[1,2]thiazolo[2,3-a]pyridine
3-oxohexahydro[1.3]oxazolo[3,4-a]pyridine
2,2-dioxido-2-thiaspiro[3.5]nonane
1,1 -dioxidohexahydropyrido[1,2-d][1,3,4]oxathiazine
In some embodiments, heterocyclic groups contain 3-12 ring members, including both carbon and non-carbon heteroatoms, and frequently 3-8 or 3-6 ring members. In certain preferred embodiments, substituent groups comprising 3-12 membered heterocycles are selected from 5 azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, diazepanyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl and thiomorpholinyl rings, each of which are optionally substituted as described for the particular substituent group, to the extent such substitution makes Chemical sense.
In some embodiments of the présent invention, cycloalkyl and heterocyclyl groups are 10 optionally substituted by one or more optional substituents, and preferably by 1 to 3 optional substituents, which are independently F, OH, CN, NR’2 (where each R’ is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl), C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fiuoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fiuoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2.
It is understood that no more than two N, O or S atoms are ordinarily connected sequentially, except where an oxo group is attached to N or S to form a nitro or sulfonyl group, or in the case of certain Leteroaromatic rings, such as triazine, triazole, tetrazole, oxadiazole, thiadiazole, and the like.
The term heterocyclylalkyl may be used to describe a heterocyclic group ofthe specified 20 size that is connected to the base molécule through an alkylene linker of the specified length.
Typically, such groups contain an optionally substituted 3-12 membered heterocycle attached to the base molécule through a C1-C4 alkylene linker. Where so indicated, such groups are optionally substituted on the alkylene portion by the same groups that are described herein as suitable for alkyl groups and on the heterocyclic portion by groups described as suitable for 25 heterocyclic rings.
16
Aryl or “aromatic” refer to an optionally substituted monocyclic or fused bicyclic or polycyclic ring system having the well-known characteristics of aromaticity, wherein at least one ring contains a completely conjugated pi-electron system. Typically, aryl groups contain 6 to 20 carbon atoms (C6-C20 aryl) as ring members, preferably 6 to 14 carbon atoms (Ce-Cu aryl) or 5 more preferably, 6 to 12 carbon atoms (C6-C12 aryl). Fused aryl groups may include an aryl ring (e.g., a phenyl ring) fused to another aryl or heteroaryl ring or fused to a saturated or partially unsaturated carbocyclic or heterocyclic ring, provided the point of attachment to the base molécule on such fused ring Systems is an atom of the aromatic portion of the ring system. Examples, without limitation, of aryl groups include phenyl, biphenyl, naphthyl, anthracenyl, 10 phenanthrenyl, indanyl, indenyl, and tetrahydronaphthyl. The aryl group is unsubstituted or substituted as further described herein.
Similarly, heteroaryl or “heteroaromatic” refer to monocyclic or fused bicyclic or polycyclic ring Systems having the well-known characteristics of aromaticity that contain the specified number of ring atoms and include at least one heteroatom selected from N, O and S as 15 a ring member in an aromatic ring. The inclusion of a heteroatom permits aromaticity in 5-membered rings as well as 6-membered rings. Typically, heteroaryl groups contain 5 to 20 ring atoms (“5-20 membered heteroaryl”), preferably 5 to 14 ring atoms (“5-14 membered heteroaryl”), and more preferably 5 to 12 ring atoms (“5-12 membered heteroaryl”). Heteroaryl rings are attached to the base molécule via a ring atom ofthe heteroaromatic ring, such that aromaticity is 20 maintained. Thus, 6-membered heteroaryl rings may be attached to the base molécule via a ring C atom, while 5-membered heteroaryl rings may be attached to the base molécule via a ring C or N atom. Heteroaryl groups may also be fused to another aryl or heteroaryl ring or fused to a saturated or partially unsaturated carbocyclic or heterocyclic ring, provided the point of attachment to the base molécule on such fused ring Systems is an atom of the heteroaromatic 25 portion of the ring system. Examples of unsubstituted heteroaryl groups often include, but are not limited to, pyrrole, furan, thiophene, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, triazole, oxadiazole, thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pfyrazine, benzofuran, benzothiophene, indole, benzimidazole, indazole, quinoline, isoquinoline, purine, triazine, naphthryidine and carbazole. In frequent preferred embodiments, 5- or 6-membered 30 heteroaryl groups are selected from the group consisting of pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, isoxazoiyl, oxazolyl, isothiazolyl, thiazolyl, triazolyl, pyridinyl and pyrimidinyl, pyrazinyl or pyridazinyl rings. The heteroaryl group is unsubstituted or substituted as further described herein.
Aryl and heteroaryl moieties described herein as optionally substituted may be substituted 35 by one or more substituent groups, which are selected independently unless otherwise indicated. The total number of substituent groups may equal the total number of hydrogen atoms on the aryl, heteroaryl or heterocyclyl moiety, to the extent such substitution makes Chemical sense and aromaticity is maintained m the case of aryl and heteroaryl rings. Optionally substituted aryl or heteroaryl groups typically contain from 1 to 5 optional substituents, sometimes 1 to 4 optional substituents, preferably 1 to 3 optional substituents, or more preferably from 1-2 optional substituents.
Optional substituent groups suitable for use with aryl and heteroaryl rings include, but are not limited to: Ci-Ce alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, C6-C12 aryl and 5-12 membered heteroaryl; and halo, =0, -CN, -C(O)RX, -C02Rx, -C(O)NRxRy, - SRX, -SORX, -SO2RX, -SO2NRxRy, -NO2, -NRxRy, -N RxC(O)Ry, -NRxC(O)NRxRy, -NRXC(O)ORX, -NRxSO2Ry, -NRxSO2NRxRy, -ORX, -OC(O)RX and -OC(O)NRxRy; where each Rx and Ry is independently H, Ci-Ce alkyl, CrCe acyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, C6-Ci2 aryl, or 5-12 membered heteroaryl, or Rx and Ry may be taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl, each optionally containing 1,2 or 3 additional heteroatoms selected from O, N and S(O)Z where z is 0-2; each Rx and Ry is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, =0, =S, =N-CN, =N-OR', =NR', -CN, -C(O)R', -CO2R', -C(O)NR'2, SR', -SOR', -SO2R', -SO2NR'2, -NO2, -NR'2, -NR'C(O)R', -NR'C(O)NR'2, -NR'C(O)OR', -NR'SO2 R', -NR'SO2NR'2, -OR', -OC(O)R' and -OC(O)NR'2, wherein each R' is independently H, Ci-C8 alkyl, CrCe acyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, C6-C12 aryl, or 5-12 membered heteroaryl; and each said Ci-Ce alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, C6-C12 aryl and 5-12 membered heteroaryl is optionally substituted as further defined herein.
In typical embodiments, optional substitution on aryl, heteroaryl and heterocyclyl rings includes one or more substituents, and preferably 1 to 3 substituents, independently selected from the group consisting of halo, CrCe alkyl, -OH, Ci-Ce alkoxy, -CN, =0, -C(O)RX, -COORX, -OC(O)kx, -C(O)NRxRy, -NRxC(O)Ry, -SRX, -1
SORX, -SO2RX, -SO2NRxRy, -NO2, -NRxRy, -NRxC(O)Ry, -NRxC(O)NRxRy, -NRxC(O)ORy NRxSO2Ry, -NRxSO2NRxRy, -0C(0)Rx, -OC(O)NRxRy, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, C6-C12 aryl, 5-12 membered heteroaryl, -O-(C3-Cb cycloalkyl),-0-(3-12 membered । heterocyclyl), -O-(C6-Ci2 aryl) and -0-(5-12 membered heteroaryl); where each Rx and Ry is i independently H or C1-C4 alkyl, or Rx and Ry may be taken together with the N to which they are attached form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S(O)q where q is 0-2; and wherein each said CrCe alkyl, CrCe alkoxy, C3-C8 cycloalkyl, 3-12 membered heterocyclyl, C6-C12 aryl, 5-12 membered heteroaryl, -O-(C3-Ce cycloalkyl),-0-(3-12 membered _ 18 heterocyclyl), -O-(Ce-Ci2 aryl) and -0-(5-12 membered heteroaryl) that is described as an optional substituent or is part of Rx or Ry is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, -OH, =0, C1-C4 alkyl, C1-C4 alkoxy, Οι-Ce haloalkyl, Ci-Cs hydroxyalkyl, C1-C4 aIkoxy-Ci-Ce alkyl, -CN, -NH2, -NH(Ci-C4 5 alkyl), -N(Ci-C4 alkyl)2 and N-pyrrolidinyl.
Examples of monocyclic heteroaryl groups include, but are not limited to:
ô | ô | ô | ô N | |
pyrrole | furan | thiophene | pyrazole | imidazole |
(pyrrolyl) | (furanyl) | (thiophenyl) | (pyrazolyl) | (imidazolyl) |
/A GN | û N | GN | ô 'L- N | A N |
isoxazole | oxazole | isothiazole | thiazolyl | 1,2,3-triazole |
(isoxazolyl) | (oxazolyl) | (isothiazolyl) | (thiazolyl) | (1,2,3-triazolyl) |
1,3,4-triazole (1,3,4-triazolyl)
1-oxa-2,3-diazole (1-oxa-2,3-diazolyl)
-oxa-2,4-diazole (1 -oxa-2,4-diazolyl)
N, ,N
1-oxa-2,5-diazole (1-oxa-2,5-diazolyl)
N-N
1-oxa-3,4-diazole (1-oxa-3,4-diazoIyi)
1-thia-2,3-diazole (1-thia-2,3-diazolyl)
1-thia-2,4-diazole (1-thia-2,4-diazolyl) _S.
N, ,N
1-thia-2,5-diazole (1-thia-2,5-diazolyl)
N-N
1-thia-3,4-diazole tetrazole (1-thia-3,4-diazolyl) (tetrazolyl) pyridine (pyridinyl) pyridazine (pyridazinyl) pyrimidine (pyrimidinyl)
pyrazine (pyrazinyl)
Illustrative examples of fused heteroaryl groups include, but are not limited to:
benzofuran benzothiophene (benzofüranyl) (benzothiophenyl)
(indolyl)
benzimidazole (benzimidazolyl)
indazole (indazolyl)
benzotriazole (benzotriazolyl) pyrrolo[2,3-b]pyridine pyrrolo[2,3-c]pyridine pyrrolo[3,2-c]pyridine (pyrrolo[2,3-b]pyridinyl) (pyrrolo[2,3-c]pyridinyl) (pyrrolo[3,2-c]pyridinyl)
pyrrolo[3,2-b]pyridine (pyrrolo[3,2-b]pyridinyl) imidazo[4,5-b]pyridine imidazo[4,5-c]pyridine pyrazolo[4,3-d]pyridine (imidazo[4,5-b]pyridinyl) (imidazo[4,5-c]pyridinyl) (pyrazolo[4,3-d]pyidinyl)
pyrazolo[4,3-c]pyridine pyrazoio[3,4-c]pyridine pyrazolo[3,4-b]pyridine (pyrazolo[4,3-c]pyidinyl) (pyrazolo[3,4-c]pyidinyl) (pyrazolo[3,4-b]pyidinyl) isoindole (isoindolyi)
indazole purine (indazolyl) (purinyl) indolizine imidazo[1,2-a]pyridine imidazo[1,5-a]pyridine (indolininyl) (imidazo[1,2-a]pyridinyl) (imidazo[1,5-a]pyridinyl)
pyrazolo[1,5-a]pyridine (pyrazolo[1,5-a]pyridinyl) pyrrolo[1,2-b]pyridazine (pyrroio[1-2,b]pyridazinyl) imidazo[1,2-c]pyrimidine (imidazo[1,2-c]pyrimidinyl)
quinoline (quinolinyl)
isoquinoline (isoquinolinyl)
cinnoline (cinnolinyl)
quinazoline (azaquinazoline)
quinoxaline (quinoxalinyl)
1,6-naphthyridine (1,6-naphthyridinyl)
1,7-naphthyridine (1,7-naphthyridinyl)
1,8-naphthyridine (1,8-naphthyridinyl) phthalazine (phthalazinyl)
1,5-naphthyridine (1,5-naphthyridinyl)
2,6-naphthyridine (2,6-naphthyridinyl)
2,7-naphthyridine (2,7-naphthyridinyl)
pyrido[3,2-d]pyrimidine (pyrido[3,2-d]pyrimidinyl) pyrido[4,3-d]pyrimidine (pyrido[4,3-d]pyrimidinyl) pyrido[3,4-d]pyrimidine (pyrido[3,4-d]pyrimidinyl)
pyrido[2,3-d]pyrimidine (pyrido[2,3-d]pyrimidinyl)
pyrido[2,3-b]pyrazine (pyrido[2,3-b]pyrazinyl)
pyrido[3,4-b]pyrazine (pyrido[3,4-b]pyrazinyl)
pyrimido[5,4-d]pyrimidine (pyrimido[5,4-d]pyrimidinyl) pyrazino[2,3-b]pyrazine (pyrazino[2,3-b]pyrazinyl) pyrimido[4,5-d]pyrimidine (pyrimido[4,5-d]pyrimidinyl)
An qrylalkyl group refers to an aryl group as described herein which is linked to the base molécule through an alkylene or similar linker. Arylalkyl groups are described by the total number of carbon atoms in the ring and linker. Thus, a benzyl group is a Cyarylalkyl group and a 5 phenylethyl is a Cs-arylalkyl. Typically, arylalkyl groups contain 7-16 carbon atoms (“C7-C16 arylalkyl”), wherein the aryl portion contains 6-12 carbon atoms and the alkylene portion contains 1-4 carbon atoms. Such groups may also be represented as -Ci-C4alkylene-C6-Ci2aryl.
Heteroarylalkyl refers to a heteroaryl group as described above that is attached to the base molécule through an alkylene linker, and differs from arylalkyl in that at least one ring atom 10 of the aromatic moiety is a heteroatom selected from N, O and S. Heteroarylalkyl groups are sometimes described herein according to the total number of non-hydrogen atoms (i.e., C, N, S and O atoms) in the ring and linker combined, excluding substituent groups. Thus, for example, pyridinylmethyl may be referred to as a “C7”-heteroarylalkyl. Typically, unsubstituted heteroarylalkyl groups contain 6-20 non-hydrogen atoms (including C, N, S and O atoms), wherein the heteroaryl portion typically contains 5-12 atoms and the alkylene portion typically contains 1-4 carbon atoms. Such groups may also be represented as -C1-C4 aikylene-5-12 membered heteroaryl.
Similarly, “arylalkoxy” and “heteroarylalkoxy” refer to aryl and heteroaryl groups, attached to the base molécule through a heteroaikylene linker (i.e., -O-alkylene-), wherein the groups are described according to the total number of non-hydrogen atoms (i.e., C, N, S and O atoms) in the ring and linker combined. Thus, -O-CHz-phenyl and -O-CHz-pyridinyl groups would be referred to as Ce-arylalkoxy and Ce-heteroarylaikoxy groups, respectively.
Where an arylalkyl, arylalkoxy, heteroarylalkyl or heteroarylalkoxy group is described as optionally substituted, the substituents may be on either the divalent linker portion or on the aryl or heteroaryl portion of the group. The substituents optionally présent on the alkylene or heteroaikylene portion are the same as those described above for alkyl or alkoxy groups generally, while the substituents optionally présent on the aryl or heteroaryl portion are the same as those described above for aryl or heteroaryl groups generally.
Hydroxy refers to an OH group.
“Acyloxy” refers to a monovalent group -OC(O)alkyl, wherein the alkyl portion has the specified number of carbon atoms (typically Οι-Ce, preferably Ci-Ce or C1-C4) that are optionally substituted by groups suitable for alkyl. Thus, C1-C4 acyloxy includes an -OC(O)Ci-C4 alkyl substituent, e.g., -OC(O)CH3.
“Acyl” refers to a monovalent group -C(O)alkyl, wherein the alkyl portion has the specified number of carbon atoms (typically CrCs, preferably Ci-Ce or C1-C4) and may be optionally substituted by groups suitable for alkyl, e.g., by F, OH or alkoxy. Thus, optionally substituted -C(O)Ci-C4 alkyl includes unsubstituted acyl groups, such as -C(O)CH3 (i.e., acetyl) and -C(O)CH2CH3 (i|e., propionyl), as well as substituted acyl groups èuch as -C(O)CF3 (trifluoroacetyl), -C(O)CH2OH (hydroxyacetyl), -C(O)CH2OCH3 (methoxyacetyl), -C(O)CF2H (difluoroacetyl), and the like.
“Acylamino” refers to a monovalent group, -NHC(O)alkyl or -NRC(0)alkyl, wherein the alkyl portion has the specified number of carbon atoms (typically Ci-Ce, preferably Ci-Ce or C1-C4) and is optionally substituted by groups suitable for alkyl. Thus, C1-C4 acylamino includes an NHC(O)Ci-C4 alkyl substituent, e.g., -NHC(O)CH3.
“Aryloxy” or “heteroaryloxy” refer to optionally substituted O-aryl or O-heteroaryl, in each case where aryl and heteroaryl are as further defined herein.
‘Arylamino” or “heteroarylamino” refer to an optionally substituted -NH-aryl, -NR-aryl, NH-heteroaryl or -NR-heteroaryl, m each case where aryl and heteroaryl are as further defined herein and R represents a substituent suitable for an amine, e.g., an alkyl, acyl, carbamoyl or sulfonyl group, or the like.
Cyano refers to a -C=N group.
Unsubstituted amino refers to a group -NH2. Where the amino is described as substituted or optionally substituted, the term includes groups of the form -NRxRy, where each or Rx and Ry is independently H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, acyl, thioacyl, aryl, heteroaryl, cycloalkylalkyl, arylalkyl or heteroarylalkyl, in each case having the specified number of atoms and optionally substituted as described herein. For example, “alkylamino refers to a group -NRxRy, wherein one of Rx and Ry is an alkyl moiety and the other is H, and “dialkylamino” refers to -NRxRy wherein both of Rx and Ry are alkyl moieties, where the alkyl moieties having the specified number of carbon atoms (e.g., -NH-C1-C4 alkyl or-N(Ci-C4 aikyl)2). Typically, alkyl substituents on amines contain 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, or more preferably 1 to 4 carbon atoms. The term also includes forms wherein Rx and Ry are taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each of which may itself be optionally substituted as described herein for heterocyclyl or heteroaryl rings, and which may contain 1 to 3 additional heteroatoms selected from N, O and S(O)X where x is 0-2 as ring members, provided that such rings do not contain two contiguous oxygen atoms.
“Halogen” or “halo” refers to fluoro, chloro, bromo and iodo (F, Cl, Br, I). Preferably, halo refers to fluoro or chloro (F or Cl).
Optional or optionally means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs and instances in which it does not.
The terms “optionally substituted” and “substituted or unsubstituted” may be used interchangeably to indicate th^t the particular group being described may hâve no nor^-hydrogen substituents (i.e., unsubstituted), or the group may hâve one or more non-hydrogen substituents (i.e., substituted). If not otherwise specified, the total number of substituents that may be présent is equal to the number of H atoms présent on the unsubstituted form of the group being described. Where an optional substituent is attached via a double bond, such as an oxo (=0) substituent, the group occupies two available valences, so the total number of other substituents that are included is reduced by two.
Frequently, optionally substituted groups are substituted by 1 or more substituents independently selected from the list of optional substituents. In some embodiments, optionally substituted groups are substituted by 1,2, 3, or more than 3 substituents independently selected
from the list of optional substituents. For example, an alkyl group described as optionally substituted by Rx means the alkyl group is optionally substituted by 1 or more Rx substituents independently selected from the list of Rx substituents provided for the alkyl group. Where deemed necessary, the description of an optionally substituted group herein may be revised to 5 state that the group is optionally substituted by 1 or more of the indicated substituents. In the case where optional substituents are selected from a list of alternatives, the selected groups are independently selected and may be the same or different.
Throughout the disclosure, it will be understood that the number and nature of optional substituent groups will be limited to the extent that such substitutions make Chemical sense. 10
In one aspect, the invention provides a compound of Formula (I):
or a pharmaceutically acceptable sait thereof, wherein: A is N or CH;
R1 is H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl or C1-C2 alkoxy, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
U is NR2 or CR3;
V is N or CR4 when U is N R2; and
V is NR5 when U is CR3;
X is CR6 or N; | |
Y is CR7 or N; .....
Z is CR8 or N; R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21; R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, C(O)Ra, C(O)NRb2, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20, each said C3-C8 cycloalkyl _ 24 and 3-6 membered heterocyclyl is optionally substituted by R21, Ra is C1-C2 alkyl, and each Rb is independently H or C1-C2 alkyl; and .
R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20; or
R2 can be taken together with R4, or R3 can be taken together with R5, to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)m as a ring member, which ring is optionally substituted by R21;
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3;
R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or
C1-C2 fluoroalkoxy, where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 fluoroalkoxy is optionally substituted by R20;
R9 is H, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
Q is NR11 or O; or
Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 or O as a ring member, which ring is optionally further substituted by R10;
R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or
CONR18R19, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20, SO2R14, SO2NR15R18, COR17, COOR17 or CONR18R19;
R14 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R15 and R16 is independently H or CH3;
R17is C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C3 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20 and each said C3-Ce cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
| each R18 and R19 is independently H, c|i-C4 alkyl or C1-C4 fluoroalkyl, where each said
C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NR22R23, C3-Ce
I 30 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered i heterocyclyl is optionally substituted by R21; I each R21 is independently F, OH, CN, N R22 R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2;
each R22 and R23 is independently H, Ci-C3 alkyl, Ci-C3 fluoroalkyl, C3-Cs cycloalkyl or 3-6 membered heterocyclyl, where each said Ci-C3 alkyl and Ci-C3 fluoroalkyl is optionally further
substituted by OH, C1-C2 alkoxy or C1-C2 fluoroalkoxy and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally further substituted by F, OH, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy; or
R22 and R23 may be taken together with the nitrogen atom to which they are attached to 5 form an azetidinyl ring, where said ring is optionally substituted by F, OH, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy;
R24 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R25, SO2NR26R27, COR28, COOR28 or CONR29R30;
R25 is C1-C4 alkyl or C1-C4 fluoroalkyl; .
each R26 and R27 is independently H or CH3;
R28 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2!
each R29 and R30 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, 15 CN, NH2, NHCH3 or N(CH3)2;
m is 0,1 or 2;
n is 0,1, 2, 3 or 4;
p is 1, 2 or 3; and q is 0,1,2 or 3;
wherein the sum of p and q is an integer from 1 to 4.
In another aspect, the invention provides a compound of Formula (II):
I or a pharmaceutically acceptable sait thereof, whèrein:
I R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl,। where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
UisNR2ôrCR3;
V is N or CR4 when U is NR2; and '
V is NR5 when U is CR3;
X is CR6 or N;
Y is CR7 or N;
Z is CR8 or N; R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20;
R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
RB is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3;
R7 and R8 are independently H, F, Cl, CN, CrC2 alkyl, Ci-C2 fluoroalkyl, Ci-C^ alkoxy or Ci-C2 fluoroalkoxy, where each said CrC2 alkyl, Ci-C2 fluoroalkyl, CrC2 alkoxy and Ci-C2 fluoroalkoxy is optionally substituted by R20;
R9is H, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, Ci-C2 alkyl or Ci-C2 fluoroalkyl, where each said CrC2 alkyl and Ci-C2 fluoroalkyl is optionally substituted by R20;
Q is NR11 or O; or
Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 or O as a ring member, which ring is optionally further substituted by R10;
R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19;
R14 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R15 and R16 is independently H or CH3;
R17 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
eaçh R18 and R19 is independently H, C1-C4 alkyl or Ci-C|4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, Ci-C2 alkoxy, Ci-C2 fluoroalkoxy, CN or N R22R23;
each R21 is independently F, OH, CN, NR22R23, C1-C4 alkyl, |Ci-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2;
each R22 and R23 is independently H, Ci-C2 alkyl or Ci-C2 fluoroalkyl; or
R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH;
n is 0,1, 2, 3 or 4;
p is 1, 2 or 3; and qisO, 1,2 or 3;
wherein the sum of p and q is an integer from 1 to 4.
In another aspect, the invention provides a compound of Formula (III):
or a pharmaceutically acceptable sait thereof, wherein:
R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
U is NR2 or CR3;
V is N or CR4 when U is NR2; and
V is NR5 when U is CR3;
X is CR6 or N;
Y is CR7 or N;
Z is CR8 or N;
R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fiuoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fiuoroalkoxy is optionally substituted by R20;
R5 is H, Ci-^4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl| and C1-C4 fluoroalkyl is optionally substituted by R20;
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3;
R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxyl where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 25 fiuoroalkoxy is optionally substituted by R20;
R9isH, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
Q is NR11 or O; or
Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 or O as a ring member, which ring is optionally further substituted by R10;
R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19;
R14 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R15 and R16 is independently H or CH3;
R17is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20; each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, Ci-C2 alkoxy, CrC2 fluoroalkoxy, CN or N R22 R23;
each R21 is independently F, OH, CN, NR^R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2!
each R22 and R23 is independently H, Ci-C2 alkyl or Ci-C2 fluoroalkyl; or
R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH;
n is 0,1, 2, 3 or 4;
p is 1, 2 or 3; and q is 0,1,2 or 3;
wherein the sum of p and q is an integer from 1 to 4.
In another aspect, the invention provides a compound of Formula (IV):
or a pharmaceutically acceptable sait thereof, wherein:
R1 is H, F, Cl, CN, Ci-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
U is NR2 or CR3;
V is N or CR4 when U is N R2; and
V is NR5 when U is CR3; .
XisCR6orN;
Y is CR7 or N;
Z is CR8 or N;
R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20; and
R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-G4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20; or
R2 can be taken together with R4, or R3 can be taken together with R5, to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(0)m as a ring member, which ring is optionally substituted by R21;
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3;
R7 and R8 are independently H, F, Cl, CN, CrC2 alkyl, Ci-C2 fluoroalkyl, Ci-C2 alkoxy or Ci-C2 fluoroalkoxy, where each said CrC2 alkyl, Ci-C2 fluoroalkyl, Ci-C2 alkoxy and Ci-C2 fluoroalkoxy is optionally substituted by R20;
R9is H, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, Ci-C2 alkyl or Ci-C2 fluoroalkyl, where each said Ci-C2 alkyl and CrC2 fluoroalkyl is optionally substituted by R20;
Q is NR11 or O; or
Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 or O as a ring member, which ring is optionally further substituted bjy R10; |
R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19; - ........
R14 is C1-C4 alkyl or C1-C4 fluôroalkyl;i each R15 and R16 is independently H or CH3;I
R17is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;l each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkÿl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, Ci-C2 alkoxy, Ci-C^ fluoroalkoxy, CN or NR22R23;
each R21 is independently F, OH, CN, NR^R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2;
each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl; or
R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH;
R24 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R25, SO2NR26R27, COR28, COOR28 or CONR29R30;
R25 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R26 and R27 is independently H or CH3;
R28 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2;
each R29 and R30 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, 15 CN, NH2, NHCH3 or N(CH3)2;
m is 0,1 or 2;
n is 0,1, 2, 3 or 4;
p is 1,2 or 3; and q is 0,1,2 or 3;
wherein the sum of p and q is an integer from 1 to 4.
In another aspect, the invention provides a compound of Formula (V):
or a pharmaceutically acceptable sait thereof, wherein:
R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
UisNR2orCR3;
V is N or CR4 when U is NR2; and , : :
V is NR5 when U is CR3; ‘ -
X is CR6 or N;
Y is CR7 or N;
ZisCR8orN; - : ·
R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20; and
R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20; or
R2 can be taken together with R4, or R3 can be taken together with R5, to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)m as a ring member, which ring is optionally substituted by R21;
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3;
R7 and R8 are independently H, F, Cl, CN, Ci-C2 alkyl, Ci-C2 fluoroalkyl, Ci-C2 alkoxy or Ci-C2 fluoroalkoxy, where each said Ci-C2 alkyl, Ci-C2 fluoroalkyl, Ci-C2 alkoxy and Ci-C2 fluoroalkoxy is optionally substituted by R20;
R9is H, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, Ci-C2 alkyl or Ci-C2 fluoroalkyl, where each said CrC2 alkyl and Ci-C2 fluoroalkyl is optionally substituted by R20;
Q is NR11 or O; or
Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 or O as a ring member, which ring is optionally further substituted by R10;
R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19;
| R14 is C1-C4 alkyl or C1-C4 fluoroalkyl; | each R15 and R18 is independently H or CH3;
R17 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is
I optionally substituted by R20; |
I each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, Ci-C2 alkoxy, Ci-C2 fluoroalkoxy, CN or NR^R23;
each R21 is independently F, OH, CN, N R22 R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2;
_ 32 each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroaikyl; or
R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH;
R24 is H, C1-C4 alkyl, C1-C4 fluoroaikyl, SO2R25, SO2NR26R27, COR28, COOR28 or
CONR29R3°;
R25 is C1-C4 alkyl or C1-C4 fluoroaikyl;
each R26 and R27 is independently H or CH3;
R28is C1-C4 alkyl or C1-C4 fluoroaikyl, where each said C1-C4 alkyl and C1-C4 fluoroaikyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2!
each R29 and R30 is independently H, C1-C4 alkyl or C1-C4 fluoroaikyl, where each said
C1-C4 alkyl and C1-C4 fluoroaikyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2;
m is 0,1 or 2;
n is 0,1,2, 3 or 4;
p is 1,2 or 3; and q is 0,1, 2 or 3;
wherein the sum of p and q is an integer from 1 to 4.
In frequent embodiments of Formula (IV) and Formula (V), R2 is taken together with R4, or R3 is taken together with R5, to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)m as a ring member, which ring is optionally substituted by R21.
In some embodiments, the compounds of Formulae (I) to (V) hâve the absolute stereochemistry as shown in one of Formulae (l-A), (l-B), (l-C) or (l-D); (ll-A), (ll-B), (ll-C) or (IID); (IIl-A), (lll-B), (lll-C) or (lll-D); (IV-A), (IV-B), (IV-C) or (IV-D); and (V-A), (V-B), (V-C) or (V-D):
(l-C) to (V-C) (l-D) to (V-D) wherein A in Formula (l-A) to (l-D) is N or CH; A in Formula (ll-A) to (ll-D) is replaced by N; A in Formula (lll-A) to (lll-D) is replaced by CH; A in Formula (IV-A) to (IV-D) is replaced by N; and A in Formula (V-A) to (V-D) is replaced by CH; or a pharmaceutically acceptable sait of one ofthe foregoing.
Each ofthe aspects and embodiments described herein with respectto Formula (I) is also applicable to compounds of Formulae (l-A), (l-B), (l-C) or (l-D).
Each of the aspects and embodiments described herein with respect to Formula (II) is also applicable to compounds of Formulae (ll-A), (II-B), (ll-C) or (ll-D).
Each of the aspects and embodiments described herein with respect to Formula (III) is also applicable to compounds of Formulae (lll-A), (lll-B), (lll-C) or (lll-D).
Each of the aspects and embodiments described herein with respect to Formula (IV) is also applicable to compounds of Formulae (IV-A), (IV-B), (IV-C) or (IV-D).
Each of the aspects and embodiments described herein with respect to Formula (V) is also applicable to compounds of Formulae (V-A), (V-B), (V-C) or (V-D).
In compounds of Formula (I), A is N or CH. In some embodiments, A is N. In other embodiments, A is CH.
In compounds of Formula (I), R1 is H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl or C1-C2 alkoxy, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In some embodiments, R^1 is F or Cl. In some such embodiments, R1 is F. In sJme such embodiments, R1 is Cl.
In compounds of Formula (I), U is NR2 or CR3; V is N or CR4 when U is NR2; and
V is NR5 when U is CR3. In some embodiments, U is NR2 and V is N or CR4. In some such embodiments, U is NR2 and V is CR4. In some such embodiments, U is NR2 and V is N. In some embodiments, U is CR3 and V is NR5.
In compounds of Formula (I), X is CR6 or N. In some embodiments, X is CR6. In some embodiments, X is N,
In compounds of Formula (I), Y is CR7 or N. In some embodiments, Y is CR7. In some embodiments, Y is N.
λ 34
In compounds of Formula (I), Z is CR8 or N. In some embodiments, Z is CR8. In some embodiments, Z is N.
In frequent embodiments of Formula (I), X is CR6, Y is CR7 and Z is CR8. In other embodiments of Formula (I), at least one ofX, Y and Z is N. . .. . - ________
In some embodiments of Formula (I), R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21.
In some such embodiments, R2 and R3 are H, C1-C5 alkyl or C1-C5 fluoroalkyl, where each 10 said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20. In other such embodiments, R2 and R3 are C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21.
In some embodiments of Formula (I), R2 is C1-C5 alkyl or C1-C5 fluoroalkyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20. In some embodiments of 15 Formula (I), R3 is C1-C5 alky or C1-C5 fluoroalkyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20.
In some embodiments of Formula (I), R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, C(O)Ra, C(O)NRb2, C3-C8 cycloalkyl or 3-6 membered heterocyclyl; where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally 20 substituted by R20, each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21, Ra is C1-C2 alkyl, and each Rb is independently H or C1-C2 alkyl.
In some such embodiments, R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20. In some such embodiments, R4 is C1-C4 alkyl or C1-C4 fluoroalkyl, 25 , where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some such embodiments, R20 is OH. In other such embodiments, R20 is C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where eacf| said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21.
In other such embodiments, R4 is C(O)Ra or C(O)NRb 2, where Ra is C1-C2 alkyl, and each 30 Rb is independently H or C1-C2 alkyl. In still other such embodiments, R4 is C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered I heterocyclyl is optionally substituted by R21. .
In some embodiments of Formula (I), R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20.
Iri other embodiments of Formula (I), R2 can be takeri together with R4, or R3 can be taken together with R5, to form a 5-7 membered heterocyclic ring, optionally containing an additional _ 35 heteroatom selected from NR24, O and S(O)m as a ring member, which ring is optionally substituted by R21. - - In some embodiments of Formula (I), R2 is taken together with R4 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24,0 and S(O)m 5 as a ring member, which ring is optionally substituted by R21. In some such embodiments, the 57 membered heterocyclic ring contains O as an additional heteroatom. In some such embodiments, the 5-7 membered heterocyclic ring contains NR24 as an additional heteroatom.
In some embodiments of Formula (I), R3 is taken together with R5to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24,0 and S(O)m 10 as a ring member, which ring is optionally substituted by R21. In some such embodiments, the 57 membered heterocyclic ring contains O as an additional heteroatom. In some such embodiments, the 5-7 membered heterocyclic ring contains NR24as an additional heteroatom.
In compounds of Formula (I), R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3. In some embodiments, R6 is F or Cl. In some such embodiments, R6 is F. In some such embodiments, 15 R6 is Cl. In some embodiments, R6 is H. In other embodiments, R6 is CN, CH3, CH2F, CHF2 or CF3.
In compounds of Formula (I), R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy, where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 fluoroalkoxy is optionally substituted by R20. In some such embodiments, 20 R7 is H. In some such embodiments, R8 is H. In some such embodiments, R7 and R8 are H.
In compounds of Formula (I), R9 is H, OH, NH2, NHCH3 or N(CH3)2- In preferred embodiments of Formula (I), R9 is OH.
In compounds of Formula (I), each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In 25 some embodiments, n is 0 and R10 is absent. In other embodiments, n is 1 or 2 and R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl. In some embodiments, n is 1 or 2 and R10 is independently F or CH3. | |
In some embodiments of Formula (I), Q is NR11 or O. In some embodiments, Q is O. In some embodiments, Q is O, p is 2 and q is 1. In some such embodiments, n is 0 and R10 is 30 absent. ί i
In other embodiments of Formula (I), Q is NR11. In some embodiments, Q is NR11] p is 2 and q is 1. In some such embodiments, R11 is SO2R14. In other such embodiments, R11 is COR17. In some such embodiments, n is 0 and R10 is absent.
In some embodiments of Formula (I), Q is CR12R13, where R12 and R13 are taken together 35 with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing — 36
NR11 or O as a ring member, which ring is optionally further substituted by R10. In some such embodiments, n is 0 and R10 is absent.
In compounds of Formula (I), R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally 5 substituted by R20, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19.
In some embodiments, R11 is SO2R14. In other embodiments, R11 is COR17. In still other embodiments, R11 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19. In some such embodiments, R11 is C1-C4 alkyl substituted by SÜ2R14or COR17. In some such 10 embodiments, R11 is C1-C4 alkyl substituted by R20.
In compounds of Formula (I), R14is C1-C4 alkyl or C1-C4 fluoroalkyl. In some embodiments, R14is C1-C4 alkyl. In some such embodiments, R14is C1-C2 alkyl. In some embodiments, R14is C1-C4 fluoroalkyl. In some such embodiments, R141SC1-C2fluoroalkyl. In particular embodiments, R14is CH3 orC2H5.
In compounds of Formula (I), each R15 and R16 is independently H or CH3.
In compounds of Formula (I), R17is C1-C4 alkyl, C1-C4 fluoroalkyl, C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20 and each said C3-C3 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21. In some embodiments, R17 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said 20 C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some embodiments, R17 is
C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C3-Ce cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21.
In compounds of Formula (I), each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20.
In compounds of Formula (I), each R20 is independently OH, C1-C2 alkoxy, C1-C2 fiuoroalkoxy, CN, N R22 R23, C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C3-Ce cycloalkyl and 3-6 membered heterocyclyl ijs optionally substituted by R21. |
In some embodiments, each R20 is independently OH, C1-C2 alkoxy, C1-C2 fiuoroalkoxy, CN or N R22R23. In some such embodiments, R20 is OH. In some such embodiments, R20 is OH, 30 C1-C2 alkoxy or NRZ2R23. In some such embodiments, R20 is OH, In some embodiments, R20 is i
C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C3-Ce cycloalkyl and 3-6 I membered heterocyclyl is optionally substituted by R21.
In compounds of Formula (I), each R21 is independently F, OH, CN, N R22R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fiuoroalkoxy, where each said C1-C4 alkyl, C1-C4 35 fluoroalkyl, C1-C4 alkoxy and C1-C4 fiuoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2. In some embodiments, each R21 is independently F, OH or C1-C4 alkyl.
_ 37
In some embodiments of Formula (I), each R22 and R23 is independently H, C1-C3 alkyl, C1-C3 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C3 alkyl and C1-C3 fluoroalkyl is optionally further substituted by OH, C1-C2 alkoxy or C1-C2 fluoroalkoxy and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally further substituted 5 by F, OH, Ci-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy.
In some such embodiments, each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl. In some such embodiments, each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl.
In some embodiments of Formula (I), R22 and R23 may be taken together with the nitrogen 10 atom to which they are attached to form an azetidinyl ring, where said ring is optionally substituted by F, OH, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy. In some such embodiments, R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F, OH or C1-C2 alkyl.
In compounds of Formula (I), R24 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R25, SO2NR26R27, 15 COR28, COOR28 or CONR29R30. In some embodiments, R24 is H or C1-C4 alkyl. In some embodiments, R24 is H or C1-C2 alkyl.
In compounds of Formula (I), R25 is C1-C4 alkyl or C1-C4 fluoroalkyl. In some embodiments, R25 is C1-C2 alkyl.
In compounds of Formula (I), each R26 and R27 is independently H or CH3.
In compounds of Formula (I), R28 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2. In some embodiments, R28is C1-C4 alkyl optionally substituted by OH or C1-C2 alkoxy. In some embodiments, R28is C1-C2 alkyl.
In compounds of Formula (I), each R29 and R30 is independently H, C1-C4 alkyl or C1-C4 25 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2. In some embodiments, each R29 | and R30 is independently H or C1-C4 alkyl where each said C1-C4 alkyl is optionally substituted by OH or C1-C2 alkoxy. In somë embodiments, each R29 and R30 is independently H or C1-C2 alkyl.
In compounds of Formula (I), m is 0,1 or 2. In some embodiments, m is 2.
30; In compounds of Formula (I), n is 0,1, 2, 3 or 4. In some embodiments, n is 0 and R10 is
I absent. In some embodiments, n is 1 or2. I
In compounds of Formula (I), p is 1, 2 or 3; wherein the sum of p and q is an integer from 1 to 4. In some embodiments, p is 2. In other embodiments, p is 1. In some embodiments, the sum of p and q is an integer from 1 to 3. . ____ ς : s — ___ — 38
In compounds of Formula (I), q is 0, 1, 2 or 3; wherein the sum of p and q is an integer from 1 to 4. In some embodiments, q is 1. In other embodiments, q is 0. In some embodiments, the sum of p and q is an integer from 1 to 3.
In some embodiments, p is 2 and q is 1. In other embodiments, p is 1 and q is 1. In other . 5 embodiments, p is 1 and q is 0. In further embodiments, the sum of p and q is an integer from 1 to 3.
In certain embodiments, the invention provides a compound of Formula (I), (l-A), (l-B), (ΙΟ) or (l-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: A is N; R1 10 is Cl; U is NR2 and V is CR4; R2 is C1-C5 alkyl; or R2 is i-CsH?; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 or C(OH)(CH3)2! X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14 ; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (I), (l-A), (l-B), (I15 C) or (l-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: A is N; R1 is Cl; U is CR3 and V is NR5; R3 is C1-C5 alkyl; or R3 is 1-C3H7; R5 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and 20 R10 is absent; p is 2; and q is 1.
In a preferred embodiment, the invention provides a compound of Formula (I), (l-A), (l-B), (l-C) or (l-D), or a pharmaceutically acceptable sait thereof, wherein: A is N; R1 is Cl; U is NR2; R2 is C1-C5 alkyl; or R2 is 1-C3H7; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8;
R8 is H; R9 is OH; Q is O; n is 0 and R10 is absent; p is 2; and q is 1.
In another preferred embodiment, the invention provides a compound of Formula (I), (IA), (I-|b), (l-C) or (l-D), or a pharmaceutically acceptable sait |thereof, wherein: A is N; R1 is Cl; U is NR2; R2 is C1-C5 alkyl; or R2 is 1-C3H7; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; X is CR6; R6 is F; Y is CR7; R7 is H; Z is 30 CR8; R8 is H; R9is OH; Q is NR11, where R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent;
p is 2; and q is 1. I
In another embodiment, the invention provides a compound of Formula (I), (l-A), (l-B), (ΙΟ) or (l-D), or a pharmaceutically acceptable sait thereof, wherein: A is N; R1 is Cl; U is NR2; R2 is C1-C5 alkyl; or R2 is 1-C3H7; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where R20 35 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; n is 0 and R10 is absent; p is 2; and q is 1.
— 39
In another preferred embodiment, the invention provides a compound of Formula (I), (ΙΑ), (l-B), (l-C) or (l-D), or a pharmaceutically acceptable sait thereof, wherein: A is CH; R1 is Cl; U is NR2; R2 is C1-C5 alkyl; or R2 is i-CsH?; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; X is CR6; R6 is F; Y is CR7; R7 is H;
Z is CR8; R8 is H; R9is OH; Q is NR11, where R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (I), (l-A), (l-B), (ΙΟ) or (l-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: A is CH; R1 10 is Cl; U is CR3 and V is NR5; R3 is C1-C5 alkyl; or R3 is i-C3H?; R5 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
Each ofthe aspects and embodiments described herein with respect to Formula (I) is also 15 applicable to compounds of Formulae (ll)-(XII) that are not inconsistent with such aspect or embodiment.
In compounds of Formula (II), R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In some embodiments, R1 is F or Cl. In some embodiments, R1 is F. In some embodiments, R1 is Cl.
In compounds of Formula (II), X is CR6 or N. In some embodiments, X is CR6. In some embodiments, X is N,
In compounds of Formula (II), Y is CR7 or N. In some embodiments, Y is CR7. In some embodiments, Y is N.
In compounds of Formula (II), Z is CR8 or N. In some embodiments, Z is CR8. In some 25 embodiments, Z is N.
In frequent embodiments of Formula (II), X is CR6, Y is CR7 and Z is CR8. In other embodiments |of Formula (II), at least one of X, Y and Z is N. |
In compounds of Formula (II), U is NR2 or CR3; V is N or CR4 when U is NR2; and V is NR5 when U is CR3. In some embodiments, U is NR2 and V is N or CR4. In some such 30 embodiments,! U is NR2 and V is CR4. In some such embodiments, U is NR2 and V is N. In other embodiments,! U is CR3 and V is NR5. I
In some embodiments of Formula (II), U is NR2and R2 is H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-Ce cycloalkyl and 3-6 membered heterocyclyl is ’ 35 optionally substituted by R21.
40
In compounds of Formula (II), R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl/where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21. — .
In some such embodiments, R2 is C1-C5 alkyl or C1-C5 fluoroalkyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20. In some such embodiments, R2 is C1-C5 alkyl optionally substituted by R20. In some such embodiments, R20 is OH. In particular embodiments, R2 is CH3, C2H5, n-CsH?, 1-C3H7, n-C4H9, S-C4H9, Î-C4H9, t-C4Hg, CHF2 or CH2CHF2 (i.e., methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, difluoromethyl or 10 difluoroethyl), each optionally substituted by R20. In spécifie embodiments, R2 is isopropyl or tertbutyl. In spécifie embodiments, R2 is isopropyl (i-CsH?) In some embodiments, R2 is C1-C5 alkyl or C1-C5 fluoroalkyl optionally substituted by R20 where R20is OH.
In other embodiments, R2 is C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21. In some such embodiments, R2 is 3-6 membered heterocyclyl optionally substituted by R21. In particular embodiments, R2 is oxetan-3-yl or azetidin-3-yI, each optionally substituted by R21. In spécifie embodiments, R2 is oxetan-3-yl. In other embodiments, R2 is C3-C8 cycloalkyl, where said C3-C8 cycloalkyl is optionally substituted by R21. In some such embodiments, R21 is F, OH or C1-C4 alkyl.
In some embodiments ofthe foregoing where U is NR2, V is N. In other embodiments of the foregoing where U is N R2, V is CR4.
In other embodiments of Formula (II), U is CR3 and R3 is H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is 25 optionally substituted by R21.
In some such embodiments, R3 is C1-C5 alkyl or C1-C5 fluoroalkyl, where each said C1-C5 alkyl and C1-C5 fluoroal|<yl is optionally substituted by R20. In some such embodiments, R3 is C1-C5 alkyl optionally substituted by R20. In some such embodiments, R20is OH or N R22 R23. In some such embodiments, R20 is OH. In some such embodiments, R3 is CH3, C2H5, n-CsH?, 1-C3H7, n-.
C4H9, S-C4H9, i-C4H9. t-C4H9, CHF2 or CH2CHF2, each optionally substituted bÿ R20. In spécifie embodiments, R3 is i-CsH/or t-C4H9(i.e., isopropyl or tert-butyl). In spécifie embodiments, R2 is isopropyl.
In other embodiments, R3 is C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21. In some 35 such embodiments, R3 is 3-6 membered heterocyclyl optionally substituted by R21. In particular embodiments, R3 is oxetan-3-yl or azetidin3-yl optionally substituted by R21. In some such embodiments, R21 is F, OH or C1-C4 alkyl. In spécifie embodiments, R3 is oxetan-3-yl. In other embodiments, R3 is C3-C8 cycloalkyl, where said C3-C8 cycloalkyl is optionally substituted by R21. In some such embodiments, R21 is F, OH or C1-C4 alkyl.
In the foregoing embodiments where U is CR3, V is NR8. —
In some embodiments of Formula (II), V is CR4 when U is NR2.
In compounds of Formula (II), R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20. In some embodiments, R4 is H. In other embodiments, R4 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally 10 substituted by R20. In some such embodiments, R4 is C1-C4 alkyl optionally substituted by R20. In some such embodiments, R20 is OH, OCH3, NH2, NHCH3 or NH(CH3)2. In some such embodiments, R20 is OH or NH2. In some such embodiments, R20 is OH. In certain embodiments, R4 is Ci-C2 alkyl optionally substituted by R20, where R20 is OH or NH2. In spécifie embodiments, R4 optionally substituted by R20 (i.e., R4-R20) is H, CH3, C2Hs, CH2OH, CH(OH)CH3, CH2CH2OH 15 or CH2NH2(i.e., methyl, ethyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl or aminomethyl). In some embodiments, R4 substituted by R20 is CH(OH)CH3 or C(OH)(CH3)2. In other such embodiments, R4 is C1-C4 fluoroalkyl optionally substituted by R20. In other embodiments, R4 is C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20.
In some embodiments of Formula (II), V is NR5 when U is CR3.
In compounds of Formula (II), R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some embodiments, R5 is H. In other embodiments, R5 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some such embodiments, R5 is C1-C4 alkyl 25 optionally substituted by R20. In other such embodiments, R5 is C1-C4 fluoroalkyl optionally substituted by R20. In spécifie embodiments, R5 is CrC2 alkyl or Ci-C2 fluoroalkyl. In spécifie embodiments, R5 is CH3, C2(t5. CHF2 or CH2CHF2 (i.e., methyl, ethyl, difluoronjethyl or difluoroethyl). _ — _
In compounds of Formula (II), R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3. In some 30 embodiments, R6 is H. In other embodiments, R6 is F. In other embodiments, R6 is Cl. In further embodiments, R6 is CN. In other embodiments, R6 is CH3, CH2F, CHF2 or CF3. I
In compounds of Formula (II), R7 and R8 are independently H, F, Cl, CN, Ci-C2 alkyl, CrC2 fluoroalkyl, CrC2 alkoxy or Ci-C2 fluoroalkoxy, where each said CrC2 alkyl, Ci-C2 fluoroalkyl, Ci-C2 alkoxy and Ci-C2 fluoroalkoxy is optionally substituted by.R20. :. : ~
In some embodiments of Formula (II), R7 is H. In other embodiments, R7 is F or Cl. In further embodiments, R7 is Ci-C2 alkyl or Ci-C2 fluoroalkyl, where each said Ci-C2 alkyl and CrC2 fluoroalkyl is optionally substituted by R20. In some such embodiments, R7 is CH3, optionally substituted by R20. In some embodiments, R7 is CH3. ~
In some embodiments of Formula (II), R8 is H. In other embodiments, R8 is F or Cl. In further embodiments, R8 is C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 5 fluoroalkyl is optionally substituted by R20. In some such embodiments, R8 is CH3, optionally substituted by R20. In some embodiments, R8 is CH3.
In some embodiments, R7 and R8 are H.
In compounds of Formula (11), R9is H, OH, NH2, NHCH3 or N(CH3)2. In some preferred embodiments, R9 is OH. In other embodiments, R9 is NH2, NHCH3 or N(CH3)2. In further 10 embodiments, R9 is H.
In compounds of Formula (11), each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In some embodiments, n is 0 and R10 is absent. In other embodiments, n is 1, 2, 3 or 4 and each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and 15 C1-C2 fluoroalkyl is optionally substituted by R20. In other embodiments, n is 1 or 2 and R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl. In some embodiments, n is 1 or 2 and R10 is independently F or CH3.
In compounds of Formula (II), Q is NR11 or O; or Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic 20 ring containing NR11 or O as a ring member, which ring is optionally further substituted by R10.
In some embodiments of Formula (II), Q is NR11. In some embodiments, Q is NR11, p is 2 and q is 1. In some such embodiments, R11 is SO2R14. In other such embodiments, R11 is COR17. In some such embodiments, n is 0 and R10 is absent.
In compounds of Formula (II), R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, 25 COR17, COOR17 or CONR18R19. In some embodiments, R11 is H, C1-C4 alkyl or C1-C4 fluoroalkyl. In some embodiments, R11 is Hr In other embodiments, R11 is C1-C4 alkyl or C1-C4 fluoroalkyl. In some embodiments, R11 is C1-C4 alkyl. l|n other embodiments, R11 is C1-C4 fluoroalkyl. In some| embodiments, R11 is SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19. In some embodiments, R11 is SO2R14 or SO2NR15R16. In some embodiments, R11 is SO2R14. In other 30 embodiments, R11 is SO2NR15R16. In some embodiments, R11 is COR17, COOR17 or CONR18R19J In some embodiments, R11 is COR17i. In some embodiments, R11 is COOR17. In other embodiments, R11 is CONR18R19.
In other embodiments of Formula (II), Q is O. In some embodiments, Q is O, p is 2 and q is1. In some suclrembodiments, n is 0 and R10 is absent. ........ . :......
Ih further embodiments of Formula (II), Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing
NR11 or O as a ring member, which ring is optionally further substituted by R10. In some such embodiments, R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 as a ring member, which ring is optionally furthersubstituted by R10..In othersuch embodiments, R12and R13 are taken togetherwith the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing O as a ring member, which ring is optionally further substituted by R10. In some such embodiments, R12 and R13 are taken together to form a 4-membered optionally substituted heterocyclic ring. In other such embodiments, R12 and R13 are taken together to form a 5-membered optionally substituted heterocyclic ring. In other such embodiments, R12 and R13 are taken together to form a 6membered optionally substituted heterocyclic ring. In each case, said 4-6 membered heterocyclic ring contains NR11 or O as a ring member and is optionally further substituted by R10, where each of R10 and R11 is as further defined herein. In some such embodiments, n is 0 and R10 is absent.
In the foregoing embodiments, each R10 is independently selected from the group as defined herein.
In compounds of Formula (II), R14 is C1-C4 alkyl or C1-C4 fluoroaikyl. In some embodiments, R14 is C1-C4 alkyl. In some embodiments, R14 is C1-C4 fluoroaikyl. In spécifie embodiments, R14 is CH3 or C2H5 (i.e., methyl or ethyl).
In compounds of Formula (II), each R15 and R16 is independently H or CH3.
In compounds of Formula (II), R17is C1-C4 alkyl or C1-C4fluoroaikyl, where each said C1-C4 alkyl and C1-C4 fluoroaikyl is optionally substituted by R20. In some embodiments, R17 is C1-C4 alkyl or C1-C4 fluoroaikyl. In some embodiments, R17 is C1-C4 alkyl optionally substituted by R20. In some embodiments, R17 is C1-C4 fluoroaikyl optionally substituted by R20. In spécifie embodiments, R17 is CH3 or C2H5.
In compounds of Formula (II), each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroaikyl, where each said C1-C4 alkyl and C1-C4 fluoroaikyl is optionally substituted by R20. In some embodiments, each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroaikyl. In some embodiments, each R18 and R19 is indepentjlently H or C1-C4 alkyl optionally substituted by R20. In some embodiments, each R18 and R19 is independently H or C1-C4 fluoroaikyl optionally substituted by R20. In spécifie embodiments, each R18and R19 is independently H, CH3 or C2H5.
In compounds of Formula (II), each R20 is independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN or NR22R23. In some embodiments, R20 is OH. In some such embodiments, R20 is OH, C1-C2 alkoxy or N R22 R23. In other embodiments, R20 is C1-C2 alkoxy or C1-C2 fluoroalkoxy. In further embodiments, R20 is CN. In still other embodiments, R20 is N R22 R23.
In compounds of Formula (II), each R21 is independently F, OH, CN, N R22 R23, C1-C4 . alkyl, C1-C4 fluoroaikyl, C1-C4 alkoxÿ or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroaikyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, _ 44
NHCHa or N(CH8)2. In some embodiments, R21 is F. In some embodiments, R21 is OH. In some embodiments, each R21 is independently F, OH or C1-C4 alkyl. In other embodiments, R21 is CN. In other embodiments, R21 is C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2.
In compounds of Formula (II), each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl; or R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH.
In some embodiments, each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 10 fluoroalkyl. In spécifie embodiments, each R22 and R23 is independently H or CH3. In other embodiments, R22 and R23 are taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH.
In compounds of Formula (II), n is 0,1, 2, 3 or 4. In some embodiments, n is 0 and R10 is absent. In other embodiments, n is 1, 2, 3 or 4 and R10 is as defined herein. In some 15 embodiments, n is 1 or 2.
In compounds of Formula (II), p is 1,2 or 3; and q is 0,1,2 or 3; wherein the sum of p and q is an integer from 1 to 4. In some embodiments, the sum of p and q is an integer from 1 to 3.
In some embodiments, p is 2 and q is 1. In other embodiments, p is 2 and q is 2. In some embodiments, p is 1 and q is 0. In other embodiments, p is 1 and q is 1. In still other embodiments, 20 p is 1 and q is 2. In further embodiments, p is 1 and q is 3. In some embodiments, p is 2. In other embodiments, p is 1. In some embodiments, q is 1. In other embodiments, q is 0.
In certain embodiments, the invention provides a compound of Formula (II), (ll-A), (ll-B), (ll-C) or (II-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; U 25 is NR2 and V is CR4; R2 is C1-C5 alkyl; or R2 is 1-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 or C(OH)(CH3)2î X is CR6; R6 is Y is CR7; Z is CR8; R7 and R8 are H; R9 is OH; Q is 0; or Q is NR11, where R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (II), (ll-A), (ll-B), 30 (H-C) or (ll-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or morè, of the following features: R1 is Cl; U is CR3 and V is NR5; R3 is C1-C5 alkyl; or R3 is 1-C3H7; R5 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20; R20 is OH; X is CR6; R6 is F; Y is CR7; Z is CR8; R7 and R8 are H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 35 2;andqis1. .
_ 45
In a preferred embodiment, the invention provides a compound of Formula (II), (ll-A), (IIB), (ll-C) or (ll-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; U is NR2; R2 is C1-C5 alkyl; or R2 is i-C3H7; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is 5 H; R9is OH; Q is O; n is 0 and R10 is absent; p is 2; and q is 1.
In another preferred embodiment, the invention provides a compound of Formula (II), (IIA), (ll-B), (ll-C) or (ll-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; U is NR2; R2 is C1-C5 alkyl; or R2 is i-C3H7; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 or C(OH)(CH3)2; X is CR6; R6 is F; Y is CR7; R7 is H; Z is 10 CR8; R8 is H; R9 is OH; Q is NR11, where R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent;
p is 2; and q is 1.
In compounds of Formula (III), R1 is H, F, Cl, CN, Ci-C2 alkyl or Ci-C2 fluoroalkyl, where each said Ci-C2 alkyl and Ci-C2fluoroalkyl is optionally substituted by R20. In some embodiments, R1 is F or Cl. In some embodiments, R1 is F. In some embodiments, R1 is Cl.
In compounds of Formula (III), X is CR6 or N. In some embodiments, X is CR6. In some embodiments, X is N,
In compounds of Formula (III), Y is CR7 or N. In some embodiments, Y is CR7. In some embodiments, Y is N.
In compounds of Formula (III), Z is CR8 or N. In some embodiments, Z is CR8. In some 20 embodiments, Z is N.
In frequent embodiments of Formula (III), X is CR6, Y is CR7 and Z is CR8. In other embodiments of Formula (III), at least one of X, Y and Z is N.
In compounds of Formula (III), U is NR2 or CR3; V is N or CR4 when U is NR2; and V is NR5 when U is CR3. In some embodiments, U is NR2 and V is N or CR4. In some such 25 embodiments, U is NR2 and V is CR4. In some such embodiments, U is NR2 and V is N. In other embodiments, U is CR3 and V is NR5.
In sc|me embodiments of Formula (III), U is NR2and R2 is H, IC1-C5 alkyl, C1-C5 fluoroalkyl, C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-Ce cycloalkyl and 3-6 membered heterocyclyl is 30 optionally substituted by R21. I
In compounds of Formula (III), R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-Ce cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21, r: 7 / ' .
In some such embodiments, R2 is C1-C5 alkyl or C1-C5 fluoroalkÿl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20. In some such embodiments, R2 is
C1-C5 alkyl optionally substituted by R20. In some such embodiments, R20 is OH. In particular embodiments, R2 is CHs, C2H5, n-CsHy/i-CsH?, n-C4Hg, S-C4H9, i-C4Hg, t-C4Hg, CHF2 or CH2CHF2 (i.e., methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, difiuoromethyl or difluoroethyl), each optionally substituted by R20. Jn spécifie embodiments, R2 is isopropyl or tertbutyl. In spécifie embodiments, R2 is isopropyl. In some embodiments, R2 is C1-C5 alkyl or C1-C5 fluoroalkyl optionally substituted by R20 where R20is OH.
In other embodiments, R2 is C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21. In some such embodiments, R2 is 3-6 membered heterocyclyl optionally substituted by R21. In particular embodiments, R2 is oxetan-3-yl or azetidin-3-yl, each optionally substituted by R21. In spécifie embodiments, R2 is oxetan-3-yl. In other embodiments, R2 is C3-C8 cycloalkyl, where said C3-C8 cycloalkyl is optionally substituted by R21. In some such embodiments, R21 is F, OH or C1-C4 alkyl.
In some such embodiments, R3 is C1-C5 alkyl or C1-C5 fluoroalkyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20. In some such embodiments, R3 is C1-C5 alkyl optionally substituted by R20. In some such embodiments, R20is OH or N R22R23. In some such embodiments, R20 is OH. In some such embodiments, R3 is CH3, C2H5, n-CsH?, 1-C3H7, nC4H9, s-C4H9, i-C4H9, t-C4Hg, CHF2 or CH2CHF2, each optionally substituted by R20. In spécifie embodiments, R3 is 1-C3H7 or t-C4Hg (i.e., isopropyl or tert-butyl). In spécifie embodiments, R2 is isopropyl.
In other embodiments, R3 is Ο3-Ο8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21. In some such embodiments, R3 is 3-6 membered heterocyclyl optionally substituted by R21. In particular embodiments, R3 is oxetan-3-yl or azetidin3-yl optionally substituted by R21. In some such embodiments, R21 is F, OH or C1-C4 alkyl. In spécifie embodiments, R3 is oxetan-3-yl. In other embodiments, R3 is C3-C8 cycloalkyl, where said C3-C8 cycloalkyl is optionally substituted by R21. In some such embodiments, R21 is F, OH or C1-C4 alkyl. |
In the foregoing embodiments where U is CR3, V is NR5.
In some embodiments of Formula (III), V is CR4 when U is NR2.
In compounds of Formula (III), R4 is H, C1-C4 alkyl, C1-C4fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where ëaeh said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20. In some embodiments, R4 is H. In other embodiments, R4 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-G4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some such embodiments, R4 is Cî-C4 alkyl optionally substituted by R20. In some such embodiments, R20 is OH, OCH3, NH2, NHCH3 or NH(CH3)2. In some such embodiments, R20 is OH or NH2. In some such embodiments, R20 is OH. In certain embodiments,
R4 is C1-C2 alkyl optionally substituted by R20, where R20 is OH or NH2. In spécifie embodiments,
R4-R20 is H, CH3, C2H5, CH2OH, CH(OH)CH3, CH2CH2OH or CH2NH2 (i.e., methyl, ethyl, - hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl or aminomethyl). In some embodiments, R4 substituted by R20 is CH(OH)CH3 or C(OH)(CH3)2. In other sUch embodiments, R4 is C1-C4 fluoroalkyl optionally substituted by R20. In other embodiments, R4 is C1-C4 alkoxy or C1-C4 fiuoroalkoxy, where each said C1-C4 alkoxy and C1-C4 fiuoroalkoxy is optionally substituted by R20. ~ - - ..... In some embodiments of Formula (III), V is NR5 when U is CR3.
In compounds of Formula (III), R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some embodiments, R5 is H. In other embodiments, R5 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some such embodiments, R5 is C1-C4 alkyl optionally substituted by R20. In other such embodiments, R5 is C1-C4 fluoroalkyl optionally substituted by R20. In spécifie embodiments, R5 is C1-C2 alkyl or C1-C2 fluoroalkyl. In spécifie embodiments, R5 is CH3, C2H5. CHF2 or CH2CHF2 (i.e., methyl, ethyl, difluoromethyl or difluoroethyl).
In compounds of Formula (III), R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3. In some embodiments, R6 is H. In other embodiments, R6 is F. In other embodiments, R6 is Cl. In further embodiments, R6 is CN. In other embodiments, R6 is CH3, CH2F, CHF2 or CF3.
In compounds of Formula (III), R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fiuoroalkoxy, where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 fiuoroalkoxy is optionally substituted by R20.
In some embodiments of Formula (III), R7 is H. In other embodiments, R7 is F or Cl. In further embodiments, R7 is C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In some such embodiments, R7 is CH3, optionally substituted by R20. In some embodiments, R7 is CH3. ------- _
In some embodiment^ of Formula (III), R8 is H. In other embodiments, R8 is|F or Cl. In further embodiments, R8 is C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In some such embodiments, R8 is CH3, optionally substituted by R20. In some embodiments, R8 is CH3. I
In some embodiments, R7 and R8 are H. I
In compounds of Formula (III), R9is H, OH, NH2, NHCH3 or N(CH3)2. In some preferred embodiments, R9 is OH. In other embodiments, R9 is NH2, NHCH3 or N(CH3)2. In further 2 embodiments, R9 is H. . . . . . „ . . . .......
In compounds of Formula (III), each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In _ 48 some embodiments, n is 0 and R10 is absent. In other embodiments, n is 1, 2, 3 or 4 and each R10 is independently F, CN, C1-C2 alkyl or Ci-C2 fluoroalkyl, where each said Ci-C2 alkyl and Ci-C2 fluoroalkyl is optionally substituted by R20. In other embodiments, n is 1 or 2 and R10 is independently F, CN, Ci-C2 alkyl or Ci-C2 fluoroalkyl. In some embodiments, n is 1 or 2 and R10.
is independently F or CH3.
In compounds of Formula (III), Q is NR11 or O; or Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 or O as a ring member, which ring is optionally further substituted by R10.
In some embodiments of Formula (III), Q is NR11. In some embodiments, Q is NR11, p is 10 2 and q is 1. In some such embodiments, R11 is SO2R14. In other such embodiments, R11 is
COR17. In some such embodiments, n is 0 and R10 is absent.
In compounds of Formula (III), R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19. In some embodiments, R11 is H, C1-C4 alkyl or C1-C4 fluoroalkyl. In some embodiments, R11 is H. In other embodiments, R11 is C1-C4 alkyl or 15 C1-C4 fluoroalkyl. In some embodiments, R11 is C1-C4 alkyl. In other embodiments, R11 is C1-C4 fluoroalkyl. In some embodiments, R11 is SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19. In some embodiments, R11 is SO2R14 or SO2NR15R16. In some embodiments, R11 is SO2R14. In other embodiments, R11 is SO2NR15R16. In some embodiments, R11 is COR17, COOR17 or CONR18R19. In some embodiments, R11 is COR17. In some embodiments, R11 is COOR17. In other 20 embodiments, R11 is CONR18R19.
In other embodiments of Formula (III), Q is O. In some embodiments, Q is O, p is 2 and qis1. In some such embodiments, n is 0 and R10 is absent.
In further embodiments of Formula (III), Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring 25 containing NR11 or O as a ring member, which ring is optionally further substituted by R10. In some such embodiments, n is 0 and R10 is absent. In some such embodiments, R12 and R13 are taken together with the C atom to which thefy are attached to form a 4-6 membered heterocyclic ripg containing NR11 as a ring member, which ring is optionally further substituted by R10. In other such embodiments, R12 and R13 are taken together with the C atom to which they are attached to . 30 form a 4-6 membered heterocyclic ring containing O as a ring member, which ring is optionally further substituted by R10. In some such embodiments, R12 and R13 are taken together to form a 4-membered optionally substituted heterocyclic ring. In other such embodiments, R12 and R13 are taken together to form a 5-membered optionally substituted heterocyclic ring. In other such embodiments, R12 and R13 are taken together to form a 6-membered optionally substituted 35 heterocyclic ring. In each case, said 4-6 membered heterocyclic ring contains NR11 or O as a 49 ring member and is optionally further substituted by R10, where each of R10 and R11 is as further defined herein. In some such embodiments, n is 0 and R10 is absent.
In the foregoing embodiments, each R10 is independently selected from the group as defined herein. — . ... ----------- . _ ---------- ------ .. ---5 In compounds of Formula (III), R14 is C1-C4 alkyl or C1-C4 fluoroalkyl. In some embodiments, R14 is C1-C4 alkyl. In some embodiments, R14 is C1-C4 fluoroalkyl. In spécifie embodiments, R14 is CH3 or C2H5 (i.e., methyl or ethyl). In compounds of Formula (III), each R15 and R16 is independently H or CH3.
In compounds of Formula (III), R17 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said
C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some embodiments, R17is
C1-C4 alkyl or C1-C4 fluoroalkyl. In some embodiments, R17 is C1-C4 alkyl optionally substituted by R20. In some embodiments, R17 is C1-C4 fluoroalkyl optionally substituted by R20. In spécifie embodiments, R17 is CH3 or C2H5.
In compounds of Formula (III), each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some embodiments, each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl. In some embodiments, each R18 and R19 is independently H or C1-C4 alkyl optionally substituted by R20. In some embodiments, each R18 and R19 is independently H or C1-C4 fluoroalkyl optionally substituted by R20. In spécifie embodiments, each R18 and R19 is independently H, CH3 or C2H5.
In compounds of Formula (III), each R20 is independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN or N R22R23. In some embodiments, R20 is OH. In some such embodiments, R20 is OH, C1-C2 alkoxy or NR^R23. In other embodiments, R20 is C1-C2 alkoxy or C1-C2 fluoroalkoxy. In further embodiments, R20 is CN. In still other embodiments, R20 is NR22R23.
In compounds of Formula (III), each R21 is independently F, OH, CN, N R22 R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, | NHCH3 or N(CH3)2. In some embodiments, R2] is F. In some embodiments, R21 is OH. In some | embodiments, each R21 is independently F, OH or C1-C4 alkyl. In other embodiments, R21 is CN. In other embodiments, R21 is C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 | 30 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 i
I fluoroalkoxy is optionally further substituted by ÔH, NH2, NHCH3 or N(CH3)2. i
In compounds of Formula (III), each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl; or R22 and R23 may be taken together with the nitrogen atom to which they are attached ..... to form an azetidinyl ring, which is optionally substituted by E or OH. . . _ - .
Ih some embodiments, each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl. In spécifie embodiments, each R22 and R23 is independently H or CH3. In other embodiments, R22 and R23 are taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH.
In compounds of Formula (III), n is 0,1,2,3 or 4. In some embodiments, n is 0 and R10 is absent. In other embodiments, n is 1, 2, 3 or 4 and R10 is as defined herein. In some 5 embodiments, n is 1 or 2.
In compounds of Formula (III), p is 1, 2 or 3; and q is 0, 1, 2 or 3; wherein the sum of p and q is an integer from 1 to 4. In some embodiments, the sum of p and q is an integer from 1 to 3.
In some embodiments, p is2 and q is 1. In other embodiments, p is 2 and q is 2. In some 10 embodiments, p is 1 and q is 0. In other embodiments, p is 1 and q is 1. In still other embodiments, p is 1 and q is 2. In further embodiments, p is 1 and q is 3. In some embodiments, p is 2. In other embodiments, p is 1. In some embodiments, q is 1. In other embodiments, q is 0.
In certain embodiments, the invention provides a compound of Formula (III), (lll-A), (IIIB), (lll-C) or (lll-D), or a pharmaceutically acceptable sait thereof, having a combination of two or 15 more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; U is NR2 and V is CR4; R2 is C1-C5 alkyl; or R2 is i-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 or C(OH)(CH3)2, X is CR6; R6 is F; Y is CR7; Z is CR8; R7 and R8 are H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (III), (lll-A), (IIIB), (lll-C) or (lll-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more.of the following features: R1 is Cl; U is CR3 and V is NR5; R3 is C1-C5 alkyl; or R3 is i-C3H7; R5 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20; R20 is OH; X is CR6; R6 is F; Y is CR7; Z is CR8; R7 and R8 25 are H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
| In a preferred embodiment, the invention provides a compound of Formula (III), (lll-A), (IIl-B), (lll-C) or (lll-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; U is NR2; R2 is C1-C5 alkyl; or R2 is i-C3H7; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where 30 R20 is OH; or R4 is CH(OH)CH3 or C(OH)(CH3)2; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8;
R8 is H; R9 is OH; Q is O; n is 0 and R10 is absent; p is 2; and q is 1.
In another preferred embodiment, the invention provides a compound of Formula (III), (IIIA), (lll-B), (lll-C) or (lll-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; U is NR2; R2 is C1-C5 alkyl; or R2 is i-C3H7; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, 35 where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; X is CR6; R6 is F; Y is CR7; R7 is H; Z is — 51
CR8; R8 is H; R9is OH; Q is NR11, where R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent;
p is 2; and q is 1. In certain embodiments, the invention provides a compound of Formula (II), (ll-A), (ll-B), (ll-C) or (ll-D), br a pharmaceutically acceptable sait theréof, or a compound of Formula (lll), (III5 A), (lll-B), (lll-C) or (Ill-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is F or Cl; U is NR2 and V is CR4; R2 is C1-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R2 is CH3,1-C3H7, i-C4Hg,s-C4Hg, t-C4Hg, CH2F.CHF2, CH2CHF2 or oxetan-3-yl; R4 is H or C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by OH, NH2, NHCH3 or N(CH3)2î or R4 is H, CH3, C2H5, CH2OH, CH(OH)CH3, CH2CH2OH or CH2NH2; X is CR6; R6 is H or F; Y is CR7; Z is CR8; R7 and R8 are H; R9 is OH; n is 0 and R10 is absent; Q is NR11; R11 is SO2R14; and R14is C1-C4 alkyl; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (II), (ll-A), (ll-B), (ll-C) or (ll-D), or a pharmaceutically acceptable sait thereof, or a compound of Formula (lll), (III15 A), (lll-B), (lll-C) or (III-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, ofthe following features: R1 is F or Cl; U is CR3 and V is NR5; R3 is C1-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R3 is CH3,1-C3H7, i-C4Hg.s-C4Hg, t-C4Hg, CH2F.CHF2, CH2CHF2 or oxetan-3-yl; R5 is H or C1-C4 alkyl; or R5 is H or CH3; X is CR6; R6 is H or F; Y is CR7; Z is CR8; R7 and R8 are H;
R9 is OH; n is 0 and R10 is absent; Q is NR11; R11 is SO2R14; and R14is C1-C4 alkyl; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (II), (ll-A), (ll-B), (ll-C) or (ll-D), or a pharmaceutically acceptable sait thereof, or a compound of Formula (lll), (IIIA), (lll-B), (lll-C) or (lll-D), or a pharmaceutically acceptable sait thereof, having a combination of 25 two or more, preferably three or more, and more preferably four or more, of the following features:
R1 is F or Cl; U is NR2 and V is N; R2 is Ci-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R2 is CH3,1-C3H7, i-C4Hg, s-C4Hg, t-C4Hg, CH2F, c(tF2, CH2CHF2 or oxetan-3-yl; X is CR6; R6 is H or F; Y is CR7; Z is CR8; R7 and R8 are H; R9 is OH; n is 0 and R10 is absent; Q is NR11; R11 is SO2R14; and R14is C1-C4 alkyl; p is 2; and q is 1.
In compounds of Formula (IV), R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2fluoroalkyl is optionally substitutecl by R20. In some embodiments, R1 is F or Cl. In some embodiments, R1 is F. In some embodiments, R1 is Cl.
In compounds of Formula (IV), U is NR2 or CR3; V is N or CR4 when U is NR2; and
V is NR5 when U is CR3. In some embodiments, U is NR2 and V is N or CR4. In some such. 35 embodiments, U is NR2 and V is N. In some such embodiments, U is NR2 and V is CR4. In some embodiments, U is CR3 and V is NR5.
— 52
In compounds of Formula (IV), X is CR6 or N. In some embodiments, X is CR6. In some embodiments, X is N, ...
In compounds of Formula (IV), Y is CR7 or N. In some embodiments, Y is CR7. In some embodiments, Y is N.
In compounds of Formula (IV), Z is CR8 or N. In some embodiments, Z is CR8. In some embodiments, Z is N.
In frequent embodiments of Formula (IV), X is CR6, Y is CR7 and Z is CR8. In other embodiments of Formula (IV), at least one of X, Y and Z is N.
In some embodiments of Formula (IV), R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, 10 C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21.
In some such embodiments, R2 and R3 are H, C1-C5 alkyl or C1-C5 fluoroalkyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20. In other such embodiments, 15 R2 and R3 are C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21. In some embodiments, R2 is C1-C4 alkyl optionally substituted by R20 where R20is OH. In some embodiments, R3 is C1-C4 alkyl optionally substituted by R20 where R20is OH.
In some embodiments of Formula (IV), R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy 20 or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20. In some embodiments, R4 is C1-C4 alkyl optionally substituted by R20 where R20is OH.
In some embodiments of Formula (IV), R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some embodiments, 25 R5 is C1-C4 alkyl optionally substituted by R20. In some such embodiments, R20 is OH.
In some embodiments of Formula (IV), R2 can be taken together with R4, or R3 can be taken together wjth R5, to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24,0 and S(O)m as a ring member, which ring is optionally substituted by R21. It will be understood that R2 is taken together with R4, or R3 is taken together 30 with R5 in combination with the atoms to which they are attached through {a C3-C5 alkylene or C3C5 heteroalkylene linker, which linker is optionally substituted as further dèflned herein.
In some embodiments of Formula (IV), R2 is taken together with R4 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)m as a ring member, which ring is. optionally substituted by R21. In some such 35 embodiments, the 5-7 membered heterocyclic ring contains O as an additional heteroatom. In _ 53 some such embodiments, the 5-7 membered heterocyclic ring contains NR24 as an additional heteroatom. - .
In some embodiments, R2 is taken together with R4 to form a 5-membered ring containing no additional heteroatoms (i.e., pyrrolidine),.which is optionally substituted by R21. In other 5 embodiments, R2 is taken together with R4 to form a 6-membered ring containing no additional heteroatoms (i.e., piperidine), which is optionally substituted by R21. In other embodiments, R2 is taken together with R4 to form a 6-membered ring containing NR24(i.e., piperazine), which is optionally substituted by R21. In further embodiments, R2 is taken together with R4 to form a 6membered ring containing O or S (i.e., morpholine or thiomorphoiine), which is optionally 10 substituted by R21. In further embodiments, R2 is taken together with R4 to form a 7-membered ring which may contain no additional heteroatoms (i.e., homopiperidine) or may contain NR24 (i.e., homopiperazine), in each case optionally substituted by R21.
In other embodiments of Formula (IV), R3 is taken together with R5 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, 15 O and S(O)m as a ring member, which ring is optionally substituted by R21. In some such embodiments, the 5-7 membered heterocyclic ring contains O as an additional heteroatom. In some such embodiments, the 5-7 membered heterocyclic ring contains NR24 as an additional heteroatom.
In some embodiments, R3 is taken together with R5 to form a 5-membered ring containing 20 no additional heteroatoms (i.e., pyrrolidine), which is optionally substituted by R21. In other embodiments, R3 is taken together with R5 to form a 6-membered ring containing no additional heteroatoms (i.e., piperidine), which is optionally substituted by R21. In other embodiments, R3 is taken together with R5 to form a 6-membered ring containing NR24 (i.e., piperazine), which is optionally substituted by R21. In further embodiments, R3 is taken together with R5 to form a 625 membered ring containing O or S(O)m (i.e., morpholine or thiomorphoiine), which is optionally substituted by R21. In further embodiments, R3 is taken together with R5 to form a 7-membered ring which may contain no ^dditional heteroatoms (i.e., homopiperidine) or may con|tain NR24 (i.e., homopiperazine), in each case optionally substituted by R21.
In compounds of Formula (IV), R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3. In some 30 embodiments, R6 is F or Cl. In some such embodiments, R6 is F. In some such embodiments, R6 is Cl. In some embodiments, R6 is H. In other embodiments, R6 is CN, CH3, CH2F, CHF2 or CF3.
In compounds of Formula (IV), R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroaikyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy, where each said C1-C2 alkyl, Cî-C2 35 fluoroalkÿl, C1-C2 alkoxy and C1-C2 fluoroalkoxy is optionally sübstituted bÿ R20. In some such _ 54 embodiments, R7 is H. In some such embodiments, R8 is H. In some such embodiments, R7 and R8 are H.
In compounds of Formula (IV), R9 is H, OH, NH2, NHCH3 or N(CH3)2. In preferred embodiments of Formula (IV), R9 is OH.
In compounds of Formula (IV), each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In some embodiments, n is 0 and R10 is absent. In other embodiments, n is 1 or 2 and R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl. In some embodiments, n is 1 or 2 and R10 is independently F or CH3. — ~
In some embodiments of Formula (IV), Q is NR11 or O. In some embodiments, Q is O. In some embodiments, Q is O, p is 2 and q is 1. In some such embodiments, n is 0 and R10 is absent.
In other embodiments of Formula (IV), Q is NR11. In some embodiments, Q is NR11, p is 2 and q is 1. In some such embodiments, R11 is SO2R14. In other such embodiments, R11 is 15 COR17. In some such embodiments, n is 0 and R10 is absent.
In some embodiments of Formula (VI), Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 or O as a ring member, which ring is optionally further substituted by R10. In some such embodiments, n is 0 and R10 is absent.
In compounds of Formula (IV), R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14,
SO2NR15R16, COR17, COOR17 or CONR18R19. In some embodiments, R11 is SO2R14. In other embodiments, R11 is COR17.
In compounds of Formula (IV), R14 is C1-C4 alkyl or C1-C4 fluoroalkyl. In some embodiments, R14 is C1-C4 alkyl. In some such embodiments, R14 is C1-C2 alkyl. In some embodiments, R14 is C1-C4 fluoroalkyl. In some such embodiments, R14 is C1-C2 fluoroalkyl. In particular embodiments, R14 is CH3 or C2H5TIn compounds of Formula (lÿ), each R15 and R16 is independently H or CH3. |
In compounds of Formula (IV), R17is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some embodiments, R17 is
C1-C4 alkyl, where each said C1-C4 alkyl is optionally substituted by R20.I
In compounds of Formula (IV), each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20.
In compounds of Formula (IV), each R20 is independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, or N R22 R23. ... . ... . . . .... .. .
In compounds of Formula (IV), each R21 is independently F, OH, CN, NR22R23, C1-C4 alkyl,
C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 _ 55 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2. In some embodiments, each R21 is independently F, OH or C1-C4 alkyl.
In some embodiments of Formula (IV), each R22 and R23 is independently H, C1-C2 alkyl, C1-C2 fluoroalkyl. In other embodiments of Formula (IV), R22 and R23 may be taken together with 5 the nitrogen atom to which they are attached to form an azetidinyl ring, where said ring is optionally substituted by F or OH.
In compounds of Formula (IV), R24 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R25, SO2NR26R27, COR28, COOR28 or CONR29R30. In some embodiments, R24 is H or C1-C4 alkyl. In some embodiments, R24 is H or C1-C2 alkyl. .. 10 In compounds of Formula (IV), R25 is C1-C4 alkyl or C1-C4 fluoroalkyl. . In some embodiments, R25 is C1-C2 alkyl.
In compounds of Formula (IV), each R26 and R27 is independently H or CH3.
In compounds of Formula (IV), R28is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2. In some embodiments, R28is C1-C4 alkyl optionally substituted by OH or C1-C2 alkoxy. In some embodiments, R28is C1-C2 alkyl.
In compounds of Formula (IV), each R29 and R30 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2. In some embodiments, each R29 20 and R30 is independently H or C1-C4 alkyl where each said C1-C4 alkyl is optionally substituted by OH or C1-C2 alkoxy. In some embodiments, each R29 and R30 is independently H or C1-C2 alkyl.
In compounds of Formula (IV), m is 0,1 or 2. In some embodiments, m is 2.
In compounds of Formula (IV), n is 0,1, 2, 3 or 4. In some embodiments, n is 0 and R10 25 is absent. In some embodiments, n is 1 or 2.
In compounds of Formula (IV), p is1,2 or 3; wherein the sum of p and q is an integer from 1 to 4. In some embodiments, p is 2. In oth^r embodiments, p is 1. In some embodiments, the sum of p and q is an integer from 1 to 3. In compounds of Formula (IV), q is 0,1, 2 or 3; wherein the sum of p and q is an integer 30 from 1 to 4. In some embodiments, q is 1. In other embodiments, q is 0. In some embodiments, the sum of p and q is an integer from 1 to 3. i
In some embodiments, p is 2 and q is 1. In other embodiments, p is 1 and q is 1. In other embodiments, p is 1 and q is 0. In further embodiments, the sum of p and q is an integer from 1 to 3. . — _________ .
Ih certain embodiments, the invention provides a compound of Formula (IV), (IV-A), (IVB), (IV-C) or (IV-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; U is NR2 and V is CR4; R2 is C1-C5 alkyl; or R2 is 1-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 or C(OH)(CH3)2; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14 ; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (IV), (IV-A), (IVB), (IV-C) or (IV-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; U is CR3 and V is NR5; R3 is C1-C5 alkyl; or R3 is 1-C3H7; R5 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20; R20 is OH; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In a preferred embodiment, the invention provides a compound of Formula (IV), (IV-A), (IV-B), (IV-C) or (IV-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; U is NR2; R2 is C1-C5 alkyl; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; n is 0 and R10 is absent; p is 2; and q is 1.
In another preferred embodiment, the invention provides a compound of Formula (IV), (IVA), (IV-B), (IV-C) or (IV-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; U is NR2; R2 is C1-C5 alkyl; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9is OH; Q is NR11, where R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (IV), (IV-A), (IVB), (IV-C) or (IV-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; U is NR2; V is CR4; R2 is taken together with R4 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)iïras a ring member, which | ring is optionally substituted by R21; each R21 is indep|endently F, OH or C1-C4 alkyl; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
! In certain embodiments, the invention provides a compound of Formula (IV), (IV-A), (IVI B), (IV-C) or (IV-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; U is CR3; V is NR5; R3 is taken together with R5 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)m as.a ring _ member, which ring is optionally substituted bÿ R21; each R21 is independently F, OH or C1-C4 _ 57 alkyl; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In compounds of Formula (V), R1 is H, F, CI, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In some embodiments, 5 R1 is F or Cl. In some embodiments, R1 is F. In some embodiments, R1 is Cl.
In compounds of Formula (V), U is NR2 or CR3; V is N or CR4 when U is NR2; and
V is NR5 when U is CR3. In some embodiments, U is NR2 and V is N or CR4. In some such embodiments, U is NR2 and V is N. In some such embodiments, U is NR2 and V is CR4. In some embodiments, U is CR3 and V is NR5.
In compounds of Formula (V), X is CR6 or N. In some embodiments, X is CR6. In some embodiments, X is N,
In compounds of Formula (V), Y is CR7 or N. In some embodiments, Y is CR7. In some embodiments, Y is N. '
In compounds of Formula (V), Z is CR8 or N. In some embodiments, Z is CR8. In some 15 embodiments, Z is N.
In frequent embodiments of Formula (V), X is CR6, Y is CR7 and Z is CR8. In other embodiments of Formula (V), at least one of X, Y and Z is N.
In some embodiments of Formula (V), R2 and R3 are H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl 20 is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21.
In some such embodiments, R2 and R3 are H, C1-C5 alkyl or C1-C5 fluoroalkyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20. In other such embodiments, R2 and R3 are C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl 25 and 3-6 membered heterocyclyl is optionally substituted by R21. In some embodiments, R2 is C1-C4 alkyl optionally substituted by R20 where R20is OH. In some embodiments, R3 is C1-C4 alkyl optionally substituted by R20 where R20 is OH. |
In some embodiments of Formula (V), R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 30 fluoroalkoxy is optionally substituted by R20. In some embodiments, R4 is C1-C4 alkyl optionally substituted by R20 where R20is OH. I
In some embodiments of Formula (V), R5 is H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-G4 fluoroalkyl is optionally substituted by R20. In some embodiments, R5 is C1-C4 alkyl optionally substituted by R20. In some such embodiments, R20 is OH.
In some embodiments of Formula (V), R2 can be taken together with R4, or R3 cari bë taken together with R5, to form a 5-7 membered heterocyclic ring, optionally containing an — 58 additional heteroatom selected from NR24,0 and S(O)m as a ring member, which ring is optionally substituted by R21. It will be understood that R2 is taken together with R4, or R3 is taken together with R5 in combination with the atoms to which they are attached through a C3-C5 alkylene or C3C5 heteroalkyiene linker, which linker is optionally substituted as further defined herein. -------- 5 In some embodiments of Formula (V), R2 is taken together with R4 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24,0 and S(O)m as a ring member, which ring is optionally substituted by R21. In some such embodiments, the 57 membered heterocyclic ring contains O as an additional heteroatom. In some such embodiments, the 5-7 membered heterocyclic ring contains NR24as an additional heteroatom.
In some embodiments, R2 is taken together with R4 to form a 5-membered ring containing no additional heteroatoms (i.e., pyrrolidine), which is optionally substituted by R21. In other embodiments, R2 is taken together with R4 to form a 6-membered ring containing no additional heteroatoms (i.e., piperidine), which is optionally substituted by R21. In other embodiments, R2 is taken together with R4 to form a 6-membered ring containing NR24 (i.e., piperazine), which is optionally substituted by R21. In further embodiments, R2 is taken together with R4 to form a 6membered ring containing O or S (i.e., morpholine or thiomorpholine), which is optionally substituted by R21. In further embodiments, R2 is taken together with R4 to form a 7-membered ring which may contain no additional heteroatoms (i.e., homopiperidine) or may contain NR24(i.e., homopiperazine), in each case optionally substituted by R21.
In other embodiments of Formula (V), R3 is taken together with R5 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24,0 and S(O)m as a ring member, which ring is optionally substituted by R21. In some such embodiments, the 57 membered heterocyclic ring contains O as an additional heteroatom. In some such embodiments, the 5-7 membered heterocyclic ring contains NR24as an additional heteroatom.
In some embodiments, R3 is taken together with R5 to form a 5-membered ring containing no additional heteroatoms (i.e., pyrrolidine), which is optionally substituted by R21. In other embodiments, f^3 is taken together with R5 to form a 6-membered rinc| containing no additional heteroatoms (i.e., piperidine), which is optionally substituted by R21. In other embodiments, R3 is taken together with R5 to form a 6-membered ring containing NR24 (i.e., piperazine), which is optionally substituted by R21. In further embodiments, R3 is taken together with R5 to form a 6membered ring' containing O or S(O)m (i.e., morpholine or thiomorpholine), which is optionally substituted by R21. In further embodiments, R3 is taken together with R5 to form a 7-membered ring which may contain no additional heteroatoms (i.e., homopiperidine) or may contain NR24(i.e., homopiperazine), in each case optionally substituted by R21.
In compounds of Formula (V), R6 is H, F, CI, CN, CH3, CH2F, CHF2 or CF3. In some embodiments, R6 is F or Cl. In some such embodiments, R6 is F. In some such embodiments,
R6 is Cl. In some embodiments, R6 is H. In other embodiments, R6 is CN, CH3, CH2F, CHF2 or
CF3. In compounds of Formula (V), R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy,‘where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 fluoroalkoxy is optionally substituted by R20. In some such embodiments, R7 is H. In some such embodiments, R8 is H. In some such embodiments, R7 and R8 are H.
In compounds of Formula (V), R9 is H, OH, NH2, NHCH3 or N(CH3)2. In preferred embodiments of Formula (V), R9 is OH. _ - In compounds of Formula (V), each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In some embodiments, n is 0 and R10 is absent. In other embodiments, n is 1 or 2 and R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl. In some embodiments, n is 1 or 2 and R10 is independently F or CH3.
In some embodiments of Formula (V), Q is NR11 or O. In some embodiments, Q is O. In some embodiments, Q is O, p is 2 and q is 1. In some such embodiments, n is 0 and R10 is absent.
In other embodiments of Formula (V), Q is NR11. In some embodiments, Q is NR11, p is 2 and q is 1. In some such embodiments, R11 is SO2R14. In other such embodiments, R11 is COR17. In some such embodiments, n is 0 and R10 is absent.
In some embodiments of Formula (V), Q is CR12R13, where R12 and R13 are taken together with the C atom to which they are attached to form a 4-6 membered heterocyclic ring containing NR11 or O as a ring member, which ring is optionally further substituted by R10. In some such embodiments, n is 0 and R10 is absent.
In compounds of Formula (V), R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19. In some embodiments, R11 is SO2R14. In other - embodiments, R11 is CO|r17. |
In compounds of Formula (V), R14 is C1-C4 alkyl or C1-C4 fluoroalkyl. In some embodiments, R14 is C1-C4 alkyl. In some such embodiments, R14 is C1-C2 alkyl. In some embodiments, R14is Ci-'C4 fluoroalkyl. In some such embodiments, R14is C1-C2 fluoroalkyl. In particular embodiments,! R14 is CH3 or C2H5. I
In compounds of Formula (V), each R15 and R16 is independently H or CH3.
In compounds of Formula (V), R17 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said : C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some embodiments, R17is _ C1-C4 alkyl, where each said C1-C4 alkyl is optionally substituted by R20.
— 60
In compounds of Formula (V), each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20.
In compounds of Formula (V), each R20 is independently OH, C1-C2 alkoxy, C1-C2 fiuoroalkoxy, CN, or N R22 R23. ... __________ Y________ ~Y— . ... ..
In compounds of Formula (V), each R21 is independently F, OH, CN, N R22 R23, C1-C4 alkyl,
C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fiuoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fiuoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2. In some embodiments, each R21 is independently F, OH or C1-C4 alkyl.
In some embodiments of Formula (V), each R22 and R23 is independently H, C1-C2 alkyl,
C1-C2 fluoroalkyl. In other embodiments of Formula (V), R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, where said ring is optionally substituted by F or OH.
In compounds of Formula (V), R24 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R25, SO2NR26R27, COR28, COOR28 or CONR29R3°. In some embodiments, R24 is H or C1-C4 alkyl. In 15 some embodiments, R24 is H or C1-C2 alkyl.
In compounds of Formula (V), R25 is C1-C4 alkyl or C1-C4 fluoroalkyl. . In some embodiments, R25 is C1-C2 alkyl.
In compounds of Formula (V), each R26 and R27 is independently H or CH3.
In compounds of Formula (V), R28is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said
C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fiuoroalkoxy, CN, NH2, NHCH3 or N(CH3)2. In some embodiments, R28is C1-C4 alkyl optionally substituted by OH or C1-C2 alkoxy. In some embodiments, R28 is C1-C2 alkyl.
In compounds of Formula (V), each R29 and R30 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, 25 C1-C2 alkoxy, C1-C2 fiuoroalkoxy, CN, NH2, NHCH3 or N(CH3)2. In some embodiments, each R29 and R30 is independently H or C1-C4 alkyl where each said C1-C4 alkyl is optionally substituted by OH or C1-C2 alkoxy. In some ^mbodiments, each R29 and R30 is independently H or φ-ΰ2 alkyl.
In compounds of Formula (V), m is 0,1 or 2. In some embodiments, m is 2.
In compounds of Formula (V), n is 0, 1, 2, 3 or 4. In some embodiments, n is 0 and R10 is absent. In some embodiments, n is 1 or 2. I
In compounds of Formula (V), p is 1,2 or 3; wherein the sum of p and q is an integer from to 4. In some embodiments, p is 2. In other embodiments, p is 1. In some embodiments, the sum of p and q is an integer from 1 to 3. ...... ...... _____ _______ .
_ 61
In compounds of Formula (V), q is 0, 1, 2 or 3; wherein the sum of p and q is an integer from 1 to 4. In some embodiments, q is 1. In other embodiments, q is 0. In some embodiments, the sum of p and q is an integer from 1 to 3.
In some embodiments, p is 2 and q is 1. In other embodiments, p is 1 and q is 1. In other. .
embodiments, p is 1 and q is 0. In further embodiments, the sum of p and q is an integer from 1 to 3.
In certain embodiments, the invention provides a compound of Formula (V), (V-A), (V-B), (V-C) or (V-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is
Cl; U is NR2 and V is CR4; R2 is C1-C5 alkyl; or R2 is 1-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14 ; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (V), (V-A), (V-B), (V-C) or (V-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; U is CR3 and V is NR5; R3 is C1-C5 alkyl; or R3 is 1-C3H7; R5 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20; R20 is OH; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In a preferred embodiment, the invention provides a compound of Formula (V), (V-A), (VB), (V-C) or (V-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; U is NR2; R2 is C1-C5 alkyl; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9is OH; Q is O; n is 0 and R10 is absent; p is 2; and 25 q is 1.
In another preferred embodiment, the invention provides a compound of Formula (V), (VA), (V-B), (V-C) or (V-D), or a pharmacei|tically acceptable sait thereof, wherein: R1 is Cl; U is | NR2; R2 is C1-C5 alkyl; V is CR4; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is NR11, where R11 is SO2R14;
R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1. j
In certain embodiments, the invention provides a compound of Formula (V), (V-A), (V-B), i (V-C) or (V-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; U is NR2; V is CR4; R2 is taken together with R4 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from.NR24, O and S(O)m as a ring member, which ring is optionally substituted by R21; each R21 is independently F, OH of C1-C4 alkyl; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14is CrC4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (V), (V-A), (V-B), (V-C) or (V-D), or a pharmaceutically acceptable sait thereof, having a.combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; U is CR3; V is NR5; R3 is taken together with R5 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)m as a ring member, which ring is optionally substituted by R21; each R21 is independently F, OH or C1-C4 alkyl; X is CR6; R6 is F; Y is CR7; R7 is H; Z is CR8; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (IV), (IV-A), (IVB), (IV-C) or (IV-D), or a pharmaceutically acceptable sait thereof, or a compound of Formula (V), (V-A), (V-B), (V-C) or (V-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is F or Cl; U is NR2 and V is CR4; R2 is C1-C5 alkyl, C1-C5 fluoroaikyl or 3-6 membered heterocyclyl; or R2 is CH3,1-C3H7,1-C4H9, S-C4H9, t-C4Hg, CH2F.CHF2, CH2CHF2 or oxetan-3-yl; R4 is H or C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by OH, NH2, NHCH3 or N(CH3)2! or R4 is H, CH3, C2H5, CH2OH, CH(OH)CH3, CH2CH2OH or CH2NH2; or R2 is taken together with R4 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)m as a ring member, which ring is optionally substituted by R21; or R4 is CH(OH)CH3 orC(OH)(CH3)2; X is CR6; R6 is H or F; Y is CR7; Z is CR8; R7 and R8 are H; R9 is OH; Q is NR11; R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (IV), (IV-A), (IVB), (IV-C) or (IV-D), or a pharmaceutically acceptable sait thereof, or a compound of Formula (V), (V-A), (V-B), (V-C) or (V-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four ormore, of the following features: R1 is F or Cl; U is CR3 and V is NR5; R3 is φι-Cs alkyl, C1-C5 fluoroaikyl or 3-6 membered heterocyclyl; or R3 is CH3, 1-C3H7, i-C4Hg.s-C4H9, t-C4Hg, CH2F.CHF2, CH2CHF2 or oxetan-3-yl; R5 is H or C1-C4 alkyl; or R5 is H or CH3; or R3 is taken together with R5 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24,0 and S(O)m as a ring member, which ring is optionally substituted by R21; X is CR6; R6 is H or F; Y is CR7; Z is CR8; R7 and R8 are H; R9 is OH; n is 0 and R10 is absent; Q is NR11; R11 is SO2R14; and R14is C1-C4 alkyl; p is 2; and q is 1. . — _________
In compounds of Formula (II) and (IV), R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroaikyl, where each said C1-C2 alkyl and C1-C2 fluoroaikyl is optionally substituted by R20.
In some embodiments of Formula (II) and (IV), R1 is H. In other embodiments, R1 is F or
Cl. In other embodiments, R1 is Cl. In further embodiments, R1 is C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In some such embodiments, R1 is CH3, optionally substituted by R20. In particular embodiments, R1 is CH3.
In compounds of Formula (II) and (IV), the ring system comprising U, V, X, Y and Z is a fused biaryl ring system.
In compounds of Formula (II) and (IV), U is NR2 or CR3. In some embodiments, U is NR2. In other embodiments, U is CR3.
In compounds of Formula (II) and (IV), V is N or CR4 when U is NR2; and V is NR5 when U is CR3. In some such embodiments, V is CR4. In other such embodiments, V is N. In further such embodiments, V is NR5.
In compounds of Formula (ll) and (IV), X is CR6 or N. In some embodiments, X is CR6.
In other embodiments, X is N.
In compounds of Formula (II) and (IV), Y is CR7 or N. In some embodiments, Y is CR7.
In other embodiments, Y is N.
In compounds of Formula (II) and (IV), Z is CR8 or N. In some embodiments, Z is CR8.
In other embodiments, Z is N.
In some embodiments of Formula (II) and (IV), X is CR6, Y is CR7 and Z is CR8. In some such embodiments, U is NR2and V is CR4. In other such embodiments, U is NR2and V is N. In still other such embodiments, U is CR3 and V is NR5.
In some embodiments of Formula (II) and (IV), X is N, Y is CR7, and Z is CR8.
In some embodiments of Formula (II) and (IV), X is CR6, Y is N, and Z is CR8.
In some embodiments of Formula (ll) and (IV), X is CR6, Y is CR7, and Z is N.
In some embodiments of Formula (II) and (IV), X is N, Y is N, and Z is CR8.
In some embodiments of Formula (II) and (IV), X is CR6, Y is N, and Z is N.
In some embodiments of Formula (ll) and (IV), X is N, Y is CR7; and Z is N. --------------— | In other embodiments of Formula (II) and (IV), at lea^t one of X, Y and Z is N. In some such embodiments, U is NR2and V is CR4. In other such embodiments, U is NR2and V is N. In still other such embodiments, U is CR3 and V is NR5. .....
i In further embodiments of Formula (II) and (IV), two of X, Y and Z are N. In some such embodiments, U is NR2and V is CR4. In other such embodiments, U is NR2and V is N. In still other such embodiments, U is CR3 and V is NR5.
In compounds of Formula (III) and (V), R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is.optionally substituted by R20.
In some embodiments of Formula (III) and (V), R1 is H. In other embodiments, R1 is F or Cl. In other embodiments, R1 is Cl. In further embodiments, R1 is C1-C2 alkyl or C1-C2 fluoroalkyl, — 64 where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20. In some such embodiments, R1 is CH3, optionally substituted by R20. In particular embodiments, R1 is CH3.
In compounds of Formula (III) and (V), the ring system comprising U, V, X, Y and Z is a fused biaryl ring system. ------ ...... _ ~ . *. · _ . — ,
In compounds of Formula (III) and (V), U is NR2 or CR3. In some embodiments, U is
NR2. In other embodiments, U is CR3.
In compounds of Formula (lll) and (V), V is N or CR4 when U is NR2; and V is NR5 when U is CR3. In some such embodiments, V is CR4. In other such embodiments, V is N. In further such embodiments, V is NR5. .
In compounds of Formula (II!) and (V), Xis CR6 or N. In some embodiments, Xis CR6.
In other embodiments, X is N.
In compounds of Formula (lll) and (V), Y is CR7 or N. In some embodiments, Y is CR7.
In other embodiments, Y is N.
In compounds of Formula (lll) and (V), Z is CR8 or N. In some embodiments, Z is CR8.
In other embodiments, Z is N.
In some embodiments of Formula (lll) and (V), X is CR6, Y is CR7 and Z is CR8. In some such embodiments, U is NR2and V is CR4. In other such embodiments, U is NR2and V is N. In still other such embodiments, U is CR3 and V is NR5.
In some embodiments of Formula (lll) and (V), X is N, Y is CR7, and Z is CR8.
In some embodiments of Formula (lll) and (V), X is CR6, Y is N, and Z is CR8.
In some embodiments of Formula (lll) and (V), X is CR6, Y is CR7, and Z is N.
In some embodiments of Formula (lll) and (V), X is N, Y is N, and Z is CR8.
In some embodiments of Formula (lll) and (V), X is CR6, Y is N, and Z is N.
In some embodiments of Formula (lll) and (V), X is N, Y is CR7, and Z is N.
In other embodiments of Formula (11!) and (V), at least one of X, Y and Z is N. In some such embodiments, U is NR2and V is CR4. In other such embodiments, U is NR2and V is N. In still other suc|h embodiments, U is CR3 and V is NR5. |
In further embodiments of Formula (lll) and (V), two of X, Y and Z are N. In some such embodiments, U is NR2and V is CR4. In other such embodiments, U is NR2and V is N. In still 30 other such embodiments, U is CR3 and V is NR5. I
In particular embodiments of each of Formulae (I), (II), (lll), (IV) and (V), the fused biaryl ring system comprising U, V, X, Y and Z is selected from the group consisting of:
where the * represents the point of attachment to the pyrimidine ring or pyridine ring, and
R2, R3, R4, R5, R6, R7 and R8 are as further defined herein. j
In another aspect, the invention provides a compound of Formula (VI):
or a pharmaceutically acceptable sait thereof, wherein:_____
R1, R2, R4, R6 to R23, Q, n, p and q are as defined for Formula (II); or
R1, R2, R4, R6 to R30, Q, m, n, p and q are as defined for Formula (IV).
In particular embodiments, the invention provides a compound of Formula (VI), (Vl-A), (Vl-B), (Vl-C) or (Vl-D), or a pharmaceutically acceptable sait thereof, wherein:
R1, R2, R4, R6 to R23 and n are as defined for Formula (II).
In other embodiments, the invention provides a compound of Formula (VI), (Vl-A), (VIB), (Vl-C) or (Vl-D), or a pharmaceutically acceptable sait thereof, wherein:
R1, R2, R4, R6 to R30, m and n are as defined for Formula (IV).
In some embodiments, the compound of Formula (VI) has the absolute stereochemistry as shown in one of Formulae (Vl-A), (Vl-B), (Vl-C) or (Vl-D):
or a pharmaceutically acceptable sait thereof.
Each of the aspects and embodiments described herein with respect to Formula (II) is also applicable to compounds of Formula (VI) that are not inconsistent with such aspect or embodiment. . . . .
Each of the aspects and embodiments described herein with respect to Formula (IV) is also applicable to compounds of Formula (VI) that are not inconsistent with such aspect or embodiment. .....
In certain embodiments, the invention provides a compound of Formula (VI), (Vl-A), (VIB), (Vl-C) or (Vl-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; R2 is C1-C5 alkyl; or R2 is i-C3H7; R4 is Ci-C4 alkyl, where said Ci-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 or C(OH)(CH3)2; R6 is F; R7 is H; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14 ; R14is CrC4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (VI), (Vl-A), (VIB), (Vl-C) or (Vl-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; R3 is C1-C5 alkyl; or R3 is i-C3H7; R5 is C1-C4 alkyl, where said CrC4 alkyl is optionally substituted by R20; R20is OH; R6 is F; R7 is H; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 is SO2R14; R14is CrC4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In a preferred embodiment, the invention provides a compound of Formula (VI), (Vl-A), (Vl-B), (Vl-C) or (Vl-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; R2 is C1-C5 alkyl; R4 is Ci-C4 alkyl optionally substituted by R20, where R20 is OH; R6 is F; R7 is H; R8 is H; R9 is OH; Q is O; n is 0 and R10 is absent; p is 2; and q is 1.
In another preferred embodiment, the invention provides a compound of Formula (VI), (VIA), (Vl-B), (Vl-C) or (Vi-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; R2 is C1-C5 alkyl; R4 is C1-C4 alkyl optionally Substituted by R20, where R20 is OH; R6 is F; R7 is H; F^8 is H; R9is OH; Q is NR11, where R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (VI), (Vl-A), (VIB), (Vl-C) or (Vl-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is F or Cl; R2 is C1-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R2 is CH3, i-C3H7, i-C4H9, s-C4H9, t-C4H9, CH2F, CHF2, CH2CHF2 or oxetan-3-yl; R4 is H or Ci-C4 alkyl, where said C1-C4 alkyl is optionally substituted by OH, NH2, NHCH3 or N(CH3)2; or R4 is H, CH3, C2H5, 68
CH2OH, CH(OH)CH3i CH2CH2OH or CH2NH2; R6 is H or F; R7 and R8 are H; R9 is OH; Q is NR11;
R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (VI), (Vl-A), (VIB), (Vl-C) or (Vl-D), or a pharmaceutically acceptable sait thereof, having a combination of two 5 or more, preferably three or more, and more preferably four or more, of the following features: R1 is F or Cl; R2 is C1-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R2 is CH3, i-C3H7, i-C4H9, S-C4H9, t-C4H9, CH2F, CHF2i CH2CHF2 or oxetan-3-yi; R4 is H or C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by OH, NH2, NHCH3 or N(CH3)2; or R4 is H, CH3, C2Hs, CH2OH, CH(OH)CH3i CH2CH2OH or CH2NH2; or R2 is taken together with R4 to form a 5-7 10 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)m as a ring member, which ring is optionally substituted by R21; R6 is H or F; R7 and R8 are H; R9 is OH; Q is NR11; R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In another aspect, the invention provides a compound of Formula (VII):
or a pharmaceutically acceptable sait thereof, wherein:
R1, R3, R5 to R23, Q, n, p and q are as defined for Formula (II); or
R1, R3, R5 to R30, Q, m, n, p and q are as defined for Formula (IV).
In particular embodiments, the invention provides a compound of Formula (VII), (VII-A), 20 (Vll-B), (Vll-C) or (Vll-D), or a pharmaceutically acceptable sait thereof, wherein:
R1, R2, R4, R6 to R23 and n are as defined for Formula (II).
In other embodiments, the invention provides a compound of Formula (VII), (VII-A), (VIIB), (Vil-C) or (Vll-D), or a pharmaceutically acceptable sait thereof, wherein:
R1, R2, R4, R6 to R30, m and n are as defined for Formula (IV).
In some embodiments, the compound of Formula (VII) has the absolute stereochemistry as shown in one of Formulae (VII-A), (Vll-B), (Vll-C) or (Vll-D):
(Vll-A) (Vll-B)
(Vll-C) (Vll-D) or a pharmaceutically acceptable sait thereof.
Each of the aspects and embodiments described herein with respect to Formula (II) is also applicable to compounds of Formula (VII) that are not inconsistent with such aspect or embodiment.
Each of the aspects and embodiments described herein with respect to Formula (IV) is also applicable to compounds of Formula (VII), that are not inconsistent with such aspect or embodiment.
In certain embodiments, the invention provides a compound of Formula (VII), (Vll-A), (VIIB), (Vll-C) or (Vll-D), or a pharmaceutically acceptable s^ilt thereof, having a combination of two or more, preferably three or more, and more preferably four or more, ofthe following features: R1 is Cl; R3 is C1-C5 alkyl; or R3 is 1-C3H7; R5 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20; R20 is OH; R6 is F; R7 is H; R8 is H; R9 is OH; Q is O; or Q is NR11, where R11 isSO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In a preferred embodiment, the invention provides a compound of Formula (VII), (Vll-A), (Vll-B), (Vll-C) or (Vll-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; R3 is C1-C5 alkyl; R5 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; R6 is F; R7 is H; R8 is H; R9is OH; Q is O; n is 0 and R10 is absent; p is 2; and q is 1.
In another preferred embodiment, the invention provides a compound of Formula (VII), (Vll-A), (Vll-B), (Vll-C) or (Vll-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl;
R3 is C1-C5 alkyl; R5 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; R6 is F; R7 is
H; R8 is H; R9is OH; Q is NR11, where R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (VII), (Vll-A), (VIIB), (Vll-C) or (Vll-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, ofthe following features: R1 is F or Cl; R3 is C1-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R3 is CH3, 1-C3H7, i-C4Hg, S-C4H9, t-C4Hg, CH2F.CHF2, CH2CHF2 or oxetan-3-yl; R5 is H or C1-C4 alkyl; or R5 is H or CH3;R6 is H or F; R7 and R8 are H; R9 is OH; Q is NR11; R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1. ------ -----In certain embodiments, the invention provides a compound of Formula (VII), (Vll-A), (VIIB), (Vll-C) or (Vll-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is F or CI; R3 is C1-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R3 is CH3,1-C3H7, i-C4Hg, s-C4Hg, t-C4Hg, CH2F.CHF2, CH2CHF2 or oxetan-3-yl; R5 is H or C1-C4 alkyl; or R5 is H or CH3; or R3 is taken together with R5 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)m as a ring member, which ring is optionally substituted by R21; R6 is H or F; R7 and R8 are H; R9 is OH; Q is NR11;R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In another aspect, the invention provides a compound of Formula (VIII):
or a pharmaceutically acceptable sait thereof, wherein:
R1,' R2, R6 to R23, Q, n, p and q are as defined for Formula (II); or
R1 J R2, R6 to R30, Q, m, n, p and q are as defined for Formôla (IV).
In particular embodiments, the invention provides a compound of Formula (VIII), or a pharmaceutically acceptable sait thereof, wherein: 7 R1, R2, R4, R6 to R23 and n are as defined for Formula (liy— __ _
In other embodiments, the invention provides a compound of Formula (VIII), or a pharmaceutically acceptable sait thereof, wherein:
R1, R2, R4, R6 to R30, m and n are as defined for Formula (IV).
In some embodiments, the compound of Formula (VIII) has the absolute stereochemistry as shown in one of Formulae (Vlll-A), (Vlll-B), (Vlll-C) or (Vlll-D):
(Vlll-C) (Vlll-D) or a pharmaceutically acceptable sait thereof. Each of the aspects and embodiments described herein with respect to Formula (II) is also applicable to compounds of Formula (VIII) that are not inconsistent with such aspect or embodiment.
Each of the aspects and embodiments described herein with respect to Formula (IV) is also applicable to compounds of Formula (VIII) that are not inconsistent with such aspect or embodiment. | I
In an embodiment, the invention provides a compound of Formula (VIII), (Vlll-A), (Vlll-B), (Vlll-C) or (Vlll-D), or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; R2 is C1-C5 alkyl optionally substituted by R20, where R20 is OH; R6 is F; R7 is H; R8 is H; R9is OH; Q is O; or Q is NR11; R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In certain embodiments, the invention provides a compound of Formula (VIII), (Vlll-A), 20 (Vlll-B), (Vlll-C) or (Vlll-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is F or Cl; R2 is C1-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R2 is CH3, i-C3H7,1-C4H9. S-C4H9, t-C4H9, CH2F, CHF2, CH2CHF2 or oxetan-3-yl; R6 is H or F; R7 and R8 are H; R9 is OH; Q is O; or Q is NR11; R11 is SO2R14; R14is C1-C4 alkyl; n is 0 and R10 is absent; p is 2; and q is 1.
In particular embodiments of Formulae (I) to (VIII), the ring comprising Q is selected from the group consisting of:
where the * represents the point of attachment to the 2-amino substituent.
In particular embodiments of Formulae (I) to (VIII), the ring comprising Q is selected from the group consisting of:
where the * represents the point of attachment to the 2-amino substituent.
In particular embodiments of Formulae (I) to (VIII), the ring comprising Q is selected from 5 the group consisting of:
where the * represents the point of attachment to the 2-amino substituent. !
In spécifie embodiments of Formulae (I) to (VIII), the ring comprising Q is selected from the group consisting of:
where the * represents the point of attachment to the 2-amino substituent.
or a pharmaceutically acceptable sait thereof, wherein:
R1, R2, R4, R6 to R11, R14 to R23 and n are as defined for Formula (II); or
R1, R2, R4, R6 to R11, R14 to R30, m and n are as defined for Formula (IV).
In somé embodiments, the invention provides a compound of Formula (IX), or a pharmaceutically acceptable sait thereof, wherein R1, R2, R4, R6 to R11, R14 to R23 and n are as defined for Formula (II).
In embodiments of Formula (IX) wherein the substituent groups are as defined for Formula (II), the invention provides a compound of Formula (IX): —
R1
R7
H
R6
R8
N
R?
(R'°)n
R2
R4
R11 (IX) or a pharmaceutically acceptable sait thereof, wherein:
R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
R2 is H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted .byR20; .
I R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3; '
R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or । C1-C2 fluoroalkoxy, where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 । fluoroalkoxy is optionally substituted by R20; !
R9 is H, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
R11 is H, C1-C4 alkyl, Ç1-C4 fluoroalkyl, SO2R14, SQ2NR15R16, COR17, COOR17 or CONR18R19;
R14 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R15 and R16 is independently H or CH3;
R17is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said
C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN or NR22R23 * 25;
each R21 is independently F, OH, CN, NR^R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2;
each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl; or
R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH; and n is 0,1, 2, 3 or 4.
In other embodiments, the invention provides a compound of Formula (IX’), or a pharmaceutically acceptable sait thereof, wherein R1, R2, R4, R6 to R11, R14 to R23 and n are as defined for Formula (IV).
In embodiments of Formula (IX) wherein the substituent groups are as defined for Formula (IV), the invention provides a compound of Formula (IX’):
or a pharmaceutically acceptable sait thereof, wherein:
R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and
C1-C2 fluoroalkyl is optionally substituted by R20; i
R2 is H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said
C3-Ce cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21; and
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20; or
R2 can be taken together with R4 to form a 5-7 membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24, O and S(O)m as a ring member, which ring is optionally substituted by R ,
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3; —- R7 and R8 are independently H, F, Cl, CN, Ci-C2 alkyl, Ci-C2 fluoroalkyl, Ci-C2 alkoxy or C1-C2 fiuoroalkoxy, where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 fiuoroalkoxy is optionally substituted by R20;
R9 is H, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
R11 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or CONR18R19;
R14 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R15 and R16 is independently H or CH3;
R17 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, C1-C2 alkoxy, C1-C2 fiuoroalkoxy, CN or N R22R23;
each R21 is independently F, OH, CN, NR22R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fiuoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fiuoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2;
each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl; or
R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH;
R24 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, SO2R25, SO2NR28R27, COR28, COOR28 or
CONR29R30; | I
R25 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R26 and R27 is independently H or CH3;
R28 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fiuoroalkoxy, CN, NH2, NHCH3 or N(CH3)2;
each R29 and R30 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fiuoroalkoxy, CN, NH2, NHCH3 or N(CH3)2;
m is 0,1 or 2; and n is 0,1,2, 3 or 4.
In some embodiments, the compound of Formula (IX) or (IX’) has the absolute stereochemistry as shown in one of Formulae (IX-A), (IX-B), (IX-C) or (IX-D), or Formulae (IXA), (IX’-B), (IX’-C) or (IX’-D)
or a pharmaceutically acceptable sait thereof.
— Each of the aspects and embodiments described herein with respect to Formula (II) is also applicable to compounds of Form|jlae (IX), (1X-A), (IX-B), (IX-C) or (IX-D) that are not| inconsistent with such aspect or embodiment.
Each of the aspects and embodiments described herein with respect to Formula (IX) is also applicable to compounds of Formulae (IX-A), (IX-B), (IX-C) or (IX-D). |
In certain embodiments, the invention provides a compound of Formula (IX), (IX-A), (IXB), (IX-C) or (IX-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is CI,\R2 is C1-C5 alkyl; or R2 is 1-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 or C(OH)(CH3)2; R6 is F; R7 is H; R8 is H; R9 is OH; R11 is SO2R14; R14 is C1-C4 alkyl; n is 0 and R10 is absent.
79
In a preferred embodiment, the invention provides a compound of Formula (IX), (IX-A), (IX-B), (IX-C) or (IX-D),or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; R2 is C1-C5 alkyl; or R2 is i-C3H7; R4 is C1-C4 alkyl optionally substituted by R20; where R20 is OH; or R4 is
CH(OH)CH3 orC(OH)(CH3)2; R6 is F; R7 is H; R8 is H; R9is OH; R11 is SO2R14; R14is C1-C4 alkyl;
n is 0 and R10 is absent.
In certain embodiments, the invention provides a compound of Formulae (IX), (IX-A), (IXB), (IX-C) or (IX-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features:R1 is F or Cl; R2 is C1-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R2 is CH3, i-C3H7, 10 i-C4H9. s-C4H9, t-C4H9, CH2F, CHF2i CH2CHF2 or oxetan-3-yl; R4 is H or C1-C4 alkyl, where said
C1-C4 alkyl is optionally substituted by OH, NH2, NHCH3 or N(CH3)2î or R4 is H, CH3, C2H5, CH2OH, CH(OH)CH3, CH2CH2OH or CH2NH2; R6 is H or F; R7 and R8 are H; R9 is OH; n is 0 and R10 is absent; R11 is SO2R14; and R14is C1-C4 alkyl. —
In spécifie embodiments, the invention provides a compound of Formulae (IX), (IX-A), (IX15 B), (IX-C) or (IX-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; R2 is C1-C5 alkyl; R4 is H or C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20; R6 is F; R7 and R8 are H; R9is OH; R11 is SO2R14; R14is C1-C4 alkyl; and R20 is OH.
Each of the aspects and embodiments described herein with respect to Formula (IV) is 20 also applicable to compounds of Formulae (IX’), (IX’-A), (IX’-B), (IX’-C) or (IX’-D) that are not inconsistent with such aspect or embodiment.
Each of the aspects and embodiments described herein with respect to Formula (IX’) is also applicable to compounds of Formulae (IX’-A), (IX’-B), (IX’-C) or (IX’-D). .
In certain embodiments, the invention provides a compound of Formulae (IX’), (IX’-A), 25 (IX’-B), (IX’-C) or (IX’-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more,ofthe following features: | R1 is F or Cl; R2 is C1-C5 alkyl, Ci-C£fluorôalkyl |)r 3-6 membered heterocyclyl; or R2 is CH3, iC3H7, i-C4H9, s-C4H9, t-C4H9, CH2F, CHF2, CH2CHF2 or oxetan-3-yl; R4 is H or C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by OH, NH2, NHCH3 orN(CH3)2; or R4 is H, CH3, C2H5, 30 CH2OH, CH(OH)CH3, CH2CH2OH or CH2NH2; or R2 is taken together with R4 to form a 5-7
I membered heterocyclic ring, optionally containing an additional heteroatom selected from NR24,
O and S(O)m as a ring member, which ring is optionally substituted by R21; R6 is H or F; R7 and R8 are H; R9 is OH; n is 0 and R10 is absent; R11 is SO2R14; and R14 is C1-C4 alkyl.
In spécifie embodiments, the invention provides a compound of Formulae (IX’), (IX’-A), 35 (IX’-B), (IX’-C) or (IX’-D), or a pharmaceutically acceptable sait thefêof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features:R1 is F or Cl; R2 is CH3,1-C3H7, i-C4H9,s-C4H9, t-C4H9, CH2F, CHF2, CH2CHF2 or oxetan3-yl; R4 is H, CH3, C2H5, CH2OH, CH(OH)CH3, CH2CH2OH or CH2NH2; or R2 is taken together with R4 to form a 5-membered heterocyclic ring optionally substituted by R21; each R21 is independently F, OH, NH2, Ci-C2 alkyl or Ci-C2 fluoroalkyl; R6 is F; R7 and R8 are H; R9 is OH; n is 0 and R10 is absent; R11 is SO2R14; and R14is CH3.
In spécifie embodiments, the invention provides a compound of Formulae (IX’), (IX’-A), (IX’-B), (IX’-C) or (IX’-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, ofthe following features: R1 is Cl; R2 is C1-C5 alkyl; R4 is H or C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted 10 by R20; R6 is F; R7 and R8 are H; R9 is OH; R11 is SO2R14; R14 is C1-C4 alkyl; and R20 is OH.
In another aspect, the invention provides a compound of Formula (X):
or a pharmaceutically acceptable sait thereof, wherein:
R1 is H, F, Cl, CN, Ci-C2 alkyl or Ci-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
R2 is H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
। R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy (j)r C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20;
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3;
। R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy, where each said C1-C2 alkyl, C1-C2; fluoroalkyl, C1-C2 alkoxy and C1-C2 fluoroalkoxy is optionally substituted by R20;
R9 is H, OH, NH2, NHCH3 or N(CH3)2; ________ each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN or N R22R23;
each R21 is independently F, OH, CN, N R22R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2!
each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl; or
R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH; and n is 0,1, 2, 3 or 4.
In another aspect, the invention provides a compound of Formula (XI):
or a pharmaceutically acceptable sait thereof, wherein:
R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
R2 is H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20;
or
R2 can be taken together with R4 to form a 5-7 membered heterocyclic ring, optionally containing dn additional heteroatom selected from NR24, O and S(0)m as a ring member, which ring is optionally substituted by R21;
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3; I i
R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy, where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 fluoroalkoxy is optionally substituted by R20;
R9is H, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN or N R22 R23;
each R21 is independently F, OH, CN, NR22R23, C1-C4 alkyl, C1-C4 fluoroaikyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroaikyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2î each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkÿl; or 5 R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, which is optionally substituted by F or OH;
R24 is H, C1-C4 alkyl, C1-C4 fluoroaikyl, SO2R25, SO2NR26R27, COR28, COOR28 or CONR29R30;
R25 is C1-C4 alkyl or C1-C4 fluoroaikyl; 10 each R26 and R27 is independently H or CH3;
R28 is C1-C4 alkyl or C1-C4 fluoroaikyl, where each said C1-C4 alkyl and C1-C4 fluoroaikyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NH2, NHCH3 or N(CH3)2!
each R29 and R30 is independently H, C1-C4 alkyl or C1-C4 fluoroaikyl, where each said C1-C4 alkyl and C1-C4 fluoroaikyl is optionally substituted by OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, 15 CN, NH2, NHCH3 or N(CH3)2;
m is 0,1 or 2; and n is 0,1, 2, 3 or 4.
In some embodiments, the compound of Formula (X) or (XI) has the absoiute stereochemistry as shown in one of Formulae (X-A), (X-B), (X-C) or (X-D) or (Xl-A), (Xl-B), (Xl-C) or (Xl-D):
(X-C) (X-D) (Xl-C) (Xl-D) or a pharmaceutically acceptable sait thereof.
Each of the aspects and embodiments described herein with respect to Formula (II) is also applicable to compounds of Formulae (X), (X-A), (X-B), (X-C) or (X-D) that are not inconsistent with such aspect or embodiment.
Each of the aspects and embodiments described herein with respect to Formula (X) is also applicable to compounds of Formulae (X-A), (X-B), (X-C) or (X-D).
In certain embodiments, the invention provides a compound of Formula (X), (X-A), (X-B), (X-C) or (X-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; R2 is C1-C5 alkyl; or R2 is i-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; R6 is F; R7 is H; R8 is H; R9 is OH; n is 0 and R10 is absent.
In a preferred embodiment, the invention provides a compound of Formula (X), (X-A), (XB), (X-C) or (X-D),or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; R2 is C1-C5 alkyl; or R2 is i-C3H7; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; R6 is F; R7 is H; R8 is H; R9 is OH; n is 0 and R10 is absent.
In certain embodiments, the invention provides a compound of Formulae (X), (X-A), (XB), (X-C) or (X-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is F or Cl; R2 is C1-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R2 is CH3, i-C3H7, iC4H9i s-C4H9, t-C4H9, CH2F, CHF2i CH2CHF2 or oxetan-3-yl; R4 is H or C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by OH, NH2, NHCH3 or N(CH3)2; or R4 is H, CH3, C2Hs, CH2OH, CH(OH)CH3i C(OH)(CH3)2 orCH2CH2OH; R6 is H or F; R7 is H; R8 is H; R9 is OH; n is 0 and R10 is absent.
Each of the aspects and embodiments described herein with respect to Forr|nula (IV) is also applicable to compounds of Formulae (XI), (Xl-A), (Xl-B), (Xl-C) or (Xl-D) that are not inconsistent with such aspect or embodiment.
Each of the aspects and embodiments described herein with respect to Formula (XI) is also applicable to compounds of Formulae (Xl-A), (Xl-B), (Xl-C) or (Xl-D). I
In certain embodiments, the invention provides a compound of Formula (XI), (Xl-A), (XIB), (Xl-C) or (Xl-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is Cl; R2 is C1-C5 alkyl; or R2 is i-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; R6 is F; R7 is H; R8 is
H; R9 is OH; n is 0 and R10 is absent.
In a preferred embodiment, the invention provides a compound of Formula (XI), (Xl-A), (Xl-B), (Xl-C) or (Xl-D),or a pharmaceutically acceptable sait thereof, wherein: R1 is Cl; R2 is C1-C5 alkyl; or R2 is i-C3H7; R4 is C1-C4 alkyl optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; R6 is F; R7 is H; R8 is H; R9 is OH; n is 0 and R10 is absent.
In certain embodiments, the invention provides a compound of Formulae (XI), (Xl-A), (XIB), (Xl-C) or (Xl-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: R1 is F or Cl; R2 is C1-C5 alkyl, C1-C5 fluoroalkyl or 3-6 membered heterocyclyl; or R2 is CH3, i-C3H7, i-C4H9, S-C4H9, t-C4H9, CH2F, CHF2i CH2CHF2 or oxetan-3-yl; R4 is H or C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by OH, NH2, NHCH3 or N(CH3)2î or R4 is H, CH3, C2H5, CH2OH, CH(OH)CH3, C(OH)(CH3)2 orCH2CH2OH; R6 is H or F; R7 is H; R8 is H; R9 is OH; n is 0 and R10 is absent.
In another aspect, the invention provides a compound of Formula (XII):
or a pharmaceutically acceptable sait thereof, wherein:
A is N or CH;
R1 is H, F or Cl;
R2 is H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-Ce cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy, C1-C4 fluoroalkoxy, C(O)Ra, C(O)NRb2, C3-Cs cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20, each said C3-Ce cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21, Ra is C1-C2 alkyl, and each Rb is independently H or C1-C2 alkyl; ..... . ·
R6 is H or F;
R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy; .
Q is O; or
QisNR11;
R11 is SO2R14 or COR17;
R14 is C1-C4 alkyl or C1-C4 fluoroalkyl;
R17 is C1-C4 alkyl, C1-C4 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
each R20 is independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN, NR22R23, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
each R21 is independently F, OH, CN, N R22R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 15 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2;
each R22 and R23 is independently H, C1-C3 alkyl, C1-C3 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C3 alkyl and C1-C3 fluoroalkyl is optionally further substituted by OH, C1-C2 alkoxy or C1-C2 fluoroalkoxy and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally further substituted by F, OH, C1-C2 alkyl, C1-C2 fluoroalkyl, 20 C1-C2 alkoxy or C1-C2 fluoroalkoxy; or
R22 and R23 may be taken together with the nitrogen atom to which they are attached to form an azetidinyl ring, where said ring is optionally substituted by F, OH, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy.
In some embodiments, the compound of Formula (XII) has the absolute stereochemistry 25 as shown in one of Formulae (Xll-A), (Xll-B), (Xll-C) or (Xll-D):
(Xll-A) (Xll-B)
(Xll-C) (Xll-D) or a pharmaceutically acceptable sait thereof.
Each of the aspects and embodiments described herein with respect to Formula (l)-(XI) 5 is also applicable to compounds of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D) that are not inconsistent with such aspect or embodiment.
Each of the aspects and embodiments described herein with respect to Formula (XII) is also applicable to compounds of Formulae (Xll-A), (Xll-B), (Xll-C) or (Xll-D).
In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), A is N. In some 10 embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), A is CH.
In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), R1 is Cl.
In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), R2 is C1-C5 alkyl or C1-C5 fluoroalkyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20. In some such embodiments, R2 is C1-C5 alkyl. In spécifie embodiments, R2 15 is isopropyl.
In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), R2 is C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21.
In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), R4 is H, C1-C4 20 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optioifially substituted by R20.
In some such embodiments, R20 is OH. In some embodiments, R4 is C1-C4 alkyl optionally substituted by R20where R20 is OH. In spécifie embodiments, R4 is CH(OH)CH3 orC(OH)(CH3)2. I l ! In other such embodiments, R20 is C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where 25 each said GrCe cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21. In some such embodiments, R4 is C1-C4 alkyl optionally substituted by R20 where R20 is C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21. - ------In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), R4 is C(O)Ra, 30 C(O)NRb2, Ra is C1-C2 alkyl, and each Rb is independently H or C1-C2 alkyl.
In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), R4 is C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21.
In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), R6 is F.
In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), R7 and R8 are independently H or F. In some such embodiments, R7 and R8 are H.
In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), Q is O.
In some embodiments of Formulae (XII), (Xll-A), (Xll-B), (Xll-C) or (Xll-D), Q is NR11. In some such embodiments, R11 is SO2R14. In some such embodiments, R14is C1-C4 alkyl. In some such embodiments, R11 is COR17. In some such embodiments, R17 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20. In some such embodiments, R17is C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21.
In certain embodiments, the invention provides a compound of Formula (XII), (Xll-A), (XIIB), (Xll-C) or (Xll-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, ofthe following features: A is N; R1 is Cl; R2 is C1-C5 alkyl; or R2 is 1-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; R6 is F; R7 is H; R8 is H; and Q is O.
In certain embodiments, the invention provides a compound of Formula (XII), (Xll-A), (XIIB), (Xll-C) or (Xll-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: A is N; R1 is Cl; R2 is C1-C5 alkyl; or R2 is 1-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 or C(OH)(CH3)2; R6 is F; R7 is H; R8 is H; Q is NR11; R11 is SO2R14; and R14is C1-C4 alkyl.
In certain embodiments, the invention provides a compound of Formula (XII), (Xll-A), (XIIB), (XIl-c|) or (Xll-D), or a pharmaceutically acceptable sait there|of, having a combination of two or more, preferably three or more, and more preferably four or more, of the following features: A is CH; R1 is Cl; R2 is C1-C5 alkyl; or R2 is 1-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; R6 is F; R7 is H; R8 is H; and Q is O. i
In certain embodiments, the invention provides a compound of Formula (XII), (Xll-A), (XIIB), (Xll-C) or (Xll-D), or a pharmaceutically acceptable sait thereof, having a combination of two or more, preferably three or more, and more preferably four or more, ofthe following features: A is CH; R1 is Cl; R2 is C1-C5 alkyl; or R2 is 1-C3H7; R4 is C1-C4 alkyl, where said C1-C4 alkyl is A 88 optionally substituted by R20, where R20 is OH; or R4 is CH(OH)CH3 orC(OH)(CH3)2; R6 is F; R7 is H; R8 is H; Q is NR11; R11 is SO2R14; and R14is C1-C4 alkyl.
In another aspect, the invention provides a compound selected from the group consisting of: Γ .
(3R,4R)-4-({5-chloro-4-[4-fluoro-2-methyl-1 -(propan-2-yl)-1 H-benzimidazol-6yl]pyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol;
(3R,4R)-4-({4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2yl}amino)-1-(methanesulfonyl)piperidin-3-ol;
4-(1-tert-butyl-4-fIuoro-1H-benzimidazol-6-yl)-5-fluoro-N-(1-methylpiperidin-410 yI)pyrimidin-2-amine;
(3R,4R)-4-({5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol;
(3R,4R)-4-({5-ethyl-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol;
(3R,4R)-4-({5-chloro-4-[1-(propan-2-yl)-1 H-benzotriazol-6-yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol;
(3R,4R)-4-({4-[4-fluoro-2-methyl-1 -(propan-2-yI)-1 H-benzimidazol-6-yl]-5methylpyrimidin-2-yI}amino)-1-(methanesuifonyl)piperidin-3-ol;
(3R,4R)-4-({4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]-520 methoxypyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol;
(3R,4R)-4-({4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazoI-6-yl]-5-(propan-2yl)pyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol;
(3R,4R)-4-({5-chloro-4-[4-fluoro-2-methyl-1-(oxetan-3-yl)-1H-benzimidazol-6yl]pyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol,· (3R,4R)-4-({5-chloro-4-[4-fluoro-2-(hydroxymethyl)-1-(propan-2-yl)-1H-benzimidazol-6yl]pyrimidin-2-yI}amino)-1-(methanesulfonyl)piperidin-3-ol;
(3R,4R)-4-|({4-[1-(azetidin-3-yl)-4-fluoro-2-methyl-1 H-benzimidazol(-6-yl]-5fluoropyrimidin-2-yl}amino)-1-(methànesulfonyl)piperidin-3-ol;
(3R,4R)-4-{[4-(1-tert-butyl-1H-benzimidazol-6-yl)-5-fluoropyrimidin-2-yl]amino}-130 (methanesulfonyl)piperidin-3-ol; j (3R,4R)-4-({5-fluoro-4-[2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2yl}amino)-1-(methanesulfonyl)piperidin-3-ol;
(3R,4R)-4-({5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin2-yl}amino)piperidin-3-ol;
1 -[(3R,4R)-4-({5-fIuoro-4-[4-fIuoro-2-methyl-1 -(propan-2-yl)-1 H-benzimidazol-6yl]pyrimidin-2-yl}amino)-3-hydroxypiperidin-1-yl]ethanone;
(3R,4R)-4-{[4-(1-tert-butyl-4-fluoro-1H-benzimidazol-6-yl)-5-fIuoropyrimidin-2-yl]amino}1-(methanesulfonyl)pipendin-3-ol;
(3S,4S)-4-({5-fIuoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin2-yl}amino)-1-methylpiperidin-3-ol;
(3S,4S)-4-({5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin2-yl}amino)-1-(methanesuIfonyl)piperidin-3-ol;
1,5-anhydro-3-[(5-chloro-4-{4-fluoro-2-[(1 R)-1-hydroxyethyl]-1-(propan-2-yl)-1 Hbenzimidazol-6-yl}pyrimidin-2-yl)amino]-2,3-dideoxy-D-threo-pentitol;
1,5-anhydro-3-[(5-chloro-4-{4-fluoro-2-[(1S)-1-hydroxyethyl]-1-(propan-2-yl)-1Hbenzimidazol-6-yl}pyrimidin-2-yI)amino]-2,3-dideoxy-D-threo-pentitol;
(2S)-1-[(3R,4R)-4-{[4-(1-tert-butyl-4-fIuoro-1H-benzimidazol-6-yl)-5-chloropyrimidin-2yl]amino}-3-hydroxypiperidin-1-yI]-2-hydroxypropan-1-one;
(3R,4R)-4-({5-chIoro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1Hbenzimidazol-6-yl]pyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol;
(3R,4R)-4-[(5-chloro-4-{4-fluoro-2-[(1 R)-1 -hydroxyethyl]-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl}pyrimidin-2-yl)amino]-1-(methanesulfonyl)piperidin-3-ol; and
1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-t/jreo-pentitol;
or a pharmaceutically acceptable sait thereof.
In another aspect, the invention provides a compound selected from the group consisting of the compounds exemplified in the Examples provided herein, including A1-A94, B1-B2, 01C2, D1-D6, E1, F1-F33, G1 and H1-H11, inclusive, or a pharmaceutically acceptable sait thereof.
In another aspect, the invention provides (3R,4R)-4-[(5-chloro-4-{4-fIuoro-2-[(1R)-1hydroxyethyl]-1-(propan-2-yl)-1H-benzimidazol-6-yl}pyrimidin-2-yl)amino]-1(methanesulfonyl)piperidin-3-ol, or a pharmaceutically acceptable sait thereof.
In another aspect, the invention provides (3R,4R)-4-[(5-chloro-4-{4-fluoro-2-[(1R)-1hydroxyethyl]-1-(propan-2-|4)-1H-benzimidazol-6-yl}pyrimidin-2-yl)amino]-1- | (methanesuIfonyl)piperidin-3-ol.
In another aspect, the invention provides a pharmaceutically acceptable sait of (3R,4R)4-[(5-chloro-4-{4-fluoro-2-[(1 R)-1 -hydroxyethyl]-1 -(propan-2-yl)-1 H-benzimidazol-6-yl}pyrimidin2-yl)amino]-1-(methanesulfonyl)piperidin-3-ol. I
In another aspect, the invention provides 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-Dthreo-pentitol, or a pharmaceutically acceptable sait thereof.
— 90
In another aspect, the invention provides 1,5-anhydro-3-({5-chloro-4-[4-fIuoro-2-(2hydroxypropan-2-yI)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-Dforeo-pentitol.
In another aspect, the invention provides a pharmaceutically acceptable sait of 1,55 anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yI)-1 -(propan-2-yl)-1 H-benzimidazoI-6yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-t/7reo-pentitol.
A pharmaceutical composition refers to a mixture of one or more of the compounds of the invention, or a pharmaceutically acceptable sait, solvaté, hydrate or prodrug thereof as an active ingrédient, and at least one pharmaceutically acceptable carrier or excipient. In some 10 embodiments, the pharmaceutical composition comprises two or more pharmaceutically acceptable carriers and/or excipients. In other embodiments, the pharmaceutical composition further comprises at least one additional anticancer therapeutic agent.
In one aspect, the invention provides a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable sait thereof, and a pharmaceutically 15 acceptable carrier or excipient. In some embodiments, the pharmaceutical composition comprises two or more pharmaceutically acceptable carriers and/or excipients.
In some embodiments, the pharmaceutical composition further comprises at least one additional anti-cancer therapeutic agent. In some such embodiments, the combination provides an additive, greater than additive, or synergistic anti-cancer effect.
The term “additive” is used to mean that the resuit of the combination of two compounds, components or targeted agents is no greater than the sum of each compound, component or targeted agent individually.
The term “synergy” or “synergistic” are used to mean that the resuit of the combination of two compounds, components or targeted agents is greater than the sum of each compound, 25 component or targeted agent individually. This improvement in the disease, condition or disorder being treated is a “synergistic” effect. A “synergistic amount” is an amount of the combination of the two compounds, components (or targeted agents that results in a synergistic effecjt, as “synergistic” is defined herein.
Determining a synergistic interaction between one or two components, the optimum range 30 for the effect and absolute dose ranges of each component for the effect may be definitively measured by administration of the components over different dose ranges, and/or dose ratios to patients in need of treatment. However, the observation of synergy in in vitro models or in vivo models can be prédictive of the effect in humans and other species and /n vitro models or in vivo models exist, as described herein, to measure a synergistic effect. The results of such studies . 35 can also be used to predict effective dose and plasma concentration ratio ranges and the absolute _ 91 doses and plasma concentrations required in humans and other species such as by the application of pharmacokinetic and/or pharmacodynamies methods.
Unless indicated otherwise, ail référencés herein to the inventive compounds include référencés to salts, solvatés, hydrates and complexes thereof, and to solvatés, hydrates and 5 complexes of salts thereof, including polymorphs, stereoisomers, and isotopically labelled versions thereof.
Compounds of the invention may exist in the form of pharmaceutically acceptable salts such as, e.g., acid addition salts and base addition salts of the compounds of one of the formulae provided herein. As used herein, the term “pharmaceutically acceptable sait” refers to those salts 10 which retain the biological effectiveness and properties of the parent compound. The phrase “pharmaceutically acceptable salt(s), as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be présent in the compounds of the formulae disclosed herein.
For example, the compounds of the invention that are basic in nature are capable of 15 forming a wide variety of salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animais, it is often désirable in practice to initially isolate the compound of the présent invention from the reaction mixture as a pharmaceutically unacceptable sait and then simply couvert the latter back to the free base compound by treatment with an alkaline reagent and subsequently couvert the latter free base to 20 a pharmaceutically acceptable acid addition sait. The acid addition salts of the base compounds of this invention can be prepared by treating the base compound with a substantially équivalent amount of the selected minerai or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or éthanol. Upon évaporation of the solvent, the desired solid sait is obtained. The desired acid sait can also be precipitated from a solution of the free base in 25 an organic solvent by adding an appropriate minerai or organic acid to the solution.
The acids that may be used to prépare pharmaceutically acceptable acid addition salts of such basic compounds of those that form |non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, 30 citrate, acid citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, giuconate, glucuronate, saccharatë, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate salts.
Examples of salts include, but are not limited to, acetate, acrylate, benzenesulfonate, benzoate (such as chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, and 35 methoxybenzoate), bicarbonaté, bisulfate, bisulfite, bitartrate, borate, bromide, butyne-1,4-dioate, calcium edetate, camsylate, carbonate, chloride, caproate, caprylate, _ 92 clavulanate, citrate, decanoate, dihydrochloride, dihydrogenphosphate, edetate, edislyate, estolate, esylate, ethylsuccinate, formate, fumarate, gluceptate, gluconate, glutamate, glycollate, glycollylarsanilate, heptanoate, hexyne-1,6-dioate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, γ-hydroxybutyrate, iodide, isobutyrate, isothionate, lactate, 5 lactobionate, laurate, malate, maleate, malonate, mandelate, mesylate, metaphosphate, methane-sulfonate, methylsulfate, monohydrogenphosphate, mucate, napsylate, naphthalene-1-sulfonate, naphthalene-2-suIfonate, nitrate, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phenylacetates, phenylbutyrate, phenylpropionate, phthalate, phospate/diphosphate, polygalacturonate, propanesulfonate, propionate, propiolate, 10 pyrophosphate, pyrosulfate, salicylate, stéarate, subacetate, suberate, succinate, sulfate, sulfonate, sulfite, tannate, tartrate, teoclate, tosylate and valerate salts.
Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary, and tertiary amines and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, 15 potassium, magnésium, manganèse, iron, copper, zinc, aluminum and lithium.
The compounds of the invention that include a basic moiety, such as an amino group, may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above.
Alternatively, the compounds useful that are acidic in nature may be capable of forming 20 base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali métal or alkaline-earth métal salts and particularly, the sodium and potassium salts. These salts are ail prepared by conventional techniques. The Chemical bases which are used as reagents to préparé the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds herein. These salts may be prepared by 25 any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali métal hydroxide or alkaline earth | métal hydroxide, or the like. These salts can also tj»e prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced 30 j pressure. Alternatively, they may also be prepared I by mixing lower alkanolic solutions of the I acidic compounds and the desired alkali métal alkbxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantifies of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product. ------ — — ·
The Chemical bases that may be used as reagents to préparé pharmaceutically acceptable base salts of the compounds of the invention that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to, those derived from such pharmacologically acceptable cations such as alkali métal cations (e.g., potassium and sodium) and alkaline earth métal cations (e.g., calcium and magnésium), ammonium or water-soluble amine addition salts such as. . : N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.
Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
For a review on suitable salts, see Handbook of Pharmaceutical Salts: Properties, Sélection, and Use by Stahl and Wermuth (Wiley-VCH, 2002). Methods for making pharmaceutically acceptable salts of compounds of the invention, and of interconverting sait and free base forms, are known to one of skill in the art.
Salts of the présent invention can be prepared according to methods known to those of skill in the art. A pharmaceutically acceptable sait of the inventive compounds can be readily prepared by mixing together solutions of the compound and the desired acid or base, as appropriate. The sait may precipitate from solution and be collected by filtration or may be recovered by évaporation of the solvent. The degree of ionization in the sait may vary from completely ionized to almost non-ionized.
Itwill be understood bythose of skill in the artthatthe compounds ofthe invention in free base form having a basic functionality may be converted to the acid addition salts by treating with a stoichiometric excess of the appropriate acid. The acid addition salts of the compounds of the invention may be reconverted to the corresponding free base by treating with a stoichiometric excess of a suitable base, such as potassium carbonate or sodium hydroxide, typically in the presence of aqueous solvent, and at a température of between about 0° C and 100° C. The free base form may be isolated by conventional means, such as extraction with an organic solvent. In addition, acid addition salts ofthe compounds ofthe invention may be interchanged bytaking — advantjage of differential solubilities of the salts, volatilities or ^cidities of the acids, or by treating with the appropriately loaded ion exchange resin. For example, the interchange may be affected by the reaction of a sait of the compounds of the invention with a slight stoichiometric excess of an acid of a lower pK than the acid component of the starting sait. This conversion is typically carried out at a température between about 0°C and the boiling point of the solvent being used as the medium for the procedure. Similar exchanges are possible with base addition salts, typically via the intermediacy of the free base form. .
The compounds ofthe invention may exist in both unsolvated and solvated forms. When.... ...... the solvent or water is tightly bound, thé complex will hâve a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvatés and hygroscopic compounds, the water/solvent content will be dépendent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm. The term 'solvaté’ is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molécules, for example, éthanol. The term ‘hydrate’ is employed when the solvent is water. Pharmaceutically acceptable solvatés in accordance with the invention include hydrates and solvatés wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, de-acetone, de-DMSO.
Also included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvatés, the drug and host are présent in stoichiometric or non-stoichiometric amounts. Also included are complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975), the disclosure of which is incorporated herein by reference in its entirety.
The invention also relates to prodrugs of the compounds of the formulae provided herein. Thus, certain dérivatives of compounds of the invention which may hâve little or no pharmacological activity themselves can, when administered to a patient, be converted into the inventive compounds, for example, by hydrolytic cleavage. Such dérivatives are referred to as ‘prodrugs’. Further information on the use of prodrugs may be found in ‘Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Sériés (T Higuchi and W Stella) and ‘Bioreversible Carriers in Drug Design’, Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association), the disclosures of which are incorporated herein by reference in their entireties.
Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities présent in the inventive compounds with certain moieties known to those skilled in the art as ‘pro-moieties’ as described, for example, in Design of Prodrugs by H Bundgaard (Elsevier, 1985), the disclosure of which is incorporated herein by reference in its entirety. | |
Some non-limiting examples of prodrugs in accordance with the invention include:
(i) where the compound contains a carboxylic acid functionality (-COOH), an ester thereof, for example, replacement of the hydrogen with (Ci-Ceialkyl; j (ii) where the compound contains an alcohol functionality (-ÔH), an ether thereof, for example, replacement of the hydrogen with (Ci-Cejalkanoyloxymethyl, or with a phosphate ether group; and - · (iii) where the compound contains a:primary or secondary amino functionality (-NH2 or -NHR where R # H), an amide thereof, for example, replacement of one or both hydrogens _ 95 with a suitably metabolically labile group, such as an amide, carbamate, urea, phosphonate, sulfonate, etc. Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned references. -
Finally, certain inventive compounds may themselves act as prodrugs of other of the inventive compounds.
Also included within the scope of the invention are métabolites of compounds of the formulae described herein, i.e., compounds formed in vivo upon administration ofthe drug.
The compounds of the formulae provided herein may hâve asymmetric carbon atoms.
The carbon-carbon bonds of the compounds of the invention may be depicted herein using a solid line (------), a solid wedge ( — ), or a dotted wedge (.....ml111 ). The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that ail possible stereoisomers (e.g. spécifie enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that ail possible stereoisomers are meant to be included and the attached stereocenter. For example, unless stated otherwise, it is intended thatthe compounds ofthe invention can exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
Compounds ofthe invention that hâve chiral centers may exist as stereoisomers, such as 25 racemates, enantiomers, or diastereomers.
Stereoisomers ofthe compounds ofthe formulae herein can include cis and trans isomers, optical isomers such as|(R) and (S) enantiomers, diastereomers, géométrie istjmers, rotational isomers, atropisomers, conformational isomers, and tautomers of the compounds of the invention, including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs). i
Also included are acid addition salts or base addition salts, wherein the counterion is optically active, for example, d-lactate or l-lysine, or racemic, for example, dl-tartrate or dl-arginine.
When any racemate crystallizes, crystals of two different types are possible. The first type 35 is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer. .
The compounds of the invention may exhibit the phenomena of tautomerism and structural isomerism. For example, the compounds may exist in several tautomeric forms, including the enol and imine form, and the keto and enamine form and géométrie isomers and mixtures thereof. Ail such tautomeric forms are included within the scope of compounds of the invention. Tautomers exist as mixtures of a tautomeric set in solution. In solid form, usually one tautomer prédominâtes. Even though one tautomer may be described, the présent invention includes ail tautomers of the compounds of the formulae provided.
In addition, some of the compounds of the invention may form atropisomers (e.g., substituted biaryls). Atropisomers are conformational stereoisomers which occur when rotation about a single bond in the molécule is prevented, or greatly slowed, as a resuit of steric interactions with other parts of the molécule and the substituents at both ends of the single bond are unsymmetrical. The interconversion of atropisomers is slow enough to allow séparation and isolation under predetermined conditions. The energy barrier to thermal racemization may be determined by the steric hindrance to free rotation of one or more bonds forming a chiral axis.
Where a compound of the invention contains an alkenyl or alkenylene group, géométrie cisltrans (or Z/E) isomers are possible. Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallization.
Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a sait or dérivative) using, for example, chiral high-pressure liquid chromatography (HPLC) or superfluid critical chromatography (SFC).
Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound contains an acidic or basic moiety, an a^id or base such as tartaric acid or 1-phenylethylamir|)e. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to one skilled in the art. i
Chiral compounds of the1 invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1% _ diethylamihe. Concentration of the eluaté affords the enriched mixture.
Stereoisomeric conglomérâtes may be separated by conventional techniques known to those skilled in the art; see, for example, “Stereochemistry of Organic Compounds” by E L Eliel (Wiley, New York, 1994), the disclosure of which is incorporated herein by reference in its entirety.
The enantiomeric purity of compounds described herein may be described in terms of .. enantiomeric excess (ee), which indicates the degree to which a sample contains one enantiomer in greater amounts than the other. A racemic mixture has an ee of 0%, while a single completely pure enantiomer has an ee of 100%. Similarly, diastereomeric purity may be described in terms of diasteriomeric excess (de).
The présent invention also includes isotopically-Iabeled compounds, which are identical to those recited in one of the formulae provided, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Isotopically-Iabeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-Iabeled reagent in place of the non-labeled reagent otherwise employed.
Examples of isotopes that may be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as, but not limited to, 2H, 3H, 13C, 14C, 15N, 18O, 17O, 32P, 35S, 18F and 36CI. Certain isotopically-Iabeled compounds of the invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of préparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically-Iabeled compounds of the invention may generally be prepared by carrying out th^ procedures disclosed in the Schemes and/or in the | Examples and Préparations below, by substituting an isotopically-Iabeled reagent for a non-isotopically-labeled reagent.
Compounds of the invention intended for pharmaceutical use may be administered as i crystalline or amorphous products, or mixtures thereof. They may be obtained, for example, as i solid plugs, powders, or films by methods such as précipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used. Therapeutic Methods and Uses . __________ . .. _ .
— 98
The invention further provides therapeutic methods and uses comprising administering the compounds of the invention, or pharmaceutically acceptable salts thereof, alone or in combination with other therapeutic agents or palliative agents.
In one aspect, the invention provides a method for the treatment of abnormal cell growth 5 in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable sait thereof.
In another aspect, the invention provides a method for the treatment of abnormal cell growth in a subject in need thereof, comprising administering to the subject an amount of a compound of the invention, or a pharmaceutically acceptable sait thereof, in combination with an 10 amount of an additional therapeutic agent (e.g., an anticancer therapeutic agent), which amounts are together effective in treating said abnormal cell growth.
In another aspect, the invention provides a compound of the invention, or a pharmaceutically acceptable sait thereof, for use in the treatment of abnormal cell growth in a subject.
In a further aspect, the invention provides the use of a compound of the invention, or a pharmaceutically acceptable sait thereof, for the treatment of abnormal cell growth in a subject.
In another aspect, the invention provides a pharmaceutical composition for use in the treatment of abnormal cell growth in a subject in need thereof, which pharmaceutical composition comprises a compound of the invention, or a pharmaceutically acceptable sait thereof, and a 20 pharmaceutically acceptable carrier or excipient.
In another aspect, the invention provides a compound of the invention, or a pharmaceutically acceptable sait thereof, for use as a médicament, in particular a médicament for the treatment of abnormal cell growth.
In yet another aspect, the invention provides the use of a compound of the invention, or a 25 pharmaceutically acceptable sait thereof, for the manufacture of a médicament for the treatment of abnormal cell growth in a subject. . . | In frequent embodiments of the methods provided herein, the abnormal cell growth is cancer. Compounds of the invention may be administered as single agents or may be administered in combination with other anti-cancer therapeutic agents, in particular with standard of care agents 30 appropriate for the particular cancer. ί
I In some embodiments, the methods provided resuit in one or more of the following effects:
(1) inhibiting cancer cell prolifération; (2) inhibiting cancer cell invasiveness; (3) inducing apoptosis of cancer cells; (4) inhibiting cancer cell metastasis; or (5) inhibiting angiogenesis.
In another aspect, the invention provides a method for the treatment of a disorder mediated 35 by CDK4 in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount that is effective for treating said disorder, in particular cancer.
In preferred aspects and embodiments of the compounds, compositions, methods and uses described herein, the compounds of the invention are sélective for CDK4 over CDK6. In frequent embodiments, the binding affinity for CDK6 is at least 10-fold, 15-fold, 20-fold, 25-fold, 30-fold, 40-fold, 50-fold, 60-fold, 75-fold, 100-fold, or greater than 100-fold largerthan the binding affinity for CDK4.
In view of the potentiel rôle of CDK6 in hématologie toxicities, such as neutropenia or leukopenia, a CDK4 sélective inhibitor may provide an improved safety profile, improved dosing schedule (e.g., by decreasing the need for dose réduction or dosing holidays), and/or enhanced overall efficàcy, due to the potential of higher dosing, use of a continuous dosing regimen, and/or extended time of overall treatment as compared to current dual CDK4/6 inhibitors. Animal models to assess neutropenia are described in the art. For example, see Fine et al. A Spécifie Stimulator of Granulocyte Colony-Stimulating Factor Accélérâtes Recover from Cyclophophamide-lnduced Neutropenia in the Mouse (1997) Blood, 90(2):795-802; Hu et al., Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Différentiation from Cytotoxic Chemotherapies (2016), Clin. Cancer Res. 22(8):2000-2008.
It may also be préférable to obtain selectivity for CDK4 over other CDKs, such as CDK1, CDK2 or CDK9.
Compounds ofthe invention include compounds of any ofthe formulae described herein, or pharmaceutically acceptable salts thereof.
In another aspect, the invention provides a method of inhibiting cancer cell prolifération in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount effective to inhibit cell prolifération.
In another aspect, the invention provides a method of inhibiting cancer cell invasiveness in a subject, comprising administering to ihe subject a compound of the invention, or a phaifmaceutically acceptable sait thereof, in an amount effective to inhibit cell invasiveness.
In another aspect, the invention provides a method of inducing apoptosis in cancer cells in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount effective to induce apoptosis.
I In another aspect, the invention provides a method of inhibiting cancer cell metastasis in a subject, comprising administering to the subject a compound of the invention, or a pharmaceutically acceptable sait thereof, in an amount effective to inhibit cell metastasis......
In another aspect, the invention provides a method of inhibiting angiogenesis in a subject,. comprising administéring to the subject a compoünd of the invention, or a pharmaceutically acceptable sait thereof, in an amount effective to inhibit angiogenesis.
— 100
In frequent embodiments of the methods provided herein, the abnormal cell growth is cancer. In some such embodiments, the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer (including NSCLC, SCLC, squamous cell carcinoma or adenocarcinoma), esophageal cancer, head and 5 neck cancer, colorectal cancer, kidney cancer (including RCC), liver cancer (including HCC), pancreatic cancer, stomach (i.e., gastric) cancer and thyroid cancer. In further embodiments of the methods provided herein, the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, liver cancer, pancreatic cancer and stomach cancer.
In other embodiments, the cancer is breast cancer, including, e.g., ER-positive/HR-positive,
HER2-negative breast cancer; ER-positive/HR-positive, HER2-positive breast cancer; triple négative breast cancer (TNBC); or inflammatory breast cancer. In some embodiments, the breast cancer is endocrine résistant breast cancer, trastuzumab or pertuzumab résistant breast cancer, or breast cancer demonstrating primary or acquired résistance to CDK4/CDK6 inhibition. In some 15 embodiments, the breast cancer is advanced or metastatic breast cancer.
In some embodiments, the compound of the invention is administered as first line therapy. In other embodiments, the compound of the invention is administered as second (or later) line therapy. In some embodiments, the compound ofthe invention is administered as second (or later) line therapy following treatment with an endocrine therapeutic agent and/or a CDK4/CDK6 inhibitor.
In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with an endocrine therapeutic agent, e.g., an aromatase inhibitor, a SERM or a SERD. In some embodiments, the compound ofthe invention is administered as second (or later) line therapy following treatment with a CDK4/CDK6 inhibitor. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with one or more chemotherapy regimens, e.g., including taxanes or platinum agents. In some embodiments, the compound of the invention is administered as second (or later) line therapy following treatment with HER2 targeted agents, e.g., trastuzumab. |
As used herein, an “effective dosage or “effective amount” of drug, compound or pharmaceutical composition is an amount sufficient to affect any one or more bénéficiai or 30 desired, including biochemical, histological and / or behavioral symptoms, of the disease, its complications and intermediate pathological phenotypes presenting1 during development of the disease. For therapeutic use, a “therapeutically effective amount” refers to that amount of a compound being administered which will relieve to some extent one or more ofthe symptoms of the disorder being treated. In reference.to the treatment of cancer, a therapeutically effective 35 amount refers to that amount which has the effect of (1) reducing the size of the tumor, (2) inhibiting (that is, slowing to some extent, preferably stopping) tumor metastasis, (3) inhibiting to
101 some extent (that is, slowing to some extent, preferably stopping) tumor growth or tumor invasiveness, (4) relieving to some extent (or, preferably, eliminating) one or more signs or symptoms associated with the cancer, (5) decreasing the dose of other médications required to treat the disease, and/or (6) enhancing the effect of another médication, and/or (7) delaying the progression of the disease in a patient.
An effective dosage can be administered in one or more administrations. For the purposes of this invention, an effective dosage of drug, compound, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly. As is understood in the clinical context, an effective dosage of drug, 10 compound or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound or pharmaceutical composition.
“Tumor” as it applies to a subject diagnosed with, or suspected of having, a cancer refers to a malignant or potentially malignant neoplasm or tissue mass of any size and includes primary tumors and secondary neoplasms. A solid tumor is an abnormal growth or mass of tissue that 15 usually does not contain cysts or liquid areas. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukaemia’s (cancers of the blood) generally do not form solid tumors (National Cancer Institute, Dictionary of Cancer Terms).
“Tumor burden” or “tumor load’, refers to the total amount of tumorous material distributed throughout the body. Tumor burden refers to the total number of cancer cells or the total size of 20 tumor(s), throughout the body, including lymph nodes and bone marrow. Tumor burden can be determined by a variety of methods known in the art, such as, e.g., using callipers, or while in the body using imaging techniques, e.g., ultrasound, bone scan, computed tomography (CT), or magnetic résonance imaging (MRI) scans.
The term “tumor size” refers to the total size of the tumor which can be measured as the 25 length and width of a tumor. Tumor size may be determined by a variety of methods known in the art, such as, e.g., by measuring the dimensions of tumor(s) upon removal from the subject, e.g., using callipers, c|r while in the body using imaging techniques, e.g., bon^ scan, ultrasound, CR or MRI scans. ---- ~ ~
As used herein, subject refers to a human or animal subject. In certain preferred 30 embodiments, the subject is a human.
The term “treat” or “treating” a cancer as used herein means to administer a compound of the présent invention to a subject having cancer, or diagnosed with cancer, to achieve at least one positive therapeutic effect, such as, for example, reduced number of cancer cells, reduced tumor size, reduced rate of cancer cell infiltration into peripheral organs, or reduced rate of tumor . 35 métastasés or tumôr growth, réversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or
102 condition. The term treatment, as used herein, unless otherwise indicated, refers to the act of treating as treating is defined immediately above. The term “treating also includes adjuvant and neo-adjuvant treatment of a subject.
For the purposes of this invention, bénéficiai or desired clinical results include, but are hot limited to, one or more ofthe following: reducing the prolifération of (or destroying) neoplastic or cancerous cell; inhibiting metastasis or neoplastic cells; shrinking or decreasing the size of a tumor; remission of the cancer; decreasing symptoms resulting from the cancer; increasing the quality of life of those suffering from the cancer; decreasing the dose of other médications required to treat the cancer; delaying the progression of the cancer; curing the cancer; overcôming one or more résistance mechanisms of the cancer; and/or prolonging survival of patients the cancer. Positive therapeutic effects in cancer can be measured in several ways (see, for example, W. A. Weber, Assessing tumor response to therapy, J. Nucl. Med. 50 Suppl. 1:1S10S (2009). For example, with respect to tumor growth inhibition (T/C), according to the National Cancer Institute (NCI) standards, a T/C less than or equal to 42% is the minimum level of antitumor activity. A T/C <10% is considered a high anti-tumor activity level, with T/C (%) = médian tumor volume of the treated / médian tumor volume of the control x 100.
In some embodiments, the treatment achieved by a compound of the invention is defined by reference to any of the following: partial response (PR), complété response (CR), overall response (OR), progression free survival (PFS), disease free survival (DFS) and overall survival (OS). PFS, also referred to as “Time to Tumor Progression” indicates the length of time during and after treatment that the cancer does not grow and includes the amount of time patients hâve experienced a CR or PR, as well as the amount of time patients hâve experienced stable disease (SD). DFS refers to the length of time during and after treatment that the patient remains free of disease. OS refers to a prolongation in life expectancy as compared to naïve or untreated subjects or patients. In some embodiments, response to a combination ofthe invention is any of PR, CR, PFS, DFS, OR or OS that is assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 respons^ criteria. |
The treatment regimen for a compound ofthe invention that is effective to treat a cancer patient may vary according to factors such as the disease state, âge, and weight of the patient, and the ability of the therapy to elicit an anti-cancer response in the subject. iWhile an embodiment of any of the aspects of the invention may not be effective in achieving la positive therapeutic effect in every subject, it should do so in a statistically significant number of subjects as determined by any statistical test known in the art such as the Student’s t-test, the chi2-test the U-test according to Mann and Whitney, the Kruskal-Wallis test (H-test), Jonckheere-Terpstrattesty and the Wilcon bn-test. .
103
The terms “treatment regimen”, “dosing protocol” and “dosing regimen” are used interchangeably to refer to the dose and timing of administration of each compound of the invention, alone or in combination with another therapeutic agent.
“Ameliorating” means a lessening or improvement of one or more symptoms upon. treatment with a combination described herein, as compared to not administering the combination. “Ameliorating” also includes shortening or réduction in duration of a symptom.
“Abnormal cell growth”, as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). Abnormal cell growth may be benign (not cancerous), or malignant (cancerous).
Abnormal cell growth includes the abnormal growth of: (1)tumor cells (tumors) that show increased expression of CDK4 and/or CDK6; (2) tumors that proliferate by aberrant CDK4 and/or CDK6 activation; and (3) tumors that are résistant to endocrine therapy, CDK4/6 inhibition, or HER2 antagonists.
The term “additional anticancer therapeutic agent” as used herein means any one or more therapeutic agent, other than a compound of the invention, that is or can be used in the treatment of cancer. In some embodiments, such additional anticancer therapeutic agents include compounds derived from the following classes: mitotic inhibitors, alkylating agents, antimetabolites, antitumor antibiotics, anti-angiogenesis agents, topoisomerase I and II inhibitors, plant alkaloids, hormonal agents and antagonists, growth factor inhibitors, radiation, signal transduction inhibitors, such as inhibitors of protein tyrosine kinases and/or serine/threonine kinases, cell cycle inhibitors, biological response modifiers, enzyme inhibitors, antisense oligonucleotides or oligonucleotide dérivatives, cytotoxics, immuno-oncology agents, and the like.
In some embodiments, the additional anticancer agent is an endocrine agent, such as an aromatase inhibitor, a SERD or a SERM. In some such embodiments, a compound of the invention may be administered in combination with a standard of care agent, such as tamoxifen, exemestane, letrozole, fulvestrant, or anastrozole.
In other embodiments, a compound of the invention may be administered in combinatio|i with a chemotherapeutic agent, such as docetaxel, paclitaxel, paclitaxel protein-bound particles, cisplatin, carboplatin, oxaliplatin, capecitabine, gemcitabine or vinorelbine, :
In some embodiments, the additional anticancer agent is an anti-angiogenesis agent, including for example VEGF inhibitors1, VEGFR inhibitors, TIE-2 inhibitors, PDGFR inhibitors, angiopoetin inhibitors, ΡΚΟβ inhibitors, COX-2 (cyclooxygenase II) inhibitors, integrins (alphav/beta-3), MMP-2 (matrix-metalloproteinase 2) inhibitors, and MMP-9 (matrix-metalloproteinase 9) inhibitors. Preferred anti-angiogenesis agents include sunitinib (Sutent™), bevacizumab (Avastin™), axitinib (AG 13736), SU 14813 (Pfizer), and AG 13958 (Pfizer). Additional antiangiogenesis agents include vatalanib (CGP 79787), Sorafenib (Nexavar™), pegaptanib _ 104 octasodium (Macugen™), vandetanib (Zactima™), PF-0337210 (Pfizer), SU 14843 (Pfizer), AZD 2171 (AstraZeneca), ranibizumab (Lucentis™), Neovastat™ (AE 941), tetrathiomolybdata (Coprexa™), AMG 706 (Amgen), VEGF Trap (AVE 0005), CEP 7055 (Sanofi-Aventis), XL 880 (Exelixis), telatinib (BAY 57-9352), and CP-868,596 (Pfizer). Other anti-angiogenesis agents 5 include enzastaurin (LY 317615), midostaurin (CGP 41251), perifosine (KRX 0401), teprenone (Selbex™) and UCN 01 (Kyowa Hakko). Other examples of anti-angiogenesis agents include celecoxib (Celebrex™), parecoxib (Dynastat™), deracoxib (SC 59046), lumiracoxib (Preige™), valdecoxib (Bextra™), rofecoxib (Vioxx™), iguratimod (Careram™), IP 751 (Invedus), SC-58125 (Pharmacia) and etoricoxib (Arcoxia™). Yet further anti-angiogenesis agents include exisulind . 10 (Aptosyn™), salsalate (Amigesic™), diflunisal (Dolobid™), ibuprofen (Motrin™), ketoprofen (Orudis™), nabumetone (Relafen™), piroxicam (Feldene™), naproxen (Aleve™, Naprosyn™), diclofenac (Voltaren™), indomethacin (Indocin™), sulindac (Clinoril™), tolmetin (Tolectin™), etodolac (Lodine™), ketorolac (Toradol™), and oxaprozin (Daypro™). Yet further antiangiogenesis agents include ABT 510 (Abbott), apratastat (TMI 005), AZD 8955 (AstraZeneca), 15 incyclinide (Metastat™), and PCK 3145 (Procyon). Yet further anti-angiogenesis agents include acitretin (Neotigason™), plitidepsin (aplidine™), cilengtide (EMD 121974), combretastatin A4 (CA4P), fenretinide (4HPR), halofuginone (Tempostatin™), Panzem™ (2-methoxyestradiol), PF-03446962 (Pfizer), rebimastat (BMS 275291), catumaxomab (Removab™), lenalidomide (Revlimid™), squalamine (EVIZON™), thalidomide (Thalomid™), Ukrain™ (NSC 631570), 20 Vitaxin™ (MEDI 522), and zoledronic acid (Zometa™).
In other embodiments, the additional anti-cancer agent is a signal transduction inhibitor (e.g., inhibiting the means by which regulatory molécules that govern the fondamental processes of cell growth, différentiation, and survival communicated within the cell). Signal transduction inhibitors include small molécules, antibodies, and antisense molécules. Signal transduction 25 inhibitors include for example kinase inhibitors (e.g., tyrosine kinase inhibitors or serine/threonine kinase inhibitors) and cell cycle inhibitors. More specifically signal transduction inhibitors include, | for example, farnesyl protein transferase inhibiteurs, EGF inhibitor, ErbB-1 (EGFR), ErbB-2, pan erb, IGF1R inhibitors, MEK, c-Kit inhibitors, FLT-3 inhibitors, K-Ras inhibitors, PI3 kinase inhibitors, JAK inhibitors, STAT inhibitors, Raf kinase inhibitors, Akt inhibitors, mTOR inhibitor, 130 P70S6 kinase inhibitors, inhibitors of the WNT pathway and multi-targeted kinase inhibitors.
i Additional examples of anti-cancer agents which may be used in conjunction with a compound of the invention and pharmaceutical compositions described herein include palbociclib (Ibrance®), ribociclib (Kisqali®), abemaciclib (Verzenio®), BMS 214662 (Bristol-Myers Squibb), lonafamib (Sarasar™), pelitrexol (AG 2037), matuzumab (EMD 7200), nimotuzumab (TheraCIM 35 h-R3™), panitumumab (Vectibix™), Vandetanib (Zactima™), pazopanib (SB 786034), ALT 110 (Alteris Therapeutics), BIBW 2992 (Boehringer lngelheim),and Cervene™ (TP 38). Other
105 examples include gefitinib (Iressa®), cetuximab (Erbitux®), erlotinib (Tarceva®), trastuzumab (Herceptin®), ado-trastuzumab emtansine (Kadcyla®), pertuzumab (Perjeta®), osimertinib (Tagrisso®), atezolizumab (Tecentriq™), sunitinib (Sutent®), ibrutinib (Imbruvica®), imatinib (Gleevec®), crizotinib (Xalkor®), lorlatinib (Lorbrena®), dacomitinib (Vizimpro®), bosutinib i (Bosulif®), glasdegib (Daurismo™), canertinib (Cl 1033), lapatinib (Tycerb™), pelitinib (EKB 569), miltefosine (Miltefosin™), BMS 599626 (Bristol-Myers Squibb), Lapuleucel-T (Neuvenge™), NeuVax™ (E75 cancer vaccine), Osidem™ (IDM 1), mubritinib (TAK-165), CP-724,714 (Pfizer), panitumumab (Vectibix™), ARRY 142886 (Array Biopharm), everolimus (Certican™), zotarolimus (Endeavor™), temsirolimus (Torisel™), AP 23573 (ARIAD), and VX 680 (Vertex), XL 647 (Exelixis), sorafenib (Nexavar™), LE-AON (Georgetown University), and GI-4000 (Globelmmune). Other signal transduction inhibitors include ABT 751 (Abbott), alvocidib (flavopiridol), BMS 387032 (Bristol Myers), EM 1421 (Erimos), indisulam (E 7070), seliciclib (CYC 200), BIO 112 (One Bio), BMS 387032 (Bristol-Myers Squibb), and AG 024322 (Pfizer), or PD-1 or PD-L1 antagonists, e.g., pembrolizumab (Keytruda®), nivolumab (Opdivo™), or avelumab (Bavencio®). abraxane,
In other embodiments, the additional anti-cancer agent is a so-called classical antineoplastic agent. Classical antineoplastic agents include but are not limited to hormonal modulators such as hormonal, anti-hormonal, androgen agonist, androgen antagonist and antiestrogen therapeutic agents, histone deacetylase (HDAC) inhibitors, DNA methyltransferase inhibitors, silencing agents or gene activating agents, ribonucleases, proteosomics, Topoisomerase I inhibitors, Camptothecin dérivatives, Topoisomerase II inhibitors, alkylating agents, antimetabolites, poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor (such as, e.g., talazoparib (Talzenna®), olaparib, rucaparib, niraparib, iniparib, veliparib), microtubulin inhibitors, antibiotics, plant derived spindle inhibitors, platinum-coordinated compounds, gene therapeutic agents, antisense oligonucleotides, vascular targeting agents (VTAs), and statins. Examples of classical antineoplastic agents used in combination therapy with a compound of the invention,optionally with one or more other agents include, but are|not limited to, glucocorticoids, such as dexamethasone, prednisone, prednisolone, méthylprednisolone, hydrocortisone, and progestins such as medroxyprogesterone, megestrol acetate (Megace), mifepristone (RU-486), Sélective Estrogen Receptor Modulators (SERMs; such as! tamoxifen, raloxifene, lasofoxifene, afimoxifene, arzoxifene, bazedoxifene, fispemifene, ormeloxifene, ospemifene, tesmilifene, toremifene, trilostane and CHF 4227 (Cheisi), Sélective Estrogen-Receptor Downregulators (SERD’s; such as fulvestrant), exemestane (Aromasin), anastrozole (Arimidex), atamestane, fadrozole, letrozole (Femara),. formestane; gonadotropin-releasing hormone (GnRH; also commonly referred to as luteinizing hormone-releasing hormone [LHRH]) agonists such as buserelin (Suprefact), goserelin (Zoladex), leuprorelin (Lupron), and triptorelin (Trelstar), abarelix
106 (Plenaxis), cyproterone, flutamide (Eulexin), megestrol, nilutamide (Nilandron), and osaterone, dutasteride, epristeride, finasteride, Serenoa repens, PHL 00801, abarelix, goserelin, leuprorelin, triptorelin, bicalutamide; antiandrogen agents, such as enzalutamide (Xtandi®), abiraterone acetate, bicalutamide (Casodex); and combinations thereof. Other examples of classical antineoplastic agents used in combination with a compound of the invention include but are not limited to PARP inhibitors, such as talazoparib, olapariv, rucaparib, niraparib, iniparib, veiiparib; suberolanilide hydroxamic acid (SAHA, Merck Inc./Aton Pharmaceuticals), depsipeptide (FR901228 or FK228), G2M-777, MS-275, pivaloyioxymethyl butyrate and PXD-101; Onconase (ranpirnase),PS-341 (MLN-341), Velcade (bortezomib), 9-aminocamptothecin, belotecan, BN10 80915 (Roche), camptothecin, difiomotecan, edotecarin, exatecan (Daiichi), gimatecan, 10hydroxycamptothecin, irinotecan HCl (Camptosar), lurtotecan, Orathecin (rubitecan, Supergen), SN-38, topotecan, camptothecin, 10-hydroxycamptothecin, 9-aminocamptothecin, irinotecan, SN-38, edotecarin, topotecan, aclarubicin, adriamycin, amonafide, amrubicin, annamycin, daunorubicin, doxorubicin, elsamitrucin, epirubicin, etoposide, idarubicin, galarubicin, hydroxycarbamide, nemorubicin, novantrone (mitoxantrone), pirarubicin, pixantrone, procarbazine, rebeccamycin, sobuzoxane, tafluposide, valrubicin, Zinecard (dexrazoxane), nitrogen mustard N-oxide, cyclophosphamide, AMD-473, altretamine, AP-5280, apaziquone, brostallicin, bendamustine, busuifan, carboquone, carmustine, chlorambucil, dacarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine, mafosfamide, mechlorethamine, melphalan, mitobronitol, mitolactol, mitomycin C, mitoxatrone, nimustine, ranimüstine, temozolomide, thiotepa, and platinum-coordinated alkylating compounds such as cisplatin, carboplatin, eptaplatin, lobaplatin, nedaplatin, oxaliplatin, streptozocin, satrplatin, and combinations thereof.
In still other embodiments, the additional anti-cancer agent is a so called dihydrofolate reductase inhibitors (such as methotrexate and NeuTrexin (trimetresate glucuronate)), purine antagonists (such as 6-mercaptopurine riboside, mercaptopurine, 6-thioguanine, cladribine, clofarabin^ (Clolar), fludarabine, nelarabine, and raltitrexed), pyrirfiidine antagonists (such as 5fluorouracil (5-FU), Alimta (premetrexed disodium, LY231514, MTA), capecitabine (Xeloda™), cytosine arabinoside, Gemzar™ (gemcitabine, Eli Lilly), Tegafur (UFT Orzel or Uforal and including TS-1 combination of tegafur, gimestat and otostat), doxifluridine, carmofur, cytarabine (including bcfosfate, phosphate stéarate, sustained release and liposomal forms), enocitabine, 5azacitidine (Vidaza), decitabine, and ethynylcytidine) and other antimetabolites such as eflornithine, hydroxyurea, leucovorin, nolatrexed (Thymitaq), triapine, trimetrexate, N-(5-[N-(3,4dihydro-2-methyl-4-oxoquinazoiin-6-ylmethyl)-N-methylamino]-2-thenoyl)-L-glutamic acid, AG35 014699 (Pfizer Inc.), ABT-472 (Abbott Laboratories), INO-1001 (Inotek Pharmacèuticals), KU0687 (KuDOS Pharmaceuticals) and GP118180 (Guiiford Pharm Inc) and combinations thereof.
107
Other exemples of classical antineoplastic cytotoxic agents include, but are not limited to,
Abraxane (Abraxis BioScience, Inc.), Batabulin (Amgen),EPO 906 (Novartis), Vinflunine (BristolMyers Squibb Company), actinomycih D, bleomycin, mitomycin C, nèocarzinostatin (Zinostatin), Vinblastine, vincristine, vindesine, vinorelbine (Navelbine), docetaxel (Taxotere), Ortataxel, paclitaxel (including Taxoprexin a DHA/paciltaxel conjugate), cisplatin, carboplatin, Nedaplatin, oxaliplatin (Eloxatin), Satraplatin, Camptosar, capecitabine (Xeloda), oxaliplatin (Eloxatin), Taxotere alitretinoin, Canfosfamide (Telcyta™), DMXAA (Antisoma), ibandronic acid, Lasparaginase, pegaspargase (Oncaspar™), Efaproxiral (Efaproxyn™ - radiation therapy), bexarotene (Targretin™), Tesmilifene (DPPE - enhances efficacy of cytotoxics), Theratope™ (Biomira), Tretinoin (Vesanoid™), tirapazamine (Trizaone™), motexafin gadolinium (Xcytrin™) Cotara™ (mAb), and NBI-3001 (Protox Therapeutics), polyglutamate-paclitaxel (Xyotax™) and combinations thereof. Further examples of classical antineoplastic agents include, but are not limited to, as Advexin (ING 201), TNFerade (GeneVec, a compound which express TNFalpha in response to radiotherapy), RB94 (Baylor College of Medicine), Genasense (Oblimersen, Genta), Combretastatin A4P (CA4P), Oxi-4503, AVE-8062, ZD-6126, TZT-1027, Atorvastatin (Lipitor, Pfizer Inc.), Provastatin (Pravachol, Bristol-Myers Squibb), Lovastatin (Mévacor, Merck Inc.), Simvastatin (Zocor, Merck Inc.), Fluvastatin (Lescol, Novartis), Cerivastatin (Baycol, Bayer), Rosuvastatin (Crestor, AstraZeneca), Lovostatin, Niacin (Advicor, Kos Pharmaceuticals), Caduet, Lipitor, torcetrapib, and combinations thereof.
In some embodiments, the additional anti-cancer agent is an epigenetic modulator, for example an inhibitor or EZH2, SMARCA4, PBRM1, ARID1A, ARID2, ARID1B, DNMT3A, TET2, MLL1/2/3, NSD1/2, SETD2, BRD4, DOT1L, HKMTsanti, PRMT1-9, LSD1, UTX, IDH1/2 or BCL6.
In further embodiments, the additional anti-cancer agent is an immunomodulatory agent, such as an inhibitor of CTLA-4, PD-1 or PD-L1 (e.g., pembrolizumab, nivolumab or avelumab), LAG-3, TIM-3, TIGIT, 4-1BB, OX40, GITR, CD40, or a CAR-T-cell therapy.
As used herein “cancer refers to any malignant and/or invasive growth or tumor caused by abnormal cell growth. Cancer includes solid tumors named for the type o[f cells that form them, cancer of blood, bone marrow, or the lymphatic system. Examples of solid tumors include sarcomas and carcinomas. Cancers of the blood include, but are not limited to, leukemia, lymphoma and myeloma. Cancer also includes primary cancer that originates at a spécifie site in the body, a meta'static cancer that has spread from the place in which it Istarted to other parts ofthe body, a récurrence from the original primary cancer after remission, and a second primary cancer that is a new primary cancer in a person with a history of previous cancer of a different type from the latter one. . . ...... _____________
Iri some èmbodiments ofthe methods provided herein, the cancer is selected from the group consisting of breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate _ 108 cancer, lung cancer (including NSCLC), esophageal cancer, head and neck cancer, liver cancer, pancreatic cancer and stomach cancer.
Dosage Forms and Regimens
Administration of the compounds of the invention may be affected by any method that 5 enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parentéral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal administration.
Dosage regimens may be adjusted to provide the optimum desired response. For example, a single bolus may be administered, several divided doses may be administered over 10 time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parentéral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, refers to physically discrète units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The spécification for the dosage unit forms of the invention are dictated by and directly dépendent on (a) the unique characteristics of the chemotherapeutic agent and the particular therapeutic or prophylactic effect to be achieved, and (b) the limitations inhérent in the art of compounding such an active compound for the treatment of sensitivity in individuals.
Thus, the skilled artisan would appreciate, based upon the disclosure provided herein, that the dose and dosing regimen is adjusted in accordance with methods well-known in the therapeutic arts. That is, the maximum tolerable dose can be readily established, and the effective amount providing a détectable therapeutic benefit to a patient may also be determined, as can the temporal requirements for administering each agent to provide a détectable therapeutic benefit to the patient. Accordingly, while certain dose and administration regimens are exemplified herein, these examples in no way limit the dose and administration regimen that may be provided to a patienj in practicing the présent invention. |
It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated and may include single or multiple doses. It is to be further understood that for 30 any particular subject, spécifie dosage regimens should be adjusted over time according to the individual need and the prdfessional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice ofthe claimed composition. For example, doses may be adjusted based on pharmacokinetic or pharmacodynamie parameters, which may include ....
clinical effects such as toxic effects and/or laboratory values. Thus, the présent invention encompasses intra-patient dose-escalation as determined by the skilled artisan. Determining
109 appropriate dosages and regimens for administration of the chemotherapeutic agent are well-known in the relevant art and would be understood to be encompassed by the skilled artisan once provided the teachings disclosed herein.
The amount of the compound ofthe invention administered will be dépendent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discrétion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7 g/day, preferably about 0.1 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adéquate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.
Formulations and Routes of Administration
As used herein, a pharmaceutically acceptable carrier refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties ofthe administered compound.
The pharmaceutical acceptable carrier may comprise any conventional pharmaceutical carrier or excipient. The choice of carrier and/or excipient will to a large extent dépend on factors such as the particular mode of administration, the effect of the carrier or excipient on solubility and stability, and the nature of the dosage form.
Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents (such as hydrates and solvatés). The pharmaceutical compositions may, if desired, contain additional ingrédients such as flavorings, binders, excipients and the like. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia. Examples, without limitation^ of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch,cellulose dérivatives, gelatin, vegetable oils and polyethylene glycols. Additionally, lubricating agents such as magnésium stéarate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Non-limiting examples of materials, therefore, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or élixirs are desired for oral administration the active compound therein may be combined with.various sweetening or flavoring agents, coloririg matters or dyes and, if desired, emulsifying agents or suspending — 110 agents, together with diluents such as water, éthanol, propylene glycol, glycerin, or combinations thereof. The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution 5 suspension, for parentéral injection as a stérile solution, suspension or émulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
Exemplary parentéral administration forms include solutions or suspensions of active compounds in stérile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms may be suitably buffered, if desired. .
The pharmaceutical composition may be in unit dosage forms suitable for single administration of précisé dosages.
Pharmaceutical compositions suitable for the delivery of compounds of the invention and methods for their préparation will be readily apparent to those skilled in the art. Such compositions and methods for their préparation can be found, for example, in ‘Remington’s Pharmaceutical 15 Sciences’, 19th Edition (Mack Publishing Company, 1995), the disclosure of which is incorporated herein by reference in its entirety.
The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from 20 the mouth.
Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays and liquid formulations.
Liquid formulations include suspensions, solutions, syrups and élixirs. Such formulations may be used as fillers in soft or hard capsules and typically include a carrier, for example, water, | éthanol, polyethylene glycol, propylene glycolj methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
! 30 The compounds ofthe invention mayialso be used in fast-dissolving, fast-disintegrating
I dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001), the disclosure of which is incorporated herein by reference in its entirety. '
For tablet dosage forms, depending on dose, the drug may make up from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples ôf disintegrants include sodium
111 starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinized starch and sodium alginate. Generally, the disintegrant.will comprise from 1 wt% to 25 wt%, preferably from . 5 wt% to 20 wt% of the dosage form.
Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinized starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
Tablets may also optionally include surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as Silicon dioxide and talc. When present, surface active agents are typically in amounts of from 0.2 wt% to 5 wt% of the tablet, and glidants typically from 0.2 wt% to 1 wt% of the tablet.
Tablets also generally contain lubricants such as magnésium stéarate, calcium stéarate, zinc stéarate, sodium stearyl fumarate, and mixtures of magnésium stéarate with sodium lauryl sulphate. Lubricants generally are present in amounts from 0.25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet.
Other conventional ingrédients include anti-oxidants, colorants, flavoring agents, preservatives and taste-masking agents.
Exemplary tablets contain up to about 80 wt% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.
Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded | before tableting. The final formulation may include orje or more layers and may be coated or uncoated; or encapsulated.
The formulation of tablets is discussed in detail in “Pharmaceutical Dosage Forms:
i Tablets, Vol. Γ, by H. Lieberman and L. Lachman, [Marcel Dekker, N.Y., N.Y., 1980 (ISBN I 0-8247-6918-X), the disclosure of which is incorporatecl herein by reference in its entirety.
Solid formulations for oral administration may be formuiated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. ... . . . . .
Suitable modified release formulations are described in U.S. Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and _ 112 coated particles can be found in Verma et al, Pharmaceutical Technology On-line, 25(2), 1-14 (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298. The disclosures of these référencés are incorporated herein by reference in their entireties.
The compounds of the invention may also be administered directly into the blood stream, 5 into muscle, or into an internai organ. Suitable means for parentéral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parentéral administration include needle (including micro needle) injectors, needle-free injectors and infusion techniques.
Parentéral formulations are typically aqueous solutions which may contain excipients 10 such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a stérile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as stérile, pyrogen-free water.
The préparation of parentéral formulations under stérile conditions, for example, by lyophilization, may readily be accomplished using standard pharmaceutical techniques well 15 known to those skilled in the art.
The solubility of compounds of the invention used in the préparation of parentéral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
Formulations for parentéral administration may be formulated to be immédiate and/or 20 modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. Thus, compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and PGLA microspheres.
The compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, [solutions, creams, ointments, dusting powders, dressi|igs, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, minerai oil, liquid petrolatum, white petrolatum, glycerin, 30 polyethylene glycol and propylene glycol. Pénétration enhancers may be incorporated; see, for examplè, J Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 1999). Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and micro needle or needle-free (e.g. Powderject™, Bioject™, etc.) injection. The disclosures of these référencés are incorporated herein by reference in their entireties. 19876
113
Formulations for topical administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
The compounds of the invention can also be administered intranasally or by inhalation, 5 typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed eomponent particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aérosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of a suitable propellant, such as
1,1,1,2-tetrafluoroethane or 1,1,1.,2,3,3,3-heptafluoropropane. For intranasal use, the powder may include a bioadhesive agent, for example, chitosan or cyclodextrin.
The pressurized container, pump, spray, atomizer, or nebulizer contains a solution or suspension of the compound(s) of the invention comprising, for example, éthanol, aqueous éthanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of the 15 active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
Prior to use in a dry powder or suspension formulation, the drug product is micronized to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical 20 fluid processing to form nanoparticles, high pressure homogenization, or spray drying.
Capsules (made, for example, from gelatin or HPMC), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnésium stearate. The lactose may be anhydrous or in the form of the 25 monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
A suitabl^ solution formulation for use in an atomizer using electrohydrodynamics to produce a fine mist may contain from 1 pg to 20mg of the compound of the invention per actuation and the actuation volume may vary from 1 pL to 100pL. Atypical formulation includes a compound 30 of the invention, propylene glycol, stérile water, éthanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyéthylène glycol.
Suitable flavors, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration. ...... . ..
Formulations for inhaled/intranasal administration may be formulated to be immédiate and/or modified release using, for example, poly(DL-lactic-coglycolic acid (PGLA). Modified 114 release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. . ... ..........
In the casé of dry powder inhalers and aérosols, the dosage unit is determined by means of a valve which delivers a metered amount. Units in accordance with the invention are typically 5 arranged to administer a metered dose or “puff” containing a desired mount of the compound of the invention. The overall daily dose may be administered in a single dose or, more usually, as divided doses throughout the day.
Compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but 10 various alternatives may be used as appropriate. ------Formulations for rectal/vaginal administration may be formulated to be immédiate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
Compounds ofthe invention may also be administered directlyto the eye or ear, typically 15 in the form of drops of a micronized suspension or solution in isotonie, pH-adjusted, stérile saline.
Other formulations suitable for ocular and aurai administration include ointments, biodégradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular Systems, such as niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for 20 example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
Formulations for ocular/aural administration may be formulated to be immédiate and/or 25 modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted, or programmed release. . .
Other Technologies | |
Compounds ofthe invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable dérivatives thereof or polyethylene glycol-containing polymers, in 30 order to improve their solubility, dissolution rate, taste-masking, bioavaiiability and/or stability for use in any of the aforemehtioned modes of administration. I
Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an 35 auxiliaryâdditive, i.e. as â carrier, diluent, or solubilizer. Most commonly used for these pürposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in PCT Publication
115
Nos. WO 91/11172, WO 94/02518 and WO 98/55148, the disclosures of which are incorporated herein by reference in their entireties.
The amount of the active compound administered will be dépendent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the 5 compound and the discrétion ofthe prescribing physician. However, an effective dosage is typically in the range of about 0.001 to about 100 mg per kg body weight per day, and frequently about 0.01 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.07 mg/day to about 7000 mg/day, more commonly, from about 10 mg/day to about 1000 mg/day. Sometimes, the dosage is about 10,20,30,40,50,60,75,100,125,150,175,200,225,250,275, 10 300, 325, 350, 375,400,425,450,475, 500, 525, 550, 575, 600, 625, 650,675, 700, 750, 800, 900 or 1000 mg/day. Sometimes, the dosage is from about 10 mg/day to about 1000 mg/day, from about 10 mg/day to about 750 mg/day, from about 10 mg/day to about 600 mg/day, from about 10 mg/day to about 300 mg/day, from about 10 mg/day to about 150 mg/day, from about 20 mg/day to about 750 mg/day, from about 20 mg/day to about to 600 mg/day, from about 20 mg/day to about 15 to 300 mg/day, from about 20 mg/day to about to 150 mg/day, from about 50 mg/day to about 750 mg/day, from about 50 mg/day to about 600 mg/day, from about 50 mg/day to about 300 mg/day, from about 50 mg/day to about 150 mg/day, from about 75 mg/day to about 750 mg/day, from about 75 mg/day to about 600 mg/day, from about 75 mg/day to about 300 mg/day, or from about 75 mg/day to about 150 mg/day.
In some instances, dosage levels below the lower limit of the aforesaid range may be more than adéquate, while in other cases still larger doses may be used without causing any harmful side effect, with such larger doses typically divided into several smaller doses for administration throughout the day.
Kit-of-Parts
Inasmuch as it may désirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the présent invention that two or more| pharmaceutical compositions, at least one of which contains a compound in accordance with the invention, may conveniently be combined in the form of a kit suitable for coadministration of the compositions. Thus, the kit of the invention includes two or 30 more separate pharmaceutical compositions, at least one of which contains a compound of the invention, and means for separatèly retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like. ......
The kit ofthe invention is particularly suitable for administering different dosage forms, for. 35 example, oral and parentéral, for administering the separate compositions at different dosage 116 intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically includes directions for administration and may be provided with a memory aid.
Combination Therapy
As used herein, the term “combination therapy” refers to the administration of a compound of the invention together with an at least one additional pharmaceutical or médicinal agent (e.g., an anti-cancer agent), either sequentially or simultaneously.
As noted above, the compounds ofthe invention may be used in combination with one or 10 more additional anti-cancer agents. The efficacy of the compounds of the invention in certain tumors may be enhanced by combination with other approved or experimental cancer thérapies, e.g., radiation, surgery, chemotherapeutic agents, targeted thérapies, agents that inhibit other signaling pathways that are dysregulated in tumors, and other immune enhancing agents, such as PD-1 or PD-L1 antagonists and the like.
When a combination therapy is used, the one or more additional anti-cancer agents may be administered sequentially or simultaneously with the compound of the invention. In one embodiment, the additional anti-cancer agent is administered to a mammal (e.g., a human) prior to administration of the compound of the invention. In another embodiment, the additional anti-cancer agent is administered to the mammal after administration of the compound of the invention. In another embodiment, the additional anti-cancer agent is administered to the mammal (e.g., a human) simultaneously with the administration ofthe compound ofthe invention.
The invention also relates to a pharmaceutical composition for the treatment of abnormal cell growth in a mammal, including a human, which comprises an amount of a compound of the invention, as defined above (including hydrates, solvatés and polymorphs of said compound or 25 pharmaceutically acceptable salts thereof), in combination with one or more (preferably one to three) additional anti-cancer therapeutic agents.
Synthetic Methods | · |
Compounds of the invention are prepared according to the exemplary procedures and Schemes provided herein, and modifications thereof known to those of skill in the art. Scheme 1 30 shows a general route for making pyrimidine compounds 6 having varying saturated heterocyclyl i or cycloalkyl moieties (comprising Q) and aiheteroaromatic ring (comprising U, V, X, Y and Z). It i will be understood that the order ofthe steps could be reversed. .....
General Scheme 1: - ~
As exemplified in Scheme 1, substituted dichloropyrimidines 1 are subjected to Suzuki coupling conditions with aryl or heteroaryl boronates 2 in the presence of a suitable catalyst (such as Pd(PPh3)4 or Pd(PPh3)2CI2) and a suitable base (such as Na2CO3 or K2CO3) in a suitable 5 solvent system (such as dioxane:water or DME:water) to afford an aryl- or heteroaryl-substituted chloropyrimidines 4. Alternatively, aryl or heteroaryl bromides 3 can be utilized in the Suzuki cross-coupling following treatment of the bromo compound with bis(pinacolato)diboron, a suitable catalyst (such as Pd(OAc)2 or Pd(dppf)CI2), ligand (such as PCy3) and base (such as KOAc or NaOAc) in a suitable solvent (such as DMSO or dioxane). The resulting heterobiaryl 10 intermediates 4 are treated under nucleophilic chloride displacement conditions with a primary heterocyclylamine or cycloalkylamine 5 in the presence of a suitable base (such as DIPEA) in a suitable solvent (e.g., DMSO), to afford amino-substituted pyrimidine compounds 6. When intermediate 4 is reacted with a primary heterocyclylamine, Q in 5 and 6 represents an appropriately substituted amino group (e.g., NR11), an appropriately protected amino group (e.g., 15 a carbamoyl, tetrahyrdopyranyl or trialkylsilyl protected amine) or oxygen. When intermediate 4 is reacted with a primary cycloalkylamine, Q in 5 and 6 represents an optionally substituted carbon.
Alternatively, the heterobiaryl intermediates 4 can be subjected to Buchwald-Hartwig | coupling conditions in the presence of a suitable apnine 5, a suitable catalyst (e.g., Pd2(dba)3, 20 chloro-2-(dimethylaminomethyl)-ferrocen-1-yl-(dinorbornylphosphine)-palladium or Pd(OAc)2, BINAP and a suitable base (e.g., Cs2CO3) in a suitable solvent (such as THF, dioxane or 2| methyl-2-butanol) to afford the compounds 6. j j It will be understood that reactive functional groups présent at any position in intermediates 1 to 5 and penultimate compounds 6 may be masked using suitable protecting 25 groups known to those of skill in the art. For examples, such compounds may contain amine or hydroxyl moieties masked with protecting groups (such as tert-butylcarbamate or tetrahydropyran) that can be removed via conditions known in art (such as TFA or HCl) in a suitable solvent. In some embodiments, Q in compound 6 may represent a protected amino group, which is removed under standard conditions to provide a free secondary amine that is
118 further we reacted with a suitabiy reactive reagent (e.g., a sulfonyi halide, acyl halide, alkyl halide or the like) to install the R11 substituent.
Analogous reactions could be used to préparé the corresponding pyridine dérivatives, as exemplified in the examples herein. : . —
General Synthetic Methods:
Abbreviations:
The following abbreviations are used throughout the Examples: “Ac” means acetyl, “AcO” or “OAc” means acetoxy, “ACN” means acetonitrile, “aq” means aqueous, “atm” means atmosphere(s), “BOC”, “Boc” or “boc” means N-terf-butoxycarbonyl, “Bn” means benzyl, “Bu” means butyl, “nBu” means normal-butyl, “tBu” means terf-butyl, “DBU” means 1,8diazabicyclo[5.4.0]undec-7-ene, “Cbz” means benzyloxycarbonyl, “DCM” (CH2CI2) means methylene chloride, “de” means diastereomeric excess, “DEA” means diethylamine, “DIPEA” means diisopropyl ethyl amine, “DMA” means Λ/,/V-dimethylacetamide, “DME” means 1,2dimethoxyethane, DMF means Λ/,/V-dimethyl formamide, “DMSO means dimethyisulfoxide, “EDTA” means ethylenediaminetetraacetic acid, “ee” means enantiomeric excess, “Et” means ethyl, “EtOAc means ethyl acetate, “EtOH” means éthanol, “HOAc” or “AcOH” means acetic acid, “i-Pr” or oiPr” means isopropyl, “IPA” means isopropyl alcohol, “l_AH” means lithium aluminum hydride, “LHMDS means lithium hexamethyldisilazide (lithium bis(trimethylsilyl)amide), “mCPBA” means meta-chloroperoxy-benzoic acid, “Me” means methyl, “MeOH” means methanol, “MS” means mass spectrometry, MTBE means methyl terf-butyl ether, “NCS” means N-chlorosuccinimide, “Ph” means phenyl, “TBHP” means terf-butyl hydroperoxide, “TFA” means trifluoroacetic acid, “THF” means tetrahydrofuran, “SFC” means supercritical fluid chromatography, “TLC” means thin layer chromatography, “Rf” means rétention fraction, “~” means approximately, “rt” means rétention time, “h” means hours, “min” means minutes, “equiv” means équivalents, “sat.” means saturated.
Sche^ne I: | i !
119
A = Cl or Br
Pd-catalyst B2Pin2
M = BPin or B(OH)2
Suzuki coupling
base-mediated SNAr or Buchwald-Hartwig coupling
As exemplified in Scheme I, a compound such as I (purchased or synthesized) can be borylated with B2Pin2 in the presence of a suitable catalyst system (such as PdCI2(dppf) or Pd(OAc)2 + PCy3) with a suitable base (such as KOAc) in an appropriate solvent (such as 1,4dioxane or DMSO) to provide a compound such as II. A compound such as II can be generated and reacted in-situ. Alternatively, a compound such as II can be isolated prior to subséquent reactions to provide the corresponding boronic acid or BPin ester. A compound such as II can undergo arylation with an aryl chloride such as III under standard Suzuki cross-coupling conditions in the presence of a suitable catalyst (such as Pd(PPh3)4 or PdCI2(PPh3)2) with a suitable base (such as K2CO3 or Na2CO3) in an appropriate solvent (such as DMSO or 1,4dioxane) to provide a compound such as IV. A compound such as IV can be coupled with an amine such as V to provide a compound such as VI under standard nucleophilic aromatic substitution conditions (3νΑγ) in the presence of a suitable base (such as DIPEA) in an appropriate sollvent (such as DMSO). Alternatively, a compound such las IV can be coupled with an amine such as V to provide a compoünd such as VI under standard Buchwaid-Hartwig coupling conditions in the presence of a suitable catalyst system (such as Pd(OÀc)2 + rac-BINAP or chloro-2-(dimethylaminomethyl)-ferrocen-1-yl-(dinorbornylphosphin'e)palladium complex) with a suitable base (such as Cs2CO3) in an appropriate solvent (such as THF or 1,4-dioxane). In some cases a compound such as VI may contain protecting groups, which can be removed by an additional step in the synthetic sequence using conditions known in the art (Protective Groups in Organic Synthesis, A. Wiley-lnterscience Publication, 1981 or Protecting groups, 10 Georg Thieme Verlag, 1994). Compounds at every step may be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC. If necessary,
120 séparation ofthe enantiomers ofVI may be carried out understandard methods known in the art such as chiral SFC or HPLC to afford single enantiomers. Variables Q, U, V, X, Z, R1, and R7, and R9 are as defined as in the embodiments, schemes, examples, and claims herein.
Scheme II:
Me
Suzuki coupling
Me oxidation
i
SO2Me base-mediated SNAr
Me
As shown in Scheme II, a compound such a VII (prepared as in Scheme I) can be coupled to an aryl chloride such as VIII under standard Suzuki cross-coupling conditions with a suitable 10 catalyst system (such as Pd(t-Bu3P)2) with a suitable base (such as K2CO3) in an appropriate solvent (such as 1,4-dic^xane) to provide a compound such as IX. A compound éuch as IX can be oxidized with a suitable oxidant (such as oxone) to provide a compound such as X. A compound such as X can be coupled to an amine such as XI under standard 8νΑγ conditions in the presence of a suitable base (such as NazCOs) in an appropriate solvent (such as THF) to provide a 15 compound such as XIIJ Compounds at every step may be purified by standard,techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC. Variables R1, and R4 are as defined as in the embodiments, schemes, examples, and claims herein.
Scheme lll:
121
Pd-catalyst B2Pin2
Suzuki coupling
Buchwald-Hartwig coupling
As shown in Scheme lll^ an aryl bromide such as compound XIII can be converted to a boronate ester such as compound XIV with B2Pin2 in the presence of a suitable catalyst (such as
Pd2Cl2(dppf)) with a suitable base (such as KOAc) in an appropriate solvent (such as 1,4dioxane). A compound such as XIV can be generated and used in-situ or isolated to provide the corresponding boronate ester. A compound such as XIV can be coupled with an aryl chloride such as compound III under standard Suzuki cross-coupling conditions with a suitable catalyst (such as PdCl2(PPh3)2) and suitable base (such as Na2CO3) in an appropriate solvent (such as
1,4-dioxane) to provide a compound such as XV. A compound such as XV can be converted to a compound such as XVI in the presence of excess /-PrNH2 in an appropriate solvent (such as DMSO). A compound such as XVI can be cyclized with an aldéhyde such as XVII in the presence of a suitable reductant (such as Na2S2O4) in an appropriate solvent (such as EtOH) to provide a _ 122 compound such as XVIII. A compound such as XVIII can be coupled with an amine such as XIX under standard Buchwald-Hartwig conditions in the presence of a suitable catalyst system (such as Pd(OAc)2 + rac-BINAP) and a suitable base (such as Cs2CO3) in an appropriate solvent system (such as 1,4-dioxane or THF) to provide a compound such as XX. Compounds ât every step may be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC. Variables Q, R1, R4, R6, and R7 are as defined as in the embodiments, schemes, examples, and claims herein.
Scheme IV:
XXI
XXIV
As shown in Scheme IV, a compound such as XXI (prepared as in Scheme I) can be coupled with an aryl chloride such as compound XXII under standard Suzuki cross-coupling conditions with a suitable catalyst (such £s PdCI2(PPh3)2) and a suitable base (such as Na2CO3)| in an appropriate solvent (such as 1,4-dioxane) to provide a compound such as XXIII. A compound such as XXIII can be coupled with an amine such as XIX under standard BuchwaldHartwig coupling conditions with a suitable palladium catalyst system (such as Bretphos-Pd-G3 or Pd2(dba)3 + rac-BINAP) with a suitable base (such as f-BuONa, CS2CO3, or phosphazene P2-1 Et) in an appropriate solvent (such as 1,4-dioxane or PhMe) to provide a compound such as
XXIV. In some cases a compound such as XXIV may contain protecting groups, which can be removed by an additional step . in the synthetic sequence using. conditions known in the art____ . .
(Protective Groups in Organic Synthesis, A. Wiley-lnterscience Publication, 1981 or Protecting groups, 10 Georg Thieme Verlag, 1994). Compounds at every step may be purified by standard
123 techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC.
Variables Q, Z, R2, R4, and R6, are as defined as in the embodiments, schemes, examples, and claims herein.
Scheme V:
XXV
XXVI o=s=o
Me base-mediated SNAr
O=S=O
Me
Suzuki coupling
As shown in Scheme V, an amine such as XI can be coupled with an aryl fluoride such । as XXV to provide a compound such as XXVI under standard 3νΑγ conditions with a suitable base (such as DIPEA) in an appropriate solvent (such as DMSO). A compound such as XXVI 10 can coupled with a compound such as XXVII (prepared as in Scheme I) under standard Suzuki , cross-coupling conditions with a suitable catalyst (such as PdCl2(PPh3)z) with a suitable base i i । (such as Na2COs) in an appropriate solvent (such as 1,4-dioxane) to provide a compound such as XXVIII. Compounds at every step may be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC.
124
As shown in Scheme VI, a compound such as XXIX (Prepared as in Scheme I or Scheme 5 IV) can be converted to a compound such as XXX under various conditions well known in the art including:
i. Carbamate formation with a chloroformate in the presence of a suitable base (such as NEU) in an appropriate solvent (such as DCM) to provide a compound such as XXX wherein R11 = CO2R17.
ii. Tertiary amine formation in the presence of a aldéhyde under standard reductive amination conditions with a suitable reducing agent (such as NaBH3CN) in a suitable solvent (such as MeOH) or alkylation with an alkyl halide with a suitable base (such as NaHCO3) in an appropriate solvent (such as EtOAc) to provide a compound such as XXX where in R11 = C1-C2 alkyl.
iii. Sulfonamide formation with a sulfonyl chloride in the presence of a suitable base (such as NaHCO3) in an appropriate solvent (such as EtOAc) to provide a compound such as XXX where in R11 = SO2R14 iv. Amide formation via acylation with an anhydride in the presence of a suitable base I (such as TEA) in an appropriate solvent (suchl as DCM) or a carboxylic acid in the presence of a suitable coupling agent (such as HATU or EDCI) and a suitable base (such as DIPEA) in an appropriate solvent (such as DCM or DMF) to provide a 25 compound such as XXX where in R11 = COR17 !
In some cases, a compound such as XXX may contain protecting groups, which can be removed by an additional step in the synthetic sequence using conditions known in the art (Protective Groups in Organic Synthesis, A. Wiley-lnterscience Publication, 1981 or Protecting 30 groups, 10 Georg Thieme Verlag, 1994). Compounds at every step may be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC. If
125 necessary, séparation of the enantiomers of XXX may be carried out under standard methods known in the art such as chiral SFC or HPLC to afford single enantiomers.
Variables U, V, W, X, Z, R1, R7, R11, R14, and R17 are as defined as in the embodiments, schemes, examples, and claims herein? _ _ ------ . :
Scheme VII:
SNAr
NH2
XI
As shown in Scheme VII, a compound such as XXXI (prepared as in Scheme I) can be oxidized with a suitable oxidant (such as MnO2, SO3*pyr, or TEMPO/NaCIO) in an appropriate 10 solvent (such as CHCh or DCM) to provide a compound such as XXXII. A compound such as XXXII can be coupled with an amine such as XI under standard SNAr conditions in the presence of a suitabl^ base (such as DIPEA) in an appropriate solvent (sûch as DMSO) to provide a compound such as XXXIII. Compounds at every step may be purified by standard techniques, such as column chromatography, crystallization, or reverse phase SFC or HPLC.
j . I
Scheme VIÎI I
1. oxidation
2. reductive amination
- - or . .
1. mesylation
2. Sn2
126
A shown in Scheme VIII, a compound such as XXXIV (prepared as in Scheme I) can be converted to a compound such as XXXV by oxidation with a suitable oxidant (such as Mn02) in an appropriate solvent (such as MeOH) followed by reductive amination in the presence of an amine with a suitable reductant (such as NaBHaCN) in an appropriate solvent (such as MeCN).
Alternatively, a compound such as XXXIV can be activated by treatment with methanesulfonyl chloride in the presence of a suitable base (such as TEA) in an appropriate solvent (such as DCM). Subséquent displacement of the mesylate with an amine in the presence of Nal and a suitable base (such as DIPEA) in an appropriate solvent (such as MeCN) can provide a compound such as XXXV. Compounds at every step may be purified by standard techniques, 10 such as column chromatography, crystallization, or reverse phase SFC or HPLC. Variables Q, R22, and R23 are as defined as in the embodiments, schemes, examples, and claims herein.
Scheme IX:
MeMgBr
XXXVII
As shown in .Scheme IX, a ketone such as XXXII (prepared as in Scheme VII) can be treated with a Grignard reagent (such as MeMgBr) in an appropriate solvent (such as THF) to provide a compound such as XXXVI. A compound such as XXXVI can be coupled with an amine such as XI under standard SNAr conditions in the presence of a suitable base (such as DIPEA) in an appropriate solvent (such as DMSO) to provide a compound such as XXXVII. Compounds at every step may be purified by standard techniques, such as column chromatography, crystallization or reverse phase SFC or HPLC.
127
Préparation of (1S)-1-(6-bromo-1-tert-butyl-4-fluoro-1H-benzimidazol-2-yl)ethan-1-oI (Int01) according to Scheme 1.
Préparation of intermediates
Scheme 1:
t-BuNH2 Cs2CO3
DMSO
90% yield step 1
OHC^OTBS fsj| Me
Na2S2O4
EtOH, H2O
18% yield
lnt-01 step 2
Step 1: Synthesis of 5-bromo-/V-terf-butyl-3-fluoro-2-nitroaniline (1b)
To a solution of 5-bromo-1,3-difluoro-2-nitrobenzene (1a) (5.0 g, 21.0 mmol) in DMSO (40.0 mL) was added 2-methylpropan-2-amine (1.54 g, 21.0 mmol) and CS2CO3 (13.7 g, 42 mmol). The reaction was stirred at 40 °C for 3 h. TLC analysis (petroleum ether) showed consumption of the starting material. The reaction was diluted with H2O (20 mL) and extracted with EtOAc (3x20 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, SiO2, 0-10% EtOAc/petroleum ether) to provide 5-bromo-/V-fert-butyl-3-fluoro-2-nitroaniline (1b) (5.5 g, 90% yield) as a red oil. 1H NMR (400 MHz, DMSO-d6) δ 7.13 - 7.01 (m, 2H), 6.94 (dd, J = 1.9,11.1 Hz, 1 H), 1.40 (s, 9H).
Step 2: Synthesis of (1S)-1-(6-bromo-1-tert-butyI-4-fluoro-1H-benzimidazol-2-yl)ethan-1-ol (lnt-01)
To a solution of 5-bromo-/V-fert-butyl-3-fluoro-2-nitroaniline (1b) (1.5 g, 5.2 mmol) and (2S)-2-{[tert-butyl(dimethyl)sil|rl]oxy}propanal (1.94 g, 10.3 mmol) in EtOH (30.0 mL) ^nd DMSO (7.5 mL) was added Na2S2O4 (4.5 g, 25.8 mmol). The reaction was stirred at 80 °C for 16 h. TLC analysis (EtOAc) showed consumption ofthe starting material. EtOAc (10 mL) and H2O (5 mL) were added and the layers were separated. The aqueous layer was extracted with EtOAc (3x10 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 12 g SiO2, 0-20% EtOAc/petroleum ether) to provide (1S)-1-(6-bromo-1-ferf-butyl-4-fluoro-1H-benzimidazol-2yl)ethan-1-ol (lnt-01) (400 mg, 18% yield) as a yellow oil. m/z (ESI) for (CigH3oBrFN20Si), 431.1 (M+H)+.
128
Préparation of 6-bromo-2-(2-([tert-butyl(dimethyl)silyl]oxy}propan-2-yl)-4-fluoro-1 (propan-2-yl)-1H-benzimidazole (lnt-02) according to Scheme 2.
Scheme 2:
i-PrNH2 CS2CO3
DMSO
70% yield step 1
OHC OTBS
.. Μθ Me
N32S£O4
EtOH, DMSO H2O
86% yield step 2
F
Br
OTBS -(-Me Me
Me lnt-02
Step 1 : Synthesis of 5-bromo-3-fluoro-2-nitro-N-(propan-2-yI)aniline (2b)
A solution of 5-bromo-1,3-difluoro-2-nitrobenzene (1a) (25.0 g, 105 mmol) and isopropylamine (8.95 mL, 105 mmol) in DMSO (525 mL) was stirred at ambient température for 4 d, after which the mixture was concentrated. The crude residue was purified by flash 10 chromatography (SiO2, 0-30% EtOAc/heptanes) to provide 5-bromo-3-fluoro-2-nitro-N-(propan2-yl)aniline (2b) (20.3 g, 70% yield) as a red/orange solid. 1H NMR (400 MHz, DMSO-de) δ 7.07 - 6.98 (m, 2H), 6.89 (dd, J = 2.0, 11.1 Hz, 1H), 3.88 (dd, J = 6.4, 13.9 Hz, 1H), 1.26-1.13 (m,
6H). m/z (ESI+) for (C9H10BrFN2O2), 278.1 (M+H)+.
Step 2: Synthesis of 6-bromo-2-(2-{[tert-butyI(dimethyl)silyl]oxy}propan-2-yl)-4-fluoro-1(propan-2-yl)-1 H-benzimidazole (lnt-02)
To a solution of 5-bromo-3-fluoro-2-nitro-A/-(propan-2-yl)aniline (2b) (1.0 g, 3.2 mmol) and 2-{[fert-butyl(dimethyl)silyl]oxy}-2-methylpropanal (655 mg, 3.2 mmol) in EtOH (8.0 mL) and DMSO (2.0 mL) was added Na2S2O4 (2.82 g, 16.2 mmol). The suspension was stirred at 90 °C 20 for 16 h. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (2x200 mL). The combined organic phases were washed with brine (150 mL), dried over Na2S(j)4, filtered, and concentrated. The residue was purified by flash chromatography (Biotage, 40 g SiO2, 1/10 EtOAc/petroleum ether) to provide 6-bromo-2-(2-{[tert-butyl(dimethyl)silyl]oxy}propan-2-yl)25 4-fluoro-1-(propan-2-yl)-1H-benzimida2ole (lnt-02) (1.2 g, 86% yield) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.51 (d, J= 1.5 Hz, 1H), 7.09 (dd, J= 1.5, 9.7 Hz, 1H), 5.62 (td, J= 7.0, l4.0 Hz, 1H), 1.85 (s, 6H), 1.71 - 1.60 (m, 6H), 0.92 (s, 9H), 0.21 - 0.17 (m, 6H).
Préparation of 6-bromo-4-fluoro-2-methyl-1-(oxetan-3-yl)-1H-benzimidazoIe (lnt-03) according to Scheme 3.
129
Scheme 3:
DMSO
55% yield step 1
ch3cho
NS2S2O4
EtOH, H2O
20% yield step 2 lnt-03
Step 1: Synthesis of N-(5-bromo-3-fluoro-2-nitrophenyl)oxetan-3-amine (3a)
To a solution of 5-bromo-1,3-difluoro-2-nitrobenzene (1.5 g, 6.3 mmol) (1 a) in DMSO (15.0 mL) was added oxetan-3-amine (507 mg, 6.93 mmol) and CS2CO3 (2.46 g, 7.56 mmol). The reaction was stirred at 25 °C for 2 h. TLC analysis (1/4 EtOAc/petroleum ether) showed consumption of the starting material. The reaction was diluted with brine (10 mL) and extracted with EtOAc (2x10 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO,
S1O2, 0-30% EtOAc/petroleum ether) to provide /V-(5-bromo-3-fiuoro-2-nitrophenyl)oxetan-3amine (3a) (1.0 g, 55% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-de) δ 7.59 (br d, J = 5.3 Hz, 1 H), 7.04 (dd, J = 1.8,10.8 Hz, 1 H), 6.69 (s, 1 H), 4.87 - 4.81 (m, 2H), 4.80 - 4.71 (m, 1 H), 4.60 - 4.47 (m, 2H).
Step 2: Synthesis of 6-bromo-4-fluoro-2-methyl-1-(oxetan-3-yl)-1H-benzimidazoIe (lnt-03)
To a solution of /V-(5-bromo-3-fluoro-2-nitrophenyI)oxetan-3-amine (3a) (500 mg, 1.72 mmol) in EtOH (16.0 mL) and H2O (4.0 mL) was added acetaldehyde (2.0 mL, 8.6 mmol) and Na2S2O4 (1.5 g, 8.6 mmol). The reaction was sealed and stirred at 80 °C with microwave irradiation for 10 h. LCMS analysis showed consumption of the starting material. The solution 20 was cooled and partitioned between EtOAc (40 mL) and H2O (20 mL). The combined layers were dried over Na2SO4, filtered, and concentrated. The crude residue was purified by flash | chromatography (S1O2, 0-100% EtOAc/petroleum ether) to provide 6-bromo-4-fluoro-2-methyI-1(oxetan-3-yl)-1H-benzimidazole (lnt-03) (100 mg, 20% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 7.95 (s, 1H), 7.34 (br d, J = 10.0 Hz, 1H), 5.66 (br t, J = 5.5 Hz, 1H), 5.11 (br | 25 t, J = 7.7 Hz, 2H), 5.03 - 4.88 (m, 2H), 2.55 (s, 3H). mlz (ESI+) for (CnHi0BrFN2O), 284.9 (M+H).
The intermediates in the below table were synthesized according to the methods used for the synthesis of (1S)-1-(6-bromo-1-fert-butyI-4-fluoro-1H-benzimidazol-2-yl)ethan-1-ol (lnt-01), 6-bromo-2-(2-{[ferf-butyl(dimethyl)silyl]oxy}propan-2-yl)-4-fIuoro-1-(propan-2-yl)-1H30 benzimidazole (lnt-02) and 6-bromo-4-fluoro-2-methyl-1-(oxetan-3-yi)-1H-benzimidazole (lnt03). The following intermediates were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
130
Compound number | Structure/IUPAC Name | Analytical data |
lnt-04 | F <^r-N Il [ Me Me 6-bromo-4-fluoro-1,2-dimethyI-1 Hbenzimidazole | m/z (ESI+) for (CgH8BrFN2), 242.6 (M+H)+ |
lnt-05 | F /A- N OTBS / Th Me A~Me Me Me 6-bromo-1 -tert-bu ty l-2-[( 1 R)-1 - {[tert- butyl(dimethyl)silyl]oxy}ethyl]-4- fluoro-1 H-benzimidazole | m/z (ESI+) for (Ci9H3oBrFN20Si), 430.9 (M+H)+ |
lnt-06 | F NHBoc Πη Br N Me Μ ^Μθ Me Me tert-butyl [(1R)-1-(6-bromo-1-tert- butyl-4-fluoro-1 H-benzimidazol-2yl)ethyl]carbamate | m/z (ESI+) for (C18H25BrFN3O2), 415.9 (M+H)+ |
lnt-07 | F /AN 1 P Br^^^N I .. /Me 1 Me 6-bromo-4-fluoro-2-(oxetan-3-yl)- 1-(propan-2-yl)-1 H-benzimidazole । i | 1H NMR (400 MHz, DMSO-cfe) δ 7.79 (d, J= 1.5 Hz, 1H), 7.30 (dd, J = 1.5,10.1 Hz, 1H), 5.01 -4.91 (m, 4H), 4.80 - 4.66 (m, 1 H), 4.55 - 4.42 (m, 1 H), 1.49 (d, J = 7.0 Hz, 6H); m/z (ESI+) for (Ci3Hi4BrFN2O), 324.2 (M+H)+ |
lnt-08 | F -N NHBoc /Me Me | 1H NMR (400 MHz, CDCI3) δ 9.16 (brs, 1H), 7.49 (d, J= 1.0 Hz, 1H), 7.09 (dd, J = 1.5, 9.5 Hz, 1H), 5.84 (br s, 1 H), 5.39 (br s, 1 H), 1.63 (s, 9H), 1.57 (s, 3H), 1.46 (s, 6H), 1.39 (s, 9H); m/z (ESI+) for |
131
tert-butyl {1-[6-bromo-4-fluoro-1(propan-2-yl)-1 H-benzimidazol-2yl]cyclopropyl}carbamate | (Ci8H23BrFN3O2), 357.9 (MtBu+H)+ | |
lnt-09 | .. F NHBoc Γ |ΊΓ Me „ À-Me Me tert-butyl {(1S)-1-[6-bromo-4- fluoro-1-(propan-2-yl)-1 H- benzimidazol-2-yl]ethyl}carbamate | 1H NMR (400 MHz, CDCI3) δ 9.58 (s,1H), 7.49 (d, J =1.5 Hz, 1H), 7.12 (dd, J = 9.7,1.5 Hz, 1H), 5.24 -5.03 (m, 1H), 4.86 (p, J =6.9 Hz, 1H), 1.66-1.57 (m, 6H), 1.47 (s, 9H), 1.35 (d, J = 7.4 Hz, 3H) |
lnt-10 | F OTBS F v~ch3 ch3 6-bromo-2-({[tertbutyl(dimethyl)silyl]oxy}methyl)-4fluoro-1-(2-fluoro-2-methylpropyl)1/7-benzimidazole | m/z (ESI+) for (Ci8H27BrF2N2OSi), 433.1 (M+H)+ |
lnt-11 | F OTBS Η3Ο-γ/ h3c μ 6-bromo-2-({[tertbutyl(dimethyl)silyl]oxy}methyl)-1- (1,1-difluoro-2-methylpropan-2-yl)4-fluoro-1 H-benzimidazole | m/z (ESI+) for (Ci8H26BrF3N2OSi), 451.2(M+H)+ |
lnt-12 I | F OTBS JL JL Me F-Y F 6-bromo-2-(2-{[tertbutyl(dimethyl)silyl]oxy}propan-2yl)-1-(2,2-difluoroethyI)-4-fluoro1H-benzimidazole | m/z (ESI+) for (Ci8H26BrF3N2OSi), 1 450.8 (M+H)+ |
132
lnt-13 | F fi T y-Me Rr^^N ^Me NHBoc tert-butyl [(2S)-2-(6-bromo-4fluoro-2-methyl-1 H-benzimidazoI1-yl)propyl]carbamate | 1H NMR (400 MHz, CDCI3) δ 7.32 (d, J = 1.5 Hz, 1 H), 7.04 (dd, J = 9.6, 1.5 Hz, 1H), 5.13 (s, 1H), 4.73 (s, 1H), 3.70 (dt, J = 11.5, 6.2 Hz, 1 H), 3.47 - 3.38 (m, 1 H), 2.56 (s, 3H), 1.61 (d, J = 7.0 Hz, 3H), 1.41 (s, 9H); mlz (ESI+) for (C16H2iBrFN3O2), 387.9 (M+H)+ |
Int-14 | F /Y-n ]| I —Me Me OMe 6-bromo-4-fluoro-1 -(1 methoxypropan-2-yl)-2-methyl-1 Hbenzimidazole | 1H NMR (400 MHz, DMSO-d6) δ 7.75 (d, J= 1.6 Hz, 1 H), 7.23 (dd, J =1.5, 10.1 Hz, 1H), 4.78 (ddd, J = 4.6, 7.1, 8.9 Hz, 1H), 3.86 (dd, J = 9.2,10.4 Hz, 1H), 3.62 (dd, J = 4.5, 10.5 Hz, 1H), 3.18 (s, 3H), 2.55 (s, 3H), 1.52 (d, J= 7.1 Hz, 3H); mlz (APCI+) for (Ci2Hi4BrFN2O), 301.0, 303.0 (M+H)+ |
Int-15 | F Me Ό 6-bromo-2-ethyl-4-fluoro-1 (oxetan-3-yl)-1 H-benzimidazole | 1H NMR (400 MHz, DMSO-d6) δ 7.97 (d, J = 1.6 Hz, 1H), 7.34 (dd, J = 10.2, 1.6 Hz, 1 H), 5.77 - 5.53 (m, 1H), 5.12 (t, J = 7.7 Hz, 2H), 4.98 (dd, J = 7.8, 5.3 Hz, 2H), 2.88 (q, J = 7.5 Hz, 2H), 1.29 (t, J = 7.4 Hz, 3H); mlz (APCI+) for (Ci2H12BrFN2O), 298.9 (M+H)+ I |
lnt-16 | F - /Y--N il I Me Br^^^N ?'Me NHBoc tert-butyl [(2R)-2-(6-bromo-4- fluoro-2-methyl-1 H-benzimidazol1 -yl)propyl]carbamate | 1H NMR (400 MHz, DMSO-d6) δ 7.77 - 7.53 (m, 1H), 7.21 (br d, J = 10.0 Hz, 1 H), 7.09 - 6.92 (m, 1 H), 6.65 (dd, J = 2.0, 7.0 Hz, 1H), 4.71 -4.60 (m, 1H), 4.45-4.33 (m, 1H), 3.83-3.60 (m, 2H), 1.61 1.46 (m, 5H), i.32 - 1.20 (m, 8H); mlz (ESI+) for (Ci6H2iBrFN3O2), 387.9 (M+H)* |
133 lnt-17
(6-bromo-1 -cyclobutyl-4-fluoro-1 Hbenzimidazol-2-yl)methanol 1H NMR (400 MHz, CDCI3) 57.63 (d, J = 1.5 Hz, 1H), 7.13 (dd, J = 1.5, 9.6 Hz, 1H), 5.31 -5.12 (m, 1H), 4.94 (s, 2H), 2.98 - 2.81 (m, 2H), 2.65 - 2.49 (m, 2H), 2.06 1.87 (m, 2H), 0.92 - 0.90 (m, 9H), 0.10 - 0.07 (m, 6H); m/z (ESI+) for (Ci8H26BrFN2OSi), 414.8 (M+H)+ lnt-18
6-bromo-2-({[tertbutyl(dimethyl)silyl]oxy}methyl)-1(3,3-difIuorocyclobutyl)-4-fluoro1H-benzimidazole 1H NMR (400 MHz, CDCI3) 5 7.51 (d, J = 1.3 Hz, 1H), 7.19 (dd, J = 1.5, 9.5 Hz, 1H), 5.27 (dquin, J = 3.7, 8.7 Hz, 1H), 4.97 (s, 2H), 3.60 -3.41 (m, 2H), 3.32-3.17 (m, 2H), 0.92-0.90 (m, 9H), 0.120.10 (m, 6H); m/z (ESI+) for (Ci8H24BrF3N2OSi), (M+H)+
Préparation of [6-bromo-4-fIuoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]methanol (lnt-19) according to Scheme 4.
Scheme 4:
Na2S2O4
EtOH/H2O
77% yield
A mixture of 5-bromo-3-fluoro-2-nitro-A/-(propan-2-yl)aniline (2b) (994 mg g, 3.59 mmol), Na2S2Ü4 (3.12 g, 17.9 mmol), and glycolaldéhyde dimer (517 mg, 4.30 mmol) in EtOH/H2O (4:1, i I mL) was stirred at 80 ’C for 21 h. The mixture was concentrated and partitioned between H2O 10 (100 mL) and EtOAc (100 mL). The layers were separated and the aqueous phase iextracted with
EtOAc (3x100 mL). The combined organic phases were washed with water (50 mL) and brine (50 mL), dried over Na2SO4, filtered, and concentrated. The crude product was purified by flash chromatography (SiO2, 40-100% EtOAc/heptanes) to provide [6-bromo-4-fIuoro-1-(propan-2-yl)1H-benzimidazol-2-yl]methanol (lnt-19) (790 mg, 77% yield) as a white waxy solid. 1H NMR (400
MHz, DMSO-d8) δ 7.81 (d, J = 1.5 Hz, 1H), 7.28 (dd, J = 10.1, 1.6 Hz, 1H), 5.71 (t, J = 5.8 Hz,
134
1H), 4.95 (hept, J = 6.8 Hz, 1H), 4.72 (d, J = 5.7 Hz, 2H), 1.56 (d, J = 6.9 Hz, 6H); m/z (APCI+) for (CnHi2BrFN2O), 286.8 (M+H)+. ------- _ _
Préparation of 6-bromo-4-fluoro-2-{[(oxan-2-yl)oxy]methyl}-1 -(propan-2-yl)-1 H5 benzimidazole (lnt-20) according to Scheme 5.
Scheme 5:
DHP, TsOHH2O
THF
86% yield
A solution of [6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]methanol (lnt-19) 10 (590 mg, 2.05 mmol), 3,4-dihydro-2H-pyran (1.21 g, 1.3 mL, 14.4 mmol) and p-TSA acid monohydrate (35.4 mg, 0.205 mmol) in THF (21 mL) was stirred at reflux température for 4 h. The mixture was concentrated and purified by flash chromatography (SiO2, 20-50% EtOAc/heptanes) to provide 6-bromo-4-fIuoro-2-{[(oxan-2-yl)oxy]methyl}-1-(propan-2-yl)-1/7benzimidazole (lnt-20) (710 mg, 93% yield) as a viscous yellow oil. 1H NMR (400 MHz, DMSO15 d6) δ 7.85 (d, J = 1.5 Hz, 1H), 7.31 (dd, J = 10.1, 1.5 Hz, 1H), 4.95-4.85 (m, 2H), 4.77-4.72 (m, 2H), 3.81-3.73 (m, 1H), 3.56-3.49 (m ,1H), 1.74-1.61 (m, 2H), 1.58 (d, J = 6.9 Hz, 6H), 1.55 - 1.45 (m, 4H); m/z (APCI+) for (C16H20BrFN2O2), 370.9 (M+H)+.
Préparation of 6-bromo-4-fluoro-2-(methoxymethyl)-1 -(propan-2-yl)-1 H-benzimidazole 20 (lnt-21) according to Scheme 6.
Scheme 6:
KOtBu, Mel
1,4-dioxane
60% yield
To a solution of [6-bromo~4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]methanoll(lnt25 19) (134 mg, 0.467 mmol) in 1,4-dioxane (4.67 mL) was added KOtPn (25% in toluene, 0.265 mL, 0.560 mmol). To the résultant dark reaction mixture at 0 °C was added Mel (66.2 mg, 0.029 mL, 0.467 mmol). After 15 min LCMS analysis showed consumption ofthe starting material with formation of the desired product mass. H2O (5 mL) was added and the mixture was extracted with DCM (3x10 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (12 g SiO2, 0-100%
135
EtOAc/heptanes) to provide (lnt-21) (85 mg, 60% yield). 1H NMR (400 MHz, CDCI3) δ 7.50 (d, J = 1.47 Hz, 1 H) 7.12 (dd, J = 9.54,1.47 Hz, 1 H) 4.91 (dt, J= 13.94, 6.97 Hz, 1H) 4.75 (s, 2H) 3.38 (s, 3H) 1.63 (d, J= 6.97 Hz, 6H).
Préparation of 6-bromo-4-fIuoro-1-(propan-2-yI)-1H-benzimidazole (lnt-22) according to
Scheme 7.
Scheme 7:
Fe°, NH4CI
H2O/MeOH, 60 C
94% yield
HC(OEt)3
EtOH, H2O 99% yield
step 1 step 2
Step 1: Synthesis of 5-bromo-3-fluoro-N1-(propan-2-yl)benzene-1,2-diamine (7a)
To a solution of 5-bromo-3-fluoro-2-nitro-N-(propan-2-yl)aniline (2b) (25.0 g, 90.2 mmol) in MeOH (300 mL) was added saturated aqueous NH4CI (150 mL) and Fe (25.2 g, 451 mmol). The reaction suspension was heated to 60 °C and stirred at this température for 3 h. LCMS analysis showed consumption of the starting material. The reaction suspension was filtered and the filter cake was washed with EtOAc. The filtrate was concentrated. The residue was taken up in EtOAc (200 mL) and filtered. The filtrate was washed with H2O (200 mL). The combined aqueous washes were extracted with EtOAc (2x200 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated to provide 5-bromo-3-fluoro-/V1-(propan-2yl)benzene-1,2-diamine (7a) (21.0 g, 94% yield). m/z (ESI+) for (CgHi2BrFN2), 246.7 (M+H)+.
Step 2: Synthesis of 6-bromo-4-fluoro-1-(|j)ropan-2-yl)-1H-benzimidazole (lnt-22)
A solution of 5-bromo-3-fluoro-/V1-(propan-2-yl)benzene-1,2-diamine (7a) (3.86 g, 15.6 mmol) in HC(OEt)3 (100 mL) was stirred at 150 °C for 15 h. LCMS analysis showed consumption of the starting material with formation of the. desired product mass. The solution was cooled to room température and concentrated to provide 6-bromo-4-fluoro-1-(propan-2-yl)-1H25 benzimidazole (lnt-22) (4.02 g, >99% yield) as a black oil, which was taken on without further purification. 1H NMR (400 MHz, DMSO-cfe) δ 8.04 (d, J = 3.3 Hz, 1H), 6.66 (dd, J = 2.0, 10.0 Hz, 1H), 6.54 (s, 1H), 3.69 - 3.56 (m, 1H), 1.15 (d, J = 6.2 Hz, 6H); m/z (ESI+) for (CioHiOBrFN2), 258.7 (M+H)+.
136
Préparation of 6-bromo-1-terf-butyl-2-methyl-1H-benzimidazole (lnt-23) according to
Scheme 8.
Scheme 8: „
JL CH3C(0Et)3 L T Me
Br ^^NH ----------- Br ^^N.
148’C Æ-Me
8a Me .LMe lnt-23 Me Me Me 86% yield
Synthesis of 6-bromo-1-fert-butyl-2-methyl-1H-benzimidazole (lnt-23)
A mixture of 4-bromo-/\/2-fert-butylbenzene-1,2-diamine (8a) (1.3 g, 5.35 mmol) and triethyl orthoacetate (8.7 g, 53.5 mmol) was stirred at 148 °C for 1 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The solution was cooled to room température and concentrated. The residue was purified by flash chromatography (20 g S1O2, 20% EtOAc/petroleum ether) to provide 6-bromo-1 -fert-butyl-2-methyl- 1Hbenzimidazole (lnt-23) (1.23 g, 95% yield) as a yellow oil. mlz (ESI+) for (Ci2Hi5BrN2), 268.7 (M+H)+.
Préparation of 6-bromo-5-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazoIe (lnt-24) according to Scheme 9.
Scheme 9:
i-PrNH2, K2CO3
THF
9a 70% yield
H2O/MeOH, 60 ’C
Fe°, NH4CI
CH3C(OEt)3 148 ’C
51% yield step 1
53% yield step 2 step 3
Step 1: Synthesis of 5-bromo-4-fluoro-2-nitro-N-(propan-2-yl)aniline (9b)
To a suspension of 1-bromo-2,5-difluoro-4-nitrobenzene (9a) (1.0 g, 4.2 mmol) in THF (10 mL) was added K2CO3 (581,4.2 mmol) and /-PrNH2 (248 mg, 4.2 mmol). The mixture was stirred at ambient température for 16 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction solution was diluted with H2O (30 mL) and extracted with EtOAc (3x20 mL). The combined organic phases were washed with brine (20 mL), _ 137 dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 20 g SiO2,10% EtOAc/petroleum ether) to provide 5-bromo-4-fluoro-2-nitro-/V-(propan-2yl)aniline (9b) (900 mg, 77% yield) as a yellow solid. mlz (ESI+) for (CgHioBrFN202), 276.7 (M+H)+. '
Step 2: Synthesis of 5-bromo-4-fIuoro-N1-(propan-2-yl)benzene-1,2-diamine (9c)
To a solution of 5-bromo-4-fluoro-2-nitro-/V-(propan-2-yl)aniline (9b) (1.9 g, 6.9 mmol) in MeOH (30 mL) was added saturated aqueous NH4CI (15 mL) and Fe° (1.9 g, 34.3 mmol). The reaction suspension was stirred at 60 °C for 16 h overnight. LCMS analysis showed consumption 10 of the starting material with formation of the desired product mass. The reaction suspension was filtered and the filter cake was washed with EtOH (50 mL). The combined filtrate was diluted with H2O (100 mL) and extracted with EtOAc (2x80 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated. The crude residue was purified by flash chromatography (40 g S1O2, 1:2 EtOAc/petroleum ether) to provide 5-bromo-4-fluoro-A/1-(propan-2-yl)benzene15 1,2-diamine (9c) (900 mg, 53% yield) as a brown gum. mlz (ESI+) for (C9Hi2BrFN2), 246.7 (M+H)+.
Step 3: Synthesis of 6-bromo-5-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazole (lnt-24)
A mixture of 5-bromo-4-fiuoro-/V1-(propan-2-yl)benzene-1,2-diamine (9c) (800 mg, 3.24 20 mmol) and triethyl orthoacetate (5.3 g, 32.4 mmol) was stirred at 148 °C for 1 h. LCMS analysis showed consumption of the starting material with formation of the desired product. The solution was cooled to room température and concentrated. The residue was combined with a parallel reaction run on 100 mg scale and purified by flash chromatography (20 g S1O2,100% EtOAc) to provide 6-bromo-5-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazole (lnt-24) (500 mg, 51% 25 yield). 1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, J = 6.2 Hz, 1H), 7.51 (d, J = 9.5 Hz, 1H), 4.74 (spt, J = 6.9 Hz, 1H), 2.55 (s, 3H), 1.53 (d, J = 7.0 Hz, 6H); mlz (ESI+) for (CiiHi2BrFN2), 270.9 (M+H)j. | „
The intermediates in the below table were synthesized according to the methods used for 30 the synthesis of 6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimiàazole (lnt-22), 6-bromo-4-fluoro1-(propan-2-yl)-1H-benzimidazole (lnt-23), and 6-bromo-5-fluoro-2-methyl-1-(propan-2-yl)-1Hbenzimidazole (lnt-24). The following intermediates were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be abletorealize. -------- . .. . ... ..... . .. . . . . ..
' —
138
Compound number | Structure/IUPAC Name | Analytical data |
lnt-25 | F XX x> Jo 6-bromo-4-fluoro-1-(oxolan-3-yl)1H-benzimidazole | 1H NMR (400 MHz, DMSO-d6) δ 8.34 (s, 1H), 7.85 (d, J = 1.6 Hz, 1H), 7.34 (dd, J =10.3, 1.6 Hz, 1H), 5.30 (ddt, J= 8.4, 5.8, 3.1 Hz, 1H), 4.13 (td, J= 8.4, 6.0 Hz, 1H), 4.01 (dd, J =10.0, 2.6 Hz, 1H), 3.93 (dd, J = 10.0, 5.6 Hz, 1H), 3.87 - 3.78 (m, 1H), 2.59 - 2.53 (m, 1H), 2.26-2.13 (m, 1 H).; m/z (ESI+) for (CnHioBrFN20), 258.7 (M+H)* |
lnt-26 | ' F XX > 6-bromo-1 -cyclopropyl-4-fluoro- 1H-benzimidazole | 1H NMR (400 MHz, CDCI3) δ 7.90 (s, 1H), 7.53 (d, J = 1.5 Hz, 1H), 7.15 (dd, J = 1.5, 9.8 Hz, 1H), 3.36 (td, J = 3.5, 7.0 Hz, 1H), 1.24-1.17 (m, 2H), 1.10-1.03 (m, 2H); mlz (ESI+) for (Ci0H8BrFN2), 256.7 (M+H)* |
lnt-27 | F XX x> __,NHBoc Me Me fert-butyl [2-(6-bromo-4-fIuoro-1H- benzimidazol-1-yl)-2methylpropyl]carbamate | mlz (ESI+) for (Ci6H2iBrFN3O2), 387.6 (M+H)* |
lnt-28 | | F JL IJ —Μθ __^NHBoc Me Me fert-buty! [2-(6-bromo-4-fluoro-2- methyl-1/7-benzimidazol-1-yl)-2methylpropyl]carbamate | I mlz (ESI+) for (Ci7H23BrFN3O2), 400.0 (M+H)* |
Préparation of tert-butyl {[6-bromo-4-fiuoro-1-(propan-2-yl)-1H-benzimidazol-2yl]methyl}methylcarbamate (lnt-29) according to Scheme 10.
139
Scheme 10: -
Me
N32S2O4
EtOH, DMSO, 80 °C
82% yield
To a solution of S-bromo-S-fluoro-A^-Cpropan^-ylJbenzene-l ,2-diamine (7a) (300 mg, 1.2 mmol) and tert-butyl methyl(2-oxoethyl)carbamate (421 mg, 2.43 mmol) in EtOH (4.0 mL) and DMSO (1.0 mL) was added Na2S2O4 (1.1 g, 6.1 mmol). The suspension was stirred at 80 °C for 16 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The mixture was concentrated to dryness. The residue was purified by flash chromatography (Biotage, 20 g SiO2,25% EtOAc/petroleum ether) to provide fert-butyl {[6-bromo4-fluoro-1-(propan-2-yl)-1/7-benzimidazol-2-yl]methyl}methylcarbamate (lnt-29) (400 mg, 82% yield) as a yellow oil. m/z (ESI+) for (Ci7H23BrFN3O2), 401.6 (M+H)+.
The intermediates in the below table were synthesized according to the methods used for the synthesis of tert-butyl {[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2yl]methyl)methylcarbamate (lnt-29). The following intermediates were synthesized with noncritical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Compound number | Structure/IUPAC Name | Analytical data I |
lnt-30 | j F I NHBoc f T —(Me Me /Me Me tert-butyl {2-[6-bromo-4-fluoro-1- (propan-2-yl)-1H-benzimidazol-2yl]propan-2-yl)carbamate | t m/z (ESI+) for (C18H25BrFN3O2), 415.7 (M+H)+ |
140
lnt-31 | F 0TBS Me 6-bromo-2-({[tertbutyl(dimethyl)silyl]oxy}methyl)-4fluoro-1 -(1 -methylcyclopropyl)-1 Hbenzimidazole | 1H NMR (400 MHz, CDCI3) δ 7.50 (d, J = 1.6 Hz, 1H), 7.10 (dd, J = 9.6, 1.6 Hz, 1H), 4.97 (s, 2H), 1.60 (s, 7H), 0.92 (s, 9H), 0.15 (s, 6H); m/z (ESI+) for (CieH26BrFN2OSi), 414.9 (M+H)+ |
Préparation of 6-bromo-4-fluoro-/V-methyl-1-(propan-2-yl)-1H-benzimidazole-2carboxamide (lnt-32) according to Scheme 11.
Scheme 11:
F ethyl 2-oxoacetate
N a2S2O4
DMSO, EtOH, 80’C Br . „ /Me
38% yield 11a Me step 1
NH2Me, DIPEA «fan 5 DMA, 80 ’c step Z
Step 1: Synthesis of ethyl 6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazole-2carboxylate (11a) . . . .. .. .
To a solution of 5-bromo-p-fluoro-/V1-(propan-2-yl)benzene-1,2-diamine (7a) (1.0 |g, 4.05 10 mmol) and ethyl 2-oxoacetate (1.65 g, 8.09 mmol) in EtOH (20.0 mL) and DMSO (5.0 mL) was added Na2S2O4 (3.5 g, 20.2 mmol). The suspension was stirred at 80 °C for 16 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The mixture was diluted with H2O (15|mL) and extracted with EtOAc (15 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 15 chromatography (ISCO, 20 g S1O2, 25% EtOAc/heptanes) to provide ethyl 6-bromo-4-fluoro-1(propan-2-yl)-1H-benzimidazole-2-carboxylate (11a) (500 mg, 38% yield) as a solid. m/z (ESI+) for (Ci3H14BrFN2O2), 328.7 (M+H)+.
141
Step 2: Synthesis of 6-bromo-4-fluoro-N-methyl-1-(propan-2-yl)-1H-benzimidazoIe-2carboxamide (lnt-32)
A mixture of ethyl 6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazole-2-carboxylate (11a) (200 mg, 0.608 mmol), DIPEA (236 mg, 1.82 mmol), and MeNH2 (22.6 mg, 0.729 mmol) in 5 DMA (8.0 mL) was stirred at 80 °C for 16 h. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The mixture was diluted with EtOAc (15 mL) and washed with H2O (15 mL). The combined organic phases were dried over Na2SÜ4, filtered, and concentrated. The material obtained was combined the product of a parallel reaction run with 48 mg of ethyl 6-bromo-4-fIuoro-1-(propan-2-yl)-1H-benzimidazole-2-carboxylate to provide 610 bromo-4-fluoro-N-methyl-1-(propan-2-yl)-1H-benzimidazole-2-carboxamide (lnt-32) (200 mg, 83% yield). m/z (ESI+) for (Ci2Hi3BrFN3O), 313.7 (M+H)+.
Préparation of 6-bromo-4-fiuoro-1-(propan-2-yl)-1H-benzimidazole-2-carboxamide (lnt-33) according to Scheme 12.
Scheme 12:
nh3
MeOH, 85-90 ’C
83% yield
Ethyl 6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazole-2-carboxylate (11a) (200 mg, 0.608 mmol) was dissolved in a solution of ammonia in MeOH (7.0 N, 15 mL) and stirred at 8520 90 °C for 16 h. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The reaction mixture was cooled to room température and concentrated to provide (lnt-33) (190 mg, >99% yield) as a solid. m/z (ESI+) for (CnHnBrFN3O), 299.7 (M+H)+.
Préparation of ferf-butyl {1-[6-brom|o-4-fIuoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]-225 methylpropan-2-yl}carbamate (lnt-34) according to Scheme 13.
Scheme 13:
142
F
EDCI pyridine
81% yield
HCl 1,4-dioxane MW, 130 °C >99% yield step 1 step 2
BOC2O, DIPEA
DCM >99% yield
step 3
Step 1: Synthesis of tert-butyl (4-{4-bromo-2-fluoro-6-[(propan-2-yl)amino]aniIino}-2methyl-4-oxobutan-2-yl)carbamate (13a)
To a stirring solution of S-bromo-S-fluoro-A^-Îpropan^-ylJbenzene-l^-diamine (7a) (1.1 g, 4.5 mmol) in pyridine (10.0 mL) was added 3-[(terf-butoxycarbonyl)amino]-3-methylbutanoic acid (967 mg, 4.5 mmol) and EDCI (1.7 g, 8.9 mmol) at 0 °C under an atmosphère of N2. The mixture was stirred at 25 °C for 4 h. LCMS analysis showed consumption of starting material with formation ofthe desired product mass. The solution was diluted with H2O (20 mL) and extracted with EtOAc (3x20 mL). The combined organic phases were washed with brine, dried over
Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 20 g S1O2, 0-50% EtOAc/petroleum ether) to provide 1-[6-bromo-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]-2-methylpropan-2-amine (13a) (1.6 g, 81% yield) as a white solid. mlz (ESI+) for (Ci9H29BrFN3O3), 446.1 (M+H)+. I
Step 2: Synthesis of 1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]-2• methylpropan-2-amine (13b) । j This reaction was run in three parallel batches. To the solid 1-[6-bromo-4-fIuoro-1(propan-2-yl)-1H-benzimidazol-2-yI]-2-methylpropan-2-amine (13a) (600 mg, 1.8 mmol) was added a solution of HCl (4.0 M in 1,4-dioxane, 10.0 mL). The mixture was stirred at 130 °C for 15 20 min under microwave irradiation. LCMS analysis showed consumption ofthe starting material with formation of the desired product mass. The three reaction batches were combined and concentrated to dryness. The residue was taken up in H2O (10 mL) and the mixture was basified with NH4OH to pH ~9. The mixture was extracted with EtOAc (3x15 mL). The combined organic 143 phases were washed with brine, dried over Na2SO4, filtered, and concentrated to provide 1-[6bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]-2-methylpropan-2-amine (13b) (T.2 g, >99% yield). m/z (ESI+) for (Ci4Hi9BrFN3), 329.9 (M+H)+.
Step 3: Synthesis of tert-butyl {1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazoI-2-yl]2-methylpropan-2-yl}carbamate (lnt-34)
To a solution of 1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]-2methylpropan-2-amine (13b) (1.2 g, 3.7 mmol) in DCM (20 mL) was added DIPEA (473 mg, 3.7 mmol) and BOC2O (958 mg, 4.4 mmol) at 0 °C. The solution was stirred at 25 °C for 18 h. LCMS 10 analysis showed consumption ofthe starting material with formation of the desired product mass.
The reaction was diluted with H2O (15 mL) and the layers were separated. The aqueous layer was extracted with DCM (3x15 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 20 g SiO2, 0-51% EtOAc/petroleum ether) to provide tert-butyl {1-[6-bromo-4-fluoro-115 (propan-2-yl)-1H-benzimidazol-2-yl]-2-methylpropan-2-yl}carbamate (lnt-34) (1.6 g, >99% yield) as a brown solid. m/z (ESI+) for (Ci9H27BrFN3O2), 430.0 (M+H)+.
The intermediate in the below table was synthesized according to the methods used for the synthesis of tert-butyl {1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]-220 methylpropan-2-yl}carbamate (lnt-34). The following intermediate was synthesized with noncritical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Compound number | Structure/IUPAC Name | Analytical data |
I lnt-35 i | F î )—NHBoc /Me Me tert-butyl {3-[6-bromo-4-fluoro-1- (propan-2-yl)-1H-benzimidazol-2_ yl]-1,1-difluoropropan-2yljcarbamate | 1H NMR (400 MHz, CDCI3) δ 7.47 (|s, 1 H), 7.11 (dd, J = 1.1,9.6 Hz, 1H), 6.30 - 5.97 (m, 1H), 5.72 (br d, J = 9.1 Hz, 1 H), 4.72 - 4.57 (m, !1 H), 4.52 - 4.30 (m, 1 H), 3.34 0.13 (m, 2H), 1.70 - 1.60 (m, 6H), 1.36 (s, 9H); m/z (ESI+) for ~ (Ci8H23BrF3N3O2),‘396.0 (M- ‘ ..... tBu+H)+ |
144
Préparation of 6-bromo-4-fluoro-2-(oxetan-2-yl)-1-(propan-2-yl)-1H-benzimidazole (lnt-36) according to Scheme 14.......
Scheme 14:
HATU, DIPEA
DMF
100% yield step 1
AcOH reflux step 2
MsCI, TEA then t-BuOK DCM/THF
53% yield
K2CO3
MeOH 44% yield (2 steps) step 3
Br step 4
/Me lnt-36 Me
Step 1: Synthesis of N-{4-bromo-2-fluoro-6-[(propan-2-yl)amino]phenyl}oxetane-210 carboxamide (14a)
To a solution of 5-bromo-3-fluoro-/V1-(propan-2-yl)benzene-1,2-diamine (7a) (1.0 g, 4.05 I I mmol) in DMF (10.0 mL) was added oxetane-2-carboxylic acid (413 mg, 4.05 mmol). Then DIPEA (1.6 g, 12.1 mmol) and HATU (2.3 g, 6.1 mmol) were added and the mixture was stirred for 16 h. TLC analysis (25% EtOAc/petroleum ether) showed consumption of the starting material. The solvent was removed in vacuum. The residue was diluted with saturated aqueous NazCOa (100 mL). The solution was extracted with EtOAc (2x100 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated to provide A/-{4-bromo-2-fluoro-6-[(propan-219876 _ 145 yl)amino]phenyl)oxetane-2-carboxamide (14a) (1.5 g, 100% yield), which was taken on directly to the next step.
Step 2: Synthesis of 3-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]-35 hydroxypropyl acetate (14b)
A brown solution of /V-{4-bromo-2-fIuoro-6-[(propan-2-yl)amino]phenyl}oxetane-2carboxamide (14a) (1.5 g, 4.5 mmol) in AcOH (20 mL) was stirred at 110 °C for 1.5 h. LCMS analysis showed consumption of the starting material with formation of the product mass. The mixture was concentrated to dryness to provide 3-[6-bromo-4-fluoro-1-(propan-2-y 1)-1/710 benzimidazol-2-yl]-3-hydroxypropyl acetate (14b) (1.5 g, 62% yield), which was taken directly into the next step without further purification, mlz (ESI+) for (CisHi8BrFN2O3), 374.9 (M+H)+.
Step 3: Synthesis of 1-[6-bromo-4-fIuoro-1-(propan-2-yl)-1H-benzimidazoI-2-yl]propane1,3-diol (14c)
To a brown solution of 3-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]-3hydroxypropyl acetate (14b) (1.5 g, 2.8 mmol) in MeOH (30 mL) was added K2CO3. The mixture was stirred at room température for 2 h. LCMS analysis showed consumption of the starting material with formation of the product mass. The reaction mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (Biotage, 40 g S1O2, 20 0-30% MeOH/EtOAc) to provide 1-[6-bromo-4-fluoro-1-(propan-2-yl)-1/7-benzimidazol-2yl]propane-1,3-diol (14c) (660 mg, 44% yield, 2 steps) as a pale brown solid. mlz (ESI+) for (Ci3Hi6BrFN2O2), 332.9 (M+H)+.
Step 4: Synthesis of 6-bromo-4-fIuoro-2-(oxetan-2-yl)-1-(propan-2-yl)-1H-benzimidazole 25 (lnt-36)
To a solution of 1-[6-bromo-4-fIuoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]propane-1,3diol (14c) (600 mg, 1^81 mmol) and TEA (275 mg, 2.72 mmol) in DCM (5.0 |mL) and THF (5.0 mL) at 0 °C was added a solution of MsCI (208 mg, 7.25 mmol) in DCM drop-wise. After 2 h, solid t-BuOK (813 mg, 7.25 mmol) was added in one portion. The resulting solution was stirred at room 30 température for 2 h. TLC analysis (EtOAc) showed consumption of the starting material. The reaction was concentrated to dryness. The residue was purified by flash chromatography (Biotage, EtOAc, Rf~0.5) to provide 6-bromo-4-fluoro-2-(oxetan-2-yl)-1-(propan-2-y 1)-1/7benzimidazole (lnt-36) (300 mg, 53% yield) as a brown gum.
Préparation ôf 6-bromo-4-fIuoro-2-(oxetan-2-ÿl)-1 -(propan-2-yl)-1 H-benzimidâzole (lnt-37) according to Scheme 15.
146
Scheme 15:
step 1
AcOH . _ reflux step 2
Step 1: Synthesis of tert-butyl (2-{4-bromo-2-fIuoro-6-[(propan-2-yl)amino]anilino}-25 oxoethyl)carbamate (15a)
To a solution of 5-bromo-3-fluoro-/V1-(propan-2-yl)benzene-1,2-cliamine (7a) (504 mg, 2.4 mmol), /V-(fert-butoxycarbonyl)gIycine (393 mg, 2.2 mmol), and HATU (1.2 g, 3.1 mmol) in THF (10.0 mL) at 0 °C was added DIPEA (0.72 mL, 4.1 mmol). The mixture was stirred at 0 °C for 30 min and then room température for 18 h. LCMS analysis showed complété consumption of the 10 starting material. The reaction mixture was quenched with water and then extracted with EtOAc (3x50 mL). The combined organic phases were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 12 g SiO2, 0-100% EtOAc/petroleum ether) to provide tert-butyl (2-{4-bromo-2-fluoro-6-[(propan-2yl)amino]anilino}-2-oxoethyI)carbamate (15a) (810 mg, 98% yield) as a foamy solid. 1H NMR (400 15 MHz, DMSO-de) δ 9.06 (s, 1H), 7.22 (t, J = 5.4 Hz, 1H), 6.64 (d, J = 8.8 Hz, 1H), 6.60 (s, 1H), 4.98 (d, J= 8.1 Hz, 1H), 3.68 (d, J = 5.6 Hz, 2H), 3.62 (dd, J = 6.6, 13.8 Hz, 1H), 1.40 (s; 9H), 1.13 (d, J = 6.2 Hz, 6H); mlz (4pCI+) for (Ci6H23BrFN3O3), 404.0, 406.1 (M+H)+. |
Step 2: Synthesis of tert-butyl {[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazoI-220 yl]methyl}carbamate (lnt-37) i i
A solution of tert-butyl (2-{4-bromo-2-fIuoro-6-[(propan-2-yl)amino]anilino}-2oxoethyl)carbamate (15a) (809 mg, 2.0 mmol) in AcOH (4.0 mL) was stirred at 90 °C for 3.5 h. LCMS analysis showed some remaining starting material. The reaction was stirred for an additional 2.5 h at 100 °C; The reaction mixture was concentrated.-The residue was purified by25 flash chromatography (ISCO, 12g SiO2,0-100% EtOAc/heptanes) to provide tert-butyl {[6-bromo4-fIuoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]methyl}carbamate (lnt-37) (547 mg, 70% yield) as
147 a white solid. 1H NMR (400 MHz, DMSO-cfe) δ 7.79 (d, J= 1.3 Hz, 1H), 7.51 (br. s., 1H), 7.28 (dd,
J= 1.3, 10.1 Hz,TH), 4.97-4.78 (m, 1H), 4.45 (d, J = 5.7 Hz, 2H), 1.53 (d, J= 6.8 Hz, 6H), 1.39 (s, 9H); mlz (APCI+) for (Ci6H2iBrFN3O2), 388.0 (M+H)+.
Préparation of tert-butyl {1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2yl]ethyl}carbamate (lnt-38) according to Scheme 16:
Scheme 16:
Me HATU, DIPEA
DMF
85% yield step 1
step 2
I.AcOH 120 ’C
2. BOC2O THF/H2O
26% yield
Step 1: Synthesis of tert-butyl (1-{4-bromo-2-fluoro-6-[(propan-2-yl)amino]anilino}1-oxopropan-2-yl)carbamate (16a)
To a solution of S-bromo-S-fluoro-A/Xpropan^-yljbenzene-l^-diamine (7a) (900 mg, 3.2 mmol) in DMF (8.0 mL) were added A/-(tert-butoxycarbonyl)alanine, DIPEA (1.26 g, 9.7 mmol), and HATU (1.85 g, 4.9 mmol). The mixture was stirred at ambient température for 16 h. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The reaction mixture was concentrated to dryness. The residue was purified by flasn chromatography (ISCO, 20 g SiO2, 30-50% EtOAc/petroleum ether) to provide tert-butyl (1-{4bromo-2-fluoro-6-[(propan-2-yl)amino]anilino}-1-oxopropan-2-yl)carbamate (16a) (1.14 g, 84% yield) as a white solid. i ;
Step 2: Synthesis of tert-butyl {1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2yl]ethyl}carbamate (lnt-38)
A mixture of tert-butyl (1-{4-bromo-2-fIuoro-6-[(propan-2-yl)amino]anilino}-1-oxopropan-2yl)carbamate (16a) (4.4 g, 10.5 mmol) in AcOH (20 mL) was stirred at 120 °Cfor 2 h. The solution was diluted with EtOAc (50 mL) and extracted with H2O (50 mL). To the aqueous solution was _ 148 added THF (100 mL) and BOC2O (1.09 g, 5.0 mmol). The mixture was stirred at room température for 16 h. TLC analysis showed consumption of the intermediate. The solution was diluted with H2O (30 mL) and extracted with EtOAc (30 mL). The organic phase was dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 20 g SiO2, 5 25% EtOAc/petroleum ether) to provide fert-butyl {1-[6-bromo-4-fluoro-1-(propan-2-yl)-1/-/benzimidazol-2-yl]ethyl}carbamate (lnt-38) (1.1 g, 26% yield) as a gummy solid. mlz (ESI+) for (Ci7H23BrFN3O2), 401.7 (M+H)+.
The intermediate in the below table was synthesized according to the methods used for the synthesis of—tert-butyl {1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2yl]ethyl}carbamate (lnt-38). The following intermediate was synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Compound number | Structure/IUPAC Name | Analytical data |
lnt-39 | Αχ '-/-NHBoc b Ar /^Me Me fert-butyl (1-{[6-bromo-4-fluoro-1- (propan-2-yl)-1H-benzimidazol-2yl]methyl}cyclopentyl)carbamate | 1H NMR (400 MHz, CDCI3) δ 7.41 (s, 1H), 7.02 (d, J = 9.7 Hz, 1H), 4.78 (p, J = 7.0 Hz, 1H), 4.66 (s, 1H), 3.35 (s, 2H), 1.89-1.59 (m, 8H), 1.54 (d, J = 7.0 Hz, 6H), 1.34 (br d, J = 6.7 Hz, 9H); mlz (ESI+) for (Ci8H26BrFN2OSi), 454.1 (M+H)+ |
Préparation of (1R)-1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]ethan-1-ol (lnt-40) according to Scheme 17. |
Scheme 17:
neat, 80 'C
149
A mixture ofthe 5-bromo-3-fIuoro-N1-(propan-2-yI)benzene-1,2-diamine (7a) (5.74 g, 23.2 mmol) and (2R)-2-hydroxypropanoic acid (17.4 g, 193 mmol) was stirred at 82 eC for 44 h. The dark, viscous mixture was carefully added into a stirring mixture of DCM (100 mL) and saturated NaHCOs (250 mL) (gas évolution). The biphasic mixture was stirred at ambient température until 5 gas évolution ceased. The layers were separated and the aqueous phase extracted was with DCM (2x100 mL). The combined organic phases were dried over MgSO4, filtered, and concentrated. The crude residue was purified by flash chromatography (S1O2, 20-80% MTBE/heptanes). The fractions containing product were further purified by first concentrating to a minimum volume. The resulting residue was dissolved in a small volume of MTBE then diluted 10 with an equal volume of heptanes. The solution was sonicated, causing précipitation. The resulting suspension was concentrated until only a small amount of solvent remained. The supernatant was decanted off. The solids were rinsed with 10% MTBE/heptanes followed by heptanes and then dried under vacuum to provide (1R)-1-[6-bromo-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]ethan-1-ol (lnt-40) (4.97 g, 71% yield) as a tan solid. 1H NMR (400 MHz, 15 DMSO-d6) δ 7.79 (d, J = 1.6 Hz, 1H), 7.26 (dd, J = 1.5, 10.1 Hz, 1H), 5.71 (d, J = 6.5 Hz, 1H), 5.17 - 5.00 (m, 2H), 1.62 - 1.51 (m, 9H); m/z (APCI+) for (Ci2Hi4BrFN2O) 300.8 (M+H)+.
The intermediates in the below table were synthesized according to the methods used for the synthesis of (1R)-1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]ethan-1-ol (Int20 40). The following intermediates were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Compound number | Structure/IUPAC Name | Analytical data |
lnt-41 | F Me .. JMe Me 1 -[6-bromo-4-fluoro-1 -(propan-2yl )-1 /-/-benzimidazol-2-yl]ethan-1 ol | m/z (APCI+) for (C12H14BrFN2O), ' 302.7 (M+H)+ |
lnt-42 | - - F OH ----------- J-Me _ _ Me ...... | m/z (APCI+) for (Ci2Hi4BrFN2O), 302.9 (M+H)+ |
150
- | (1 S)-1 -[6-bromo-4-fiuoro-1 (propan-2-yl)-1H-benzimidazol-2yl]ethan-1-ol | • - * - |
Préparation of 1-[6-bromo-1-(1,1-difluoropropan-2-yl)-4-fluoro-1H-benzimidazol-2yl]ethan-1-ol (lnt-43) according to Scheme 18
Scheme 18
neat
84% yield
HCl 1,4-dioxane 42% yield
step 1 step 2
Step 1: Synthesis of /V-{4-bromo-2-[(1,1-difluoropropan-2-yl)amino]-6-fIuorophenyl}-2hydroxypropanamide (18b)
A mixture of 5-bromo-/\r-(1,1-difluoropropan-2-yl)-3-fiuorobenzene-1,2-diamine (18a) (Prepared as in Scheme 7,1.0 g, 3.5 mmol) and 2-hydroxypropanoic acid (10.0 mL) was stirred at 85 °C for 16 h. LCMS indicated consumption of the starting material with formation of the desired product mass. H2O (15 mL) and EtOAc (15 mL) were added and the mixture was cooled to 0 °C. The mixture was adjusted to pH ~7 with 50% aqueous NaOH. The layers were separated.
The aqueoLs layer was extracted with EtOAc (2x20 mL). The comtJined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (20 g SiO2,0-50% EtOAc/petroleum ether) to provide A/-{4-bromo-2-[(1,1-difluoropropan-2-yl)amino]6-fluorophènyl)-2-hydroxypropanamide (18b) (1.0 g, 84% yield)1 as a dark oil. m/z (ESI) for (Ci2Hi4BrF3N2O2), 356.6 (M+H)+. 1
Step 2: Synthesis of 1-[6-bromo-1-(1,1-difluoropropan-2-yl)-4-fluoro-1H-benzimidazol-2yl]ethan-1- (lnt-43)
A solution of /V-{4-bromo-2-[(1,1-difluoropropan-2-yl)amino]-6-fluorophenyi}-2hydroxypropanamide (18b) (1.0 g, 3.0 mmol) in 1,4-dioxane (10 mL) was stirred at 130 °C for 15 151 min with microwave irradiation. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The solution was concentrated to dryness. The residue was taken up in H2O (3 mL) and then basified with aqueous NH4OH (1 mL) to pH -8 m. The solution was extracted with EtOAc (3x5 mL). The combined organic layèrs were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 20 g S1O2,1:1 EtOAc/petroleum ether) to provide (lnt-43) (400 mg, 42% yield) as a dark oil. 1H NMR (400 MHz, CDCI3) δ 7.47 (d, J = 8.5 Hz, 1H), 7.16 (dd, J = 1.5, 9.5 Hz, 1H), 6.31 - 5.98 (m, 1H), 5.14 (br dd, J= 6.8, 10.3 Hz, 2H), 3.69 - 3.58 (m, 1H), 1.83 - 1.70 (m, 6H); m/z (ESI) for (Ci2Hi2BrF3N2O), 338.7 (M+H)+. _ .
----- -------Préparation of 6-bromo-2-(difIuoromethyl)-4-fIuoro-1-(propan-2-yl)-1H-benzimidazo!e (Int44) according to Scheme 19.
Scheme 19:
A mixture of 5-bromo-3-fluoro-/V1-(propan-2-yl)benzene-1,2-diamine (7a) and difluoroacetic anhydride (1.47 mL, 11.8 mmol) in AcOH (4.6 mL) was stirred at 90 °C for 3 h. The solvent was removed by vacuum. The residue was taken up into DCM (30 mL). The mixture was adjusted to pH ~8-9 with 1.0 N aqueous NaOH and the layers were separated. The organic layer 20 was washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 12 g S1O2, 0-50% EtOAc/petroleum ether) to provide 6bromo-2-(difluoromethyl)-4-fluoro-1-(propan-2-yl)-1H-benzimidazole (lnt-44) (523 mg, 72% yield) as a white solid. 1H| NMR (400 MHz, DMSO-d6) δ 8.02 (d, J = 1.5 Hz, 1 H)| 7.63 - 7.28 (m, 2H), 5.04 - 4.84 (m, 1H), 1.60 (d, J = 6.8 Hz, 6H); m/z (APCI+) for (CiiHioBrF3N2), 309.1 (M+H)*.
Préparation of 6-bromo-1-tert-butyl-4-fIuoro-1H-benzimidazole (lnt-45) according to
I j
Scheme 20. i i
Scheme 20:
152
POCI3, TEA
PhMe, 10-20 ’C
64% yield
step 1 step 2
t-BuOK DMF, 70-75 ’C
36% yield
Step 1: Synthesis of N-(4-bromo-2,6-difluorophenyl)-N,-ferf-butyImethanimîdamide (20b)
A solution of 4-bromo-2,6-difluoroaniline (20a) (5.00 g, 24.0 mmol), triethylamine (4.86 g, 6.7 mL, 48.1 mmol) and /V-tert-butylformamide (2.92 g, 3.2 mL, 28.8 mmol) in PhMe (50 mL) was treated with POCI3 (5.53 g, 3.36 mL, 36.1 mmol) at 0 C (maintaining an internai température below 20 ’C). The mixture was stirred at ambient température for 15 h and then quenched with aqueous Na2CO3 (80 mL). The organic layer was collected. The aqueous layer was extracted with EtOAc (3x30 mL). The combined organic phases were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated. The crude residue was suspended in EtOAc (5 mL) and petroleum ether (40 mL), slurried for 10 min, and collected by filtration to provide A/-(4-bromo-2,6difluorophenyO-Af-fert-butylmethanimidamide (20b) (4.50 g, 64% yield) as a yellow solid. m/z (ESI+) for (CnHi3BrF2N2), 292.6 (M+H)+.
Step 2: Synthesis of 6-bromo-1-terf-butyl-4-fIuoro-1H-benzimidazole (lnt-45)
To a solution of A/-(4-bromo-2,6-difluorophenyl)-AT-tert-butylmethanimidamide (20b) (4.50 g, 15.5 mmol) in DMF (40 m^) was added KOtBu (2.60 g, 23.2 mmol) and the mixtur^ was stirred at 80 ’C for 14 h. H2O (100 mL) was added and the mixture was extracted with EtOAc (3x50 mL). The combined organic phases were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated. The crude residue was purified in two stages, first by flash chromatography (S1O2, 20 20% EtÔAc/petroleum ether) then by préparative HPLC on a Phenomenex Synergi Max-RP column (250 x 80 mm, 10 pm particle size, column température of 25 ’C), which was eluted with 35-65% MeCN/H2O (+0.225% formic acid) with flow rate of 80 mL/min to provide 6-bromo-1-tert-. .
butyl-4-fluoro-1H-benzimidazole (lnt-45) (1.5 g, 36% yield) as a grey solid. m/z (ESI+) for (Ci 1 Hi2BrFN2), 270.9 (M+H)+.
153
The intermediate in the below table was synthesized according to the methods used for the synthesis of 6-bromo-1-tert-butyl-4-fluoro-1H-benzimidazole (lnt-45). The following intermediate was synthesized with non-critical changés or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Compound number | Structure/ IUPAC name | Analytical data |
lnt-46 | F i[ £ —Me M / ~Me Me 6-bromo-4-fluoro-2-methyl-1 - (propan-2-yl)-1 H-benzimidazole | m/z (ESI+) for (CnHi2BrFN2), 270.6 (M+H)+ |
Préparation of fert-butyl 3-(6-bromo-4-fluoro-2-methyl-1H-benzimidazol-1-yl)azetidine-1carboxylate (lnt-47) according to Scheme 21.
Scheme 21:
I—<N-Boc
K2CO3
DMF
23% yield
To a solution of 6-bromo-4-fluoro-2-methyl-1/7-benzimidazole (21a) (271 mg, 1.18 mmol) and tert-butyl 3-iodoazetidine-1-carboxyIate (670 mg, 2.37 mmol) in DMF (5.9 mL) was added K2CO3 (491 mg, 3.55 mmol). The reaction mixture was stirred at 100 *C for 16 h. The reaction mixture was cooled to room température and loaded onto SiO2. The crude material was purified via flash chromatography (SiO2, 0-1 (|0% EtOAc/heptane) to provide a mixture of regioisom^rs. These compounds were subsequently separated by préparative SFC on a Waters SFC 200 Glacier/Two ZymorSPHER HADP column (150 x 21.1 mm I.D.,5 pm particle size), which was eluted with 10-35% MeOH/CO2 (100 bar, 35 ’C) with a flow rate of 80 mL/min to provide tert-butyl 3-(6-bromo-4-fluoro-2-methyI-1H-benzimidazol-1-yl)azetidine-1-carboxyIate (lnt-47) (106 mg, 23% yield) as a solid. Ή NMR (400 MHz, DMSO-d6) δ 7.55 (d, J= 1.5 Hz, 1H), 7.34 (dd, J = 1.5, 10.1 Hz, 1H), 5.41 (s, 1H), 4.48 - 4.37 (m, 2H), 4.28 (dd, J= 5.1,10.0 Hz, 2H), 2.56 (s, 3H), 1.46 (s, 9H); m/z (APÇI+) for (Ci6H19BrFN3O2), 384.0 (M+H)+.
Préparation of 6-bromo-2,4-dimethyl-1-(propan-2-yl)-1H-benzimidazole (lnt-48) according to Scheme 22.
154
Scheme 22:
Me
22a
2-iodopropane - NaH /
DMF
88% yield
Me
To a solution of 6-bromo-2,4-dimethyI-1H-benzimidazole (22a) (250 mg, 1.11 mmol) in anhydrous DMF (8.0 mL) was added 2-iodopropane (189 mg, 1.11 mmol) and NaH (60% dispersion in minerai oil, 222 mg, 5.55 mmol). The réaction mixture was stirred at ambient température 16 h. LCMS analysis showed consumption ofthe starting material with formation of the desired product mass. The reaction was quenched with Η2Ο (3 mL) and then concentrated under vacuum. The crude residue was purified by flash chromatography (ISCO, 20 g S1O2, 70%
EtOAc/petroleum ether) to provide 6-bromo-2,4-dimethyl-1-(propan-2-yl)-1H-benzimidazole (Int48) (260 mg, 88% yield). m/z (ESI+) for (C12Hi5BrN2), 268.8 (M+H)+.
The intermediate in the below table was synthesized according to the methods used for the synthesis of 6-bromo-2,4-dimethyl-1-(propan-2-yl)-1H-benzimidazole (lnt-48). The following 15 intermediate was synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Compound number | Structure/ IUPAC name | Analytical data |
lnt-49 | ci XX > । /'Me Me 6-bromo-4-chloro-1 -(propan-2-yl)- I 1 H-benzimidazole i | 1H NMR (400 MHz, CDCI3) δ 8.05 (s, 1H), 7.84 (d, J= 1.5 Hz, 1H), 7.39 (d, J =1.3 Hz, 1H), 5.40 (quin.d, J= 6.6,13.3 Hz, 1H), 1.62 (d, J = 6.5 Hz, 6H); m/z (ESI+) for (CioHioBrCIN2), 274.8 (M+H)+ |
Préparation of fert-butyl [1-(6-bromo-4-fiuoro-2-methyl-1H-benzimidazol-1-yl)propan-2yl]carbamate (lnt-50) according to Scheme 23.
Scheme 23:
To a solution of 6-bromo-4-fluoro-2-methyl-1H-benzimidazole (23a) (500 mg, 2.18 mmol) in anhydrous THF (15.0 mL) was added solid f-BuOK (294 mg, 2.62 mmol). The mixture was stirred at ambient température for 10 min followed by addition of 1-[(tert5 butoxycarbonyl)amino]propan-2-yl methanesulfonate (888 mg, 3.51 mmol). The mixture was stirred at 60 °C under an atmosphère of Ar for 17 h. LCMS analysis showed -50% consumption ofthe starting material. The reaction was cooled to room température and additional f-BuOK (122 mg, 1.09 mmol) was added followed by additional 1-[(tert-butoxycarbonyl)amino]propan-2-yl methanesulfonate (730 mg, 1.46 mmol). The mixture was stirred at 60 °C for 18 h. LCMS analysis 10 showed -65% conversion. The mixture was diluted with H2O (30 mL) and extracted with DCM (3x15 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated. The crude mixture was purified by flash chromatography (20 g SiO2, 10-65% EtOAc/petroleum ether). The fractions containing the desired product were collected and re-purified by préparative HPLC on a YMC-Actus Triart C18 column (150x40 mm, 5 pm particle size), which was eluted with 33-73% MeCN/H2O (0.05% NH4OH) with a flow rate of 25 mL/min to provide fert-butyl [1-(6bromo-4-fluoro-2-methyl-1H-benzimidazol-1-yI)propan-2-yl]carbamate (lnt-50) (112 mg, 16% yield). 1H NMR (400 MHz, CDCI3) δ 7.58 (d, J = 1.6 Hz, 1H), 7.08 (dd, J = 11.1,1.6 Hz, 1H), 4.48 (s, 1H), 4.21 (td, J = 16.1, 14.5, 6.9 Hz, 2H), 4.06 (p, J = 7.0 Hz, 1H), 2.63 (s, 3H), 1.28 - 1.20 (m, 12H); m/z (ESI+) for (Ci6H2iBrFN3O2), 387.8 (M+H)+.
Préparation of tert-butyl [1-(6-bromo-4-fluoro-2-methyl-1H-benzimidazol-1-yl)propan-2yl]carbamate (lnt-49) according to Scheme 24.
Scheme 24:
F F
JL cyclopropyl methyl ketone JL n 1/ i A :: l· * Am.
25 lnt-22 M/Me 63.Ayielcl ----------- lnt-51 Me^Me A solution of 6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazole (lnt-22) (500 mg, 1.94 mmol) in THF (20.0 mL) under a N2 atmosphère was cooled to -65 °C with a dry ice/acetone bath. A solution of LDA (2.0 M in THF, 1.94 mL, 3.89 mmol) was added drop-wise. The reaction mixture was stirred at the same température for 1 h followed by the addition of cyclopropyl methyl ketone
156 (327 mg, 3.89 mmol). After 1 h at -65 °C LCMS analysis showed consumption of the starting material with conversion to the desired product mass. The reaction mixture was quenched with saturated aqueous NH4CI (10 mL). The phases were separated. The aqueous phase was extracted with EtOAc (3x15 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated. The crude residue was purified by flash chromatography (ISCO, 1:3 EtOAc/petroleum ether) to provide [1-(6-bromo-4-fIuoro-2-methyl-1H-benzimidazol-1-yl)propan2-yl]carbamate (lnt-51) (420 mg, 63% yield) as a white solid. 1H NMR (400 MHz, CDCI3) δ 7.52 (d, J = 1.5 Hz, 1H), 7.12 (dd, J = 1.5, 9.7 Hz, 1H), 5.46 - 5.22 (m, 1H), 3.71 (s, 1H), 1.72 (s, 3H), 1.67 (dd, J = 6.1, 6.8 Hz, 6H), 1.41 - 1.30 (m, 1H), 0.77 - 0.67 (m, 1H), 0.64 - 0.53 (m, 2H), 0.52 - 0.44 (m, 1H); m/z (ESI+) for (Ci5Hi8BrFN2O), 340.7 (M+H)+.
Préparation of (4R)-7-bromo-9-fluoro-4-methyl-3,4-dihydro-1 ,4]oxazino[4,3a]benzimidazole (lnt-50) according to Scheme 24.
Scheme 25:
o
step 2 step 1
AcOH step 3
91% yield
Step 1: Synthesis of (5R)-4-(5-bromo-3-fIuoro-2-nitrophenyl)-5-methylmorpholin-3-one (25a) - ......
I I
To a solution of (5R)-5-methylmorpholin-3-one (500 mg, 4.34 mmol) in DMF (10.0 mL) was added NaH (60% dispersion in minerai oil, 208 mg, 5.21 mmol). The reaction suspension was stirred at ambient température for 30 min and then 5-bromo-1,3-difluoro-2-nitrobenzene (1a) (1.03 mg, 4.34 mmol) was added. The réaction süspehsion was stirred for 1 h. LCMS analysis showed consumption ofthe starting material. H2O (2 mL) was added and the reaction suspension was concentrated to dryness. The residue was taken up into EtOAc (80 mL) and was washed with H2O (60 mL). The organic layer was dried over Na2SÜ4, filtered, and concentrated to dryness.
157
The residue was purified by flash chromatography (ISCO, 20 g S1O2,1:3 EtOAc/petroleum ether) to provide (5R)-4-(5-bromo-3-fluoro-2-nitrophenyl)-5-methylmorpholin-3-one (25a) (760 mg, 53% yield) as a light yellow solid. m/z (ESI+) for (CnHioBrFN204), 334.3 (M+H)+.
Step 2: Synthesis of (5R)-4-(2-amino-5-bromo-3-fluorophenyl)-5-methylmorpholin-3-one (25b)
To a solution of (5R)-4-(5-bromo-3-fluoro-2-nitrophenyl)-5-methylmorpholin-3-one (25a) (760 mg, 2.28 mmol) in EtOH (16.0 mL) and H2O (4.0 mL) were added Fe° (637 mg, 11.4 mmol) and NH4CI (610 mg, 11.4 mmol). The reaction suspension was stirred at 80 eC for 4 h under an 10 atmosphère of N2. LCMS analysis indicated complété consumption ofthe starting material with formation of the desired product mass. The reaction mixture was filtered and concentrated to dryness. The residue was purified by flash chromatography (S1O2,1:3 EtOAc/petroleum ether to provide (5R)-4-(2-amino-5-bromo-3-fluorophenyl)-5-methyImorpholin-3-one (25b) (420 mg, 61% yield) as a light brown gum. m/z (ESI+) for (CnHi2BrFN2O2), 303.1 (M+H)+.
Step 3: Synthesis of (4R)-7-bromo-9-fluoro-4-methyl-3,4-dihydro-1H-[1,4]oxazino[4,3a]benzimidazole (lnt-52)
A solution of (5R)-4-(2-amino-5-bromo-3-fluorophenyl)-5-methylmorpholin-3-one (25b) (420 mg, 1.39 mmol) in AcOH (6.0 mL) was stirred at 110 °C for 2 h. LCMS analysis showed 20 consumption of the starting material with formation of the desired product mass. The reaction mixture was concentrated to dryness. The residue was taken up in EtOAc (50 mL) and washed with aqueous saturated NaHCOa (30 mL). The organic phase was dried over Na2SO4, filtered, and concentrated to provide (4R)-7-bromo-9-fluoro-4-methyl-3,4-dihydro-1H-[1,4]oxazino[4,3a]benzimidazole (lnt-52) (360 mg, 91% yield) as a light-yellow solid. m/z (ESI+) for 25 (CnHioBrFN20), 286.6 (M+H)+.
The intenjiediates in the below table were synthesized according |to the methods used for the synthesis of (4R)-7-bromo-9-fluoro-4-methyl-3,4-dihydro-1/-/-[1,4]oxazino[4,3a]benzimidazole (lnt-52). The following intermediates were synthesized with non-critical changes 30 or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize. I I
Compound number | Structure/ IUPAC name | Analytical data |
158
lnt-53 | F Αχ i m/ (4S)-7-bromo-9-fluoro-4-methyl3,4-dihydro-1 H-[1,4]oxazino[4,3a]benzimidazole | m/z (ESI+) for (CnHioBrFN20), 286.6 (M+H)+ |
Int-54 | F zAn Lia Br'^^N_p Me 7-bromo-4-ethyl-9-fluoro-3,4dihydro-1 H-[î ,4]oxazino[4,3a]benzimidazole | m/z (ESI+) for (Ci2Hi2BrFN2O), 300.9 (M+H)+ |
lnt-55 | F __N—Boc Me' fert-butyl 7-bromo-9-fluoro-4methyl-3,4-dihydropyrazino[1,2a]benzimidazole-2(1 H)carboxylate | 1H NMR (400 MHz, DMSO-d6) δ 7.79 (d, J = 1.5 Hz, 1H), 7.33 (dd, J = 1.5, 10.3 Hz, 1 H), 5.21 - 4.96 (m, 1H), 4.75 (brs, 1H), 4.264.09 (m, 1H), 3.67 - 3.57 (m, 2H), 1.46 (s, 9H), 1.35 (brd, J =6.3 Hz, 3H); m/z (ESI+) for (Ci6Hi9BrFN3O2), 385.9 (M+H)+ |
lnt-56 | F .Ah ΜεΆ Me 7-brdmo-5-fluoro-1,1 -dimethyl-2,3dihydro-1 H-pyrrolo[1,2a]benzimidazole | m/z (ESI+) for (Ci2Hi2BrFN2), 284.9 (M+H)|+ |
i
Préparation of 7-bromo-9-fluoro-4,4-dimethyl-3,4-dihydro-1H-[1,<4]oxazino[4)3a]benzimidazole (lnt-57) according to Scheme 26.
Scheme 26:
159
Br
1a
Br
N02
NH2 o
Me l/*'-.·
Me
K2CO3
F____DMF 80’C
68% yield step 1
Br
F NO2
26a
NH Më-Y Me
Fe°, NH4CI nh2
EtOH/H2O, 80 ’C
OH ‘
86% yield step 2
Br NH
Me^Y^OH
26b Me
CI^C(OEt)3 step 3
AcOH, 55 ’C
Me .. lnt-57 Me t-BuOK
N
N
94% yield
THF. 0-5 ’C
72% yield step 4
Step 1: Synthesis of 2-(5-bromo-3-fluoro-2-nitroanilino)-2-methylpropan-1-ol (26a)
To a yellow solution of 5-bromo-1,3-difluoro-2-nitrobenzene (1a) (8.0 g, 33.6 mmol) in DMF (30 mL) were added K2CO3 (9.3 g, 67.2 mmol) and 2-amino-2-methylpropan-1-ol (3.0 g, 5 33.6 mmol). The mixture was stirred at 80 °C for 1 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction was cooled to room température, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 80 g S1O2, 15% EtOAc/petroleum ether) to provide 2-(5-bromo-3-fluoro-2-nitroanilino)-2methylpropan-1-ol (26a) (7.0 g, 68% yield) as a yellow solid. m/z (ESI+) for (CioHi2BrFN203), 10 307.0 (M+H)+.
Step 2: Synthesis of 2-(2-amino-5-bromo-3-fluoroanilino)-2-methylpropan-1-ol (26b)
To a solution of 2-(5-bromo-3-fluoro-2-nitroanilino)-2-methylpropan-1-ol (26a) (7.0 g, 22.8 mmol) in EtOH (50 mL) was added saturated aqueous NH4CI (10 mL) and Fe° (6.36 mg, 114 15 mmol) and the mixture was stirrec| at 80 °C for 1 h. TLC analysis showed consumption |of the starting material. The mixture was filtered and concentrated to dryness. The residue was purified by flash chromatography (ISCO, 80 g SiO2, 30% EtOAc/petroleum ether) to provide 2-(2-amino5-bromo-3-fluoroanilino)-2-methylpropan-1-ol (26b) (5.4 g, 86% yield) as a black oil. m/z (ESI+) for (C10H14BrFN2O), 277.0, 279.0 (M+H)+. i
Step 3: Synthesis of 2-[6-bromo-2-(chloromethyl)-4-fIuoro-1H-benzimidazol-1-yl]-2methylpropan-1-ol (26c) _ . .
A yellow solution 2-(2-amino-5-bromo-3-fluoroanilino)-2-methyIpropan-1-ol (26b) (1.8 g,
6.5 mmol) and 2-chloro-1,1,1-triethoxyethane (1.5 g, 9.7 mmol) in AcOH (10.0 mL) was stirred at
160 °C for 8 min. LCMS analysis showed consumption of the starting material with formation of the product mass. After cooling to room température the reaction mixture was combined with parallel reactions run on smaller sale (5x100 mg). The combined reaction mixtures were basified with saturated aqueous NaHCO3 to adjust to pH ~7-8 and extracted with EtOAc (3x20 mL). The 5 combined organic phases were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 40 g SiO2, 30% EtOAc/petroleum ether) to provide 2-[6-bromo-2-(chloromethyl)-4-fluoro-1/7-benzimidazol-1-yl]2-methylpropan-1-ol (26c) (2.0 g, 72% yield) as a light yellow solid. 1H NMR (400 MHz, DMSOd6) δ 7.90 (d, J = 1.5 Hz, 1H), 7.36 (dd, J= 1.3, 9.8 Hz, 1H), 5.41 (t, J= 5.6 Hz, 1H), 5.18 (s, 2H), 10 3.87 (d, J = 5.3 Hz, 2H), 1.78 (s, 6H). m/z (ESI+) for (Ci2Hi3BrCIFN2O), 336.9 (M+H)*.
Step 4: Synthesis of 7-bromo-9-fluoro-4,4-dimethyl-3,4-dihydro-1H-[1,4]oxazino[4,3a]benzimidazole (lnt-57)
To a solution of 2-[6-bromo-2-(chloromethyl)-4-fluoro-1H-benzimidazol-1-yl]-215 methylpropan-1-ol (26c) in THF (5.0 mL) was added t-BuOK (251 mg, 2.23 mmol) at 0 °C. The solution was stirred at 0 °C for 30 min. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (3x10 mL). The combined organic phases were washed with brine (15 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash 20 chromatography (ISCO, 20 g S1O2,30% EtOAc/petroleum ether) to provide 7-bromo-9-fIuoro-4,4dimethyl-3,4-dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole (lnt-57) (420 mg, 94% yield) as a yellow solid. 1H NMR (400 MHz, CDCI3) δ 7.47 (d, J = 1.5 Hz, 1 H), 7.14 (dd, J = 1.5, 9.5 Hz, 1 H), 4.98 (s, 2H), 3.84 (s, 2H), 1.67 (s, 6H); m/z (ESI+) for (Ci2Hi2BrFN2O), 298.7 (M+H)*.
Préparation of 7-bromo-9-fluoro-2,4,4-trimethyl-1,2,3,4-tetrahydropyrazino[1,2a]benzimidazole (lnt-58) according to Scheme 27.
Scheme 27:
I.MsCI, DIPEA MeCN, 0 ’C
2. MeNH2, 60 ’C
43% yield
To a solution of 2-[6-bromo-2-(chloromethyl)-4-fluoro-1H-benzimidazol-1-yl]-2methylpropan-1-ol (26c) (500 mg, 1.49 mmol) and DIPEA (578 mg, 4.47 mmol) in MeCN (5.0 mL) was added MsCI (256 mg, 2.23 mmol) drop-wise. After addition, the resulting solution was allowed to warm to room température and stirred for 1 h. LCMS analysis showed consumption of
161 the starting material with formation ofthe desired product mass. To the solution was added DIPEA (963 mg, 7.45 mmol) and methylamine hydrochloride (201 mg, 2.98 mmol). The resulting solution was stirred at 60 °C for 14 h. LCMS analysis showed consumption ofthe mesylate intermediate with formation of the desired product mass. The reaction mixture was concentrated to dryness.
The residue was purified by flash chromatography (ISCO, 20 g S1O2, 30% EtOAc/petroleum ether) to provide 7-bromo-9-fIuoro-2,4,4-trimethyl-1,2,3,4-tetrahydropyrazino[1,2a]benzimidazole (lnt-58) (200 mg, 43% yield) as a yellow gum. 1H NMR (400 MHz, CDCI3) δ 7.46 (d, J= 1.3 Hz, 1H), 7.11 (dd, J = 1.4, 9.6 Hz, 1H), 3.77 (s, 2H), 2.68 (s, 2H), 2.50 (s, 3H), 1.67 (s, 6H); m/z (ESI+) for (Ci3H15BrFN3), 314.0 (M+H)+.
Préparation of 7-bromo-9-fluoro-1,4-dimethyl-3,4-dihydro-1H-[1>4]oxazino[4,3a]benzimidazole (lnt-59) according to Scheme 28.
Scheme 28:
DMF, 80 C
93% yield
K2CO3
O
OTBS
Me
Na2S2O4
EtOH/DMSO, 80 C
71% yield
step 2 step 3
TBAF THF
54% yield
TsOH
PhMe, 120 °C
80% yield step 4
Step 1: Synthesis of 2-(5-bromo-3-fluoro-2-nitroanilino)propan-1-ol (28a) । To a solution of 5-bromo-1,3-difluoro-2-nitrobenzene (1a) (4.0 g, 16.8 mmol) in DMF (40.0 । mL) was added K2CO3 (4.65 g, 33.6 mmol) and 2-aminopropan-1-ol (1.26 g, 16.9 mmol). The mixture was stirred at 80 °C for 1 h. TLC analysis (3:1 petroieum ether/EtOAc) showed consumption of the starting material. After cooling to room température, the reaction mixture was diluted with H2O (150 mL) and extracted with EtOAc (2x150 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated to provide 2-(5-bromo-3-fluoro-2nitroanilino)propan-1-ol (28a) (4.7 g, 93% yield) as a yellow oil. m/z (ESI+) for (C9HioBrFN203),
294.6 (M+H)+.
162
Step 2: Synthesis of 2-[6-bromo-2-(1-{[fert-butyl(dimethyl)silyl]oxy}ethyl)-4-fluoro-1Hbenzimidazol-1-yl]propan-1-ol (28b)
To a yellow solution of 2-(5-bromô-3-fluoro-2-nitroanilino)prdpàn-1-ol (28a) (1.3 g, 3.3 . mmol) and 2-{[fert-butyl(dimethyl)silyl]oxy}propanal (1.0 g, 5.3 mmol) in EtOH (10.0 mL) and DMSO (3.0 mL) was added Na2S2O4 (2.9 g, 16.4 mmol). The suspension was stirred at 80 °C for 16 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The mixture was concentrated to remove the EtOH. The solution was diluted with EtOAc (100 mL) and washed with H2O (50 mL). The organic phase was dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 20 g S1O2, 25% EtOAc/petroleum ether) to provide 2-[6-bromo-2-(1-{[tert-butyl(dimethyl)silyl]oxy]ethyl)-4fiuoro-1H-benzimidazol-1-yl]propan-1-ol (28b) (1.0 g, 71% yield) as a white solid. m/z (ESI+) for (Ci8H28BrFN2O2Si), 432.8 (M+H)+.
Step 3: Synthesis of 2-[6-bromo-4-fluoro-2-(1-hydroxyethyl)-1H-benzimidazol-1-yl]propan1-01 (28c)
To a solution of 2-[6-bromo-2-(1-{[tert-butyl(dimethyl)silyl]oxy)ethyl)-4-fIuoro-1Hbenzimidazol-1-yl]propan-1-ol (28b) (1.0 g, 2.32 mmol) in THF (5.0 mL) was added TBAF (1.2 g, 4.64 mmol) at ambient température. After 1 h, TLC analysis (100% EtOAc) showed consumption of the starting material. The reaction solution was diluted with EtOAc (100 mL) and washed with H2O (2x50 mL). The organic phase was dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 20 g S1O2, 80% EtOAc/petroleum ether) to provide 2-[6-bromo-4-fluoro-2-(1-hydroxyethyl)-1H-benzimidazol-1-yl]propan-1-ol (28c) (400 mg, 54% yield) as a white solid. m/z (ESI+) for (C12Hi4BrFN2O2), 316.7 (M+H)+.
Step 4: Synthesis of 7-bromo-9-fIuoro-1,4-dimethyI-3,4-dihydro-1H-[1,4]oxazino[4,3ajber^zimidazole (lnt-59) |
A solution of 2-[6-bromo-4-fluoro-2-(1-hydroxyethyl)-1H-benzimidazol-1-yl]propan-1-ol (28c) (400 mg, 1.26 mmol) and TsOH (434 mg, 2.52 mmol) in PhMe (5.0 mL) was stirred at 120 °C for 16 h. To the solution was added saturated aqueous NaHCOs (20 mL). The mixture was extracted with EtOAc (2x100 mL). The combined organic I phases were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 20 g S1O2, 80-90% EtOAc/petroleum ether) to provide 7-bromo-9-fluoro-1,4-dimethyl-3,4-dihydro-1/-/[1,4]oxazino[4,3-a]benzimidazole (lnt-59) (300 mg, 80% yield, diastereoisomeric mixture) as a yellow oil. m/z (ESI+) for (Ci2Hi2BrFN2O), 298.7 (M+H)+. ' .
163
Préparation of 6-bromo-1-(propan-2-yl)-1H-benzotriazole (lnt-60) according to Scheme 29.
Scheme 29:
HBr, NaNO2
H2O
80% yield
To a solution of 4-bromo-A/2-(propan-2-yl)benzene-1,2-diamine (29a) (3.00 g, 13.1 mmol) in hydrobromic acid (2.0 M in H2O, 30 mL) was added a solution of sodium nitrite (1.36 g, 19.6 mmol) in H2O (15 mL) at 0 °C. The reaction mixture was stirred at this température for 30 min then allowed to warm to ambient température over a period of 2 h. The reaction mixture was poured into saturated aqueous Na2CO3 (150 mL) and extracted with EtOAc (2x150 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated. The crude residue was purified by flash chromatography (SiO2, 0-30% EtOAc/petroleum ether) to provide 6-bromo-1-(propan-2-yl)-1/-/-benzotriazole (lnt-60) (2.50 g, 80% yield) as a brown oil. m/z (ESI+) for (C9Hi0BrN3), 239.6 (M+H)+.
Préparation of 2-(5-bromo-2-methyl-2H-indazol-3-yl)propan-2-ol (lnt-61) according to Scheme 30.
Scheme 30:
30a
LDA; acetone
THF
31% yield
To a stirred solution of 5-bromo-2-methyl-2H-indazole (30a) (300 mg, 1.42 mmol) in THF (10.0 mL) was added LDA (2.0 M in THF, 2.13 mL, 4.26 mmol) at -78 °C. The reaction mixture was stirred at (| °C for 10 min and then cooled to -78 °C. Acetone (124 rpg, 2.14 mmol) was added to the reaction mixture at -78 °C. The reaction was then allowed to warm to ambient température and stirred for 18 h. LCMS analysis showed consumption ofthe starting material with formation of the desired | product mass. The reaction was quenched with saturated aqueous NaHCOs (10 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (3x10 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 20 g SiO2, 0-100% EtOAc/petroleum ether) to provide 2-(5-bromo-2-methyl-2H-indazol-3-yl)propan-2-ol (lnt-61) (120 mg, 31% yield) as a colorless oil. m/z (ESI+) for (CnHi3BrN2O(, 270.9 (M+H)+.
164
Préparation of 5-bromo-2-methyl-3-(propan-2-yl)-2H-indazole (lnt-62) according to
Scheme 31.
Scheme 31:
74% yield
To a stirring solution of 2-(5-bromo-2-methyl-2H-indazol-3-yl)propan-2-ol (lnt-61) in DCM (10 mL) were added TFA (847 mg, 7.43 mmol) and Et3SiH (846 mg, 7.43 mmol) at 0 °C. The mixture was stirred at 25 °C for 36 h. LCMS analysis showed consumption of the starting material. The reaction was quenched with H2O, adjusted to pH ~8 with saturated aqueous NaHCOs, and extracted with DCM (3x10 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 4 g SiO2, 0-100% EtOAc/petroleum ether) to provide 5-bromo-2-methyl-3-(propan-2-yl)-2Hindazole (lnt-62) (140 mg, 74% yield) as a yellow oil. 1H NMR (400 MHz, CDCI3) δ 7.91 - 7.88 (m, 1H), 7.50 (d, J = 9.0 Hz, 1H), 7.29 (d, J = 1.8 Hz, 1H), 4.12 (s, 3H), 3.40 (td, J = 7.2, 14.2 Hz, 1 H), 1.49 (d, J = 7.0 Hz, 6H); m/z (ESI+) for (CnHi3BrN2), 252.8 (M+H)+.
Préparation of 9-bromo-7-fIuoro-1,1-dimethyl-3,4-dihydro-1H-[1,4]oxazino[4,3-b]indazole (lnt-61) according to Scheme 32.
Scheme 32:
Br^°H NaOMe
MeOH, 85 *C | 32% yield step 1
32b
LDA; acetone
73% yield
THF, -78 C - rt
p-TSA PhMe, 120 ’C i ! 55% yield step 3
F
Step 1: Synthesis of 2-(5-bromo-7-fluoro-2H-indazol-2-yl)ethan-1-ol (32b) ..... '
To a solution of 5-bromo-7-fluoro-1H-indazole (32a) (2.5 g, 11.6 mmol) in MeOH (10.0 mL) was added NaOMe (1.26 g, 23.3 mmol) and 2-bromoethan=1-ol (2.0 g, 11.6 mmol) under an
165 atmosphère of N2. The résultant solution stirred at 85 °C for 16 h. The reaction mixture was cooled to room température. TLC analysis (1:1 EtOAc/petroleum ether) showed partial consumption of the starting material. The réaction mixture was concentrated to dryness and purified by flash chromatography (ISCO, 80 g S1O2, 0-100% EtOAc/petroleum ethër) to provide 2-(5-bromo-75 fluoro-2H-indazol-2-yl)ethan-1-ol (32b) (950 mg, 32% yield) as a white solid. m/z (ESI+) for (C9H8BrFN2O), 260.8 (M+H)+.
Step 2: Synthesis of 2-[5-bromo-7-fiuoro-2-(2-hydroxyethyl)-2H-indazol-3-yl]propan-2-ol (32c)
A solution of 2-(5-bromo-7-fluoro-2H-indazol-2-yl)ethan-1-ol (32b) (550 mg, 2.12 mmol) in THF (10.0 mL) was purged with N2 and then a solution of LDA (2.0 M in THF, 2.34 mL, 4.67 mmol) was added at -78 °C. The solution was stirred at -10 °C for 30 min and then cooled back to -78 eC. To the solution was added acetone (247 mg, 4.25 mmol). The resulting solution was stirred for 16 h at room température. LCMS analysis showed complété consumption ofthe starting material with formation of the desired product mass. The reaction was quenched with H2O (30 mL) and extracted with EtOAc (50 mL). The organic layer was dried over Na2SO4, filtered, and concentrated. The crude residue was purified by flash chromatography (ISCO, 20 g SiO2, 5070% EtOAc/petroleum ether) to provide 2-[5-bromo-7-fluoro-2-(2-hydroxyethyl)-2H-indazol-3yI]propan-2-ol (32c) (490 mg, 73% yield) as a colorless oil.
Step 3: Synthesis of 9-bromo-7-fIuoro-1,1-dimethyl-3,4-dihydro-1H-[1,4]oxazino[4,3b]indazole (lnt-63)
To a solution of 2-[5-bromo-7-fIuoro-2-(2-hydroxyethyl)-2H-indazol-3-yl]propan-2-ol (32c) (490 mg, 0.61 mmol) in PhMe (10.0 mL) was added p-TSA (210 mg, 1.22 mmol) at 0 °C. The 25 mixture was stirred at 120 °C for 16 h. LCMS analysis indicated consumption of the starting material with formation of the desired product mass. The reaction mixture was concentrated to dryness and the residue was| purified by flash chromatography (ISCO, 20 g Si(^2, 50% EtOAc/petroleum ether) to provide 9-bromo-7-fluoro-1,1-dimethyl-3,4-dihydro-1H[1,4]oxazino[4,3-b]indazole (lnt-63) (100 mg, 55% yield) as a yellow oil. m/z (ESI+) for (C12Hi2BrFN2O), 298.6 (M+H)+. j i
Préparation of tert-butyl [2-(5-bromo-7-fiuoro-2-methyl-2H-indazol-3-yl)propan-2yl]carbamate (lnt-64) according to Scheme 33.
Schemè 33:
166
step 1 step 2
HCl cfnn 3 MeOH step 3
97% yield
Boc2O, NaHCO3
EtOAc, H2O 82% yield
step 4
Step 1 : Synthesis of 5-bromo-7-fluoro-2-methyl-2H-indazole (33a)
To a solution of 5-bromo-7-fluoro-1H-indazole (32a) (550 mg, 2.12 mmol) in EtOAc (30.0 mL) was added trimethyloxonium tertrafluoroborate (1.97 g, 13.3 mmol). The resulting solution was stirred at ambient température for 5 h. LCMS analysis showed consumption of starting material with formation of the desired product mass. The reaction solution was diluted with H2O (20 mL) and extracted with EtOAc (100 mL). The organic phase was dried over Na2SO4, filtered, and concentrated. The crude residue was purified by flash chromatography (ISCO, 40 g S1O2, 20-25% EtOAc/petroleum ether) to provide 5-bromo-7-fIuoro-2-methyl-2H-indazole (33a) (1.6 g, 10 68% yield) as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 8.45 (d, J = 2.7 Hz, 1 H), 7.79 (d, J = 1.3 Hz, 1H), 7.22 (dd, J = 1.3, 11.0 Hz, 1H), 4.20 (s, 3H); m/z (ESI+) for (C8H6BrFN2), 230.9 (M+H)+. ... - . _ --------I I
Step 2: Synthesis of N-[2-(5-bromo-7-fluoro-2-methyI-2H-indazol-3-yI)propan-2-yl]-215 methylpropane-2-sulfinamide (33b)
To a solution of 5-bromo-7-fluoro-2-methyl-2/7-indazole (33a) (1.0 g, 4.4 mmol) in PhMej (10 mL) was added a solution of LDA (2.0 M in THF, 2.6 mL, 5.24 mmol) at -78 eC. The réaction! mixture was stirred at -78 °C for 1 h. 2-Methyl-/V-(propan-2-ylidene)propane-2-sulfinamide (704 mg, 4.4 mmol) was then added to the reaction mixture at -78 eC. The reaction mixture was allowed to warm to room température and stirred for 24 h. LCMS analysis showed complété consumption of the starting material with formation of the desired product mass; The reaction was quenched by addition of saturated aqueous NH4CI (10 mL) and extracted with EtOAc (2x30 mL). The 167 combined organic phases were dried over Na2SO4, filtered, and concentrated. The crude residue was purified by flash chromatography (ISCO, 20 g S1O2, 30-40% MeOH/EtOAc) to provide N-[2(5-bromo-7-fluoro-2-methyl-2H-indazol-3-yl)propan-2-yl]-2-methylpropane-2-sulfinamide (33b) (420 mg, 25% yield) as a yellow gum. m/z (ESI+) for (CisH2iBrFN3OS), 392.0 (M+H)+.
Step 3: Synthesis of 2-(5-bromo-7-fIuoro-2-methyl-2H-indazol-3-yl)propan-2-amine (33c)
To a yellow solution of /V-[2-(5-bromo-7-fiuoro-2-methyl-2H-indazol-3-yl)propan-2-yl]-2methylpropane-2-sulfinamide (33b) (420 mg, 1.08 mmol) in MeOH (5.0 mL) was added concentrated HCl (1.0 mL) at room température. The reaction mixture was stirred for 2 h. LCMS 10 analysis showed consumption ofthe starting material with formation ofthe desired product mass. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in DCM (10 mL) and TEA (2 mL) was added. The mixture was stirred for 20 min. The reaction solution was extracted with DCM (2x20 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated to provide 2-(5-bromo-7-fluoro-2-methyl-2/7-indazol-315 yl)propan-2-amine (33c) (300 mg, 97% yield) as a yellow solid. m/z (ESI+) for (CnHi3BrFN3), 268.9 (M+H)+.
Step 4: Synthesis of tert-butyl [2-(5-bromo-7-fiuoro-2-methyl-2H-indazol-3-yl)propan-2yl]carbamate (lnt-64)
To a yellow solution of 2-(5-bromo-7-fluoro-2-methyl-2H-indazol-3-yl)propan-2-amine (33c) (300 mg, 0.75 mmol) in THF (3.0 mL) was added saturated aqueous NaHCOs (3.0 mL) and BOC2O (659 mg, 3.0 mmol). The mixture was stirred at room température for 16 h. The reaction solution was diluted with H2O (10 mL) and extracted with EtOAc (2x30 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated. The crude residue was purified by flash chromatography (ISCO, 20 g SiO2, EtOAc/petroleum ether) to provide (lnt-64) (240 mg, 82% yield) as a yellow oil. m/z (ESI+) for (Ci6H2iBrFN3O2), 387.6 (M+H)+.
II
Préparation of 5-bromo-7-fluoro-2-methyl-3-(propan-2-yl)-2H-indazole (lnt-65) according to Scheme 34.
30j
I Scheme 34:I
168
BPin
step 1
PdCI2(dppf), K2C03
1,4-dioxane/H20,100 °C Br
89% yield step 2 step 3
Rh(PPH3)3CI, H2 THF/MeOH 50 psi, 50 °C
100% yield
Step 1 : Synthesis of 5-bromo-7-fluoro-3-iodo-2-methyl-2H-indazoIe (34a)
To a solution of 5-bromo-7-fluoro-2-methyl-2H-indazoIe (33a) (500 mg, 2.18 mmol) in DCM (10.0 mL) was added bis(trifluoroacetoxy)iodobenzene (1.13 g, 2.62 mmol) and pyridine (259 mg, 3.27 mmol). The mixture was stirred at 30 °C for 30 minutes and then h (556 mg, 2.62 mmol) was added. The mixture was stirred at 30 °C for 16 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction mixture was diluted with EtOAc (50 mL) and then filtered. The filtrate was concentrated to dryness. The residue was purified by flash chromatography (ISCO, 40 g S1O2,30-40% EtOAc/petroleum ether) to provide 5-bromo-7-fIuoro-3-iodo-2-methyl-2H-indazole (34a) (700 mg, 90% yield) as a pale yellow solid. m/z (ESI+) for (C8H5BrFIN2), 354.8 (M+H)+.
Step 2: Synthesis of 5-bromo-7-fIuoro-2-methyl-3-(prop-1-en-2-yl)-2H-indazole (34b)
A mixture of 5-bromo-7-fluoro-3-iodo-2-methyl-2H-indazole (34a) (400 mg, 1.13 mmol), isopropenylboronic acid pinacol ester (189 mg, 1.13 mmol), K2CO3 ( 467 mg, 3.38 mmol), and Pd(dppf)Cl2 (82.5 mg, 0.113 mmol) in 1,4-dioxane (6.0 mL) and H2O (1.0 mL) was stirred under — an [atmosphère of N2 at 100 °C for 3 h. The reaction suspension became black. LCMS analysis showed complété consumption ofthe starting material with formation ofthe desired product mass.
The suspension was diluted with EtOAc (50 mL) and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (ISCO, 20 g S1O2, 30% EtOAc/petroleum ether) to provide 5-bromo-7-fluoro-2-methyl-3-(prop-1-en-2-yl)-2H-indazole (34b) (270 mg, 89% yield) as a yellow oil. m/z (ESI+) for (CnHioBrFN2), 268.9 (M+H)+.
Step 3: Synthesis of 5-bromo-7-fiuoro-2-methyl-3-(propan-2-yl)<-2H-indazole (lnt-65)
A solution of 5-bromo-7-fluoro-2-methyl-3-(prop-1-en-2-yl)-2/7-indazole (34b) (270 mg,
1.0 mmol) and Rh(PPh3)3CI (92.8 mg, 0.1 mmol) in MeOH (10.0 mL) and THF (10.0 mL) was
169 sparged with H2 and then stirred at 50 °C for 16 h under H2 at a pressure of 50 psi. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction mixture was concentrated to dryness and the residue was purified by flash chromatography (ISCO, 1:1 EtOAc/petroleum ether) to provide 5-bromo-7-fluoro-2-methyl-3(propan-2-yl)-2H-indazole (lnt-65) (300 mg, >99% yield) as a pale brown gum. m/z (ESI+) for (CiiHi0BrFN2), 270.8 (M+H)+.
Préparation of 6-bromo-1-(propan-2-yl)-1H-imidazo[4,5-b]pyridine (lnt-66) according to Scheme 35.
Scheme 35:
acetone TFA, NaB(OAc)3H /-PrOAc
35a 89% yield
NH2
NH
At^O
AcOH, 90°C
52% yield
JMe lnt-66 Me
Step 1: Synthesis of S-bromo-AP-fpropan^-ylJpyridine^.S-diamine (35b)
To a solution of 5-bromopyridine-2,3-diamine (35a) (2.51 g, 13.4 mmol) and acetone (1.2 mL, 16 mmol) in /-PrOAc (20 mL) were added TFA (2.25 mL, 29.3 mmol) and NaBH(OAc)3 (4.25 g, 20 mmol) at 0 °C. The mixture was stirred at room température for 2 h. EtOAc (50 mL) was added to quench the reaction. The mixture was washed with saturated aqueous NaHCOs (40 mL) and brine (30 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (40 g S1O2,0-65% EtOAc/petroleum ether) to provide S-bromo-AP-Îpropan2-yl)pyridine-2,3-diamine (35b) (2.7 g, 89% yield) as a brown gum. 1H NMR (400 MHz, DMSOd6) δ 7.28 (d, J = 2.1 Hz, 1H), 6.66 (d, J = 1.8 Hz, 1H), 4.97 (br. s., 1H), 3.55 (td, J= 6.1,12.3 Hz, 1 H), 1.15 (d, J = 6.2 Hz, 6H); m/z (APCI) for (C8Hi2BrN3), 230.1,232.2 (M+H)+.
Step 2: Syrjthesis of 6-bromo-1-(propan-2-yl)-1H-imidazo[4,5-bJpyridine (lnt-66)
A mixture of 5-bromo-N3-(propan-2-yl)pyridine-2,3-diamine (35b) (1.5 g, 6.52 mmol) and Ac2O (30.8 mL, 32.6 mmol) in AcOH (12.5 mL) was stirred at 90 °C overnight. The solvent was removed by|evaporation. The residue was taken up in DCM (50 mL);and adjusted to pH ~8-9 with aqueous NaOH (1.0 N). The organic layer was collected, washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography (24 g S1O2, 10% MeOH/EtOAc) to provide 6-bromo-1-(propan-2-yl)-1H-imidazo[4,5-b]pyridine (lnt-66) (866 mg, 52% yield) as a light brown solid. 1H NMR (400 MHz, DMSO-cfe) δ 8.42 - 8.32 (m, 2H), 4.76 (td, J = 6.9,13.8 Hz, 1 H), 2.61 (s, 3H), 1.54 (d, J = 7.0 Hz, 6H); m/z (APCI) for (C9H10BrN3), 254.2,256.1 (M+H)+. ..... 19876
170
Préparation of 5-chloro-2-methyl-3-(propan-2-yl)-3H-imîdazo[4,5-b]pyridine (lnt-67) according to Scheme 36.
Scheme 36:
36a /-PrBr K2CO3
DMS0
76% yield
To a slurry of K2CO3 (4.1 g, 29.8 mmol) in DMSO (6.0 mL) were added 5-chloro-2-methyî3H-imidazo[4,5-b]pyridine (36a) (1.0 g, 5.7 mmol) and 2-bromopropane (2.8 mL, 29.8 mmol). The mixture was stirred for 20 h at room température and an additional 1 h at 60 °C. LCMS analysis 10 showed consumption of the starting material with formation of the desired product mass (~4:1 mixture of regioisomers). The mixture was partitioned between H2O (25 mL) and EtOAc (25 mL). The aqueous layer was extracted with EtOAc (3x25 mL). The combined organic layers were washed with H2O (2x25 mL) and brine (25 mL), dried over Na2SO4, filtered, and concentrated directly onto S1O2. The crude material was purified by flash chromatography (SiO2, 80-100% 15 EtOAc/heptanes) to provide 5-chloro-2-methyl-3-(propan-2-yl)-3H-imidazo[4,5-b]pyridine (lnt-67) (950 mg, 76% yield) as the first eluting regioisomer. 1H NMR (400 MHz, CDCI3) δ 7.85 (d, J = 8.3 Hz, 1H), 7.17 (d, J = 8.3 Hz, 1H), 4.84 (p, J = 7.0 Hz, 1H), 2.68 (s, 3H), 1.69 (d, J = 7.0 Hz, 6H); m/z (APCI) for (C10Hi2CIN3), 209.9 (M+H)+.
Préparation of 6-bromo-1-(propan-2-yl)-1H-imidazo[4,5-b]pyridine (lnt-68) according to
Scheme 37.
Scheme 37:
37a 79% yield । step 1 ^^-NOz ί T Fe°, NH4CI
CI^N^NH -------..Y.. EtOH, H2O, 6O’(
37b Me I Me z
Me
95% yield step 2
37c Me J. Me Me । p-TSA, CH(0Et)3 PhMe, 110 ’C
95% yield step 3 cr N' N „ A~Me lnt-68 Me Me
Step 1 : Synthesis of AMert-butyl-6-chloro-3-nitropyridin-2-amine (37b)
171
To a solution of 2,6-dichloro-3-nitropyridine (37a) in PhMe (30 mL) was added 2methylpropan-2-amme (3.8 g, 51.8 mmol) at 0 C. The yellow solution was stirred at room température for 16 h. LCMS analysis showed consumption of the starting material with formation ofthe desired product mass. The reaction was concentrated to dryness. The residue was purified by flash chromatography (ISCO, 20 g S1O2, 100% petroleum ether) to provide /V-tert-butyl-6chloro-3-nitropyridin-2-amine (37b) (4.7 g, 79% yield) as a yellow solid. m/z (ESI) for (C9H12CIN3O2), 229.9 (M+H)+.
Step 2: Synthesis of M-terf-butyl-6-chloropyridine-2,3-diamine (37c) - —
To a solution of A/-tert-butyl-6-chloro-3-nitropyridin-2-amine (37b) (4.7 g, 20.5 mmol) in EtOH (200 mL) was added saturated aqueous NH4CI (60 mL) and Fe° (5.7 g, 102 mmol). The mixturewas stirred at60 °Cfor3 h. LCMS analysis indicated consumption ofthe starting material with formation ofthe desired product mass. The mixture was filtered and concentrated to remove EtOH. The mixture was diluted with H2O (100 mL) and extracted with EtOAc (200 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated to provide Af-tert-butyl-e-chloropyridine^.S-diamine (37c) (3.9 g, 95% yield) as a black oil, which was taken on without further purification, m/z (ESI) for (C9H14CIN3), 199.9 (M+H)+.
Step 3: Synthesis of 3-tert-butyl-5-chloro-3H-imidazo[4,5-b]pyridine (lnt-68)
To a black mixture of AF-fert-butyl-e-chloropyridine^.S-diamine (37c) (3.0 g, 15.0 mmol) and CH(OEt)3 (4.5 g, 30.0 mmol) in PhMe (40.0 mL) was added p-TSA monohydrate (286 mg, 1.5 mmol). The mixture was stirred for 16 h at 110 °C. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The mixture was washed with saturated aqueous NaHCOs (60 mL). The aqueous layers were extracted with EtOAc (2x100 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated to provide 3fert-butyl-5-chloro-3H-imidazo[4,5-b]pyridine (lnt-68) as a black solid, which was taken on without further purification, m/z (ESI) for (C10H12CIN3), 209.8 (M+H)+. |
Préparation of (3R,4R)-4-Amino-1-(methanesulfonyl)piperidin-3-ol (lnt-69) according to Scheme 38. | '
Scheme 38:
172
CbzCI, Na2CO3
H2O/DCM
85% yield step 1
NHCbz
HO.
N i Boc
38b
HO
1. HCl, EtOH
NHCbz
H0KÂ
2. NaHCO3, MsCI EtOAc/H2O
71% yield step 2
N
38c H step 3
H2, Pd/C DCM/MeOH
90% yield
NH2
Int-69 SO2Me
Step 1: Synthesis of tert-butyl (3R,4R)-4-{[(benzyloxy)carbonyl]amino}-3hydroxypiperidine-1-carboxylate (38b)
To a solution of tert-butyl (3R,4R)-4-amino-3-hydroxypiperidine-1-carboxylate (38a) (13.0 5 g, 60.1 mmol) in DCM (100 mL) and saturated Na2CO3 (100 mL) was added benzyl chloroformate (24.1 mL, 72.1 mmol, 50 % in PhMe) drop-wise at 0 °C. The mixture was stirred for 4 h then the organic phase was collected. The aqueous phase was extracted with DCM (2x100 mL). The combined organic phases were washed with H2O (2x100 mL) and brine (100 mL), dried over Na2SO4, filtered, and concentrated. The crude residue was purified by flash chromatography 10 (SiO2, 0-60% EtOAc/hexanes) to provide tert-butyl (3R,4R)-4-{[(benzyloxy)carbonyl]amino}-3hydroxypiperidine-1-carboxylate (38b) (18.0 g, 85% yield) as a light yellow oil. m/z (ESI+) for (Ci8H26N2O5), 251.3 (M+H-Boc)+.
Step 2: Synthesis of benzyl [(3R,4R)-3-hydroxy-1-(methanesulfonyl)piperidin-415 yl]carbamate (38c)
A solution of fert-butyl (3R,4R)-4-{[(benzyloxy)carbonyl]amino}-3-hydroxypiperidine-1carbox-ylate (38b) (18.0 g, 51.4 mmol) and HCl in EtOH (1.25 M in EtOH, 123 mL, 154 mmol) was stirred at ambient température for| 6 h and then concentrated. The residue was diluted w|th EtOAc (100 mL). Saturated aqueous NaHCOs (100 mL) was added and the mixture was cooled 20 to 0 °C. Methanesulfonyl chloride (6.5 mL, 83.9 mmol) was added drop-wise and the mixture was stirred at this température for 4 h. The layers were separated and the aqueous layer extracted with EtOAc (2x100 mL). The combined organic phases were washed with H2O (2x100 mL) and brine (100 mL), dried over Na2SO4, filtered, and concentrated. The residue was triturated with pentaneto provide benzyl [(3R,4R)-3-hydroxy-1-(methanesulfonyl)piperidin-4-yl]carbamate (38c) (12.0 g, 71% yield) as a white solid. m/z (ESI+) for (Ci4H20N2O5S), 329.4 (M+H)+. _
Step 3: Synthesis of (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (lnt-69) 173
A solution of benzyl [(3R,4R)-3-hydroxy-1-(methanesulfonyl)piperidin-4-yl]carbamate (38c) (12.0 g, 36.5 mmol) in DCM:MeOH (5:4,180 mL) was stirred in the presence of 15% Pd/C (0.583 g, 5.48 mmol) under a balloon of hydrogen at ambient température for 16 h. The reaction mixture was filtered through celite and washed with methanol (100 mL). The filtrate was 5 concentrated under reduced pressure to provide (lnt-69) (6.41 g, 90% yield) as white solid. 1H NMR (400 MHz, CD3OD) δ 3.83 (ddd, J= 11.6, 5.0, 2.2 Hz, 1H), 3.73 (ddt, J = 12.3, 4.8, 2.5 Hz, 1H), 3.46 (td, J= 9.8, 5.0 Hz, 1H), 2.89-2.75 (m, 5H), 2.58 (dd, J= 11.6,10.1 Hz, 1H), (ddt, J = 13.1, 5.0, 2.7 Hz, 1H) 1.66 - 1.54 (m, 1H); m/z (APCI+) for (C6H14N2O3S), 195.0 (M+H)+; [a]D 19° (c 0.1, MeOH).
Préparation of (3/?,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (2S)-2-hydroxy-3phenylpropanoic acid sait (lnt-70) according to Scheme 39.
Scheme 39:
Boc
39a
HCl
MeOH >99% yield
MsCI, TEA
DCM
88% yield
O=S=O i 39c Me m-CPBA DCM
94% yield
lnt-70
1. LIBr, NH4OH MeCN, 18-40 C
MeOH, reflux
O=S=O Me
39d
-, 5 । 25% yield (2 steps)
Step 1: Synthesis of 1,2,3,6-tetrahydropyridine hydrochloride (39b)
To tert-butyl 3,6-dihydropyridine-1(2H)-carboxylate (39a) (150 g, 819 mmol) was added a solution of HCI (4.0 N in MeOH, 500 mL) and tije mixture was stirred at room température for 16 h. LCMS analysis showed consumption of the starting material. The reaction was concentrated 20 to dryness to provide 1,2,3,6-tetrahydropyridine hydrochloride (39b) (97.9 g, >99% yield), which was taken on without further purification. 1H NMR (400 MHz, D2O) δ 5.96 (tdd, J = 1.7, 3.9,10.5 Hz, 1H), 5.80-5.61 (m, 1H), 3.65 (brs, 2H), 3.31 (t, J =6.1 Hz, 2H), 2.49- 2.28 (m, 2H).
Step 2: Synthesis of 1-(methanesulfonyl)-1,2,3,6-tetrahydropyridine (39c)
174
To a slurry of 1,2,3,6-tetrahydropyridine hydrochloride (39b) (97.9 g, 818 mmol) in DCM (1.0 L) was added TEA (248 g, 2.5 mol). The mixture was cooled to 0-5 °C and then treated slowly dropwise with methane sulforiylchloride (112 g, 982 mmol), maintaining the reaction température <20 °C._ After addition the mixture was stirred a further 16 h at room température. ______ 5 The reaction was quenched by slow addition of H2O (1. L). The phases were separated. The aqueous layer was extracted with DCM (1.5 L). The combined organics were washed successively with saturated aqueous NH4CI (500 mL), saturated aqueous NaHCOa (500 mL), saturated aqueous NH4CI (500 mL), and brine (500 mL), dried over Na2SO4, filtered, and concentrated. The résultant yellow solid was triturated with DCM/petroleum ether (1:15,500 mL).
The solids were collected by filtration and dried under vacuum to provide l-(methanesulfonyl)1,2,3,6-tetrahydropyridine (39c) (116 g, 88% yield) as a light yellow solid, which was taken on without further purification. 1H NMR (400 MHz, CDCI3) δ 5.86 (dtd, J =1.7, 4.0, 8.1 Hz, 1H), 5.71 (dtd, J =1.2, 3.4, 8.5 Hz, 1H), 3.76 (quin, J = 2.8 Hz, 2H), 3.37 (t, J = 5.7 Hz, 2H), 2.81 (s, 3H), 2.26 (tt, J = 2.9, 5.7 Hz, 2H)
Step 3: Synthesis of 3-(methanesulfonyl)-7-oxa-3-azabicyclo[4.1.0]heptane (39d)
To a solution of 1-(methanesulfonyl)-1,2,3,6-tetrahydropyridine (39c) (116 g, 720 mmol) in DCM (1.5 L) was added m-CPBA (175 g, 863 mmol) portion-wise. The mixture was stirred at ambient température for 48 h. TLC analysis indicated consumption of the starting material. The 20 heterogeneous mixture was filtered to remove the solids. The filtrate was basified with saturated aqueous Na2COs (1.0 L) and washed with saturated aqueous Na2SO3 (1.5 L). The aqueous layer was extracted with DCM (2x1.5 L). The combined organics were washed with brine (1.5 L), dried over Na2SO4, filtered, and concentrated to provide 3-(methanesulfonyl)-7-oxa-3azabicyclo[4.1.0]heptane (39d) (120 g, 94% yield) as a light yellow solid, which was taken on without further purification. 1H NMR (400 MHz, CDCI3) δ 3.84 (ddd, J = 1.0, 3.6, 14.3 Hz, 1H), 3.57 (d, J = 14.3 Hz, 1 H), 3.36 (dd, J = 2 0, 3.7 Hz, 1H), 3.34 - 3.26 (m, 2H), 3.09 (ddd, J=4.7, έ.4, 12.9 Hz, 1 H), 2.82 (s, 3H), 2.21 - 2.04 (m, 2H). |
Step 4: Synthesis of (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (2S)-2-hydroxy-3I I .
phenylpropanoic acid sait (lnt-70) !
। To a solution of 3-(methanesulfonyl)-7-oxa-3-azabicyclo[4.1.0]heptane (39d) (10.0 g, 56 mmol) in MeCN (100 mL) was added LiBr (1.96 g, 22.6 mmol) and NH4OH (14.1 g, 113 mmol). The mixture was stirred at ambient température for 48 h. TLC analysis (1:1 petroleum ether/EtOAc) indicated remaining starting material. The reaction mixture was warmed to 40 °C 35 and stirred at this température for 36 h. TLC analysis (1:1 petroleum ether/EtOAc) indicated consumption of the starting material. The reaction was concentrated to dryness to provide rac19876
175 (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (11 g, crude). The crude mixture containing rac-(3R,4R)-4-amino-1-(methanesulfonyI)piperidin-3-ol (11 g) was taken up in MeOH (120 mL) and the mixture was warmed to reflux until the solution became clear. The mixture was cooled to room température and a solution of (2S)-2-hydroxy-3-phenylpropanoic acid (9.41 g, 56.6 mmol) in MeOH (30 mL) was added. The solution tumed cloudy followed by extensive précipitation. The mixture was stirred at reflux for 10 min and then allowed to slowly cool to room température. The solution was stirred at room température for 16 h. The precipitate was collected by filtration. The solids were taken up in MeOH (30 mL) and stirred at reflux for 10 min. The solution was slowly cooled to room température. The résultant precipitate was collected by filtration to provide (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (2S)-2-hydroxy-3-phenylpropanoic acid sait (lnt-70) (5.0 g, 25% yield) as a white solid. Enantiomeric excess (97% ee) was determined for the corresponding N-CBz protected dérivative by chiral SFC with a Chiralpak AS-3 column (4.6x150 mm, 3 pm particle size, 35 °C), which was eluted with 5-40% EtOH/COz (+0.05% diethylamine) with a flow rate of 2.5 mL/min. 1H NMR (400 MHz, CD3OD) δ 7.35 - 7.13 (m, 5H), 4.14 (dd, J =3.5, 8.2 Hz, 1H), 3.89 (ddd, J = 2.1, 5.0,11.7 Hz, 1H), 3.83-3.73 (m, 1H), 3.60 (dt, J = 5.1, 10.0 Hz, 1 H), 3.13 (dd, J = 3.4, 13.8 Hz, 1 H), 2.98 (ddd, J = 4.5, 9.8,12.1 Hz, 1 H), 2.92 - 2.77 (m, 5H), 2.69 - 2.56 (m, 1 H), 2.18 - 2.02 (m, 1H), 1.78 - 1.60 (m, 1H).
Préparation of Examples
Example 1 (Scheme A-1): Préparation of (3/?,4R)-4-({5-chloro-4-[4-fluoro-2-methyl-1(propan-2-y])-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1-(methanesu!fonyl)piperidin-3ol
Scheme A-1:
i
176
lnt-46
Pd(OAc)2, PCy3 AcOK, B2Pin2
DMSO, 100 “C . 73% yield
Pd(PPh3)4, K2CO3 1,4-dioxane, 90 'C
98% yield
Me
DIPEA
DMSO, 120 °C
19% yield
Step 1: Synthesis of 4-fIuoro-2-methy 1-1-(propan-2-yl)-6-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)-1H-benzimidazole (A-1)
A suspension of 6-bromo-4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazole (lnt-46) 5 (90 g, 331.95 mmol), bis(pinacolato)diboron (126 g, 498 mmol), AcOK (80 g, 815.15 mmol), tricyclohexylphosphine (14 g, 49.8 mmol), and Pd(OAc)2 (7.45 g, 33.2 mmol) in DMSO (1.0 L) was sparged with N2 and then stirred at 100 ’C for 16 h. TLC analysis (1:1 petroleum ether/EtOAc) showed complété consumption of the starting material. The black suspension was poured into H2O (3.0 L) and extracted with EtOAc (2x3 L). The combined organic phases were washed with 10 brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (Biotage, 1.0 kg, 0-40% EtOAc/petroleum ether) to provide 4-fIuoro-2-methyl-1(propan-2-yl)-6-(4,|4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimid^zole (A-1) (77 g, 73% yield) as a yellow solid. 1H NMR (400 MHz, CDCI3) δ 7.69 (s, 1H), 7.33 (d, J = 10.8 Hz, 1H), 4.77 -4.61 (m, 1H), 2.65 (s, 3H), 1.65 (d, J= 7.0 Hz, 6H), 1.36 (s, 12H); m/z (ESI+) for (C17H24BFN2O2), 15 319.2 (M+H)+. |
Step 2: Synthesis of 6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-2-methyl-1-(propan-2-yl)-1Hbenzimidazole (A-2)
A mixture of 4-fluoro-2-methyl-1-(propan-2-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan20 2-yl)-1H-benzimidazole (A-1) (300 mg, 0.943 mmol), 2,4,5-trichloropyrimidine (259 mg, 0.16 mL,
1.41 mmol) and K2CO3 (260 mg, 1.89 mmol) in 1,4-dioxane (9 mL) and H2O (3 mL) was sparged _ 177 with N2for 5 min. Pd(PPh3)4 (54.5 mg, 0.047 mmol) was added and the mixture was sparged with N2for an additional 10 min. The mixture was stirred at 90 °C for 16 h before being cooled to . ambient température, diluted with H2O (15 mL), and extracted with EtOAc (3x10 mL). The combined organic.phases were washed with brine (10 mL), dried over.Na2SO4, filtered, and . .
concentrated. To this crude mixture was added a second crude mixture from a reaction run in analogous fashion on a 100 mg scale. The résidé was purified by flash chromatography (SiO2, 100% EtOAc) to provide 6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-2-methyl-1-(propan-2-yl)-1Hbenzimidazole (A-2) (420 mg, 98% yield). m/z (ESI+) for (Ci5Hi3N4FCI2), 338.9 (M+H)+.
Step 3: Synthesis of (3R,4R)-4-({5-chloro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1HbenzimidazoI-6-yl]pyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-oI (Example A1)
To a yellow suspension of 6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-2-methyl-1-(propan-2yl)-1H-benzimidazole (A-2) (210 mg, 0.619 mmol) in DMSO (5 mL) was added DIPEA (240 mg, 0.331 mL, 1.86 mmol) and (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (lnt-69) (241 mg, 15 1.24 mmol). The mixture was stirred at 120 °C for 16 h and then diluted with H2O (20 mL) and extracted with EtOAc (3x20 mL). The combined organic phases were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated. The crude residue was purified by préparative HPLC with an Agela Durashell C18 column (150x25 mm, 5 pm particle size; column température 25 ’C), which was eluted with 34-54% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide (3R,4R)-4-({5-chloro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6yl]pyrimidin-2-yI}amino)-1-(methanesulfonyI)piperidin-3-ol (Example A1) (54.7 mg, 19% yield) as a yellow solid. Ή NMR (400 MHz, DMSO-£/6) δ 8.41 (s, 1H), 8.02 - 7.79 (m, 1H), 7.54 - 7.27 (m, 2H), 5.24 (d, J = 4.5 Hz, 1 H), 4.86 - 4.71 (m, 1 H), 3.86 - 3.74 (m, 1 H), 3.60 (br d, J = 9.5 Hz, 2H), 3.53 - 3.45 (m, 1H), 2.94 - 2.79 (m, 4H), 2.69 - 2.59 (m, 4H), 2.07 (s, 1H), 1.62 - 1.46 (m, 7H);
m/z (ESI+) for (C2iH26CIFN6O3S), 497.3 (M+H)+.
The examples in th^ below table were synthesized according to the method^ used for the synthesis of (3R,4R)-4-({5-chloro-4-[4-fluoro-2-methyI-1 -(propan-2-yl)-1 /-/-benzimidazol-6yl]pyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-oI (Example A1). The following 30 examples were synthesized with non-critical changes or substitutions to thé exemplified procedures that someonel who is skilled in the art would be able to realize. 'If necessary, séparation ofthe enantiomers ofwas carried out understandard methods known in the art, such as chiral SFC or HPLC, to afford single enantiomers. ; --------- . — .
Example | Structure/Name | LCMS | NMR | |
number |
178
A2 | Ν^γρ JJ ---------'y > —y n k J N J N Me—/ \. i \ Me 0—S—O Me Me (3R,4R)-4-({5-fluoro-4-[4-fluoro2-methyl-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-1- (methanesulfonyl)piperidin-3-ol | 481.2 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.44 (d, J = 4.03 Hz, 1H), 8.16 - 8.03 (m, 1H), 7.71 - 7.50 (m, 1H), 7.32 - 7.17 (m,-1H), 5.28-5.19 (m, 1H), 4.90-4.74 (m, 1H), 3.87-3.72 (m, 1H), 3.70 - 3.57 (m, 2H), 3.54 - 3.45 (m, 1 H), 2.92 (s, 3H), 2.89 2.83 (m, 1 H), 2.73 - 2.66 (m, 1 H), 2.64 (s, 3H), 2.36-2.30 (m, 1H), 1.60 (d, J =6.85 Hz, 6H), 1.57-1.50 (m, 1H) |
A3 | n-Vf J HN N T Jn T 'J--7 Me Me Me 4-(1-fert-butyl-4-fluoro-1H- benzimidazol-6-yl)-5-fluoro-/V(1-methylpiperidin-4yl)pyrimidin-2-amine | 401.1 [M+H]* (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.51 (brs, 1H), 8.43-8.34 (m, 3H), 7.82 (d, J =12.0 Hz, 1H), 4.19-4.06 (m, 1H), 3.503.40 (m, 2H), 3.29-3.13 (m, 2H), 2.83 (s, 3H), 2.35 - 2.25 (m, 2H), 1.95-1.82 (m, 11 H) |
A4 | hn nY y HO^Â. JJ Tl \ ,N < J n-4 N Me—/ i \ Me O-S-O Me Me (3R,4R)-4-({4-[4-fluoro-2- methyl-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2yljamino) J (methanesulfonyl)piperidin-3-ol | 463.3 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-cfe) δ 8.35 (d, J= 5.3 Hz, 1H), 8.22 (s, 1H), 7.76 (d, J =12.3 Hz, 1H), 7.32 (d, J =5.5 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 5.27 (brd, J = 4.0 Hz, 1H), 4.90-| 4.75 (m, 1H), 3.84 (br s, 1H), 3.73 - 3.44 (m, 3H), 3.05 - 2.87 (m, 4H), 2.69-2.65 (m, 1H),| 2.62 (s, 3H), 2.19-2.00 (m,j 1H), 1.61 (d, J = 6.3 Hz, 7H) |
179
A5 | N'Y F λ AA ΗΝ Ν Υη HCX χ ΠΑ II \ ,Ν k J ν-4 N Me—/ ι \ Me O-S-O Me Me (3R,4R)-4-({4-[5-fluoro-2methyl-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-1(methanesulfonyl)piperidin-3-ol | 463.1 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-cfe) δ 8.39 - 8.09 (m, 2H), 7.47 7.41 (m, 1H), 7.20 (d, J = 7.8 Hz, 1 H), 7.03 (brs, 1 H), 5.27 (brs, 1H), 4.85-4.70 (m, 1H), 3.82 (br s, 1 H), 3.75 - 3.60 (m, 2H), 3.56-3.45 (m, 1H), 2.91 (s, 3H), 2.88-2.79 (m, 1H), 2.70 — 2.60 (m, 1H), 2.59 (s, 3H), 2.20- 2.00 (m, 1H), 1.65 1.60 (m, 7H) |
A6 | nV F A A A HN N ]ίη HO. AA Il \ ,N L J n-4 N Me—/ i \ Me O-S-0 Me Me (3R,4R)-4-({5-chloro-4-[5fluoro-2-methyl-1-(propan-2-yl)1 H-benzimidazol-6-yl]pyrimidin2-yl}amino)-1(methanesulfonyI)piperidin-3-ol | 497.3 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) 6 8.42 (s, 1H), 7.73 (d, J =6.0 Hz, 1H), 7.66-7.48 (m, 1H), 7.44 (d, J= 10.5 Hz, 1H), 5.22 (d, J = 4.3 Hz, 1 H), 4.85 - 4.70 (m, 1H), 3.79 (br s, 1H), 3.653.55 (m, 2H), 3.50 - 3.40 (m, 1H), 2.88 (br s, 4H), 2.702.60 (m, 1H), 2.58 (s, 3H), 2.08 (s, 1H), 1.60-1.45 (m, 7H) |
A7 | n'A F A A A hn n ji η ho. y. VA il \ ,N - LJ. n-4 . . N Me—/ i \ Me . O-S-O Me Me ' (3R,4R)-4-({5-fluoro-4-[5-fluoro2-m ethyl-1 -( pro pan-2-y 1)-1/7benzimidazol-6-yl]pyrimidin-2yl}amino)-1- (methanesuIfonyI)piperidin-3-ol | 481.3 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.42 (d, J= 2.0 Hz, 1H), 7.82 (d, J =6.0 Hz, 1H), 7.46 (d, J = 10.8 Hz, 1H), 7.32 (brs, 1H), . 5.21 (d, J = 4.5 Hz, 1H), 4.854.70 (m, 1H), 3.73 (brs, 1H), 3.67 - 3.56 (m, 2H), 3.50 - 3.40 (m, 1H), 2.88 (s, 3H), 2.86 - 2.78 (m, 1H), 2.70 - 2.60 (m, 1H), 2.59 (s,3H), 2.07 (s, 1H), 1.60-1.45 (m,7H) |
180
A8 | N-ycl ΗΝ^Ν^Αγ^^ hov.λ L II \ ,Ν . k J N-4f _ _ Ν ΜθΖ Me O=S=O Me (3R,4R)-4-{[5-chloro-4-(4fluoro-1,2-dimethyl-1 Hbenzimidazol-6-yl)pyrimidin-2yl]amino}-1(methanesulfonyl)piperidin-3-ol | 469.2 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-de) δ 8.42 (s, 1H), 7.77 (brs, 1H), 7 60 - 7.31 (m, 2H), 5.22 (d, J = 4.5 Hz, 1H); 3.81 (brs, 1H); 3.79 (s, 3H), 3.67 - 3.55 (m, 2H),3.50 - 3.40 (m, 1 H), 2.89 (s, 3H), 2.88-2.82 (m, 1H), 2.70-2.60 (m, 1 H), 2.58 (s, 3H), 2.04 (brs, 1H), 1.59-1.42 (m, 1H) |
A9 | nV HN N 7i ho^a Là Il \ N LJ N-Ÿ N Me-^/ \ O=S=O Më/X^ Me (3R,4R)-4-{[5-chloro-4-(5fluoro-1,1-dimethyl-2,3-dihydro1 H-pyrrolo[1,2-a]benzimidazol7-yl)pyrimidin-2-yl]amino}-1(methanesulfonyl)piperidin-3-ol | 509.3 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 7.84 (brs, 1H), 7.59 - 7.32 (m, 2H), 5.22 (br s, 1 H), 3.78 (br s, 1 H), 3.59 (br d, J = 10.0 Hz, 2H), 3.48 (br d, J = 11.7 Hz, 1H), 3.08 (t, J = 7.5 Hz, 2H), 2.89 (s, 3H), 2.86 2.79 (m, 1H), 2.69-2.61 (m, 1H), 2.58-2.53 (m, 2H), 2.05 (brs, 1H), 1.62 (s, 6H), 1.52 (br d, J =11.7 Hz, 1H) |
A10 | Ν^γ'01 JL -sîLx^^F HN N || L^k Il \ N k J N— N Me··/ \ o=s=o V/ Me (3R,4R)-4-({5-chloro-4-[(4S)-9fluoro-4-methyI-3,4-dihydro-1 H[1,4]oxazino[4,3a]benzimidazol-7-yI]pyrimidin2-yl}amino)-1(methanesulfonyl)piperidin-3-or | 5l|l.2 [M+H]+ (ESI) i | 1H NMR (400 MHz, DMSO-d6) δ 8.44 (s, 1H), 7.89 (brs, 1H), 7.58 - 7.39 (m, 2H), 5.22 (d, J = 4.5 Hz, 1H), 5.09-5.03 (m, 1H), 4.97-4.91 (m, 1H), 4.70 (brd, J = 5.5 Hz, 1H), 4.174.10 (m, 1H), 4.06-3.98 (m, 1 H), 3.82 (br d, J = 5.8 Hz, 1 H), 3.67 - 3.57 (m, 2H), 3.50 - 3.40 (m, 1H), 2.93 - 2.82 (m, 4H), 2.70 - 2.60 (m, 1 H), 2.11 - 2.00 (m, 1H), 1.60-1.45 (m, 4H) |
181
A11 | N^VCI . xk J^x^^-F HN N HO^xk ΙχχΑ Tl \ ,N ψ (,e^M o=s=o V/ Me (3R,4R)-4-({5-chloro-4-[(4R)-9fluoro-4-methyl-3,4-dihydro-1 H[1,4]oxazino[4,3a]benzimidazol-7-yl]pyrimidin2-yl}amino)-1- (methanesuIfonyl)piperidin-3-ol | 511.2 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.44 (s, 1H), 7.82 (s, 1H), 7.59 - 7.44 (m, 2H), 5.23 (d, J = 4.8 Hz, 1H), 5.13-5.07 (m, 1H), 5.02-4.96 (m, 1H), 4.42 (dd, J =3.0,12.0 Hz, 1H), 4.19 (dd*d, J = 3.5, 6.3,10.0 Hz, 1H), 3.90 - 3.76 (m, 2H), 3.68 - 3.56 (m, 2H), 3.50 — 3.40 (m, 1H), 2.90 (s, 3H), 2.88 - 2.81 (m,1H), 2.73-2.61 (m, 1H), 2.11-2.00 (m, 1H), 1.62-1.46 (m, 1H), 1.38 (d, J =6.3 Hz, 3H) |
A12 | ν·^<01 xk HN N HO^^< ICY Il ' //N k U N-X O Me-( ^0Η Me^e 1,5-anhydro-3-[(5-chloro-4-{4fluoro-2-[(1S)-1-hydroxyethyl]- 1 -(propan-2-yl)-1 H- benzimidazol-6-yl)pyrimidin-2yl)amino]-2,3-dideoxy-D-#jreopentitol | 450.1 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.37-8.31 (m, 1H), 8.05 (s, 1H), 7.50 (brd, J= 11.5 Hz, 1H), 5.39-5.29 (m, 1H), 5.23 (q, J =6.6 Hz, 1H), 4.03-3.88 (m, 3H), 3.63 (dt, J = 4.8, 9.4 Hz, 1H), 3.48 (dt, J =2.0,11.6 Hz, 1H), 3.21 (dd, J =9.8,11.0 Hz, 1H), 2.19-2.09 (m, 1H), 1.75-1.53 (m, 10H) |
A13 I | N'^V'01 HN^N^Xr^V1 HC^xk Il V ,N k χΙ n-4 0 ΜθΥ >·..ΟΗ . Mewe 1,5-anhydro-3-[(5-chloro-4-{4fluoro-2-[(1 R)-1-hydro xyethyl]- 1 -(propan-2-yl)-1 Hbenzimidazol-6-yl}pyrimidin-2yl)amino]-2,3-dideoxy-D-t/7reopentitol | 450.3 [M+H]+ (ESI) | Ή NMR (400 MHz, DMSO-d6) 8.43 (s, 1H), 8.09-7.83 (m, 1H), 7.59-7.32 (m, 2H), 5.79 (brd, J =6.4 Hz, 1H), 5.20|5.15(m, 1H), 5.14-5.06 (m, ÏH), 4.96 (br d, J = 5.2 Hz, 1 H), 3.88 - 3.78 (m, 3H), 3.51 (br s, 1H), 3.10-2.98 (m, 1H), 1.96 (brs, 1H), 1.65-1.55 (m, 10H). one signal obscured by residual water |
182
A14 | N^CI JL HN N J| I I \ ,N LJ N— rA o=s=o 4 \ Me ° *first eluting stereoisomer (3R,4R)-4-({5-chloro-4-[4fluoro-1-(oxolan-3-yl)-1Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-1(methanesulfonyl)piperidin-3-ol | 511.1 [M+H]+ (ESI) | Ή NMR (400 MHz, DMSO-d6) δ 8.44 (s, 2H), 7.98 (brs, 1H), 7.64 - 7.36 (m, 2H), 5.36 (br s, 1H), 5.22 (d, J = 4.5 Hz, 1 H), 4.20 - 4.12 (m, 1H), 4.07 (br d, J = 9.0 Hz, 1H), 4.01-3.94 (m, 1H), 3.88 - 3.78 (m, 2H), 3.67 3.56 (m, 2H), 3.49 (s, 1 H), 2.90 (s, 3H), 2.87-2.81 (m, 1H), 2.66 (brt, J =10.8 Hz, 1H), 2.61 -2.54 (m, 1H), 2.32 -2.20 (m, 1H), 2.10-1.99 (m, 1H), 1.60-1.47 (m, 1H) |
A15 | N^1 JL HN N ]| HO. L^L Il \ ,N Ψ X o=s=o n/ Me (3R,4R)-4-{[5-chloro-4-(1 cyclopropyI-4-fluoro-1 Hbenzimidazol-6-yl)pyrimidin-2yl]amino}-1- (methanesulfonyl)piperidin-3-ol | 481.2 [M+H]+ (ESI) | 1H NMR (4500 MHz, CD3OD) δ 8.38 (s, 1H), 8.35 (s, 1H), 8.06 (s,1H), 7.56 (dd, J = 1.0, 11.7 Hz, 1H), 3.98-3.92 (m, 1 H), 3.85 (ddd, J = 1.8, 4.7,11.7 Hz, 1H), 3.76 (dt, J = 4.9, 9.0 Hz, 1H), 3.72-3.67 (m, 1H), 3.60 (m, 1H), 2.96 (dt, J =2.7,11.9 Hz, 1H), 2.90 (s, 3H), 2.77 (dd, J =9.5, 11.6 Hz, 1H), 2.25 (br dd, J =3.7, 13.4 Hz, 1H), 1.801.61 (m, 1H), 1.31-1.22 (m, 2H), 1.20-1:09 (m, 2H) |
A16 | N^1 HnAnA^/^CI HO. Λ. > . LM\ III \ ,N L J I n-^ N Me--/ O=S=O Me (3R,4R)-4-({5-chioro-4-[4chIoro-1-(propan-2-yl)-1Hbenzimidazol-6-yl]pyrimidin-2- | 521.1 [M+Na]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.44 (s, 1H), 8.04 (s, 1H), 7.67 (d, J =1.1 Hz, 1H), 7.55 (brs, 1 H)! 5.23 (d, J = 4.5 Hz, 1H), 4.83 (td, J = 6.7,13.4 Hz, 1H), 3.81 (brd, J = 5.6 Hz, 1H), 3.70-3.55 (m, 2H), 3.50 - 3.40 (m, 1 H), 2.96 2.77 (m, 4H), 2.72 - 2.61 (m, |
183
— | yl}amino)-1(methanesulfonyl)piperidin-3-ol | 1H), 2.06 (brs, 1H), 1.64-1.46 (m, J =6.7 Hz, 7H) | |
A17 | ΗΝΛ ΝΑργΡ AA L 1 \ ,n o=s=o Vo/ Me *first eluting 2 stereoisomer (3R,4R)-4-{[4-(4-ethyl-9-fIuoro3,4-dihydro-1H[1,4]oxazino[4,3a]benzimidazol-7-yl)-5fluoropyrimidin-2-yl]amino}-1(methanesulfonyl)piperidin-3-ol | 509.0 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.45 (d, J = 4.0 Hz, 1H), 8.05 (s, 1H), 7.70 (d, J =12.0 Hz, 1H), 7.24 (d, J =7.8 Hz, 1H), 5.21 (d, J = 4.5 Hz, 1H), 5.13- 5.02 (m, 1H), 4.99-4.89 (m, 1H), 4.54 (brs, 1H), 4.22 (d, J = 12.0 Hz, 1H), 4.04 (dd, J = 3.5,12.3 Hz, 1H), 3.78 (brs, 1H), 3.67 - 3.55 (m, 2H), 3.55 3.45 (m, 1H), 2.99-2.83 (m, 4H), 2.75-2.61 (m, 1H), 2.21 2.05 (m, 1H), 2.00-1.84 (m, 2H), 1.65-1.45 (m, 1H), 0.99 (t, J = 7.5 Hz, 3H); [a]D 20 = -66 (c=0.1,MeQH) |
A18 | n^Yf A HN N YV HO^ A. AA Il \ /N Me N-/ o=s=o MeAQ/ Me (3R,4R)-4-{[5-fIuoro-4-(9-fluoro- 4,4-dimethyl-3,4-dihydro-1 H[1,4]oxazino[4,3-, a]benzimidazol-7-yl)pyrlmidin2-yi]amino}-1(methanesuIfonyl)piperidin-3-ol | 509.1 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.45 (d, J = 3.8 Hz, 1H), 8.18 (s, 1H), 7.68 (brd, J=11.8 Hz, 1 H), 7.26 (br d, J = 7.8 Hz, 1 H), 5.23 (d, J = 4.5 Hz, 1H), 4.99 (s, 2H), 3.93 (s, 2H), 3.78 (br s, 1H), 3.69 - 3.57 (m, 2H), 3.55 3.45 (m, 1H), 2.93-2.83 (m, 4H), 2.71-2.65 (m, 1H), 2.11 (brs, 1H), 1.65 (s, 6H), 1.561.46 (m,1H) |
A19 | aIAp HN N |A HO^^k AA i Ί \ ,N : A 1,5-anhydro-2,3-dideoxy-3-{[5fluoro-4-(9-fluoro-4,4-dimethyl- | 432.1 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-de) δ 8.44 (d, J = 4.0 Hz, 1 H), 8.21 (brs, 1H), 7.67 (d, J = 12.0 Hz, 1H), 7.23 (d, J =7.8 Hz, 1H), 5.02 - 4.93 (m, 3H), 3.93 (s, 2H), 3.87 - 3.76 (m, 3H), 3.55 - |
184
3,4-dihydro-1H- [1,4]oxàzino[4,3a]benzimidazol-7-yl)pyrimidin2-yl]amino}-D-t/7reo-pentitol | - -- ’ - | 3.45 (m, 1H), 3.32 (brs, 1H), 3.06 (t, J= 10.4 Hz,1H), 2.00 (br s, 1H), 1.65 (d, J = 1.8 Hz, 6H), 1.56 - 1.44 (m,1H) | |
A20 | HN N y . HCUxk Il ' Z/N ° Me—4 \ „ V 7—Me *second eluting 0 stereoisomer 1,5-anhydro-3-{[5-chloro-4-(9fluoro-1,4-dimethyl-3,4-dihydro- 1 H-[1,4]oxazino[4,3a]benzimidazol-7-yl)pyrimidin2-yl]amino}-2,3-dideoxy-Dthreo-pentitol | 447.8 [M+H]+ (ESI) | 1H NMR (400 MHz, CDCI3) δ 8.33 (s, 1H), 7.64 (d, J =1.2 Hz, 1 H), 7.47 (dd, J = 1.2,11.2 Hz, 1H), 5.29 (br d, J = 5.9 Hz, 1H),4.99 (q, J = 6.6 Hz,1H), 4.48 (q, J = 6.8 Hz, 1 H), 4.12 (d, J = 1.5 Hz, 2H), 4.06 (dd, J = 5.0,11.4 Hz, 1H), 3.99 (br dd, J =4.3, 11.3 Hz, 1H), 3.893.80 (m, 1H), 3.63 (dt, J = 5.0, 9.4Hz, 1H), 3.46 (dt, J = 2.1, 11.8 Hz, 1H), 3.18 (t, J = 10.7 Hz, 1H), 2.10-2.01 (m, 1H), 1.80 (d, J =6.6 Hz, 3H), 1.771.67 (m, 1H), 1.64 (d, J = 6.6 Hz, 3H) |
A21 | ΗΝ^Ν^ψ^ HO^ Il ' J ν-λ ° Me—4 \ _____γ _y— Me *first eluting 0 stereoisomer 1,5-anhydro-3-{[5-chIoro-4-(9fluoro-1,4-dimethÿl-3,4-dihydro- 1 H-[1,4]oxazino[4,3a]benzimidazol-7-yl)pyrimidin2-yl]amino}-2,3-dideoxy-Dtbreo-pentitol | 447.8 [M+H]+ (ESI) | 1H NMR (400 MHz, CDCI3) δ 8.33 (s, 1H), 7.62 (s, 1H), 7.47 (dd, J = 1.1, 11.2 Hz, 1H), 5.28 (brd, J=5.7 Hz, 1H), 5.064.72 (m, 2H), 4.48 (q, J- 6.6 Hz, 1 H), 4.12 (d, J =1.7 Hz, 2H), 4.06 (dd, J = 5.0,11.4 Hz, -1H),-3.99 (br dd, J = 4.3,11.7 Hz, 1 H), 3.90 - 3.80 (m, 1 H), 3.63 (dt, J = 4.8, 9.4 Hz, 1H), 3.51-3.42 (m, 1H), 3.18 (t, J = 10.6 Hz, 1 H), 2.09 - 2.01 (m, -1 H),1.81 (d, J = 6.6 Hz, 3H). 1.77-1.69 (m, 1H), 1.64 (d, J = - ’ 6.6 Hz, 3H) |
185
A22 | N^CI Ηθ/χ UA Il \ ,N Y/ Me Me-Λ / Me 1,5-anhydro-3-{[5-chloro-4-(9- fluoro-2,4,4-trimethyl-1,2,3,4tetrahydropyrazino[1,2- a]benzimidazol-7-yl)pyrimidin2-yl]amino}-2,3-dideoxy-Dfhreo-pentitol | 461.1 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s, 1 H), 8.09 - 7.88 (m, 1 H), 7.47 (br s, 2H), 4.94 (br d, J = 5.4 Hz, 1H), 3.86-3.71 (m, 5H), 3.50 (br s, 1 H), 3.29 - 3.25 (m, 1H), 3.03 (brt, J =10.3 Hz, 1 H), 2.75 (s, 2H), 2.44 (s, 3H), 1.95 (brs, 1H), 1.65 (s, 6H), 1.56 - 1.48 (m, ï H) |
A23 | n^<ci JL HO^A. YY. Il \ N L J n-4 .. O Me—/ \^Me *first eluting Me 0H stereoisomer 1,5-anhydro-3-({5-chloro-4-[2(1 -cyclopropyl-1 -hydroxyethyl)4-fluoro-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-2,3-dideoxy-D-tbreopentitol | 490.0 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-de) δ 8.42 (s, 1H), 8.12-7.87 (m, 1H), 7.63 - 7.26 (m, 2H), 5.90 5.75 (m, 1H), 5.64 (s, 1H), 4.98 (brd, J =5.0 Hz, 1H), 3.943.76 (m, 3H), 3.58 - 3.48 (m, 1H), 3.32-3.27 (m, 1H), 3.03 (brt, J =10.5 Hz, 1H), 2.051.87 (m, 1H), 1.70-1.56 (m, 9H), 1.51 (brd, J =13.1 Hz, 1H), 1.42-1.31 (m, 1H), 0.740.61 (m, 1H), 0.55-0.34 (m, 3H); Md22 = -6 (c=0.1, MeOH) |
A24 | N-ycl LÀ Il ' //N L J N—< 0 Me—/ V^Me MeÂ^On ‘second eluting stereoisomer 1,5-anhydro-3-({5-chloro-4-[2(1 -cyclopropyl-1 -hydroxyethyl)4-fluoro-1-(propan-2-yl)-1/7benzimidazol-6-yl]pyrimidin-2- | I 490.11 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) 6 8.42 (s, 1H), 8.13-7.81 (m, 1H), 7.62 - 7.15 (m, 2H), 5.90 5.75 (m, 1H), 5.64 (s, 1H), 4.97 (brd, J =5.0 Hz, 1 H), 3.943.70 (m, 3H), 3.59 - 3.47 (m, 1 H), 3.32-3.25 (m, 1H), 3.03 (brt, J =10.3 Hz, 1H), 2.04 1.84 (m, 1 H), 1.70 -1.57 (m, 9H), 1.55 - 1.45 (m, 1 H), 1.42 1.31 (m, 1 H), 0.74-0.63 (m, |
186
yl}amino)-2,3-dideoxy-D-f/7reopentitol | - -- . | 1H), 0.59-0.30 (m, 3H); [ah22 = -22(c=0.1,MeOH) | |
A25 | N'^YCI JL HN n L A LJ K 'N Y ΜθΎ Me O=S=O Me Me (3R,4R)-4-({5-chloro-4-[7fluoro-2-methyl-3-(propan-2-yl)2H-indazol-5-yl]pyrimidin-2yl}amino)-1(methanesulfonyl)piperidin-3-ol | 496.9 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.40 (s, 1H), 8.18 (brs, 1H), 7.57 - 7.34 (m, 2H), 5.22 (br s, 1H), 4.17 (s, 3H), 3.79 (brs, 1H), 3.67 - 3.56 (m, 3H), 3.55 3.45 (m, 1H), 2.89 (s, 3H), 2.87 -2.80 (m, 1H), 2.66 (brt, J = 10.5 Hz, 1H), 2.05 (brs, 1H), 1.60-1.40 (m, 1H), 1.46 (brd, J =6.7 Hz, 6H) |
A26 | N-YCI JL HN n YY HO. II___À LJ L-N Μθ>/Λ O=S=O Me o-/ Me (3R,4R)-4-{[5-chloro-4-(7fluoro-1,1-dimethyl-3,4-dihydro1 H-[1,4]oxazino[4,3-b]indazol9-yl)pyrimidin-2-yl]amino}-1(methanesulfonyl)piperidin-3-ol | 525.1 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.42 (s, 1H), 8.04 (brs, 1H), 7.68 - 7.24 (m, 2H), 5.22 (d, J = 4.5 Hz, 1H), 4.46 (t, J = 4.8 Hz, 2H), 4.22 (brt, J = 4.6 Hz, 2H),3.93 - 3.72 (m, 1H), 3.60 (brd, J =8.8 Hz, 2H), 3.49 (br d, J=11.3 Hz, 1H), 2.90 (s, 3H), 2.88 - 2.80 (m, 1H), 2.74 2.55 (m, 2H), 2.07 (br d, J = 10.8 Hz, 1 H), 1.70 (s, 6H), 1.53 (brd, J =10.0 Hz, 1 H) |
ί Α27| | n^Yci JL HN N T| HCYxk *1___X U L-N Me^YN Me k / O—* 1,5-anhydro-3-{[5-chloro-4-(7fluoro-1,1-dimethyl-3,4-dihydro- 1 H-[1,4]oxazino[4,3-b]indazol- 9-yI)pyrimidin-2-yl]amino}-2I3dideoxy-D-fhreo-pentitol | 448.0 [M+H]* (ESI) | 1H h^MR (500 MHz, DMSO-cfe) 5 8.40 (s, 1H), 8.03 (brs, 1H), 7.57 - 7.34 (m, 2H), 4.94 (d, J = 5.3 Hz, 1 H), 4.45 (t, J = 5.0 Hz, 2H), 4.21 (t, J = 4.9 Hz, 2H),3.86 - 3.77 (m, 3H), 3.49 (brd, J = 4.1 Hz, 1H), 3.03(t, J = 10.5 Hz, 1H), 1.94 (brs, 1H), 1.68 (s, 6H), 1.57-1.40 (m, |
187
1 H); one proton obscured by solvent peak | |||
A28 | N-VC' Λ A hok/\ LA l J L ^N^ Me—(/ N> o-s-o Me Me (3R,4R)-4-({5-chloro-4-[2methyl-3-(propan-2-yl)-2Hindazol-5-yl]pyrimidin-2yl}amino)-1(methanesulfonyl)piperidin-3-ol | 479.3 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-</6) 5 8.38 (s, 1H), 8.32-8.22 (m, 1 H), 7.59 (br s, 2H), 7.51 - 7.35 (m, 1H), 5.22 (d, J = 4.3 Hz, 1H), 4.13 (s, 3H), 3.84-3.74 (m, 1H), 3.65-3.53 (m, 3H), 3.53-3.47 m, 1H), 2.89 (s, 3H), 2.87 - 2.78 (m, 1H), 2.69 2.60 (m, 1H), 2.13-1.97 (m, 1 H), 1.57-1.50 (m, 1H), 1.46 (d, J =6.8 Hz, 6H) |
A29 | Λ A HN N^iP] HO^Â. U___1 T J λ 'St Me O=S=O HO Me (3R,4R)-4-({5-chloro-4-[3-(2hydroxypropan-2-yl)-2-methyl2H-indazol-5-yl]pyrimidin-2yl}amino)-1(methanesulfonyl)piperidin-3-ol | 495.3 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.39 (s, 1H), 8.37-8.24 (m, 1 H), 7.60 (br d, J = 7.0 Hz, 2H), 7.53-7.38 (m, 1H), 5.76 (s, 1H), 5.22 (d, J =4.5 Hz, 1H), 4.33 (s, 3H), 3.83 - 3.74 (m, 1H), 3.59 (m, 2H), 3.51-3.44 (m, 1H), 2.89 (s, 3H), 2.872.79 (m, 1H), 2.68-2.60 (m, 1H), 2.10-1.99 (m, 1H), 1.75 (s, 6H), 1.58-1.46 (m, 1H) |
A30 | I HN N Y HO^ /k AA Il ' //N k J N-K N Me—/ O=S=O Me [Tl I Me 0 (3R,4R)-4-({5-chloro-4-[4fluoro-2-(oxetan-3-yl)-1 (propan-2-yl)-1 H-benzimidazoI6-yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol | 539.2 [M+H]+ (APCI) | 1H NMR (400 MHz, DMSO-d6, VT 80°C) 5 8.39 (s, 1H), 7.95 (d, J= 1.0 Ης|, 1H), 7.44 (dd, J = 0.9, 11.9 Hz, 1H), 7.18 (d, J = 7.7 Hz, 1H), 5.05-4.93 (m, 5H), 4.83 - 4.71 (m, 1H), 4.64 4.50 (m, 1Hj, 3.88-3.75 (m, 1H), 3.72 - 3.60 (m, 1H), 3.59 3.46 (m, 1H), 3.20 (d, J = 4.6 Hz, 2H), 2.95 - 2.83 (m;4H), 2.78 - 2.63 (m, 1H), 2.12 (dd, J |
188
= 3.4,13.4 Hz, 1H), 1.56 (d, J = 6.8 Hz, 6H) | |||
A31 | aX^f HN N T AA Il ' //N k fi N—X n Me-γ 0=8=0 Μβ o^7 Me *first eluting stereoisomer (3R,4R)-4-({5-chloro-4-[4fluoro-2-(oxetan-2-yl)-1 (propan-2-yl)-1 H-benzimidazol6-yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol | 538.9 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 8.09-7.96 (m, 1H), 7.56-7.47 (m, 1H), 6.19 (dd, J = 7.1,7.9 Hz, 1H), 4.91 4.88 (m, 1H), 4.86-4.82 (m, 1 H), 4.78 - 4.69 (m, 1 H), 4.00 3.88 (m, 1H), 3.86-3.78 (m, 1H), 3.76-3.71 (m, 1H), 3.703.64 (m, 1H), 3.51 -3.40 (m, 1H), 3.21-3.08 (m, 1H), 2.982.89 (m, 1H), 2.88 (s, 3H), 2.79 -2.68 (m, 1H), 2.27-2.17 (m, 1H), 1.74-1.62 (m,7H) |
A32 | ajC^f HN N HO. AA Il ' //N k fi N—X n Me-γ 0=S=0 Me 0^7 Me *second eluting stereoisomer (3R,4R)-4-({5-chloro-4-[4fluoro-2-(oxetan-2-yl)-1 (propan-2-yl)-1 H-benzimidazol6-yl]pyrimidin-2-yl}amino)-1 (methanesulfonyl)piperidin-3-ol | 539.1 [M+HJ* (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 8.09-7.97 (m, 1H), 7.56-7.47 (m, 1H), 6.19 (dd, J =7.0, 7.9 Hz, 1H), 4.91 4.88 (m, 1H), 4.86-4.82 (m, 1H), 4.78-4.69 (m, 1H), 4.003.89 (m, 1H), 3.86-3.78 (m, 1H), 3.77 - 3.62 (m, 2H), 3.52 3.38 (m, 1H), 3.20-3.08 (m, 1H), 2.98-2.90 (m, 1H), 2.88 (s, 3H), 2.79-2.67 (m, 1H), 2.31 -2.16 (m, 1H), 1^1-1-63 (m, J =1.0, 6.9 Hz, 7H) |
A33 | N^0' HN Ν^ιγ^ ΗΟ^Λ i AA Il ' //N k fi N—X O Me-^ Λ NH2 Me o 1,5-anhydro-3-({4-[2carbamoyl-4-fluoro-1 -(propan2-yl)-1 /-/-benzimidazol-6-yl]-5- | 449.1 [M+H]+ (ESI) | 1H NMR (500 MHz, DMSO-de) δ 8.51 -8.38 (m,2H), 8.187.99 (m, 2H), 7.65 - 7.42 (m, 2H), 6.04 - 5.80 (m, 1H), 4.98 - 4.91 (m, 1H), 3.90-3.73 (m, 3H), 3.57 - 3.44 (m, 1H), 3.10 -. 2.96 (m, 1H), 2.05-1.85 (m, |
189
chloropyrimidin-2-yl}amino)- 2,3-dideoxy-D-threo-pentitol | 1H), 1.62 (d, J =7.0 Hz, 6H), 1.53 - 1.37 (m, 1 H) | ||
A34 | N^J A HN N J y JJ Il ' //N k > N—\ ° MeJ JJnh Me o Me 1,5-anhydro-3-({5-chloro-4-[4fluoro-2-(methylcarbamoyl)-1(propan-2-yl)-1 H-benzimidazol6-yl]pyrimidin-2-yl)amino)-2,3dideoxy-D-fhreo-pentitol | 463.2 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.36 (s, 1H), 8.15-8.04 (m, 1H), 7.54 (d, J =11.5 Hz, 1H), 6.04-5.83 (m, 1H), 4.04-3.84 (m, 3H), 3.70-3.55 (m, 1H), 3.52 - 3.42 (m, 1H), 3.25 - 3.15 (m, 1H), 2.97 (s, 3H), 2.172.06 (m, 1H), 1.70 (d, J =6.8 Hz, 6H), 1.67-1.57 (m, 1H) |
A35 | HN N y^ HO^^k JJ il ' //N k J N—\ O Me^ -y0H *first eluting Me MeMe stereoisomer 1,5-anhydro-3-({5-chloro-4-[4- fluoro-2-(2-hydroxypropan-2y I )-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl)amino)-2,3-dideoxy-e/ythropentitol | 464.1 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) 6 8.44 (s, 1H), 8.05-7.87 (m, 1H), 7.53 - 7.27 (m, 1H), 7.06 6.90 (m, 1H), 5.98-5.66 (m, 2H), 5.06 - 4.75 (m, 1H), 4.06 3.94 (m, 1H), 3.87-3.68 (m, 3H), 3.48 - 3.38 (m, 2H), 2.01 1.83 (m, 1H), 1.66 (s, 6H), 1.63 -1.55 (m, 7H); [a]o20 =-41.9 (c=0.14, MeOH) |
A36 | JOC^f hn N yy< HO^xk ° p' ÿ—OH Me Me *second eluting stereoisomer j 1,5-anhydro-3-({5-chloro-4-[1(1,1-difluoropropan-2-yl)-4fluoro-2-(1 -hydroxyethyl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-2,3-dideoxy-D-fhreopentitol | 485.9 [M+H]+ (ESI) | 1H NMR (700MHz, DMSO-cf6) δ 8.42 (s, 1H), 8.13-7.73 (m, 1H), 7.60-7.27 (m, 2H), 6.63 J 6.40 (m, 1H), 6.00-5.82 (m, 1H), 5.55-5.41 (m, 1H), 5.22- 5.13 (m, 1 H), 5.01 -4.85(m, ' 1H), 3.91 - 3.74 (m, 3H), 3.53 3.45 (m, 1H), 3.07-2.97 (m, 1H), 2.04-1.85 (m, 1H),1.68 (d, J=7.1 Hz, 3H), 1.62 (d, J = 6.7 Hz, 3H), 1.55-1.42 (m, |
190
1H); [a]D 22 = -37.3 (c=0.1, MeOH) |
Example A37 (Scheme A-2): Préparation of (3R,4R)-4-({5-fluoro-4-[4-fiuoro-2-methyl-1(propan-2-yI)-1H-benzimidazol-6-yi]pyrimidin-2-yl}amino)piperidin-3-oI
Scheme A-2:
A-3 Example A37
A solution of tert-butyl (3R,4R)-4-({5-fIuoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1Hbenzimidazol-6-yl]pyrimidin-2-yl}amino)-3-hydroxypiperidine-1-carboxylate (A-3) (prepared as in Example A1,1.25 g, 2.49 mmol) in DCM (10 mL) was treated with TFA (10 mL) and then stirred at ambient température for 1 h. The mixture was concentrated and the crude residue was taken up into DCM (10 mL). The pH was adjusted to ~7-8 with NH4OH. The product was extracted with water (20 mL). The aqueous phase was washed with DCM (3x15 mL). A white solid formed in the aqueous layer, which was collected by filtration to provide (3R,4R)-4-({5-fluoro-4-[4-fluoro-2methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)piperidin-3-ol (Example A37) (880 mg, 88% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.47 (d, J = 3.8 Hz, 1H), 8.10 (s, 1H), 7.73 - 7.57 (m, 1H), 7.51 - 7.39 (m, 1H), 5.69 - 5.62 (m, 1H), 4.90 - 4.72 (m, 1H), 4.43 - 4.30 (m, 1H), 4.08 - 3.93 (m, 1H), 3.90 - 3.77 (m, 1H), 3.50 - 3.39 (m, 2H), 3.07 - 2.96 (m, 1H), 2.95 - 2.82 (m, 1H), 2.63 (s, 3H), 2.28 - 2.15 (m, 1H), 1.74 - 1.64 (m, 1H), 1.59 (d, J = 6.8 Hz, 6H); m/z (ESI+) for (C20H24F2N6O), 403.1 (M+H)+.
Example A38 (Scheme A-3): Préparation of (3R,4R)-4-[(4-{1-[(2R)-1-aminopropan-2-yl]-4fluoro-2-methyl-1H-benzimidazol-6-yl}-5-chloropyrimidin-2-yl)amino]-1(methanesulfonyl)piperidin-3-ol .
Scheme A-3:
191
Example A3S
HCl
MeOH, 1,4-dioxane 34% yield tert-butyl {(2R)-2-[6-(5-chloro-2-{[(3R,4R)-3-hydroxy-1 (methanesulfonyl)piperidin-4-yl]amino}pyrimidin-4-yl)-4-fIuoro-2-methyl-1H-benzimidazol-1yl]propyl)carbamate (A-4) (Prepared as in Example A1,130 mg, 0.212 mmol) in MeOH (2.5 mL) was added a solution of HCl (4.0 M in 1,4-dioxane, 2.5 mL) dropwise at 0 °C. After the addition the reaction solution was stirred at room température for 2 h. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The reaction was concentrated to dryness. The residue was purified by préparative HPLC on a DuraShell column (150x25 mm, 5 pm particle size) which was eluted with 7-37% MeCN/HsO (+0.05% HCl) with a flow rate of 30 mL/min to provide (3R,4R)-4-[(4-{1-[(2R)-1-aminopropan-2-yl]-4-fluoro-2-methyl1H-benzimidazol-6-yl}-5-chloropyrimidin-2-yl)amino]-1-(methanesuIfonyl)piperidin-3-ol (Example A38) (39.5 mg, 34% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-de) δ 8.39 (s, 1 H), 8.06 - 7.97 (m, 1 H), 7.67 - 7.52 (m, 1 H), 5.06 - 4.79 (m, 1 H), 3.81 - 3.70 (m, 1 H), 3.66 - 3.54 (m, 3H), 3.51 - 3.43 (m, 1H), 3.42 - 3.33 (m, 1H), 2.85 (s, 3H), 2.82 - 2.77 (m, 1H), 2.74 (s, 3H),
2.68 - 2.56 (m, 1 H), 2.05 - 1.96 (m, 1 H), 1.64 (d, J = 6.8 Hz, 3H), 1.58 - 1.45 (m, 1 H); m/z (ESI+) for (C2iH27CIFN7O3S), 512.2 (M+H)+.
The examples in the below table were synthesized according to the methods used for the synthesis of (3R,4R)-4-({5-hloro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1/7-benzimidazol-620 yl]pyrimidin-2-yl)amino)-1-(methanesulfonyl)piperidin-3-ol (Example A37) (Scheme A-2) and । (3R,4R)-4-[(4-{1-[(2R)-1-aminopropan-2-yl]-4-fluoro-2-rnethyl-1/-/-benzimidazol-6-yl}-5chloropyrimidin-2-yl)amino]-1-(methanesulfonyl)piperidin-3-ol (Example A38) (Scheme A-3). The following examples were synthesized with non-critical changes or substitutions to the , exemplified procedures that someone who is skilled in the art would be able to realize. If
I !
i necessary, séparation of the enantiomers was carried out under standard methods known in the art, such as chiral SFC or HPLC, to afford single enantiomers.
Example | Structure/Name | LCMS | NMR |
number | -- |
192
A39 | N-ycl ΗΝ^Ν<Υ''<^ HO^^k Il \ ,N k J N— N Mei·./ o=s=o ) Me H2N (3R,4R)-4-[(4-{1-[(2S)-1aminopropan-2-yl]-4-fluoro-2methyl-1 H-benzimidazol-6-yÎ}5-chloropyrimidin-2-yl)amino]1-(methanesulfonyl)piperidin-3ol | 534.2 [M+Na]+ (ESI) | 1H NMR (400 MHz, DMSO-cfe) δ 8.45-8.27 (m, 1H), 8.037.87 (m, 1H), 7.65-7.49 (m, 1H), 5.08-4.85 (m, 1H), 3.833.68 (m, 1H), 3.67-3.56 (m, 2H), 3.54 - 3.35 (m, 2H), 2.91 2.79 (m, 4H), 2.75 - 2.61 (m, 4H), 2.12-1.95 (m, 1H), 1.71 1.50 (m, 4H) |
A40 | N-YCI HO^xk kxA Il ' //N i \ Me o=s=o L·.. 1 >1 Μθ Me H2N (3R,4R)-4-({4-[1-(2aminopropyl)-4-fluoro-2-methyl1 H-benzimidazol-6-yl]-5chloropyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol | 512.2 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) 6 8.39 (s, 1H), 8.01-7.82 (m, 1H), 7.58-7.31 (m, 1H), 4.484.34 (m, 2H), 3.82- 3.72 (m, 1H), 3.71-3.63 (m, 1H), 3.633.54 (m, 2H), 3.51 - 3.42 (m, 1H), 2.85 (s, 3H), 2.82-2.73 (m, 1H), 2.67-2.57 (m,4H), 2.10-1.95 (m, 1 H), 1.59-1.45 (m, 1H), 1.24 (d, J =6.5 Hz, 3H) |
A41 ί | N^YCI HC^xk Il ' //N k y N-χ „ O Me-γ y,Me Μθ Me' 3-({4-[2-(2-aminopropan-2-yl)4-fluoro-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]-5chloropyrimidin-2-yl)amino)1,5-anhydro-2,3-dideoxy-Dtbreo-pentitol | 463.4 [M+H]+ (ESI) | 1H NMR (500 MHz, DMSO-de) 6 8.41 (s, 1H), 8.05-7.81 (m, 1H), 7.57-7.22 (m, 2H), 6.24^.06 (m, 1 H), 4.99 - 4.89 (m, 1H), 3.90-3.73 (m, 3H), 3.543.46 (m, 1H), 3.32-3.30 (m, 1l}l), 3.07-2.95 (m, 1H), 2.33^.22 (m, 1H), 2.04-1.88 (m, 1H), 1.60-1.56 (m, 12H), 1.53 -1.40(m, 1H) |
193
A42 | N^' xk hn nY y il ' //N k > N-X ° mX J^nh2 Me MeMè 3-[(4-{2-[(1R)-1-aminoethyl]-1fert-butyl-4-fluoro-1 Hbenzimidazol-6-yl}-5chloropyrimidin-2-yl)amino]-1,5anhydro-2,3-dideoxy-D-threopentitol | 463.4 [M+H]* (ES!) | 1H NMR (500 MHz, CD3OD) δ 8.34 (s, 1H), 8.25-8.14 (m, 1H), 7.56-7.38 (m, 1H), 4.844.77 (m, 1H), 4.66-4.58 (m, 1H), 4.01 - 3.94 (m, 2H), 3.933.87 (m, 1H), 3.65-3.57 (m, 1H), 3.52 - 3.44 (m, 1H), 3.24 3.13 (m, 1H), 2.17-2.07 (m, 1H), 1.94 (s, 9H), 1.68 -1.61 (m, 1H), 1.59 (d, J = 6.6 Hz, 3H) |
A43 | Ν^γει HO.. A 'LÿÀ Il ' z/N k x1 N-X ° MeY j\-NH2 Me 3-({4-[2-(1-aminocyclopropyl)4-fluoro-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]-5chloropyrimidin-2-yl}amino)1,5-anhydro-2,3-dideoxy-Dthreo-pentitol | 461.3 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s, 1H), 8.03-7.82 (m, 1H), 7.57-7.22 (m, 2H), 5.505.24 (m, 1H), 4.99-4.91 (m, 1H), 3.91 - 3.75 (m, 3H), 3.57 - 3.44 (m, 1H), 3.09-2.96 (m, 1H), 2.63 - 2.54 (m, 1H), 2.06 - 1.86 (m, 1H), 1.62 (d, J =7.0 Hz, 6H), 1.56-1.41 (m, 1H), 1.21 - 1.13 (m, 2H), 1.03-0.94 (m, 2H) |
A44 | N^yCI HhA/VV^ HO^xk LiA Il ' //N k S N-X Me—γ VNH I Me Me 1,5-anhydro-3-[(5-chloro-4-{4fluoro-2-[(methylamino)methyl]- 1 -(propan-2-yl)-1 Hbenzimidazol-6-yl}pyrimidin-2yl)amino]-2,3-dideoxy-D-f/7reopentitol | 448.9 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-de) δ 8.41 (s, 1H), 8.05-7.75 (m, 1H), 7.55-7.26 (m, 2H), 5.11 5.01 (m, 1H), 4.99-4.89 (m, 1H), 3.99 (s, 2H), 3.88-3.74 (m, 3H), 3.54-3.46 (m, 1H), 3.06-2.98 (m, 1H), 2.32 (s, 3H), 2.0411.84 (m, 1H), 1.58 (d, J = 7.0 Hz, 6H), 1.53-1.40 (m, 1H) |
194
A45 | ΗΝ^Ν^^^^^ίΑ HO^ AA Il ' //N A> .. .N-\ Me O Me—γ \—(-NH2 Me Me 3-({4-[2-(2-amino-2methylpropyl)-4-fluoro-1(propan-2-yl)-1 H-benzimidazol6-yi]-5-chloropyrimidin-2yl}amino)-1,5-anhydro-2,3dideoxy-D-threo-pentitol | 477.1 [M+H]* (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.57 (s, 1H), 8.30 (s, 1H), 7.79 - 7.70 (m, 1H), 5.14-5.02 (m, 1H), 4.08 - 3.88 (m, 3H), 3.71 3.62 (m, 1H), 3.62-3.58 (m, 1H), 3.54 (s, 2H), 3.52-3.42 (m, 1H), 3.25-3.17 (m, 1H), 2.16-2.02 (m, 1H), 1.82-1.71 (m, 7H), 1.57 (s, 6H) |
A46 | hn n AA il \ /N Me N-/ MeA ) '—NH 1,5-anhydro-3-{[5-chloro-4-(9fluoro-4,4-dimethyI-1,2,3,4tetrahydropyrazino[1,2a]benzimidazol-7-yl)pyrimidin2-yi]amino}-2,3-dideoxy-Dfhreo-pentitol | 447.1 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6 + D2O)5 8.38(s, 1H), 7.96 (brs, 1H), 7.39 (br d, J = 7.8 Hz, 2H), 4.95 (d, J =5.3 Hz, 1H), 4.03 (s, 2H), 3.81 (brdd, J=5.3, 10.8 Hz, 3H), 3.49 (br s, 1H), 3.30 (brt, J = 11.2 Hz, 1H), 3.07 - 2.94 (m, 3H), 1.94 (br s, 1H), 1.60 (s, 6H), 1.49 (brd, J = 9.5 Hz, 1H) |
A47 | ΗΝ^Ν^η/^Α ho. AA Il ' //N k S N—\ N Me^ A O=S=b MeM/ Me *single stereoisomer (3R,fR)-4-({4-[2-(1aminoethy^)-4-fIuoro-1-(propan2-yl)-1 /-/-benzimidazol-6-yl]-5chloropyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol | 526.3 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.43 (s, 1H), 7.92 (brs, 1H), 7.57 - 7.31 (m, 2H), 5.23 (d, J = 4.5 Hz, 1H), 5.15 (td, J = 6.9, 14.0 Hz, 1H), 4.35 (q, J =6.5 Hz, 1H), 3.87-3.75 (m, 1H), 3.61 (br d, J = 8.5 Hz, 2H), 3.50 (brd, J =12.3 Hz, fl H), 2.932.82 (m, 4H), 2.66 (brt, J = 11.0 Hz, 1H), 2.20-2.04 (m, 3H), 1.67 - 1.42 (m, 10H); [a]D 20 = -13.3 (c=0.1 , MeOH) |
195
A48 | Ν^’ JL. HN N Y Y ho^A YY Il ' //N k A N—K N Me^ Λ N o=s=o MeM/ 2 Me ‘single stereoisomer (3R,4R)-4-({4-[2-(1aminoethyl)-4-fluoro-1-(propan2-yl)-1 H-benzimidazol-6-yl]-5chloropyrimidin-2-yl}amino)-1 (methanesulfonyl)piperidin-3-ol | 526.3 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.43 (s, 1H), 8.05-7.87 (m, 1H), 7.59-7.30 (m, 2H), 5.23 (d, J =4.5 Hz, 1H), 5.15 (quin, J = 6.9 Hz, 1 H), 4.35 (q, J = 6.5 Hz, 1H), 3.81 (brd, J =5.8 Hz, 1 H), 3.61 (br d, J = 9.3 Hz, 2H), 3.49 (brd, J =12.3 Hz, 1H), 2.90 (s, 3H), 2.88 - 2.79 (m, 1H), 2.70-2.61 (m, 1H), 2.16 (br s, 3H), 1.63 - 1.47 (m, 10H); [α]ο20 = -18.1 (c=0.1 , MeOH) |
A49 | N^’ JL ^^Y^^x-F hn nYY HOK A L. Y LJ L? (J Me-Y~N« Z\ Me Me nh2 3-({4-[3-(2-aminopropan-2-yl)7-fluoro-2-methyl-2H-indazol-5yl]-5-chloropyrimidin-2yl]amino)-1,5-anhydro-2,3dideoxy-D-fhreo-pentitol | 435.0 [M+H]+ (ESI) | 1H NMR (500 MHz, DMSO-d6) δ 8.53 - 8.26 (m, 2H), 7.61 7.28 (m, 2H), 4.99 - 4.88 (m, 1H), 4.49 (s, 3H), 3.86-3.75 (m, 3H), 3.53-3.43 (m, 1H), 3.07 - 2.99 (m, 1H), 2.03 - 1.89 (m, 1H), 1.72 (s, 6H), 1.571.41 (m, 1H) |
A50 | ΗΝ Ν Υγ HO. A. YY Il ' /N N MeYN~Y,i0H . MeMe (3R,4R)-4-[(5-chloro-4-{4fluoro-2-[(1 R)-1 -hydroxyethyl]1 -(propan-2-ÿl)-1 Hbenzimidazol-6-yI}pyrimidin-2yl)amino]piperidin-3-ol | 448.9 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6, 80 °Ο)δ8.87 (br. s, 1H), 8.64 (br.s, 1H), 8.43 (s, 1H), 7.99 (d, J = 1.3 Hz, 1 H), 7.51 - 7.38 (m, 2H), 5.24 (hept, J= 7.6, |.1 Hz, 1 H), 5.13 (q, J = 6.5 Hz, 1H), 3.38-3.23 (m, 2H), 3.06 -2.95 (m, 1H), 3.05-2.80 (m, 1H), 2.31 -2.19 (m, 1H), 1.82 -1.70 (m, 1H), 1.67 — 1.58 (m, 9H); two protons obscured by solvent peak |
196
A51 | ÎjÇyF HN N y LA Il A ,N LJ Me. N-y 0 MeA ^NH2 3-({4-[1-(1-amino-2- methylpropan-2-yl)-4-fluoro-1 Hbenzimidazol-6-yl]-5chloropyrimidin-2-yl}amino)1,5-anhydro-2,3-dideoxy-Dfhreo-pentitol | 435.0 [M+H]* (ESI) | 1H NMR (500 MHz, DMSO-de) δ 8.35 (s, 1 H), 8.31 (s, 1 H), 8.07 - 7.92 (m, 1 H), 7.52 - 7.30 (m, 1H), 3.88-3.69 (m, 3H), 3.56-3.43 (m, 1H), 3.38-3.21 (m, 1 H), 3.11 -2.96(m,3H), 2.00-1.86 (m, 1H), 1.64 (s, 6H), 1.54- 140 (m, 1H) |
A52 | JOX^f HN Ν γ^ y HCK/A L-Jk Il ' //N < J Me N-ξ Me^Y Me v~nh2 3-({4-[1-(1-amino-2methylpropan-2-yl)-4-fluoro-2methyl-1 H-benzimidazol-6-yl]- 5-chloropyrimidin-2-yl}amino)1,5-anhydro-2,3-dideoxy-Dfbreo-pentitol | 448.9 [M+H]* (ESI) | 1H NMR (400 MHz, D2O) δ 8.50 -8.33 (m, 1H), 8.24-8.13 (m, 1H), 7.78 - 7.64 (m, 1H), 4.03 3.89 (m, 3H), 3.87 - 3.80 (m, 2H), 3.74 - 3.62 (m, 1H), 3.59 3.44 (m, 1H), 3.30-3.20 (m, 1H), 3.15-2.97 (m, 3H), 2.121.97 (m, 7H), 1.77-1.55 (m, 1H) |
A53 | ï T ΗΟκΑ LA Il ' //N k S N-X O Me-γ ^Νύ Me Me ' 3-[(4-{2-[(1 S)-1-aminoethyl]-4- fluoro-1-(propan-2-yl)-1 Hbenzimidazol-6-yl}-5- : chloropyrimidin-2-yl)amino]-1,5anhydro-2,3-dideoxy-D-fbreopentitol | 448.9 [M+H]* (ESI) | 1H NMR (600MHz, DMSO-d6) δ 8.41 (s, 1H), 8.07-7.87 (m, 1H), 7.54 - 7.25 (m, 2H), 5.15 5.00 (m, 1H), 4.97-4.85 (m, 1H), 4.61-4.46 (m, 1 H), 3.873.75 (m, 3H), 3.59 - 3.48 (m, 1H), 3.07 - 2.98 (m, 1H), 2.03 1.89 (m, 1H), 1.60 (d, J = 6.6 Hz, 6H), 1.55-1.45 (m, 4H) |
197
A54 | N^C' ΗΝ^Ν^Α^ψF HC^A^ AA Il ' //N k S N—x O Me^ ~VNH2 Me 3-({4-[2-(aminomethyl)-4-fluoro1-(propan-2-yl)-1Hbenzimidazol-6-yl]-5chloropyrimidin-2-yl}amino)1,5-anhydro-2,3-dideoxy-Dtereo-pentitol | 435.1 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) at 80oC δ = 8.40 (s, 1 H), 8.10 7.98 (m, 1H), 7.48 (brd, J = 11.0 Hz, 1 H), 7.21-7.11 (m, 1H), 4.89 (m, 1H), 4.73 (m, 1H), 4.36 (m, 2H), 3.84 (m, 4H), 3.66-3.50 (m, 1H), 3.35 (m, 2H), 3.11 (m, 1H), 2.141.99(m, 1H), 1.73- 1.49 (m, 7H) |
A55 | HN N |< HO—Â AA Il \ ,N LA N-4 o Me—4 \ NH first eluting stereoisomer 1,5-anhydro-3-{[5-chloro-4-(9fluoro-4-methyl-1,2,3,4tetrahydropyrazino[1,2a]benzimidazoI-7-yl)pyrimidin2-yl]amino}-2,3-dideoxy-Dfhreo-pentitol | 433.1 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.42 (s, 1H), 7.83 (brs, 1H), 7.58 - 7.31 (m, 2H), 4.95 (d, J = 5.3 Hz, 1H), 4.58 (brs, 1H), 4.20 - 4.02 (m, 2H), 3.90 - 3.76 (m, 3H), 3.51 (brd, J =5.3 Hz, 2H), 3.30 - 3.24 (m, 1H), 3.12 2.99 (m, 2H), 1.95 (brd, J = 12.0 Hz, 1H), 1.50 (d, J =6.5 Hz, 4H); [a]D 20 = 27.7 (c=0.13 , MeOH) |
A56 | riA HN N HO^zk AA Il \ ,N LA N-4 0 Me—4 ‘second eluting NH stereoisomer 1,5-anhydro-3-{[5-chloro-4-(9fluoro-4-methyl-1,2,3,4— tetrahydropyrazino[1,2- a]benzimidazoi-7-yl)pyrimidin2-yi]amino}-2,3-dideoxy-Dfhreo-pentitol | 433.2 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.47 - 8.34 (m, 1H), 7.82 (br s, 1H), 7.62-7.32 (m, 2H), 4.94 (d, J = 5.3 Hz, 1 H),.4.57 (brs, 1H), 4.17-4.00 (m, 2H), 3.82 (brdd, J = 4.9,10.7 Hz, 3H), 3.50 (br s, 2H), 3.29 - 3.21 (m, 1H), 3.09- 2.97 (m, 2H), 1.97 (brs, 1 H), 1.58-1.41 (m, 4H); [a]D 20 = 48.2 (c=0.13 , MeOH) |
198
A57 | Ν^’ A HN N^rfY AA Il ' //N F\ k fi N-X >—F 0 Me— ‘second eluting Me nh2 stereoisomer 3-({4-[2-(2-amino-3,3difluoropropyl)-4-fluoro-1(propan-2-yl)-1 H-benzimidazol6-yl]-5-chloropyrimidin-2yl}amino)-1,5-anhydro-2,3dideoxy-D-fhreo-pentitol | 499.4 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.41 (s, 1H), 8.08-7.80 (m, 1H), 7.57 - 7.28 (m, 2H), 6.26 5.80 (m, 1H), 5.01 -4.78 (m, 2H), 3.91 - 3.73 (m, 3H), 3.60 3.44 (m, 2H), 3.22 - 3.11 (m, 1 H), 3.08 - 2.89 (m, 2H), 2.04 1.80 (m, 3H), 1.66- 1.55 (m, 6H), 1.53-1.44 (m, 1H) |
A58 | N^YCI A hn Ν γ y AA Il ' //N F\ k fi N-X )— F O Me-γ \ ‘first eluting Me nh2 stereoisomer 3-({4-[2-(2-amino-3,3difluoropropyl)-4-fluoro-1(propan-2-yl)-1 H-benzimidazol6-yl]-5-chloropyrimidin-2yl}amino)-1,5-anhydro-2,3dideoxy-D-frireo-pentitol | 499.0 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-cfe) 5 8.42 (s, 1H), 7.98 (brs, 1H), 7.56 - 7.17 (m, 2H), 6.21 (td, J = 55.6, 3.2 Hz, 1H), 4.91 (dq, J = 20.7, 6.9, 6.1 Hz, 2H), 3.98 3.69 (m, 4H), 3.51 (s, 1H), 3.30 -3.26 (m, 1H), 3.21-2.89 (m, 2H), 1.97 (brs, 1H), 1.60 (dd, J = 6.9, 3.5 Hz, 6H), 1.57-1.45 (m, 1H) |
A59 I I | A HN N AA Il ' //N k fi N-X γΎ o Me-γ \ 1 > Me h2n 3-[(4-{2-[(1aminocyclopentyl)methyl]-4fluoro-1-(propan-2-yl)-1Hbenzimidazol-6-yl}-5chloropyrimidin-2-yI)amino]-1,5anhydro-2,3-dideoxy-D-fhreopentitol | 503.1 [M+H]* (ESI) | 1H NMR (400 MHz, CD3OD) 5 Έ.34 (s, 1H), 8.05 (s, 1H), 7.49 (d, J = 11.5 Hz, 1H), 5.07 -4.91 , (m,· 1 H), 4.03 - 3.85 (m, 3H), ! 3.62 (s, 1 H), 3.53-3.43 (m, 1H), 3.26 - 3.14 (m, 3H), 2.19 - 2.10 (m, 1 H), 1.92-1 78 (m, 4H), 1.77 -1.56 (m, 11 H) |
199
Example A60 (Scheme A-4): Préparation of 1,5-anhyd ro-3-[(4-{1-tert-butyl-4-fluoro-2-[(1R)1-hydroxyethyl]-1H-benzimidazol-6-yI}-5-chloropyrimidin-2-yI)amino]-2,3-dideoxy-Dthreo-pentito!
Scheme A-4 . .
Example A60
To a solution of 1,5-anhydro-3-[(4-{1-fert-butyl-2-[(1R)-1-{[tertbutyl(dimethyl)silyI]oxy}ethyl]-4-fluoro-1H-benzimidazol-6-yl}-5-chloropyrimidin-2-yl)amino]-2,3dideoxy-D-threo-pentitol (A-5) (Prepared as in Example A1,70.0 mg, 0.121 mmol) in MeOH (1.0 mL) was added HCl (4.0 N in 1,4-dioxane, 3.0 mL) dropwise at 0 °C. The solution was stirred at 30 °C for 4 h. TLC analysis showed consumption of the starting material. The solution was basified with NH4OH to pH ~9 and then concentrated to dryness. The residue was purified by préparative HPLC on a Boston Uni C-18 column (40x150 mm, 5 pm particle size), which was eluted with 13-53% MeCN/H2O (+0.05% HCl) with a flow rate of 60 mL/min. The material was repurified by préparative HPLC on a DuraShell column (150x25 mm, 5 pm particle size), which was eluted with 27-47% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide 1,5anhydro-3-[(4-{1 -tert-butyI-4-fluoro-2-[(1 R)-1 -hydroxyethyl]-1 H-benzimidazol-6-yl}-5chloropyrimidin-2-yl)amino]-2,3-dideoxy-D-threo-pentitol (Example A60) (4.2 mg, 8% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s, 1H), 8.04 (br s, 1H), 7.54 - 7.32 (m, 1H), 5.53 (d, J = 7.9 Hz, 1H), 5.28 - 5.20 (m, 1H), 4.95 (d, J = 5.3 Hz, 1H), 3.86 - 3.76 (m, 3H), 3.50 (brd, J = 1.2 Hz, 1H), 3.03 (brt, J =10.3 Hz, 1H), 2.07 (s, 1H), 2.01 -1.91 (m, 1H), 1.88 (s, 9H), 1.67 (d, J = 6.^ Hz, 3H), 1.56 -1.44 (m, 1H); one proton obscured bj| solvent peak; m/z (ESI+) for (C22H27CIFN5O3), 464.1 (M+H)+.
The examples in the below table were synthesized according to the methods used for the synthesis of 1,5-anhydro-3-[(4-{1-tert-butyl-4-fIuoro-2-[(1 R)-1-hydroxyethyl]-1 /7-benzimidazol-6yl}-5-chloropyrimidin-2-yl)amino]-2,3-dideoxy-D-f/7reo-pentitol (Example A60) (Scheme A-4). The following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Example number | Structure/Name | LCMS | NMR |
200
A61 | N-yCI HN^AyJ HO^ LA k A N-X θ Μθχ A^oh Me Me Me 1,5-anhydro-3-[(4-{1-tert-butyl4-fluoro-2-[(1S)-1hydroxyethyl]-1 /7-benzimidazol6-yl}-5-chloropyrimidin-2yl)amino]-2,3-dideoxy-D-threopentitol | 464.1 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.34 (s, 1H), 8.19 (s, 1H), 7.48 (d, J=11.3 Hz, 1H), 5.46 (q, J = 6.4 Hz, 1H), 4.02-3.87 (m, 3H), 3.66 - 3.57 (m, 1 H), 3.48 (td, J=11.7, 2.3 Hz, 1H), 3.24 -3.16(m, 1H), 2.18-2.09 (m, 1H), 1.97 (s, 9H), 1.76 (d, J = 6.4 Hz, 3H), 1.70-1.57 (m, 1H) |
A62 | nY<ci HN^N^AfHL F Il \ ,N LJ ή-4 N )OH O=S=O Me Μβ Me (3R,4R)-4-[(4-{1 -tert-butyl-4fluoro-2-[(1 R)-1 -hydroxy ethyl] - 1 H-benzimidazol-6-yl}-5chloropyrimidin-2-yl)amino]-1(methanesuIfonyi)piperidin-3-ol | 541.0 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-cfe) δ 8.42 (s, 1H), 8.26-7.97 (m, 1H), 7.44 (d, J =53.2 Hz, 2H), 5.53 (d, J = 7.8 Hz, 1H), 5.29 5.21 (m, 2H), 3.80 (s, 1H), 3.60 (d,2H), 3.48 (d, J =12.0 Hz, 1H), 2.93-2.78 (m, 4H), 2.71 -2.60 (m, 1H), 2.07-1.96 (m, 1 H), 1.88 (s, 9H), 1.67 (d, J = 6.2 Hz, 3H), 1.53 (d, J =12.2 Hz, 1H) |
A63 | N^H' JL F HN N ]|^Y LA Il ' „N A AL - . A ^OH 1,5-annydro-3-({5-chloro-4-[4fluoro-2-(hydroxymethyl)-1 -(1 methylcyclopropyl)-1 HbenzimWazol-6-yl]pyrimidin-2yl}amino)-2,3-dideoxy-D-tereopentitol | 447.9 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.58 (s, 1H), 8.35 (d, J =1.1 Hz, 1H), 7.97 (d, J = 11.0 Hz, 1H), 5.29 (s, 2η, 4.07-3.92 (m, 3H), 3.67 (td, J =9.6, 4.9 Hz, 1H), 3.54 - 3.44 (m, 1H), 3.28-3.19 (m,i1 H), 2.162.08 (m, 1H), 1.82-1.70 (m, 4H), 1.49 (s, 2H), 1.36 (s, 2H) |
201
A64 | ΗΝ Ν ψ^>< HO^A. Il ' //N ° ( k_OH ΜΛΜβ 1,5-anhydro-3-({5-chIoro-4-[4fluoro-1 -(2-fluoro-2methylpropyl)-2(hydroxymethyl)-l Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-2,3-dideoxy-D-f/7reopentitol | 468.2 [M+H]+ (ESI) | 1H NMR (600 MHz, DMSO-de) 5 8.42 (s, 1H), 7.91 (brs, 1H), 7.42 (br s, 2H), 5.72 (t, J = 6.0 Hz, 1H), 4.91 (dd, J=5.4,1.3 Hz, 1 H), 4.79 (d, J =6.0 Hz, 2H), 4.63 (d, J = 22.6 Hz, 2H), 3.82 (qt, J = 10.8, 6.4 Hz, 3H), 3.56 - 3.47 (m, 1H), 3.04 (t, J = 10.4 Hz, 1H), 1.98 (brs, 1H), 1.50 (qd, J= 12.0, 4.5 Hz, 2H), 1.39 (s, 3H), 1.35 (s, 3H) |
A65 | ΝΎγ oXo EÎ Ah Me (3R,4R)-4-({5-chloro-4-[1cyclobutyl-4-fluoro-2(hydroxymethyl)-l Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-1(methanesulfonyl)piperidin-3-ol | 524.9 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.47 (s, 1H), 8.18 (brs, 1H), 7.61 (br s, 2H), 5.25 (td, J = 8.9,17.6 Hz, 1H), 4.87 (s, 2H), 3.81 (brs, 1H), 3.61 (brd, J = 10.3 Hz, 2H), 3.49 (brd, J = 12.1 Hz, 1H), 2.90 (s, 3H), 2.85 (brt, J =9.8 Hz, 3H), 2.71 2.54 (m, 3H), 2.13-1.84 (m, 3H), 1.55 (brs, 1H) |
A66 | N-VCI JL HN N Tl ' //N F? F 1,5-anhydro-3-({5-chloro-4-[1(3,3-difIuorocyclobutyl)-4fluoro-2-(hydroxymethyl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-2,3-dideoxy-D-threopentitol | 483.9 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-cfe) 5 8.46 (s, 1H), 7.99 (brs,|lH), 7.77 - 7.37 (m, 2H), 5.30 (br d, J =3.7 Hz, 1H), 4.86 (s, 2H), 3.92 - 3.74 (m, 3H), 3.64 J 3.43 (m, 3H), 3.43 - 3.25 (m, 3H), 3.04 (t, J = 10.4 Hz, 1H), 2.161.86 (m, 1H), 1.61-1.39 (m, 1H) |
202
Example A67 (Scheme A-5): Préparation of 1,5-anhydro-3-({5-chloro-4-[1-(2,2difluoroethyl)-4-fluoro-2-(2-hydroxypropan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2yI}amino)-2,3-dideoxy-D-threo-pentitoI
Scheme A-5
TBAF
THF
21% yield
Example A67
To a yellow solution of 1,5-anhydro-3-({5-chloro-4-[1-(2,2-difluoroethyl)-4-fluoro-2-(2hydroxypropan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-fhreo-pentitol (A-6) (Prepared as in Example A1,200 mg, 0.33 mmol) in THF (10.0 mL) was added TBAF (174 mg, 0.67 mmol) at room température. The mixture was stirred for 2 h, at which time LCMS analysis indicated complété consumption of starting material with formation ofthe desired product mass. The reaction was concentrated. The residue was taken up in EtOAc (50 mL), washed with H2O (2x50 mL) and brine (50 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by préparative HPLC on a DuraShell column (150x25 mm, 5 pm particle size), which was eluted with 26-46% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide 1,5-anhydro-3-({5-chloro-4-[1 -(2,2-difluoroethyl)-4-fluoro-2-(2-hydroxypropan-2-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-f/7reo-pentitol (Example A67) (34.2 mg, 21% yield) as a white solid. 1H NMR (500 MHz, DMSO-d6) δ 8.42 (s, 1H), 7.88 (s, 1H), 7.56 7.34 (m, 2H), 6.41 (tt, J = 55.9, 4.3 Hz, 1H), 5.98 (s, 1H), 5.04 (td, J = 14.0, 4.2 Hz, 2H), 4.93 (d, J=5.4Hz, 1 H)r 3.88 - 3.74 (m,3H), 3.55 - 3.46 (m,1 H), 3.03 (t,J =10.4 Hz,' 1 H), 2.04-1.83 (m, 1H), 1.68 (d, J= 1.8 Hz, 6H), 1.56 - j.42 (m, 1 H); one proton obscured by solvent peak; m/z\ (ESI+) for (C21H23CIF3N5O3), 486.0 (M+H)+.
The example in the below table Was synthesized according to the methods used for the' synthesis of 1,5-anhydro-3-({5-chloro-4-[1 -(2,2-difluoroethyl)-4-fluoro-2-(2-hydroxypropan-2-yl)1 H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-fhreo-pentitol (Example A67) (Scheme A-5). The following example was synthesized with non-critical changes or substitutions to the exemplified procédures that someone who is skilled in the art would be able to realize.
Example number | Structure/Name | LCMS | NMR |
203
A68 | JOC^f HN N HO.X JA Il ' z/N k S N-K O Me—y -y0H Me MeMe . 1,5-anhydro-2,3-dideoxy-3-({5fluoro-4-[4-fluoro-2-(2- hydroxypropan-2-yl)-1 -(propan2-yl)-1H-benzimidazol-6yl]pyrimidin-2-yl}amino)-Dfhreo-pentitol | 448.2 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-de) 5 8.43 (d, J = 4.0 Hz, 1H), 8.21 (s, 1H), 7.62 (d, J= 12.1 Hz, 1H), 7.19 (d, J =7.6 Hz, 1H), 5.92 - 5.70 (m, 2H), 4.96 (s, 1H), 3.91-3.73 (m, 3H), 3.62 -3.46 (m, 1H), 3.13-2.99 (m, 1H), 2.14-1.96 (m, 1 H), 1.67 (s, 6H), 1.65-1.44 (m, 7H); one proton obscured by solvent peak |
Example A69 (Scheme A-6): Préparation of (3R,4R)-4-({5-chloro-4-[2-(difIuoromethyl)-4fluoro-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl)amino)-15 (methanesulfonyl)piperidin-3-ol
Scheme A-6:
lnt-69
Pd(OAc)2, rac-BINAP Cs2CO3
THF, 80 C, MW
47% yield
To a solution of 6-(2,5-dichloropyrimidin-4-yl)-2-(difluoromethyl)-1-(propan-2-yI)-1H10 benzimidazole (A-7) (prepared as in Example A1,49.6 mg, 0.132 mmol) in THF (1.32 mL) were | added (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (lnt-69) (38.5 mg, 0.198 mmol), CS2CO3 (129 mg, 0.397 mmol), Pd(OAc)2 (6 mg, 0.0264 mmol), and rac-BINAP (17 mg, 0.0264 mmol). The mixture was sparged with N2 for 10 min and then stirred for 105 min at 80 °C with microwave irradiation. LCMS analysis indicated complété consumption of the starting material 15 with formation of the desired product mass. The reaction was diluted with MeOH and then filtered through a filter dise (0.2 pm). The material was purified by préparative SFC on a Nacalai Cosmosil 3-hydroxyphenyl-bonded column (150x20 mm), which was eluted with 12-23% MeOH/CO2 with
204 a flow rate of 85 mL/min to provide (3R,4R)-4-({5-chloro-4-[2-(difluoromethyl)-4-fluoro-1-(propan2-y I )-1 H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1 -(methanesulfonyl)piperidin-3-ol (Example A69) (33.1 mg, 47% yield) as a solid. 1H NMR (400 MHz, DMSO-cfe, 80 °C) δ = 8.43 (s, 1H), 8.10 (d, J = 1.0 Hz, 1H), 7.57- 7.23 (m, 3H), 5.14-5.02 (m, 1H), 4.97 (br. s., 1H), 3.90 -3.75 (m, 2H), 3.73 - 3.63 (m, 2H), 3.55 (d, J = 13.1 Hz, 1H), 2.89 - 2.86 (s, 3H), 2.78 - 2.66 (m, 1H), 2.18 - 2.08 (m, 1H), 1.68 (d, J = 6.8 Hz, 6H), 1.63-1.59 (m, 1H); m/z (APCI) for (C21H24CIF3N6O3S), 533.0 (M+H)+.
Example A70 (Scheme A-7): Préparation of (3R,4R)-4-({5-ethyl-4-[4-fluoro-2-methyl-1(propan-2-yl)-1H-benzimidazol-6-yI]pyrimidin-2-yI}amino)-1-(methanesuIfonyl)piperidin-3ol
Scheme A-7:
A solution of 6-(2-chloro-5-ethylpyrimidin-4-yl)-4-fluoro-2-methyl-1-(propan-2-yl)-1Hbenzimidazole (A-8) (prepared as in Example A1, 80.0 mg, 0.240 mmol) in 2-methyI-2-butanoI (6 mL) was treated with CS2CO3 (157 mg, 0.481 mmol) and (3R,4R)-4-amino-1(methanesulfonyl)piperidin-3-ol (lnt-69) (60.7 mg, 0.312 mmol) and sparged with N2. Chloro-2(dimethylaminomethyl)-ferrocen-1-yl-(dinorbomylphosphine)palladium (SK-CC02-A) (14.6 mg, 0.024 mmol) was added and the mixture again sparged with N2. The reaction mixture was stirred at 120 °C for 16 h. The crude mixture was combined with a second reaction run in analogous fashion on a 30 mg scale and concentrated. The residue was partitioned between water (30 mL) and EtOAc (30 mL). The aqueous phase was extracted with EtOAc (30 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated. The crude residue was purified in two stages, first by préparative TLC (SiO2,10:1 DCM/MeOH, RpO.5) and then by préparative HPLC with ah Xbridge column (150x30mm, 10 pm particle size, column température 25 °C), which was eluted with 15-55% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide (3R,4R)-4-({5-ethyl-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H19876 — 205 benzimidazol-6-yl]pyrimidin-2-yl)amino)-1-(methanesulfonyl)piperidin-3-ol (Example A70) (25.4 mg, 22% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.27 (s, 1H), 7.60 (s, 1H), 7.12 (br d, J= 11.5 Hz, 1H), 6.99 (br d, J = 7.5 Hz, 1H), 5.24 (d, J = 4.3 Hz, 1 H), 4.84 - 4.75 (m, 1H), 3.81-3.74 (m, 1 H), 3.65-3.55 (m, 2H), 3.49-3.44 (m, 1H), 2.89 (s, 3H), 2.87-2.81 (m, 1H), 2.71
- 2.64 (m, 1H), 2.61 (s, 3H), 2.59 - 2.54 (m, 2H), 2.12 - 2.04 (m, 1H), 1.57 (d, J = 6.8 Hz, 6H),
1.54 - 1.45 (m, J = 10.0 Hz, 1H), 1.04 (t, J = 7.5 Hz, 3H); m/z (ESI+) for (C23H31FN6O3S), 491.1 (M+H)+.
The examples in the below table were synthesized according to the methods used for the synthesis of (3R,4R)-4-({5-chloro-4-[2-(difluoromethyl)-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-6-yl]pyrimidin-2-yl}amino)-1-(methanesuIfonyl)piperidin-3-ol (Example A70) (Scheme A-6) and (3R,4R)-4-({5-ethyl-4-[4-fluoro-2-methyI-1-(propan-2-yl)-1H-benzimidazol-6yI]pyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol (Example A65) (Scheme A-7). The following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Example number | Structure/Name | LCMS | NMR |
A71 | N^1 A -^L^s-F AA k J N-/ ΕΥ \_Me O-S-O Q_J Me (3R,4R)-4-({5-chloro-4-[2-ethyl4-fluoro-1 -(oxetan-3-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-1(methanesulfonyl)piperidin-3-ol | 525.1 [M+H]+ (ESI) | 1H NMR (700 MHz, DMSO-d6) δ 8.73-8.18 (m, 2H), 7.836.97 (m, 2H), 5.75 (ddd, J = 13.2, 7.7, 5.4 Hz, 1H), 5.195.08 (m, 2H), 5.07-4.89 (m, 2H), 3.79 (s, 1H), 3.67-3.59 (m, 5H), 2.94-2.87 (m,5H), 2.86 —12.79 (m, 1 H), 2.64 (t, J = 10.3 Hz, 1H), 1.57-1.44 (m, 1H), 1.30 (t, J =7.5 Hz, 3H) |
A72 | jLTC' xk x^ ^F H N HO-xk AA Il ' //N o=s=o Me Me (3R,4R)-4-{[5-chloro-4-(1- cyclopropyl-4-fluoro-2-methyl- | 495.1 [M+H]+ (ESI) | 1H NMR (600 MHz, DMSO-d6) δ 7.96 (s, 1H) 7.30-7.57 (m, 1H) 6.99-7.11 (m, 1H) 6.896.98 (m, 1H) 4.74 (d, J = 4.59 Hz, 1 H) 3.30 - 3.38 (m, 1 H) 3.15 (d, J = 10.64 Hz, 2H) 3.04 (d, J = 12.10 Hz, 2H) 2.44 (s, |
206
1 H-benzimidazol-6-yl)pyrimidin2-yl]amino}-1(methanesuIfonyl)piperidin-3-ol | - | 3H)2.41 (d, J =2.38 Hz, 1H) 2.21 (s, 1H)2.18(s, 3H)1.01 1.15 (m, 1H) 0.72-0.82 (m, 3H) 0.56 - 0.64 (m, 2H) | |
A73 | HN N HO. AA Il \ ,N L J n-4 N Me—/ i *\ Me o=s=o p Me O Me ‘first eluting stereoisomer (3R,4R)-4-({5-chloro-4-[4fluoro-1-(1-methoxypropan-2yl)-2-methyl-1 H-benzimidazol6-yl]pyrimidin-2-yl)amino)-1(methanesulfonyl)piperidin-3-ol | 527.5 [M+H]+ (APCI) | 1H NMR (400 MHz, DMSO-d6) 5 8.39 (s, 1H), 7.93 (d, J =1.3 Hz, 1H), 7.40 (dd, J =11.8,1.3 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1 H), 4.98 (d, J = 4.6 Hz, 1 H), 4.84 (ddd, J = 8.4, 7.0, 4.7 Hz, 1H), 3.90 (dd, J =10.5, 8.5 Hz, 1H), 3.82 (ddd, J =12.3, 6.1, 4.3 Hz, 1H), 3.73 (dd, J =10.5, 4.8 Hz, 1H), 3.70-3.64 (m, 1H), 3.59-3.48 (m, 1H), 3.22 (s, 3H), 2.92 (dd, J =10.4, 2.0 Hz, 1H), 2.89 (s, 3H), 2.772.68 (m, 1H), 2.62 (s, 3H), 2.18 -2.08 (m, 1H), 1.68-1.50 (m, 5H); [ah22 = +42.1° (c=0.1, MeOH) |
A74 | da HN ho. AA Il ' /N Sr Me— i Λ Me | O=S=O y Me O Me ‘second eluting j stereoisomer (3R,4/?)-4-({5-chloro-4-[4fluoro-1-(1-methoxypropan-2yl)-2-methyl-1 H-benzimidazol6-yl]pyrimidin-2-yl)amino)-1(methanesulfonyl)piperidin-3-ol | 527.5 [M+H]+ (APCI) | 1H NMR (400 MHz, DMSO-d6) 5 8.39 (s, 1H), 7.93 (d, J= 1.4 Hz, 1H), 7.39 (dd, J = 11.8,1.3 Hz, 1H), 7.16 (d, J = 7.7 Hz, 1H), 4.97 (s, 1H), 4.91-4.73 (m, 1H), 3.89 (^d, J =10.5, 8.5 Hz, 1H), 3.82 (ddd, J= 9.3, 7.9, 4.5 Hz, 1H), 3.72 (dd, J= 10.5, 4.8 Hz, 1H), 3.70 — 3.63 (m, 1 H), 3.58 - 3.52 (m, 1 H), 3.22 (s, 3H), 2.94-2.89 (m, 1H), 2.89 (s, 3H), 2.77 - 2.68 (m, 1H), 2.62 (s, 3H), 2.16-2.08 (m, 1H), 1.60 (d, J =7.1 Hz, 5H) |
207
A75 | HO^xk T 1 · Lu N . .. . kx1 N-K N Me-γ O-S-O Me Me Me (3R,4R)-4-({5-chloro-4-[4fluoro-2-(methoxymethyl)-1 (propan-2-yl)-1 H-benzimidazol6-yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol | 527.1 [M+H]* (APCI) | 1H NMR (400 MHz, DMSO-d6) δ 8.40 (s, 1 H), 8.00 (d, J = 0.98 Hz, 1H), 7.38- 7.51 (m, 1H), 7.12 - 7.23 (m, 1 H), 4.96 (s, 2H), 4.76 (s, 2H), 3.75 - 3.89 (m, 1H), 3.67 (s, 2H), 3.473.58 (m, 1H), 3.37 (s, 3H), 2.89 -2.94 (m, 1H), 2.88 (s, 3H), 2.65 - 2.77 (m, 1H), 2.07 - 2.17 (m, 1H), 1.63 (d, J =6.97 Hz, 6H), 1.57-1.48 (m, 1H). |
A76 | n^ JL Y HN HO»_xk YY Il ' //N k A N-K N Me—/ i \ Me O-S-O Me Me (3R,4R)-4-({5-fluoro-4-[2methyl-1-(propan-2-yl)-1Hbenzimidazol-6-yl]pyrimidin-2yl)amino)-1(methanesulfonyl)piperidin-3-ol | 463.4 [M+H]* (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.40 (s, 1H), 8.28 (d, J =4.2 Hz, 1H), 7.99 (dt, J =8.5, 1.4 Hz, 1H), 7.65 (d, J =8.6 Hz, 1H), 3.95-3.66 (m, 4H), 2.98 (td, J= 11.8, 2.8 Hz, 1H), 2.91 (s,3H), 2.78 (dd, J=11.5, 9.1 Hz, 1H), 2.67 (s, 3H), 2.362.24 (m, 1H), 1.80-1.64 (m, 7H); one proton obscured by solvent peak |
A77 | n-Vf JL Y HN Ν'ηΥΥ HO. A L Y Il \ ,N k J N— N Me—/ O=S=Ol Μβ^θ Me 1 (3R,4R)-4-{[4-(1 -tert-butyl-1Hbenzimidazol-6-yl)-5fluoropyrimidin-2-yl]amino}-1(methanesulfonyl)piperidin-3-ol | 463.3 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.47 - 8.34 (m, 3H), 7.91 7.83 (m, 1H), 7.82-7.75 (m, 1H), 7.18 (brd, J = 7.7 Hz, 1H), 5.22 (d, J =4.4 Hz, 1H)I,3.823.46 (m, 4H), 2.95 - 2.80 (m, 4H), 2.69-2.65 (m, 1H), 2.182.02 (m, 1H), 1.75 (s, 9H), 1.63 -1.44(m, 1H) 1 |
208
A78 | JL JL . . HN nJAi . HO^A^ LA Il ' //N k J N-X N Me-/ i .. Z\ Me O=S=O Me Me Me (3R,4R)-4-{[4-(1 -tert-butyl-2methyl-1 H-benzimidazol-6-yl)5-fluoropyrimidin-2-yI]amino}-1(methanesulfonyl)piperidin-3-ol | 476.8 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.57 - 8.26 (m, 2H), 7.82 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1 H), 7.16 (d, J = 7.7 Hz, T 1H), 5.24 (d, J = 4.5 Hz, 1H), 3.84-3.72 (m, 1H), 3.723.59 (m, 2H), 3.52 (d, J= 12.0 Hz, 1H), 2.92 (s, 3H), 2.902.81 (m, 1 H), 2.78 (s, 3H), 2.71 -2.60 (m, 1H), 2.19-2.05 (m, 1H), 1.84 (s, 9H), 1.55 (q, J = 11.5 Hz, 1H) |
A79 | N^yF HO., LA L ,J n-4 N Me—/ _ i \ Me O-S-O Me Me (3R,4R)-4-({4-[2,4-dimethyl-1 - (propan-2-yl)-1 H-benzimidazol6-yl]-5-fIuoropyrimidin-2yl}amino)-1- (methanesuIfonyl)piperidin-3-ol | 476.9 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-cfe) 6 8.38 (d, J = 4.0 Hz, 1 H), 8.08 (s, 1H), 7.64 (q, J =1.2 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1H), 5.23 (d, J = 4.5 Hz, 1H), 4.78 (hept, J =6.8 Hz, 1H), 3.833.71 (m, 1H), 3.70-3.56 (m, 2H), 3.55-3.46 (m, 1H), 2.96 - 2.82 (m, 4H), 2.71 - 2.64 (m, 1H), 2.60 (s, 3H), 2.54 (s, 3H), 2.09 (d, J =13.7 Hz, 1 H), 1.64 -1.48 (m,7H) |
A80 | hoa â. LA l J L'N Y Me N ΜθΆ / O—/ 1,5-anhydro-2,3-dideoxy-3-{[5fluoro-4-(7-fluoro-1,1-dimethyI3,4-dihydro-1H[1,4]oxazino[4,3-b]indazol-9yl)pyrimidin-2-yl]amino}-Dfhreo-pentitol | 432.1 [M+H]* (ESI) | 1H NMR (500 MHz, DMSO-d6) δ 8.42 (d, J = 4.0 Hz, 1 H), 8.22 (s, 1H), 7.67 (d, J =13.1 Hz, 1 H), 7.20 (br d, J = 7.8 Hz, 1 H), 4.95 (d, J = 5.3 Hz, 1H), 4.45 (t, J = 5.0 Hz, 2H), 4.22 (t, J = 5.0 Hz, 2H), 3.87 - 3.75 (m, 3H), 3.56 - 3.45 (m, 1H), 3.06 (t, J = 10.4 Hz,1H), 2.00 (br d, J = 9.6 Hz, 1 H), 1.70 (s, 6H), 1.551.42 (m,1H) |
209
A81 | Me N^Y^Me - HO^Â. AA Il \ ,N k J N-^ N Me—/ i \ Me O-S-O Me Me (3R,4R)-4-({4-[4-fluoro-2methyl-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]-5-(propan-2yl)pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol | 504.9 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.41 (s, 1H), 7.50 (s, 1H), 7.10 - 6.95 (m, 2H), 5.23J[d, J = 4.3 Hz, 1 H), 4.86-4.73 (m, 1H), 3.77 (brs, 1H), 3.67-3.54 (m, 2H), 3.50 - 3.39 (m, 2H), 2.99 - 2.81 (m, 5H), 2.71 - 2.60 (m, 4H), 2.14 -2.03 (m, 1H), 1.56 (d, J = 6.8 Hz, 6H), 1.45 1.25 (m, 6H) |
A82 | Me nV A -îA/^^F hn n || ηΑ HO^A AA Il ' //N k fi N—X N Me—/ i \ Me O-S-0 Me Me (3R,4R)-4-({4-[4-fluoro-2methyl-1-(propan-2-yl)-1Hbenzimidazol-6-yl]-5methoxypyrimidin-2-yl)amino)1 -(methanesulfonyl)piperidin-3ol | 493.1 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.30 (s, 1H), 8.25 (s, 1H), 7.70 (d, J =12.6 Hz, 1H), 6.80 (d, J =7.5 Hz, 1H), 5.24 (d, J = 4.5 Hz, 1H), 4.88-4.73 (m, 1H), 3.83 (s, 3H), 3.74 (m, 2H), 3.69 - 3.57 (m, 2H), 2.96 2.83 (m, 4H), 2.73 - 2.65 (m, 1H), 2.61 (s, 3H), 2.12 (d, J = 13.2 Hz, 1H), 1.66-1.46 (m, 7H) |
A83 | N^VMe A HN N T| HO«_^\ AA Il \ ,n k fi N-# I V Me^ Ae । O=S=O Me Me (3R,4R)-4-({4-[4-fluoro-2methyl-1-(propan-2-yI)-1H- ! benzimidazol-6-yl]-5methylpyrimidin-2-yl}amino)-1 (methanesulfonyl)piperidin-3-ol | 477.1 [M+H]* (ESI) | 1H NMR (400 MHz, CD3OD) 5 8.22 (s, 1 H), 7.70 (d, J =1.3 Hz, 1H), 7.24 (dd,J= 11.4,1.2 Hz, 1H), 3.93-3.78 (m, 2H), 3.75 - 3.62 (m, 2H), 2.87 (s, 4H), 2.77 - 2.64 (m, 4H), 2.25 (m, 4H), 1.72-1.60 (m, 7H); one proton obscured by solvent peak ...... |
210
A84 | • jOrcl HN HCL· Il \ „N N Me—/N~N' O=S=O Me Me (3R,4R)-4-({5-chloro-4-[1(propan-2-yl)-1 H-benzotriazol6-yl]pyrimidin-2-yI}amino)-1(methanesulfonyl)piperidin-3-ol | 456.8 [M+H]* (ESI) | 1H NMR (600 MHz, DMSO-d6) δ 8.47 (s, 1H), 8.25 (b s, 1H), 8.15 (d, J = 8.6 Hz, 1H), 7.72 7.68 (m, 1H), 7.53 (bfs/IH), 5.29 (hept, J =6.7 Hz, 1H), 5.21 (m, 1H), 3.80 (b s, 1H), 3.65 - 3.57 (m, 2H), 3.52 3.46 (m, 1 H), 2.91-2.84 (m, 4H), 2.66 (t, J = 10.3 Hz, 1H), 2.10-2.01 (m, 1H), 1.66 (d, J = 6.7 Hz, 6H), 1.58-1.49 (m, 1H) |
A85 | ίΎ HN^N^Yr^N LA Il \ ,N k J n-4 > Me< Λο O=s=o Me Me (3R,4R)-4-({5-chloro-4-[2methyl-1-(propan-2-yl)-1 Himidazo[4,5-b]pyridin-6yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol | 480.1 [M+H]* (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.75 (d, J = 2.0 Hz, 1H), 8.42 - 8.37 (m, 2H), 7.23 (d, J = 7.6 Hz, 1H), 4.84 (hept, J = 6.8 Hz, 1 H), 3.63 (m, 2H), 2.95 - 2.85 (m, 4H), 2.77 - 2.64 (m, 4H), 2.19-2.08 (m, 1H), 1.801.74 (m, 3H), 1.61 (m, 7H) |
A86 | jOC ΗΝ Νγ^ HO^xk Nx Il ' //N < fi N—Y _N_ Me-γ O—S—O Me Me (3R,4R)-4-({5-chloro-4-[2- methyl-3-(propan-2-yl)-3Himidazo[4,5-b]pyridin-5yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-oI | 480. Ί [M+H]* (ESI^ | 1H NMR (600 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.03 (d, J =8.2, 1.3 Hz, 1H), 7.77 (s, 1H), 7.42 (s, 1H), 5.23 (s, 1H), 4.79 (h, J = 6.8 Hz, 1H), 3.87 - 3.78 (m, 1 H), 3.68 - 3.56 (m, 3H), 2.92 - 2.82 (m, 4H), 2.71 - 2.63 (m, 4H), 2.10-2.01 (m, 1H), 1.67 (d, J = 6.8 Hz, 6H), 1.53 (m, 1H) |
211
Example A87 (Scheme A-8): Préparation of (3/?,4R)-4-({5-chloro-4-[4-fluoro-2(hydroxymethyI)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol
Scheme A-8
HCl
MeOH, 1,4-dioxane 20% yield
Me
Example A87
A solution of (3R,4R)-4-({5-chloro-4-[4-fluoro-24[(oxan-2-yI)oxy]methyl}-1-(propan-2-yI)1 H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1 -(methanesulfonyl)piperidin-3-ol (A-9) (Prepared as in Example A69, 88 mg, 0.15 mmol) in MeOH (3.0 mL) at 0 °C was added a solution of HCl (4.0 10 N in 1,4-dioxane, 0.55 mL, 2.2 mmol). After 2.5 h, LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction mixture was concentrated to dryness. The residue was purified by préparative SFC on a Princeton HaMorpholine column (150x21.1 mm, 5 pm particle size, column température at 35 °C), which was eluted with 22-50% MeOH/CO2 with a flow rate of 60 mL/min to provide (3R,4R)-4-({5-chloro~415 [4-fluoro-2-(hydroxymethyl)-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol (Example A87) (15 mg, 20% yield) as a white solid. 1H NMR (600 MHz, DMSO-de) δ 8.42 (s, 1H), 7.97 (s, 1H), 7.52 - 7.31 (m, 2H), 5.73 (t, J = 5.5 Hz, 1H), 5.20 (d, J = 5.0 Hz, 1 H), 5.02 (hept, J = 7.0 Hz, 1 H), 4.77 (d, J = 5.7 Hz, 2H), 3.86 - 3.75 (m, 1 H), 3.68 - 3.56 (m, 2H), 3.53 - 3.46 (m, 1 H), 2.94 - 2.80 (m, 4H), 2.71 - 2.60 (m, 1 H), 2.06 (s, 1 H), 1.66 20 — 1.47 (m, 7H); m/z (ESI+) for (C21H26CIFN6O4S), 512.8 (M+H)+.
Example A88 (Scheme A-9): Préparation of (3R,4R)-4-({4-[1-(azetidin-3-yl)-4-fIuoro-2methyl-1 H-benzimidazol-6-yl]-5-fluoropyrimidin-2-yl}amino)-1 (methanesuIfonyl)piperidin-3-ol
Scheme A-9:
212
HO nh2
lnt-69
O=S=O Me
1.Pd(OAc)2 rac-BINAP, Cs2CO3 THF, 80 ’C, μW
2- HCl DCM, 1,4-dioxane
89% yield (2 steps)
A solution of fert-butyl 3-[6-(2-chloro-5-fIuoropyrimidin-4-yl)-4-fIuoro-2-methyl-1/-/benzimidazol-1-yl]azetidine-1 -carboxylate (A-10) (Prepared as in Example A1, 75.0 mg, 0.170 mmol), (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (lnt-69) (50.1 mg, 0.258 mmol), 5 Pd(OAc)2 (7.73 mg, 0.034 mmol), rac-BINAP (21.4 mg, 0.034 mmol), and CS2CO3 (168 mg, 0.516 mmol) in THF (1.7 mL) was stirred under microwave irradiation at 80 °C for 30 min. The mixture was purified via flash chromatography (S1O2, 0-100% EtOAc/heptanes). The product-containing fractions were concentrated, taken up into DCM (5 mL), and treated with HCl (4.0 M in 1,4dioxane, 1.0 mL). The mixture was stirred at ambient température for 4 h. The solution was 10 concentrated and the crude residue was purified by préparative HPLC on a Phenomenex Gemini NX C18 column (150x21.2 mm, 5 pm particle size), which was eluted with 20-100% MeCN/H2O (+10 mM NH4OAC) with a flow rate of 40 mL/min to provide (3R,4R)-4-({4-[1-(azetidin-3-yI)-4fluoro-2-methyl-1H-benzimidazol-6-yl]-5-fluoropyrimidin-2-yl}amino)-1(methanesulfonyI)piperidin-3-ol (Example A88) (76 mg, 89% yield) as a solid. 1H NMR (600 MHz, 15 DMSO-de) δ 8.70 (s, 1H), 8.47-8.29 (m, 1H), 7.64 (d, J = 12.0 Hz, 1H), 7.15 (d, J= 7.7 Hz, 1H), 5.43 (s, 1H), 4.27-3.87 (m, 4H), 3.79 (s, 1H), 3.71-3.54 (m, 2H), 3.50 (s, 1H), 3.01-2.78 (m, 5H), 2.68 (t, J = 10.3 Hz, 1H), 2.56 (d, J = 1.4 Hz, 3H), 2.12 (s, 1H), 1.62 - 1.43 (m, 1H); m/z (APCI+) for (C2iH25F2N7O3S), 494.2 (M+H)+.
Example A89 (Scheme A-10): Préparation of (3/?,4R)-4-({5-chloro-4-[4-fluoro-2-methyl-1(oxetan-3-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1-(methanesu!fonyI)piperidin-3ol
Scheme A-10:
213
PdCI2(dppf), B2Pin2, KOAc
1,4-dioxane, 90 ’C, pW then PdCI2(PPh3)2, Na2CO3 H20,110 °C, pW
Exemple A89
Pd(OAc)2, rac-BINAP Cs2CO3 THF, 90 ’C, pW
14% yield, (2 steps)
Step 1: Synthesis of 6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-2-methyl-1-(oxetan-3-yl)-1Hbenzimidazole (A-11)
A mixture of 6-bromo-4-fluoro-2-methyl-1-(oxetan-3-yl)-1H-benzimidazole (Int-03) (63.0 5 mg, 0.220 mmol), B2Pin2 (84.2 mg, 0.331 mmol), KOAc (65.1 mg, 0.663 mmol), and PdCb(dppf) (18.0 mg, 0.022 mmol) in 1,4-dioxane (1.1 mL) was sparged with N2 for 10 min and then heated in a microwave at 90 °C for 1 h. The mixture was cooled to ambient température and charged with PdCl2(PPh3)2 (7.71 mg, 0.011 mmol), aqueous Na2CO3 (2.0 M, 0.33 mL, 0.659 mmol) and 2,4,5-trichloropyrimidine (60.5 mg, 37.8 uL, 0.330 mmol). The mixture was sparged with nitrogen 10 for 10 min and then heated in the microwave at 110 °C for 70 min. The mixture was partitioned between water (2 mL) and EtOAc (2 mL). The aqueous phase was extracted with EtOAc (3x2 mL). The combined organic phases were concentrated to provide 6-(2,5-dichloropyrimidin-4-yl)4-fluoro-2-methyl-1-(oxetan-3-yl)-1H-benzimidazole (A-11), which was taken on without further purification, m/z (APCI+) for (C15H11CI2FN4O), 352.8 (M+H)+.
15 I !
Step 2: Synthesis of (3R,4R)-4-({5-chloro-4-[4-fluoro-2-methyl-1-(oxetan-3-yl)-1Hbenzimidazol-6-yl]pyrimidin-2-yl}amino)-1-(methanesulfonyI)piperidin-3-ol (Example A89)
Crude 6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-2-methyI-1-(oxetan-3-yl)-1H-benzimidazole (A-11) was dissolved in THF (1.8 mL). (3R,4R)-4-Amino-1-(methanesulfonyl)piperidin-3-oî (Int20 69) (64.4 mg, 0.331 mmol), Pd(OAc)2 (9.9 mg, 0.044 mmol), rac-BINAP (27.5 mg, 0.044 mmol), and CS2CO3 (216 mg, 0.663 mmol) were added and the mixture was sparged with N2 for 10 min.
The mixture was stirred at 90 °C for 1.5 h with microwave irradiation. The mixture was cooled to
214 ambient température, diluted with DMSO and filtered through a 0.2 micron filter dise. The crude material was purified by préparative SFC with a Princeton HA-morpholine column (150x21.1 mm, pm column particle size, column température of 35 °C), which was eluted with 15-50%
MeOH/CO2 (+10 mM NH3) with a flow rate of 80 g/min. The material was re-purified by préparative
SFC with a Diacel DC pak SFC-B (150x21.1 mm, 5 pm particle size, column température of 35 °C), which was eluted with 18-45% MeOH/CO2 with a flow rate of 80 g/min to provide (3R,4R)-4({5-chloro-4-[4-fIuoro-2-methyl-1-(oxetan-3-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol (Example A89) (15.9 mg, 14% yield over two steps) as a white solid. 1H NMR (600 MHz, DMSO-d6,75 °C) δ 8.40 (s, 1H), 8.35 (b s, 1H), 7.49 (d, J =11.7 Hz,
1H), 7.20 (d, J = 7.4 Hz, 1H), 5.76 - 5.71 (m, 1 H), 5.16 (td, J = 7.6, 2.7 Hz, 2H), 5.09 - 5.04 (m,
2H), 5.01 (b s, 1H), 3.85 - 3.78 (m, 1H), 3.70 - 3.62 (m, 2H), 3.55 - 3.50 (m, 1H), 2.91 - 2.85 (m, 4H), 2.72-2.66 (m, 1H), 2.58 (s, 3H), 2.15-2.10 (m, 1H), 1.62-1.46 (m, 1H); m/z (APCI+) for (C21H24CIFN6O4S), 510.8 (M+H)+.
Example A90 (Scheme A-11): Préparation of (3R,4R)-4-({5-chIoro-4-[4-fluoro-2(hydroxymethyI)-1-(2,2,2-trifluoroethyl)-1H-benzimidazol-6-yl]pyrimidin-2-yl)amino)-1(methanesulfonyl)piperidin-3-ol
Scheme A-11 nh2
o=s=o Me
1.Pd(OAc)2 rac-BINAP, Cs2CO3 THF, 80 ’C, pW
2. HCl MeOH/1,4-dioxane
12% yield
Example A90
To a vial was added 6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-2-{[(oxan-2-yl)oxy]methyl}-1(2,2,2-trifIuoroethyl)-1H-benzimidazôle (A-12) (Prepared according to Example A89, 121^ mg, 0.25 mmol), (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (lnt-69) (73.6 mg, 0.38 mlnol), Pd(OAc)2 (11.3 mg, 0.051 mmol), rac-BINAP (31.4 mg, 0.051 mmol), CS2CO3 (247 mg, 0.76 25 mmol), and THF (2.5 mL). The mixture was stirred at 80 °C with microwave irradiation for 30 min. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The mixture was concentrated on S1O2 and purified by flash chromatography (ISCO, 12 g S1O2, 0-100% EtOAc/heptanes). The product containing-fractions were concentrated. The _ 215 residue was taken up in MeOH (5 mL) and treated with HCl (4.0 N in 1,4-dioxane, 1.0 mL) and the mixture was stirred at ambient température for 16 h overnight. LCMS analysis showed partial consumption ofthe starting material. An additional aliquot of HCl (4.0 N in 1,4-dioxane, 1.0 mL) was added. The mixture was stirred for 6 h, at which time LCMS analysis indicated consumption 5 of the starting material. The mixture was concentrated and purified by préparative SFC with a
Princeton HA-morpholine column (150x21.1 mm, 5 pm particle size, column température 35 °C), which was eluted with 14-50% MeOH/CO2 at 80 g/min to provide (3R,4R)-4-({5-chloro-4-[4-fluoro2-(hydroxymethyl)-1-(2,2,2-trifluoroethyl)-1/7-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol (Example A90) (17 mg, 12% yield) as a gum. 1H NMR (400 MHz, 10 DMSO-de) δ 8.46 (s, 1 H), 7.99 (s, 1 H), 7.58 - 7.41 (m, 2H), 5.93 (t, J = 6.0 Hz, 1 H), 5.49 (q, J =
9.1 Hz, 2H), 5.21 (d, J = 4.5 Hz, 1H), 4.82 (d, J = 5.8 Hz, 2H), 3.81 (s, 1H), 3.68-3.56 (m, 2H), 3.49 (d, J = 12.1 Hz, 1H), 2.94-2.77 (m, 4H), 2.72-2.61 (m, 1H), 2.02 (s, 1H), 1.60-1.44 (m, 1H); m/z (ESI+) for (C20H21CIF4N6O4S), 522.9 (M+H)*.
Example A91 (Scheme A-12): Préparation of (3R,4R)-4-({5-chloro-4-[4-fluoro-2-(2hydroxypropan-2-yI)-1-(propan-2-yI)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol
Scheme A-12
A mixture of 2-(2-{[tert-butyl(dimethyl)silyl]oxy}propan-2-yl)-6-(2,5-dichloropyrimidin-4-yl)4-fluoro-1-(propan-2-yl)-1H-benzimidazole (A-13) (Prepared as in Example A89, 294 mg, 0.590 mmol), (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (lnt-69) (149 mg, 0.767 mmol), and DIPEA (0.55 mL, 2.95 mmol) in DMSO (2.8 mL) was stirred at 90 °C for 18 h. The resulting 25 solution was cooled to ambient température and partitioned between water (30 mL) and EtOAc (30 mL). The layers were separated and the aqueous phase was extracted with EtOAc (5x 30 mL). The combined organic phases were washed with water (3x20 mL), dried over Na2SO4, filtered, and concentrated. The résultant yellow foam was dissolved in THF, cooled to 0 °C, and treated with TBAF (1.0 M in THF, 1.2 mL, 1.2 mmol). The resulting solution was allowed to warm _ 216 to ambient température and stirred for 2.5 h before being concentrated. The residue was purified by préparative SFC with a ZymorSpher HADP column (150 x 21.2mm, 5 pm particle size, 40 °C column température), which was eluted with 18% MeOH/CO2 with a flow rate of 90 mL/min to provide (3R,4R)-4-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1 -(propan-2-yl)-1 H5 benzimidazol-6-yl]pyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol (Example A91) (137 mg, 43% yield) as a solid. 1H NMR (400 MHz, DMSO-d6, 80 °C) δ 8.39 (s, 1H), 7.98 (d, J = 1.3 Hz, 1H), 7.40 (dd, J = 11.8, 1.3 Hz, 1H), 7.17 (d, J= 7.7 Hz, 1H), 5.80 (h, J = 6.8 Hz, 1H), 5.56 (s, 1 H), 4.97 (d, J = 4.5 Hz, 1 H), 3.87 - 3.78 (m, 1 H), 3.71 - 3.63 (m, 2H), 3.57 - 3.51 (m, 1 H), 2.93 - 2.85 (m, 4H), 2.75 - 2.67 (m, 1H), 2.16 - 2.09 (m, 1H), 1.70 (s, 6H), 1.63 (d, J = 7.0 Hz, 10 7H); m/z (APCI+) for (C23H3oCIFN604S), 540.8 (M+H)+.
Example A92 (Scheme A-13): (3R,4R)-4-({5-chloro-4-[1-(1,1-difluoropropan-2-yl)-4-fIuoro2-(hydroxymethyl)-1H-benzimidazoI-6-yI]pyrimidin-2-yl)amino)-1(methanesulfonyl)piperidin-3-ol
Scheme A-13 nh2
o=s=o Me
1. Pd(OAc)2 rac-BINAP, Cs2CO3 THF, 80 •C, pW
2. HCl MeOH/1,4-dioxane O f/-f tbs 8o/o yie|d
Example A92
To a vial was added 2-({[fert-butyl(dimethyl)silyl]oxy}methyl)-6-(2,5-dichloropyrimidin-4yl)-1-(1,1-difluoropropan-2-yl)-4-fiuoro-1H-benzimidazole (A-14) (Prepared according to 20 । Example A89, 81 mg, 0.16 mmol), (3R,4R)-4-Amino-1-(methanesulfonyl)piperidin-3-oI (lnt-69) ’ ' i j (46.7 mg, 0.24 mmol), Pd(OAc)2 (7.2 mg, 0.032 mmol), rac-BINAP (20.0 mg, 0.032 mmol),
Cs2CO3 (157 mg, 0.48 mmol), and THF (1.6 mL). The mixture was stirred at 80 °C in a microwave for 30 min. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The mixture was concentrated onto S1O2 and purified by flash chromatography (ISCO, 12 g S1O2, 0-100% EtOAc/heptanes). The product-containing fractions were concentrated and taken up in MeOH (5.0 mL). The mixture was treated with HCl (4.0 N in
1,4-dioxane, 2.0 mL) and stirred at ambient température for 16 h. LCMS analysis showed 217 consumption of the starting material with formation of the desired product mass. The mixture was concentrated to dryness and then purified by chiral SFC with a ChiralPak AS-H column (100x4.6 mm, 3 pm particle size), which was eluted with 5-60% MeOH/CO2 with a flow rate of 4.0 mL/min to provide (3R,4R)-4-({5-chlorô-4-[1-(1,1-diflüoropropan-2-yI)-4-fIûoro-2-(hydroxymethyl)-1H5 benzimidazol-6-yl]pyrimidin-2-yl)amino)-1-(methanesulfonyl)piperidin-3-ol (Example A92) (7.4 mg, 8% yield) as the first eluting fraction. 1H NMR (400 MHz, DMSO-d6, 80 °C) δ 8.41 (s, 1H), 8.00 (s, 1H), 7.47 (d, J = 11.6 Hz, 1H), 7.19 (d, J = 7.7 Hz, 1H), 6.52 (td, J = 55.3, 3.7 Hz, 1H), 5.65 (t, J = 5.7 Hz, 1H), 5.40 - 5.26 (m, 1H), 4.97 (d, J = 4.6 Hz, 1H), 4.83 (d, J = 5.6 Hz, 2H), 3.87 - 3.76 (m, 1 H), 3.72 - 3.62 (m, 2H), 3.59 - 3.51 (m, 1 H), 2.95 - 2.84 (m, 4H), 2.75 - 2.66 (m, 1H), 2.17 - 2.09 (m, 1H), 1.75 (d, J = 7.1 Hz, 3H), 1.65 - 1.54 (m, 1H); m/z (ESI+) for (C21H24CIF3N6O4S), 522.9 (M+H)+; [ajo22 = -26.5° (c=0.1 M, MeOH).
Example A93 (Scheme A-14): Préparation of (3R,4/?)-4-[(5-chloro-4-{4-fluoro-2-[(1/?)-1hydroxyethyl]-1-(propan-2-yl)-1H-benzimidazol-6-yl)pyrimidin-2-y l)amino]-115 (methanesulfonyl)piperidin-3-ol
Scheme A-14:
Br
Α-15
FPrNH2
MeCN, 35 C
218
NO2
Me A-16
Fe°, AcOH t-AmylOH, 35 C
Br
Me
nh2
A-17
Me
75% yield
74% yield
HO
O ,OH °C
62% yield
Cl
Pd(PPh3)4, K2CO3
H2O 1,4-dioxane, 90 ’C
DIPEA DMSO, 60 °C
67% yield
Cl
Cl PinB
A-18
OH Me Me
B2Pin2, KOAc PdCI2(dppf)
Me
NH2
lnt-69
39% yield
1,4-dioxane, 90’C Ç Μβ Λ >OH Me Me lnt-40
92% yield
Step 1: Synthesis of 5-bromo-3-fluoro-2-nitro-/V-(propan-2-yl)aniline (A-16)
This transformation was run in four parallel batches. To a solution 5-bromo-1,3-difluoro5 2-nitrobenzene |(A-15) (100 g, 420.2 mmol) in MeCN (2 L) was addejl /-PrNH2 (27.5 g, 441.2 mmol) at 20-25 °C (ice-bath cooling) to provide a yellow reaction solution. The resulting mixture was stirred at 35 “C for 60 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The mixture was concentrated to dryness. The crude residue from the four parallel reactions were combined and purified by flash chromatography (S1O2, 0-2% EtOAc/petroleum ether) to provide 5-bromo-3-fIuoro-2-nitro-A/-(propan-2-yl)aniline (A-16) (350 g, 75% yield) as a yellow solid. 1H NMR (400 MHz, DMSp-de) δ 7.09 - 7.00 (m, 2H), 6.90 (dd, J = 11.1, 2.0 Hz, 1H), 3.94 - 3.84 (m, 1H), 1.20 (d, J = 6.3 Hz, 6H); m/z (ESI+) for (C9HioBrFN202), .247.0 (M+H)+; 19F NMR (377 MHz, DMSO-d6) δ-116.9. _ . .
Step 2: Synthesis of S-bromo-S-fluoro-AF-fpropan-Z-yObenzene-l ,2-diamine (A-17)
219
To a stirred mixture of AcOH (2 L) and f-AmylOH (2 L) was added 5-bromo-3-fluoro-2nitro-/V-(propan-2-yl)aniline (A-16) (200 g, 721 mmol) at 35 °C. Fe° (282 g, 5.05 mol) was added in portions at 25-35 °C (ice-bath cooling). The resulting mixture was stirred at 35 °C for 16 h to provide an off-white slurry. TLC analysis (1:9 EtOAc/petroleum ether, Rf = 0.8, UV254) showed consumption of the starting material. The mixture was diluted with EtOAc (2 L) and H2O (2 L).
The mixture was neutralized by slow addition of solid Na2CO3. The slurry was filtered and the mixture was separated. The aqueous layer was extracted with EtOAc (3x1 L). The combined organic layers were washed with saturated aqueous NaHCOs (2x1 L) and brine (2x1 L), dried over Na2SO4, filtered, and concentrated. The residue was combined with a parallel reaction in an 10 identical fashion with 150 g of 5-bromo-3-fluoro-2-nitro-N-(propan-2-yl)aniline (A-16). The mixture was purified by flash chromatography (S1O2, 0-25% EtOAc/petroleum ether) to provide 5-bromo3-fluoro-/V1-(propan-2-yl)benzene-1,2-diamine (A-17) (230 g, 74% yield) as a brown oil. 1H NMR (400 MHz, DMSO-cfe) δ 6.55 (dd, J= 10.0, 2.1 Hz, 1H), 6.38-6.34 (m, 1H), 4.93-4.41 (m, 3H), 3.55 (hept, J = 6.2 Hz, 1H), 1.14 (d, J= 6.3 Hz, 6H); 19F NMR (377 MHz, DMSO-d6) δ-132.8; m/z 15 (ESI+) for (C9HioBrFN202), 247.0 (M+H)+.
Step 3: Synthesis of (1R)-1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]ethan1-ol (lnt-40)
To a mixture of 5-bromo-3-fluoro-/V1-(propan-2-yl)benzene-1,2-diamine (A-17) (200.0 g , 20 809.4 mmol) and (2R)-2-hydroxypropanoic acid (605.1 g, 6.72 mol) was heated from 25 °C to 85 °C and then stirred at 85 °C for 16 h. TLC analysis (1:1 EtOAc/petroleum ether), Rf = 0.5, UV254) showed consumption of the starting material. The reaction mixture was cooled to 25 °C and diluted with EtOAc (1 L) and H2O (1 L). The mixture was basified with aqueous NaOH (50%, -300 mL) to pH -8-9, maintaining the internai température below 30 °C by cooling with an ice-bath. 25 The mixture was separated and the aqueous layer was extracted with EtOAc (2x1 L). The combined organics layers were dried over Na2SO4, filtered, and concentrated. To the residue was added MTBE (400 mL) Ànd petroleum ether (200 mL). A precipitate was formek The résultant slurry was stirred at 25 °C for 1 h. The slurry was filtered and the filter cake was washed with petroleum ether (2 x 80 mL). The filter cake was dried in vacuum to provide (1R)-1-[6-bromo-430 fluoro-1-(propan-2-yl)-lH-benzimidazol-2-yl]ethan-1-ol (lnt-40) (150 g, 62% yield) as a lightyellow solid. 1H NMR (40θ MHz, DMSO-d6) δ 7.80 (d, J= 1.5 Hz, 1H), 7.27 (dd, J/ = 10.1, 1.5 Hz, 1H), 5.74 (d, J = 6.6 Hz, 1H), 5.17-5.00 (m, 2H), 1.63-1.49 (m, 9H).
Step 4: Synthesis of (1 R)-1-[4-fluoro-1-(propan-2-y 1)-6-(4,4,5,5-tetramethyl-1,3,235 dioxaborolan-2-yl)-1H-benzimidazol-2-yl]ethan-1-ol (A-18) _ 220
A stirred mixture of (1 R)-1-[6-bromo-4-fluoro-1-(propan-2-yi)-1 H-benzimidazol-2-yl]ethan1 -ol (lnt-40) (150.0 g, 498.1 mmol), B2Pin2 (164.4 g, 647.5 mmol), PdCI2(dppf) (18.2 g, 24.9 mmol) and KOAc (146.6 g, 1.49 mmol) in 1,4-dioxane (1.2 L) was heated from 25 °C to 90 °C. The reaction mixture was stirred at 90 °C for 3 h under N2. TLC analysis (1:1 EtOAc/petroleum ether, 5 Rf = 0.46, UV254) indicated consumption ofthe starting material. The reaction mixture was cooled to 25 °C and quenched with H2O (800 mL). The mixture was concentrated in vacuum to remove the 1,4-dioxane. The residue was filtered and the filter cake was washed with EtOAc (2x100 mL). The filtrate was extracted with EtOAc (2x800 mL, 400 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography 10 (SiO2, 1:5 EtOAc/petroleum ether - 100% EtOAc) to provide (1R)-1-[4-fluoro-1-(propan-2-yl)-6(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]ethan-1-ol (A-18) (160 g, 92% yield) as a light-yellow solid. 1H NMR (400 MHz, CDCI3) δ 7.73 (s, 1H), 7.35 (d, J = 10.8 Hz, 1H), 5.17 (quin, J= 6.4 Hz, 1H), 4.95 (sept, J = 7.0 Hz, 1H), 4.10 (d, J = 7.0 Hz, 1H), 1.70-1.63 (m, 9H), 1.36 (s, 12H); m/z (ESI+) for (Ci8H26BFN2O3), 348.9 (M+H)+.
Step 5: Synthesis of (1R)-1-[6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]ethan-1-ol (A-19)
This transformation was carried out in two parallel batches. A stirred mixture of (1R)-1-[4fluoro-1-(propan-2-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-220 yl]ethan-1-ol (A-18) (80 g, 230 mmol), 2,4,5-trichloropyrimidine (54.7 g, 299 mmol), Pd(PPh3)4 (26.5 g, 22.9 mmol), and K2CO3 (63.5 g, 459 mmol) in 1,4-dioxane (600 mL) and H2O (250 mL) was sparged with N2. The mixture was stirred at 90 °C for 3 h under N2. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction mixture was cooled to room température and diluted with H2O (500 mL). The two parallel 25 reactions were combined and concentrated to remove the 1,4-dioxane. The residue was filtered and the filter cake was washed with EtOAc (2x150 mL). The mixture was separated. The organic layer was washed with brine (2 ¢), dried over Na2SO4, filtered, and concentrated. The Residue was purified by flash chromatography (SiO2, 1:5 EtOAc/petroleum ether ·» 100% EtOAc). The product-containing fractions were concentrated to ~400 mL, resulting in précipitation. The solids 30 were collected by filtration. The filter cake was washed with petroleum ether (200 mL) and the dried in vacuum to provide (1R)-1-[6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1/7benzimidazol-2-yl]ethan-1-ol (A-19) (70 g, 39% yield) as a white solid. 1H NMR (400 MHz, CDCI3) δ 8.68 (s, 1H), 7.98 (d, J = 1.5 Hz, 1H), 7.59 (dd, J = 1.3, 11.3 Hz, 1H), 5.19 (quin, J = 7.0 Hz, 1H), 4.96 (sept, J = 6.8 Hz, 1H), 3.11 (d, J= 7.8 Hz, 1H), 1.75 (d, J= 6.5 Hz, 3H), 1.71 (d, J = 7.0
Hz, 6H); m/z (ESI+) for (C16H15CI2FN4O), 368.8 (M+H)+.
221
Step 6: Synthesis of (3R,4R)-4-[(5-chloro-4-{4-fluoro-2-[(1R)-1-hydroxyethyl]-1-(propan-2yi)-1H-benzimidazoI-6-yl)pyrimidin-2-yl)amino]-1-(methanesulfonyl)piperidin-3-ol (Example A93) .· .
This transformation was carried out in two parallel batches. To a stirred solution of (1R)5 1 -[6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-1 -(propan-2-yl)-1 /-/-benzimidazol-2-yl]ethan-1 -ol (A-19) (50 g, 135 mmol) and (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (lnt-69) in DMSO (350 mL) was added DIPEA (85.7 g, 664 mmol). The reaction mixture was stirred at 60 °C for 56 h. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The two parallel reactions were combined and filtered through a pad of celite. The filtrate 10 was poured into stirring saturate aqueous NaHCOs (2 L). The mixture was extracted with DCM (3x2 L). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was taken up in EtOAc (2 L). Sulfhydryl silica gel (Accela, 20 g, 0.7-1.4 mmol/g) was added and the mixture was stirred for 1 h at 30 °C. The mixture was filtered and the filtrate was concentrated. The residue was purified by flash chromatography (S1O2, 1:10 EtOAc/petroleum 15 ether 100% EtOAc). The product was taken up in EtOH (200 mL) and H2O (800 mL) and then concentrated to remove the EtOH. The aqueous solution was dried by lyopilization. The solids were dried at 50 °C for 48 h under high vacuum to provide (3R,4R)-4-[(5-chloro-4-{4-fluoro-2[(1R)-1-hydroxyethyl]-1-(propan-2-yl)-1H-benzimidazol-6-yl}pyrimidin-2-yl)amino]-1(methanesulfonyl)piperidin-3-ol (Example A93) (95 g, 67% yield) as a white solid. 1H NMR (400 20 MHz, 80 °C, DMSO-de) δ 8.40 (s, 1 H), 7.99 (d, J = 1.3 Hz, 1 H), 7.42 (dd, J = 11.8, 1.3 Hz, 1 H), 7.17 (d, J =7.7 Hz, 1H), 5.50 (d, J =6.2 Hz, 1H), 5.23 (hept, J =6.9 Hz, 1H), 5.16-5.07 (m, 1H), 4.97 (d, J = 4.6 Hz, 1H), 3.88 - 3.77 (m, 1H), 3.73 - 3.62 (m, 2H), 3.58 - 3.52 (m, 1H), 2.94 2.86 (m, 4H), 2.76 - 2.68 (m, 1H), 2.17 - 2.08 (m, 1H), 1.69 - 1.54 (m, 10H); m/z (ESI+) for (C22H28CIFN6O4S), 526.8 (M+H)+; Md22 = -11.4 (c=0.1, MeOH)
222
Example A94 (Scheme A-15): Préparation of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol-6-yI]pyrimidin-2-yl)amino)-2,3dideoxy-D-fhreo-pentitoI
Scheme A-15:
;-PrNH2, Cs2CO3
THF, 30 ’C 72% yield
Fe°, NH4CI
H2O, MeOH, 68 ’C
88% yield
’C
90% yield
MeMgBr
THF, 0 ’C 91% yield
MnO2
CHCI3, 58 ’C 99% yield
lnt-20
B2Pin2, KOAc PdCI2(dppf) 1,4-dioxane, 90 ’C
61% yield
A-22
DIPEA MeCN, 80 ’C
66% yield
Step 1: Synthesis of 5-bromo-3-fluoro-2-nitro-A/-(propan-2-yl)aniline (A-16)
This reaction was carried out in three parallel batches. To a stirred solution of 5-bromo10 1,3-difluoro-2-nitrobenzene (A-15) (166 g, 697 mmol) in THF (1.7 L) was added /-PrNH2 (41.2 g,
223
697 mmol) and CS2CO3 (455 g, 1.40 mol) at 15-30 °C. Upon addition an exotherm was detected.
The reaction mixture was stirred at 30 °C for 6 h. TLC analysis (100% petroleum ether, UV254, Rf = 0.35) showed consumption of the starting material. The three reaction batches were combined. The combined mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by flash chromatography (S1O2,0-2% EtOAc/petroleum ether) to provide 5-bromo-3-fluoro-2-nitro-/V-(propan-2-yl)aniline (A-16) (420 g, 72% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 7.09 - 7.00 (m, 2H), 6.90 (dd, J = 11.1, 2.0 Hz, 1H), 3.94 - 3.84 (m, 1H), 1.20 (d, J = 6.3 Hz, 6H); 19F NMR (376 MHz, DMSO-d6) δ -116.9; m/z (ESI+) for (C9HioBrFN202), 276.1 (M+H)+.
Step 2: Synthesis of 5-bromo-3-fluoro-/V1-(propan-2-yl)benzene-1,2-diamine (A-17)
This reaction was carried out in two parallel batches. To a stirred solution of 5-bromo-3fluoro-2-nitro-A/-(propan-2-yl)aniline (A-16) (210 g, 758 mmol) in MeOH (1.8 L) was added NH4CI (81.1 g, 1.52 mol) in H2O (0.9 L) and Fe° powder (212 g, 3.79 mol) at 15 “C. The resulting mixture was heated to 68 °C (internai température) and stirred at the same température for 8 h. TLC analysis (10% EtOAc/petroleum ether, UV254, Rf = 0.8) showed consumption of the starting material. The two reaction batches were cooled to room température and combined. The two reaction mixtures were combined and filtered. The filter cake was washed with MeOH (3x500 mL). The filtrate was concentrated under vacuum to remove most of the MeOH. The résultant aqueous mixture was extracted with EtOAc (3x1 L). The combined organic layers were washed with brine (2x800 mL), dried over Na2SO4, filtered, and concentrated to provide 5-bromo-3-fluoro/\T-(propan-2-yl)benzene-1,2-diamine (A-17) (350 g, 88% yield) as a purple solid, which was taken on without further purification. 1H NMR (400 MHz, DMSO-cfe) δ 6.55 (dd, J = 10.0, 2.1 Hz, 1H), 6.38 - 6.34 (m, 1H), 4.93 - 4.41 (m, 3H), 3.55 (hept, J = 6.2 Hz, 1H), 1.14 (d, J = 6.3 Hz, 6H); 19F NMR (377 MHz, DMSO-c/6) δ -132.8; m/z (ESI+) for (C9Hi2BrFN2), 246.6 (M+H)+.
SteJ 3: Synthesis of (1R)-1-[6-bromo-4-fluoro-1-(propan^2-yl)-1H-benzimidazol-2-yl]ethan1-ol(lnt-20) ...... ......
। To a 2 L three-neck round bottom flask was added (2R)-2-hydroxypropanoic acid (951 g, 9.71^ mol) at 15 °C and compound was heated to 85 °C (internai température). To the stirred solution at 85 eC was added S-bromo-S-fluoro-A/Ypropan^-yljbenzene-lYdiamine (A-17) (300 g, 1.21 mol) portion-wise. The resulting mixture was stirred at 85 °C (internai température) for 40 h to provide a purple reaction solution. TLC analysis (1:2 EtOAc/petroleum ether, UV254, Rf = 0.8) showed consumption of the starting material. The réaction mixture was cooled to room température and diluted with THF (1.5 L). The mixture was adjusted to pH -8 with saturated aqueous LiOH at 10-15 °C with ice-water bath cooling. The mixture was extracted with MTBE
224 (3x1.5 L). The combined organic layers were washed with brine (2x800 mL), dried over Na2SO4 and filtered. The filtrate was concentrated under vacuum to provide (1R)-1-[6-bromo-4-fluoro-1(propan-2-yl)-1H-benzimidazol-2-yl]ethan-1-ol (A-18) (330 g, 90% yield) as a brown solid, which was taken on to the next step without further purification. 1H NMR (400 MHz, DMSO-cfe) δ 7.80 (d, J = 1.5 Hz, 1H), 7.27 (dd, J = 10.1,1.5 Hz, 1H), 5.74 (d, J = 6.6 Hz, 1H), 5.17-5.00 (m, 2H), 1.63 - 1.49 (m, 9H); 19F NMR (376 MHz, DMSO-d6) δ -126.3; m/z (ESI+) for (Ci2Hi4BrFN2O), 302.6 (M+H)+.
Step 4: Synthesis of 1-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]ethan-1one (A-20)
To a stirred solution of compound (1R)-1-[6-bromo-4-fIuoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]ethan-1-ol (lnt-20) (365 g, 1.21 mol) in CHCi3 (3 L) was added activated MnO2 (738 g, 8.48 mol) at room température. The reaction mixture was heated to 58 °C (internai température) and stirred at the same température for 16 h. TLC analysis (1:2 EtOAc/petroleum ether, UV254, Rf = 0.3) showed consumption ofthe starting material. The reaction mixture was cooled to room température and filtered through a pad of Celite. The filter cake was washed with EtOAc (3x500 mL) and the filtrate was concentrated under vacuum. The residue was purified by flash chromatography (SiO2, 0-30% EtOAc/petroleum ether) to provide 1-[6-bromo-4-fluoro-1(propan-2-yl)-1H-benzimidazol-2-yl]ethan-1-one (A-20) (362 g, 99% yield) as a yellow solid. 1H NMR (400 MHz, CDCI3) δ 7.54 (d, J = 1.6 Hz, 1H), 7.12 (dd, J = 9.5, 1.5 Hz, 1H), 5.82 (hept, J = 7.0 Hz, 1H), 2.79 (s, 3H), 1.56 (d, J = 7.0 Hz, 6H); 19F NMR (377 MHz, DMSO-de) δ -124.1; m/z (ESI+) for (Ci2Hi2BrFN2O), 300.6 (M+H)+.
Step 5: Synthesis of 2-[6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]propan-2ol(A-21)
This réaction was carried out in two parallel batches. A solutitjin of 1-[6-bromo-4-fIuoro-1(propan-2-yl)-1/7-benzimidazol-2-yl]ethan-1-one (A-20) (165 g, 552 mmol) in THF (1.7 L) was degassed and purged with N2 three times. The stirred solution was cooled to 0-5 °C (internai temperature).with ice-brine bath cooling and a solution of MeMgBr (3.0 M in Et20,221 mL) was added drop-wise. During the addition the purple solution turned to a gray slurry. The resulting mixture was stirred at 0-5 °C with ice-brine bath cooling for 3 h. TLC analysis (20% EtOAc/petroleum ether, UV254, Rf = 0.8) showed consumption of the starting material. The reaction mixture was slowly quenched with saturated aqueous NH4CI (400 mL) at 0-5 °C with icebrine bath cooling and then stirred at room température for 1 h. The two reaction batches were combined and diluted with EtOAc (1 L). The organic layer was separated. The aqueous layer was extracted with EtOAc (2x1 L). The combined organic layers were dried over MgSO4, filtered, and
225 concentrated. The crude residue was purified by flash chromatography (SIO2, 0-50%
EtOAc/petroleum ether) to provide 2-[6-bromo-4-fluoro-1-(propan-2-yl)-1/7-benzimidazol-2yl]propan-2-ol (A-21) (316 g, 91% yield) as a yellow solid.. 1H NMR (400 MHz, CDCI3) δ 7.49 (d, J = 1.6 Hz, 1H), 7.08 (dd, J = 9.7, 1.5 Hz, 1H), 5.45 (hept, J = 7.0 Hz, 1H), 2.87 (s, 1H), 1.77 (s, 6H), 1.63 (d, J = 7.0 Hz, 6H); 19F NMR (377 MHz, DMSO-de) δ -126.3; m/z (ESI+) for (C13Hi6BrFN2O), 314.7 (M+H)+.
Step 6: Synthesis of 2-[4-fIuoro-1-(propan-2-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan2-yl)-1H-benzimidazoI-2-yl]propan-2-ol (A-22)
A 3 L three-neck round bottom flask was charged with 2-[6-bromo-4-fluoro-1-(propan-2yl)-1H-benzimidazol-2-yl]propan-2-ol (A-21) (300 g, 952 mmol), Β2ΡΪΠ2 (290 g, 1.14 mol), Pd(dppf)Cl2 (34.8 g, 47.6 mmol), KOAc (280 g, 2.86 mol), and 1,4-dioxane (2 L). The reaction mixture was degassed and purged with N2 three times. The reaction mixture was heated to 90 °C (internai température) and stirred at this température for 3 h to provide an orange slurry. TLC analysis (1:2 EtOAc/petroleum ether, UV254, Rf = 0.4) showed consumption of the starting material. The reaction mixture was cooled to room température and filtered. The filtrate was diluted with EtOAc (2 L) and washed with brine (2x1 L). The organic layer was dried over MgSO4, filtered, and concentrated under vacuum. The residue was purified by flash chromatography (SiO2, 10-50% EtOAc/petroleum ether) to provide 2-[4-fluoro-1-(propan-2-yl)-6-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)-1/7-benzimidazol-2-yl]propan-2-oI (A-22) (210 g, 61% yield) as a light yellow solid. 1H NMR (400 MHz, CDCI3) δ 7.77 (s, 1H), 7.34 (d, J = 10.8 Hz, 1H), 5.41 (hept, J = 6.9 Hz, 1H), 3.10 (s, 1H), 1.79 (s, 6H), 1.69 (d, J= 7.0 Hz, 6H), 1.36 (s, 12H); 19F NMR (377 MHz, DMSO-de) δ -129.5; m/z (ESI+) for (Ci3Hi6FN2O), 362.9 (M+H)+.
Step 7: Synthesis of 2-(6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]propan-2-ol (A-23) ।
This reaction was carried out in two parallel batches. To a mixture of compound 2-[4fluoro-1-(propan-2-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaboroIan-2-yl)-1H-benzimidazol-2yl]propan-2-ol (A-22) (100 g, 276 mmol), and Na2CÛ3 (87. 8 g, 828 mmol) in 1,4-dioxane (1 L) ί !
and H2O (300 mL) was added 2,4,5-trichloropyrimidine (67.2 g, 359 mmol)f The mixture was degassed and purged with N2 three times. Pd(PPhs)4 (31.9 g, 27.6 mmol) was added and the mixture was degassed and purged with N2 three times. The reaction mixture was placed into a pre-heated oil bath at 100 °C and stirred at 90 °C (internai température) for 24 h. LCMS showed consumption ofthe starting material with formation ofthe desired productmass. The reaction was cooled to room température. The two reaction mixtures were combined. The combined mixture was filtered and concentrated under vacuum to remove the 1,4-dioxane. The residue was diluted
226 with EtOAc (1 L) and the organic layer was collected. The aqueous layer was extracted with
EtOAc (3x1 L). The combined organic layers were dried over MgSO4, filtered, concentrated. The crude residue was purified by flash chromatography (S1O2, 0-50% EtOAc in 1:5 petroleum ether/DCM). The pfoduct-containing fractions were concentrated under vacuum to -200 mL with concomitant précipitation of a white solid. The suspension was filtered and the filter cake was washed with petroleum ether (2x300 mL). The filter cake was collected and dried under vacuum to provide 2-(6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1 H-benzimidazol-2yl]propan-2-ol (A-23) (112 g). The filtrate was concentrated and residue was re-purified by flash chromatography (S1O2, 0-50% EtOAc in 1:5 petroleum ether/DCM). The product-containing fractions were concentrated under vacuum to -50 mL with précipitation of additional product. The suspension was filtered and the filter cake was washed with petroleum ether (2x100 mL). The filter cake was collected and dried under vacuum to provide an additional batch of 2-(6-(2,5dichloropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]propan-2-ol (A-23) (41 g). The product batches were combined to provide 2-(6-(2,5-dichIoropyrimidin-4-yl)-4-fiuoro-1 (propan-2-yI)-1H-benzimidazol-2-yl]propan-2-ol (A-23) (153 g, 71% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.01 (s, 1H), 8.06 (d, J = 1.3 Hz, 1H), 7.41 (dd, J = 11.5, 1.3 Hz, 1H), 5.85 - 5.72 (m, 2H), 1.67 (s, 6H), 1.61 (d, J = 7.0 Hz, 6H); 19F NMR (377 MHz, CDCI3) δ 128.2; m/z (ESI+) for (C17H17CI2FN4O), 383.0 (M+H)+.
Step 8: Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol (Example A94)
A 2 L three-neck round bottom flask was charged with 2-(6-(2,5-dichloropyrimidin-4-yl)-4fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]propan-2-oI (A-23) (112 g, 292 mmol), 3-amino-1,5anhydro-2,3-dideoxy-D-f/7reo-pentitol hydrochloride (51.6 g, 336 mmol), and MeCN (1.1 L). DIPEA (132 g, 1.02 mol, 178 mL) was added at room température. The reaction mixture was heated to 80 °C (internai température) and stirred at the same température for 40 h to'provide a brown solution. LCMS analysis showed remaining starting material. Additional 3-amino-1,5anhydro-2,3-dideoxy-D-f/7reo-pentitol hydrochloride (6.73 g, 43.8 mmol) was added at 80 °C (internai température) and the reaction was stirred at 80 eC (internai température) for an additional 10 h. The reaction mixture was cooled to room température and concentrated under vacuum. The residue was taken up in 1:1 EtOAc/H2O (1.5 L). Some solids were precipitated. EtOH (100 mL) was added. The organic layer was collected and the aqueous layer was extracted with EtOAc (2x500 mL). The combined organic layers were washed with H2O (2x300 mL), dried over Na2SO4, and filtered. To the filtrate was added sulfhydryl silica gel (Accela, 8 g, 0.7-1.4 mmol/g). The resulting mixture was stirred at room température for 1 h and then filtered through a pad of Celite.
_ 227
Treatment with sulfhydryl silica gel was repeated in identical fashion and the filtrate was concentrated to dryness. The crude residue was slurried in MeCN (500 mL) at room température for 16 h. The suspension was filtered and the filter cake was washed with MeCN (2x100 mL). The filter cake was slurried again with MeCN (300 mL) at room température for 6 h. The mixture was 5 filtered and the filter cake was washed with MeCN (2x100 mL). The filter cake was collected and dried under vacuum and then dried in a drying oven (45 °C for 20 h, 50 °C for 64 h) to provide 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1H-benzimidazol6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-f/7reo-pentitol (Example A94) (90 g, 66% yield) as a white solid. 1H NMR (400 MHz, 80 °C, DMSO-d6) δ 8.38 (s, 1H), 8.00 (s, 1H), 7.43 (d, J = 11.8 10 Hz, 1H), 7.13 (d, J = 7.5 Hz, 1H), 5.80 (hept, J = 7.0 Hz, 1H), 5.56 (s, 1H), 4.71 (d, J = 5.3 Hz, 1H), 3.91-3.79 (m, 3H), 3.61 -3.52 (m, 1H), 3.41-3.31 (m, 1H), 3.12-3.07 (m, 1H), 2.092.00 (m, 1H), 1.70 (s, 6H), 1.67-1.52 (m, 7H); 19F NMR (377 MHz, CDCI3) δ -127.2; m/z (ESI+) for (C22H27CIFN5O3), 464.2 (M+H)+; [ajo22 = -12.6 (c=0.2, MeOH).
Alternative préparation of 2-(6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]propan-2-ol (A-23) to Scheme A-16
SO3«pyr, TEA
DMSO 80% yield
MeMgBr THF, 0 ’C
93% yield
Step 1: Synthesis of 1-(6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1H20 benzimidazol-2-yl]ethan-1-one (A-19)
To a solution of (1S)-1-(6-(2,5-dichIoropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]ethan-1-ol (A-19) (3.86 g, 10.5 mmol) in DMSO (130 mL) was added Et3N (10.6 g, 105 mmol). Sulfur trioxide pyridine complex (10 g, 62.7 mmol) was added and mixture stirred — 228 at ambient température. After 4 h LCMS analysis showed -10% residual starting material. Additional sulfur trioxide pyridine complex (4.7 g) was added. After 1 h LCMS analysis showed consumption of the starting material Th mixture was partitioned between H2O and EtOAc. The aqueous layer was extracted with EtOAc (3x). Thé combinedidrganic layers were washed with 5 H2O, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 80 g S1O2, 10-40% EtAOc/heptane) to provide 1-(6-(2,5dichloropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]ethan-1-one (A-24) (3.1 g, 80% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 9.06 (s, 1H), 8.20 (d, J= 1.3 Hz, 1H), 7.55 (dd, J = 11.4,1.3 Hz, 1H), 5.77 (hept, J= 7.1 Hz, 1H), 2.79 (s, 3H), 1.61 (d, J= 7.0 Hz, 6H); 10 m/z (APCI) for (C16H13CI2FN4O), 366.8 (M+H)+.
Step 2: Synthesis of 2-(6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]propan-2-ol (A-23)
A solution of 1-(6-(2,5-dichloropyrimidin-4-yI)-4-fiuoro-1 -(propan-2-yl)-1 H-benzimidazoi-215 yl]ethan-1-one (A-24) (3.1 g, 8.7 mmol) in THF (87 mL) was cooled to 0 °C under an atmosphère of N2. A solution of méthylmagnésium bromide (3.0 M in Et20, 4.0 mL, 12 mmol) was added dropwise. The mixture was stirred for 30 min at 0 “C. LCMS analysis indicated consumption of starting material with formation of the desired product mass. The reaction was quenched with saturated aqueous NH4CI and partitioned between EtOAc and H2O. The aqueous layer was 20 extracted with EtOAc (2x). The combined organics were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (ISCO, 80 g S1O2, 20-60% EtOAc/heptane) to provide 2-(6-(2,5-dichioropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]propan-2-ol (A-23) (3.11 g, 93% yield) as a white solid. 1H NMR (400 MHz, DMSO-de) δ 9.01 (s, 1H), 8.06 (d, J = 1.3 Hz, 1H), 7.41 (dd, J = 11.5, 1.3 Hz, 1H), 5.85 - 5.72 25 (m, 2H), 1.67 (s, 6H), 1.61 (d, J = 7.0 Hz, 6H); m/z (APCI) for (C17H17CI2FN4O), 382.8 (M+H)+.
| Example B1 (Scheme B): Préparation |of 4-[4-fluoro-2-methyl-1-(propan-2-yl)-1Hbenzimidazol-6-yl]-2-{[(3R,4R)-3-hydroxy-1-(methanesulfonyl)piperidin-4yl]amino}pyrimidine-5-carbonitriie
I30 ί
I Scheme B: I
229
Pd(t-Bu3P)2 K2CO3
1,4-dioxane, H2O, 80 °C
76% yield
oxone
THF, H2O
85% yield
Na2CO3
THF, 65 ’C
31% yield
Step 1: Synthesis of 4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]-2(methylsulfanyl)pyrimidine-5-carbonitrile (B-1)
To a mixture of 4-chloro-2-(methylsulfanyl)pyrimidine-5-carbonitrile (150 mg, 0.808 mmol), 4-fluoro-2-methyl-1-(propan-2-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1Hbenzimidazole (A-1) (257 mg, 0.808 mmol), and K2CO3 (335 mg, 2.42 mmol) in 1,4-dioxane (15.0 mL) and H2O (2.1 mL) was added Pd(t-Bu3P)2 (41.3 mg, 0.0808 mmol). The reaction was sparged with N2 and then stirred at 80 °C for 1 h. LCMS analysis indicated consumption of the starting material with formation of the desired product mass. The mixture was combined with a second reaction run in the identical fashion with 85.7 mg 4-fluoro-2-methyl-1-(propan-2-yl)-6-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole (A-1). The mixture was diluted with EtjOAc (20 mL) and washed with H2O (5 mL). The aqueouè layer was extracted with EtOAc (3x10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (Biotage, SiO2, 1:1 petroleum ether/EtOAc) to provide 4-[4-fluoro-2-methyl-1-(propan-2-yl)-1/7-benzimidazol-6-yl]-2(methylsulfanyl)pyrimidine-5-carbonitriIe (B-1) (280 mg, 76% yield) as a yellow solid. 1H NMR (400 MHz, CDCI3) δ 8.78 (s, 1H), 8.31 - 8.22 (m, 1H), 7.82 - 7.72 (m, 1H), 2.71 (s, 3H), 2.69 (s, 3H), 2.67 - 2.64 (m, 1H), 1.72 (d, J= 6.8 Hz, 6H); m/z (ESI) for (C17Hi6FN5S), 342.0 (M+H)*.
Step 2: Synthesis of 4-[4-fluoro-2-methyl-1-(propan-2-yI)-1H-benzimidazol-6-yl]-2(methanesulfinyl)pyrimidine-5-carbonitrile (B-2) — 230
To a solution of 4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]-2(methylsulfanyl)pyrimidine-5-carbonitrile (B-1) (200 mg, 0.586 mmol) in THF (9.0 mL) and H2O (4.5 mL) was added oxone (540 mg, 0.879 mmol) at 10 °C. The résultant mixture was stirred at the same température for 1.5 h: LCMS analysis showed consumption of the starting material with 5 formation ofthe desired product mass. The reaction was combined with a parallel reaction run in identical fashion with 80 mg 4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazoI-6-yl]-2(methylsuIfanyi)pyrimidine-5-carbonitrile (B-1). The combined solution was diluted with EtOAc (20 mL) and washed with brine (10 mL). The aqueous layer was extracted with EtOAc (4x10 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered, and 10 concentrated to provide 4-[4-fluoro-2-methyl-1-(propan-2-yl)-1/-/-benzimidazol-6-yl]-2(methanesulfinyl)pyrimidine-5-carbonitrile (B-2) (250 mg, 85% yield) as an off-white solid, which was taken on without further purification, m/z (ESI) for (C17H16FN5OS), 358.3 (M+H)+.
Step 3: Synthesis of 4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]-215 {[(3R,4R)-3-hydroxy-1 -(methanesulfonyI)piperidin-4-yl]amino}pyrimidine-5-carbonitrile (Example B1)
To a mixture of 4-[4-fiuoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yI]-2(methanesulfinyl)pyrimidine-5-carbonitrile (B-2) (120 mg, 0.336 mmol) and (3R,4R)-4-amino-1(methanesuifonyI)piperidin-3-ol (lnt-69) in THF (15.0 mL) was added Na2CO3 (71.2 mg, 0.672 20 mmol). The résultant mixture was stirred at 65 °C for 12 h. LCMS analysis indicated consumption of the starting material with formation of the desired product mass. The mixture was diluted with EtOAc (30 mL) and washed with H2O (10 mL). The aqueous layer was extracted with EtOAc (2x20 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by préparative TLC (SiO2,10:1 DCM/MeOH, 25 Rf = 0.55). The material was further purified by préparative HPLC with a YMC-Actus Triait C18 column (150x30 mm, 5 pm particle size), which was eluted with 8-48% MeCN/H2O (+0.225% formic acid) to provide 4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-beijzimidazol-6-yi]-2-{[(3R,4R)-3hydroxy-1-(methanesulfonyl)piperidin-4-yl]amino}pyrimidine-5-carbonitrile (Example B1) (50 mg, 31% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.82 - 8.74 (m, 1H), 8.43 - 8.32 (m, 30 1 H), 8.21 -f 8.11 (m, 1 H), 7.59 - 7.48 (m, 1 H), 5.35 - 5.28 (m, 1 H), À.88 - 4.76 (m, 1 H),4.05 - 3.90 (m, 1H), 3.^70 - 3.59 (m, 2H), 3.56 - 3.47 (m, 1H), 2.91 - 2.81 (m, 4^), 2.71 - 2.59 (m, 4H), 2.10 1.95 (m, 1 H), 1.65 - 1.51 (m, 7H); m/z (ESI) for (C23H27FN6O3S), 488.1 (M+H)+.
The example the below table was synthesized according to the methods used for the synthesis of 4-[4-fluoro-2-methyl-1 -(propan-2-yl)-1 H-benzimidazol-6-yl]-2-{[(3R,4R)-3-hydroxy-1 (methanesulfonyl)piperidin-4-yl]amino}pyrimidine-5-carbonitrile (Example B1). The following
231 example was synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Example number | Structure/Name | -LCMS | NMR |
B2 | n^YCF3 ho^a LA Tl \ ,N L J N— N Me—/ O-S—O Me Me (3R,4R)-4-({4-[4-fIuoro-1- (propan-2-yl)-1 H-benzimidazol6-yl]-5(trifluoromethyl)pyrimidin-2yl}amino)-1- (methanesulfonyl)piperidin-3-ol | 516.9 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.71-8.66 (m, 1H), 8.51 (s, 1H), 8.20-8.09 (m, 1H), 7.64 (s, 1H), 7.23-7.14 (m, 1H), 5.27 (brs, 1H), 4.79 (hept, J = 6.6 Hz, 1H), 3.99-3.80 (m, 1H), 3.67 - 3.56 (m, 2H), 3.54 3.42 (m, 1H), 2.94-2.77 (m, 4H), 2.70 - 2.58 (m, 1H), 2.08 1.97 (m, 1H), 1.61-1.49 (m, 7H) |
Example C1 (Scheme C-1): Préparation of (3R,4R)-4-({4-[5-chloro-2-methyl-1-(propan-25 yi)-1H-benzimidazol-6-yl]-5-fIuoropyrimidin-2-yl}amino)-1-(methanesuIfonyl)piperidin-3-oI
Scheme C-1:
C-1 then PdCI2(PPh3)2, Na2CO3 H20,50 °C
PdCI2(dppf), B2Pin2, KOAc
1,4-dioxane, 70 ’C
20% yield
NH2
/rPrNH2
DN|SO, 50“C then acetaldehyde Na2S2O4 EtOH, 80 *C
46% yield
O=S=O Me
Pd(OAc)2 rac-BINAP, Cs2CO3
THF, 80 ’C
38% yield
232
Step 1: Synthesis of 2-chloro-4-(2-chloro-5-fluoro-4-nitrophenyl)-5-fluoropyrimidine (C-2)
To a solution of 1-bromo-2-chloro-5-fluoro-4-nitrobenzene (C-1) (0.5 g, 1.97 mmol) in 1,4dioxane (10.0 mL) were added KOAc (579 mg, 5.9 mmol) and B2Pin2 (749 mg, 2.95 mmol). The mixture was sparged with N2 and then PdCl2(dppf) was added. The mixture was stirred at 70 °C 5 with microwave irradiation for 30 min. LCMS analysis indicated consumption of the starting material with conversion to the boronate ester. To the mixture were added 2,4-dichloro-5fluoropyrimidine, aqueous Na2CÜ3 (2.0 M, 2.95 mL), and PdCl2(dppf) (80 mg, 0.1 mmol). The mixture was stirred at 50 °C with microwave irradiation for 2 h. LCMS analysis indicated consumption of the boronate ester with formation of the desired product mass. The mixture was 10 combined with a parallel reaction run in an identical fashion with 100 mg 1-bromo-2-chloro-5fluoro-4-nitrobenzene (C-1). The combined mixture was partitioned between EtOAc and H2O. The organic layer was washed with brine, dried over MgSO4, filtered, and concentrated onto S1O2. The crude material was purified by flash chromatography (ISCO, 40 g S1O2, 0-30% EtOAc/heptanes) to provide 2-chloro-4-(2-chloro-5-fIuoro-4-nitrophenyl)-5-fluoropyrimidine (C-2) 15 (120 mg, 20% yield) as an off-white solid. 1H NMR (400 MHz, DMSO-c/e) 9.19 (d, J= 1.3 Hz, 1H),
8.53 (d, J = 6.7 Hz, 1H), 8.01 (d, J = 11.0 Hz, 1H); m/z (ESI) for (C10H3CI2F2N3O2), 304.7 (M+H)+.
Step 2: Synthesis of 5-chloro-6-(2-chloro-5-fIuoropyrimidin-4-yl)-2-methyl-1-(propan-2-yl)1H-benzimidazole (C-3)
A mixture of 2-chloro-4-(2-chloro-5-fluoro-4-nitrophenyl)-5-fluoropyrimidine (C-2) (55 mg,
0.018 mmol) and /-PrNH2 (0.016 mL, 0.018 mmol) in DMSO (1 mL) was stirred at 50 °C with microwave irradiation for 1.5 h. LCMS analysis indicated consumption of the starting material. After cooling to room température the mixture was diluted with EtOH (0.5 mL) and treated with acetaldehyde (39.6 mg, 0.05 mL, 0.899 mmol) and Na2S2O4 (156 mg, 0.899 mmol). The mixture 25 was stirred at 80 °C for 16 h overnight. LCMS analysis indicated formation of the desired product mass. The mixture was concentrated to remove the EtOH. The remaining solution in DMSO was added dropwise to saturateà aqueous NaHCOs. The résultant yellow solids were [collected by filtration and washed with H2O. The solids were taken up into DCM/MeOH and concentrated to provide 5-chloro-6-(2-chloro-5-fluoropyrimidin-4-yl)-2-methyl-1-(propan-2-yl)-1H-benzimidazole 30 (C-3) (28 mg, 46% yield), which was taken on without further purification. 1H NMR (400 MHz,
DMSO-de) δ 9.05 (s, 1H), 7.97 (s, 1H), 7.79 (s, 1 H), 4.79 (spt, J = 6.8 Hz, 1H), 2.62 Js, 3H), 1.55 (d, J =7.0 Hz, 6H). m/z (ESI) for (C10H3CI2F2N3O2), 304.7 (M+H)+.
Step 3: Synthesis of (3/?,4R)-4-({4-[5-chIoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-635 yl]-5-fluoropyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol (Example C1)
233
To a solution of 5-chloro-6-(2-chloro-5-fluoropyrimidin-4-yl)-2-methyl-1-(propan-2-yl)-1/7benzimidazole (C-3) (28 mg, 0.083 mmol) in THF (1.0 mL) were added (3R,4R)-4-amino-1(methanesulfonyl)piperidin-3-ol (lnt-69) (24.1 mg, 0.124 mmol) and CS2CO3 (81 mg, 0.25 mmol).
The mixture wàs sparged with N2 and then Pd(OAc)2 (3.71 mg, 0.0165 mmol) and rac-BINAP (10 mg, 0.0165 mmol) were added. The mixture was heated to 80 °C overnight. LCMS analysis indicated consumption of the starting material with formation of the desired product mass. The mixture was partitioned between EtOAc and H2O. The aqueous layer was extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered, and concentrated. The residue was purified by préparative SFC with an HA-morpholine column (150x21.1 mm, 5 pm particle size, 35 °C column température), which was eluted with 10-50% MeOH/CO2 with a flow rate of 80 g/min. The material was re-purified by préparative SFC with a Nacalai Cosmosil 3hydroxyphenyl column (150x20 mm, 5 pm particle size. 35 °C column température), which was eluted with 12-50% MeOH/CO2 with a flow rate of 80 g/min to provide (3R,4R)-4-({4-[5-chloro-2methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]-5-fluoropyrimidin-2-yl}amino)-115 (methanesulfonyl)piperidin-3-ol (Example C1) (16 mg, 38% yield) as a solid. 1H NMR (600 MHz, DMSO-d6, 75 °C) δ 8.35 - 8.33 (m, 1H), 7.71 (s, 1H), 7.68 (s, 1H), 6.84 (d, J = 7.3 Hz, 1H), 5.13 (d, J = 4.0 Hz, 1H), 4.78 - 4.72 (m, 1H), 2.86 - 2.81 (m, 4H), 2.69 - 2.63 (m, 1H), 2.57 (s, 3H), 2.14 - 2.09 (m, 1H), 1.59 - 1.43 (m, 7H); four protons obscured by residual solvent peak; m/z (ESI) for (C21H26CIFN6O3S), 496.9 (M+H)+.
Example C2 (Scheme C-2): Préparation of 1,5-anhydro-3-({4-[2-(azetidin-3-yl)-4-fluoro-1(propan-2-yl)-1H-benzimidazol-6-yl]-5-chloropyrimidin-2-yl}amino)-2,3-dideoxy-D-fhreopentitol
Scheme C-2:
A solution of (C-4) (as prepared in Example C1, 155.0 mg, 0.22 mmol), 3-amino-1,5anhydro-2,3-dideoxy-D-t/7reo-pentitol (49.8 mg, 0.324 mmol), and DIPEA (126 mg, 0.173 mmol,
0.973 mmol) in DMSO (2 mL) was heated to 80 °C for 16 h overnight. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The mixture was loaded directly onto S1O2 and purified by flash chromatography (ISCO, 12 g SiO2, 0-100%
234
EtOAc/heptanes). The product-containing fractions were concentrated, taken up into DCM (5 mL), and treated with a solution of HCl (4.0 N in 1,4-dioxane, 1.0 mL). After 15 min, LCMS analysis showed conversion to the desired product. The reaction was concentrated to dryness.
The residue was purified by préparative SFC with a ChiralPak IC column (21x250 mm column,
10 pm particle size, 35 °C column température), which was eluted with 60% MeOH/CO2 (+10 mM
NH3) with a flow rate of 82 mL/min to provide 1,5-anhydro-3-({4-[2-(azetidin-3-yl)-4-fluoro-1(propan-2-yl)-1H-benzimidazol-6-yI]-5-chloropyrimidin-2-yl}amino)-2,3-dideoxy-D-fhreo-pentitol (Example C2) (72 mg, 72% yield) as a solid. 1H NMR (400 MHz, DMSO-d6,80 °C) δ 8.39 (s, 1H), 7.96 (s, 1H), 7.45 (d, J = 11.7 Hz, 1H), 7.13 (d, J = 7.6 Hz, 1H), 4.78 - 4.58 (m, 2H), 4.39 - 4.29 10 (m, 1 H), 4.15 - 3.99 (m, 2H), 3.92 - 3.77 (m, 5H), 3.66 - 3.52 (m, 2H), 3.39 - 3.31 (m, 1 H), 2.09 1.97 (m, 1H), 1.64 - 1.53 (m, 7H); m/z (ESI) for (C22H26CIFN6O2), 461.1 (M+H)+.
Example D1 (Scheme D-1): Préparation of(3/?,4R)-4-[(5-chloro-4-{4-fluoro-2-[(1S)-1hydroxyethyl]-1-(propan-2-yl)-1H-benzimidazol-6-yl}pyridin-2-yl)amino]-115 (methanesulfonyl)piperidin-3-ol
Scheme D-1:
Me OH
D-1
Pd(PPh3)4, Na2CO3
71% yield
H20,1,4-dioxane, 90 ’C
nh2
o=s=o
Me
Brettphos-Pd-G3 Cs2CO3 DMF, 1,4-dioxane, 110 °C
7% yield
Step 1: Synthesis of (1S)-1-[6-(2,5-dichloropyridin-4-yl)-4-fiuoro-1-(propan-2-yl)-1H benzimidazol-2-yl]ethan-1-ol (D-2):
235
To a solution of (1S)-1-[4-fluoro-1-(propan-2-yl)-6-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yI)-1H-benzimidazol-2-yI]ethan-1-ol (D-1) (Prepared as in Example A1, 650 mg, 1.87 mmol) in H2O (2.0 mL) and 1,4-dioxane (7.0 mL) were added 2,5-dichloro-4-iodopyridine (562 mg, 2.05 mmol), Na2CO3 (396 mg, 3.73 mmol), and Pd(PPh3)4 (216 mg, 0.187 mmol). The reaction mixture was stirred at 90 °C under an atmosphère of N2. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction was concentrated to dryness. The residue was purified by flash chromatography (ISCO, 40 g SiO2, 2:1 petroleum ether/EtOAc) to providé (1S)-1-[6-(2,5-dichloropyridin-4-yl)-4-fluoro-1 -(propan-2yl)-1H-benzimidazol-2-yl]ethan-1-ol (D-2) (490 mg, 71% yield) as a light yellow solid. m/z (ESI+) for (Ci7Hi6CI2FN3O), 368.0 (M+H)+.
Step 2: Synthesis of (3/?,4R)-4-[(5-chloro-4-{4-fluoro-2-[(1S)-1-hydroxyethyl]-1-(propan-2yl)-1 H-benzimidazol-6-yl}pyridin-2-yl)amino]-1 -(methanesulfonyl)piperidin-3-ol (Example D1):
A heterogeneous mixture of (1S)-1-[6-(2,5-dichloropyridin-4-yl)-4-fluoro-1-(propan-2-yl)1H-benzimidazol-2-yl]ethan-1-ol (D-2) (390 mg, 1.06 mmol), (3R,4R)-4-amino-1(methanesuIfonyl)piperidin-3-ol (lnt-69) (411 mg, 2.12 mmol), Cs2CO3 (1.04 g, 3.18 mmol), and Brettphos-Pd-G3 (96 mg, 0.106 mmol) in 1,4-dioxane (4.0 mL) and DMF (2.0 mL) was sparged with N2 for 3 min and then stirred at 110 °C for 4 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction was filtered and concentrated to dryness. The residue was purified by flash chromatography (ISCO, 40 g SiO2, ΟΙ 5% MeOH/EtOAc) and then re-purified by préparative HPLC with a Xtimate C18 column (250x80 mm, 10 pm particle size), which was eluted with 30-50% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min. HPLC analysis found some érosion of enatiopurity (93% ee). The material was re-purified by chiral préparative SFC with a Diacel Chiralpak AD-H column (250x30 mm, 5 pm particle size), which was eluted with 45% IPA/CO2 (+0.1% NH3) with a flow ratë of 50 mL/min to | provide (3R,4R)-4-[(5-chloro-4-{4-fluoro-2-t(1 S)-1 -hydroxyethyl]-1 -(propan-2-yl)-1 Hbenzimidàzol-6-yl)pyridin-2-yl)amino]-1-(methanesulfonyl)piperidin-3-ol (Example D1) (40.1 mg, 7% yield) as a white solid. 1H NMR (400 MHz, DMSO-de+ D2O) δ 7.99 (br s, 1 H), 7.54 (s, 1H), 17.07 (d, J = 10.8 Hz, 1H), 6.62 (s, 1H), 5.13 - 5.02 (mj 2H), 3.70 - 3.66 (m, 1H), 3.65 -3.45 m, ί 3H), 2.85 - 2.80 (m, 4H), 2.70 - 2.62 (m, 1H), 2.05 2.θθ' (m, 1H), 1.59 - 1.4 (m, 10H); m/z (ESI+) for (C23H29CIFN5O4S), 525.8 (M+H)+.
Example D2 (Scheme D-2): Préparation of 1,5-anhydro-3-[(5-chloro-4-{4-fluoro-2-[(1S)-1hydroxyethyl]-1-(propan-2-yl)-1H-benzimidazol-6-yl}pyridin-2-yl)amino]-2,3-dideoxy-Dthreo-pentitol
236
Scheme D-2:
A suspension of (1 S)-1-[6-(2,5-dichloropyridin-4-yl)-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]ethan-1-ol (D-3) (as prepared in Example D1, 680 mg, 1.85 mmol), 3-amino1,5-anhydro-2,3-dideoxy-D-fhreo-pentitol (324 mg, 2.77 mmol), BINAP (92 mg, 0.148 mmol), tBuONa (532 mg, 5.54 mmol), and Pd2(dba)3 (84.6 mg, 0.092 mmol) in PhMe (15.0 mL) was sparged with N2 for 3 min and then stirred at 110 °C for 16 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction was concentrated to dryness. The residue was purified by flash chromatography (ISCO, 40 g S1O2, 0-20% MeOH/EtOAc). The material was re-purified by préparative HPLC with a Xtimate C18 column (250x80 mm, 10 pm particle size), which was eluted with 30-50% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide 1,5-anhydro-3-[(5-chloro-4-{4-fIuoro-2-[(1S)-1hydroxyethyl]-1-(propan-2-yI)-1H-benzimidazol-6-yl}pyridin-2-yI)amino]-2,3-dideoxy-D-f/jreopentitol (Example D2) (67 mg, 8% yield) as a white solid1H NMR (400 MHz, DMSO-ds) δ 8.06 (s, 1H), 7.58 (d, J = 1.3 Hz, 1H), 7.07 (dd, J = 11.5, 1.3 Hz, 1H), 6.80 (d, J = 7.3 Hz, 1H), 6.65 (s, 1H), 5.74 (d, J = 6.5 Hz, 1H), 5.24 - 5.01 (m, 3H), 3.84 - 3.71 (m, 3H), 3.08 (dd, J = 9.5,10.8 Hz, 1H), 2.06 - 1.98 (m, 1H), 1.64 - 1.55 (m, 9H), 1.44 - 1.33 (m, 1H); two hydrogens obscured by residual solvent peak; m/z (ESI+) for (C22H26CIFN4O3), 449.1 (M+H)+.
the example the below table was synthesized according to the methods used for the synthesis of 1,5-anhydro-3-[(5-chloro-4-{4-fluoro-2-[(1 S)-1-hydroxyethyl]-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl}pyridin-2-yl)amino]-2,3-dideoxy-D-t/7reo-pentitol (Example D2). The following example was synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Example number | Structure/Name | LCMS | NMR |
237
D3 | - - HO. Â L ri ' //N k J N-X N Μβ-γ ~yMe O-S-O Me OH Me (3R,4R)-4-[(5-chloro-4-{4- fluoro-2-[(1 R)-1 -hydroxyethyl]- 1-(pro pan-2-yl )-1/7- bénzimidazol-6-yl}pyridin-2- yl)amino]-1- (methanesulfonyl)piperidin-3-ol | 525.9 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.07 (s, 1H), 7.59 (d, J =1.0 Hz, 1H), 7.07 (dd, J=11.4,1.3 Hz, 1H), 6.83 (brd, J = 7.5 Hz, 1H), 6.64 (s, 1H), 5.74 (d, J = 6.3 Hz, 1H), 5.27 (d, J = 4.5 Hz, 1H), 5.21-5.04 (m, 2H), 3.80-3.71 (m, 1H), 3.60- 3.49 (m, 2H), 3.49 - 3.39 (m, 1 H), 2.96 - 2.85 (m, 4H), 2.76 - 2.68 (m, 1H), 2.17-2.07 (m, 1H), 1.65-1.51 (m, 9H), 1.49- 1.33 (m, 1H) |
Example D4 (Scheme D-3): Préparation of (3/?,4/?)-4-({5-chloro-4-[2-methyl-3-(propan-2-yl)3H-imidazo[4,5-b]pyridin-5-yl]pyridin-2-yI}amino)-1-(methanesuIfonyI)piperidin-3-ol
Scheme D-3:
nh2
ΗΟ^χΑ | Ί lnt-69 o=s=o Me
Pd(OAc)2, BINAP P2-Et
Example D4
PhMe, 110 ’C
21% yield
To a solution of (D-4) (Prepared as in Example D1,78 mg, 0.24 mmol), (3R,4R)-4-amino1-(methanesulfonyl)piperidin-3-ol (lnt-69) (41 mg, 0.27 mmol), Pd(OAc)2 (3.4 mg, 0.015 mmol), 10 and rac-BINAP (9.45 mg, 0.73 mmol) was added phosphazene base P2-Et to provide a bright orange reaction solution. The mixture was sparged with N2 and then stirred at 110 °C for 16 h overnight. LCMS analysis indicated consumption of the starting material with formation of the desired product mass. The reaction was concentrated to dryness. The residue was purified by préparative SFC with a ZymorSPHER HADP column (150x21.1 mm, 5 pm particle size, 35 °C 15 column température), which was eluted with 12-50% MeOH/CO2 with a flow rate of 80 g/min. The material was repurified by préparative HPLC with a Phenomenex Gemini-NX C18 column
238 (150x21 mm, 5 pm particle size), which was eluted with 15-70% MeCN/FW (+10 nM NH4OAC) with a flow rate of 40 mL/min to provide (3R,4R)-4-({5-chloro-4-[2-methyl-3-(propan-2-yl)-3Himidazo[4,5-b]pyridin-5-yl]pyridin-2-yl}amino)-1-(methanesulfohyl)piperidin-3-ol (Example D4) (20 mg, 21% yield) as a sôlid. 1H NMR (600 MHz, DMSO-cfe) δ 8.08 (sr1H),'8?00 (d, J = 8.2 Hz,------5 1H), 7.46 (d, J = 8.2 Hz, 1H), 6.88 (d, J = 7.4 Hz, 1H), 6.81 (s, 1H), 5.28 - 5.24 (m, 1H), 4.82 (hept, J = 6.7 Hz, 1 H), 3.80 - 3.73 (m, 1 H), 3.61 - 3.52 (m, 2H), 3.49 - 3.44 (m, 1 H), 2.95 - 2.87 (m, 4H), 2.72 (dd, J= 11.4, 8.7 Hz, 1H), 2.63 (s, 3H), 2.15-2.10 (m, 1H), 1.67 (dd, J = 6.8, 1.6 Hz, 6H), 1.48 - 1.40 (m, 1H); m/z (APCI+) for (C21H27CIN6O3S), 478.9 (M+H)+.
The exârriple the below table was synthesized according to the methods used for the synthesis of (3R,4/?)-4-({5-chloro-4-[2-methyl-3-(propan-2-yl)-3H-imidazo[4,5-b]pyridin-5yl]pyridin-2-yi}amino)-1-(methanesulfonyl)piperidin-3-ol (Example D4). The following example was synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
239
Example number | Structure/Name | LCMS | NMR |
D5 | χχ01 HO^< N. A - Il ' /N“ Me 1,5-anhydro-3-({5-chloro-4-[2methyl-3-(propan-2-yl)-3Himidazo[4,5-b]pyridin-5yl]pyridin-2-yl}amino)-2,3dideoxy-D-fhreo-pentitol | 402.1 [M+H]+ (APCI) | 1H NMR (600 MHz, DMSO-de) δ 8.06 (s, 1H), 7.99 (d, J =8.3 Hz, 1H), 7.45 (d, J =8.2 Hz, 1H), 6.89-6.86 (m, 1H), 6.80 (s, 1H), 5.06 (br. s, 1H), 4.81 (hept, J = 6.4 Hz, 1H), 3.843.74 (m, 3H), 3.10-3.05 (m, 1H), 2.63 (s, 3H), 2.05-2.01 (m, 1H), 1.67 (dd, J =6.8, 2.3 Hz, 6H), 1.44-1.36 (m, 1H) two protons obscured by residual solvent peak |
Example D6 (Scheme D-4): Préparation of (3R,4R)-44[4-(1-tert-butyl-4-fIuoro-1Hbenzimidazol-6-yl)-5-chloropyridin-2-yl]amino}piperidin-3-ol
Scheme D-4:
D-5
Example D6
To a solution of ferf-buty (3R,4R)-4-{[4-(1-fe/i-butyl-4-fIuoro-1H-benzimidazol-6-yl)-5chloropyridin-2-yl]amino}-3-hydroxypiperidine-1-carboxylate (D-5) (Prepared as in Example D1, 10 3.4 g, 5.9 mmol) in DCM (20.0 ml_) was added a solution of HCl (1.0 M in EtOAc, 50 mL). After h LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The reaction was concentrated to dryness. The solid was taken up in H2O (50 mL) and washed with EtOAc (50 mL). The aqueous layer was lyophilized to provide (3R,4R)-4-{[4-(1fert-butyl-4-fIuoro-1H-benzimidazol-6-yl)-5-chloropyridin-2-yl]amino}piperidin-3-ol hydrochloric acid sait (Example D6) (2.7 g, 99% yield) as a yellow solid. 1H NMR (400 MHz, D2O) δ 9.35 (s,
1H), 8.12 (d, J= 0.6 Hz, 1H), 8.11 (d, J = 1.2 Hz, 1H), 7.56 (dd, J= 10.3, 1.2 Hz, 1H), 7.22 (s,
1H), 4.02-3.92 (m, 2H), 3.63-3.48 (m, 2H), 3.17 (td, J= 12.9, 3.3 Hz, 1H), 3.05 (dd, J = 12.7,
240
9.8 Hz, 1H), 2.42 - 2.34 (m, 1H), 1.98 - 1.79 (m, 10H); m/z (ESI+) for (C2iH25CIFN5O), 418.2 (M+H)+.
Example E1 (Scheme E-1): Préparation of (3R,4R)-4-[(5-chloro-4-{4-fIuoro-2-[(1S)-15 hydroxyethyI]-1-(propan-2-yl)-1H-benzimidazol-6-yl}pyridin-2-yi)amino]-1(methanesulfonyl)piperidin-3-ol
Scheme E-1:
DIPEA
DMSO, 100 ’C
44% yield
PdCI2(PPh3)2 Na2CO3 H20,1,4-dioxane
39% yield, 95 ’C
Step 1: Synthesis of (1S)-1-[6-(2,5?dichloropyridin-4-yl)-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]ethan-1-ol (E-1): '
A solution of 5-chloro-2-fluoro-4-iodopyridine (200 mg, 0.78 mmol), (3S,4S)-4-amino-1(methanesulfonyl)piperidin-3-ol (lnt-69) (181 mg, 0.93 mmol), and DIPEA (301 mg, 0.415 mL, 2.33 mmol) in DMSO (3.9 mL) was stirred at 100 °C for 16 h. LCMS analysis showed consumption 15 of the starting material with formation of the desired product mass. The reaction was loaded directly onto SiO2 and purified by flash chromatography (ISCO, 12 g SiO2, 0-100% EtOAc/heptanes) to provide (3S,4S)-4-[(5-chioro-4-iodopyridin-2-yl)amino]-1(methanesulfonyl)piperidin-3-ol (E-1) (147 mg, 44% yield) as a gum. 1H NMR (400 MHz, CDCI3) δ 7.93 (s, 1H), 7.08 (s, 1H), 4.85-4.73 (m, 1H), 4.01 -3.90 (m, 1H), 3.85-3.74 (m, 1H), 3.67 19876
241
3.58 (m, 2H), 3.44 (p, J = 6.7 Hz, 1H), 2.83 (s, 3H), 2.77 (dd, J = 12.2, 2.8 Hz, 1H), 2.68 - 2.52 (m, 1H), 2.14-2.08 (m,1H), 1.75-1.56 (m, 1 H); m/z (ESI+) for (C11H15CIIN3O3S), 431.8 (M+H)+.
Step 2: Synthesis of (3R,4R)-4-[(5-chIoro-4-{4-fIuoro-2-[(1S)-1-hydroxyethyl]-1-(propan-25 yl)-1H-benzimidazol-6-yl}pyridin-2-yl)amino]-1-(methanesulfonyl)piperidin-3-ol (Example E1):
To a solution of (3S,4S)-4-[(5-chloro-4-iodopyridin-2-yl)amino]-1(methanesulfonyl)piperidin-3-ol (E-1) (147 mg, 0.341 mmol) in 1,4-dioxane (4.7 mL) was added 4-fluoro-2-methyl-1 -(propan-2-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yI)-1 H10 benzimidazole (A-1) (108 mg, 0.341 mmol), aqueous Na2COs (2.0 M, 0.51 mL), PdCI2(PPh3)2 (12 mg, 0.017 mmol), and H2O (0.4 mL). The mixture was stirred at 95 °C for 5 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction was filtered through celite and concentrated. The material was purified by préparative SFC with a DCPak SFC-B column (150x21.2 mm, 5 pm particle size, column température 35 °C), which was eiuted with 25-35% MeOH/CO2 with a flow rate of 62 mL/min to provide (3R,4R)-4-[(5chloro-4-{4-fluoro-2-[(1S)-1-hydroxyethyl]-1-(propan-2-yl)-1H-benzimidazol-6-yl}pyridin-2yl)amino]-1-(methanesulfonyl)piperidin-3-ol (Example E1) (66 mg, 39% yield) as a white solid. 1H NMR (700 MHz, DMSO-d6) δ 8.06 (s, 1H), 7.54 (s, 1H), 7.03 (d, J = 11.2 Hz, 1H), 6.81 (d, J = 7.3 Hz, 1H), 6.64 (s, 1H), 5.29 (br. s, 1H), 4.83 - 4.76 (m, 1H), 3.78 - 3.71 (m, 1H), 3.60 - 3.50 (m, 2H), 3.48 - 3.41 (m, 1 H), 2.95 - 2.87 (m, 4H), 2.74 - 2.68 (m, 1 H), 2.60 (s, 3H), 2.14 - 2.09 (m, 1H), 1.56 (d, J = 6.8 Hz, 6H), 1.46 - 1.39 (m, 1H); m/z (APCI) for (C^H^CIFNsOsS), 495.9 (M+H)+.
Example F1 (Scheme F-1): Préparation of methyl (3R,4R)-4-({5-fIuoro-4-[4-fIuoro-2-methyl25 1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-3-hydroxypiperidine-1carboxylate | Scheme F-1: |
To a solution of (3R,4R)-4-({5-fiuoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H30 benzimidazol-6-yl]pyrimidin-2-yl}amino)piperidin-3-ol (Example A37) (Prepared as in Scheme A1,50 mg, 0.12 mmol) and TEA (18.9 mg, 0.186 mmol) in DCM (3.0 mL) at 0 °C was added methyl _ 242 chloroformate (11.7 mg, 0.124 mmol) dropwise. The reaction was stirred for 30 min at room température. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The solution was concentrated. The residue was partitioned between H2O (20 mL) and EtOAc (20 mL). The organic layer was dried over Na2SO4, filtered, and concentrated.
The residue was combined with a second batch obtained from a parallel reaction run in identical fashion with 50 mg of (SR^RH-QS-fluorcM-^-fluoro^-methyl-l-Îpropan^-yO-IH-benzimidazole-yllpyrimidin^-ylJaminoJpiperidin-S-ol (Example A37). The mixture was purified by préparative HPLC with DuraShell column (150x25 mm, 5 pm particle size), which was eluted with 22-72% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide methyl (3R,4R)-4-({5-fluoro10 4-[4-fIuoro-2-methyl-1-(propan-2-yl)-1/7-benzimidazol-6-yl]pyrimidin-2-yl}amino)-3hydroxypiperidine-1-carboxylate (Example F1) (48 mg, 42% yield) as a white solid. 1H NMR (400 MHz, DMSO-de) δ 8.43 (d, J = 4.0 Hz, 1H), 8.13 (brs, 1H), 7.61 (d, J= 12.2 Hz, 1H), 7.18 (d, J = 7.7 Hz, 1H), 5.11 (d, J = 4.8 Hz, 1H), 4.87 - 4.75 (m, 1H), 4.08 - 3.75 (m, 3H), 3.60 (s, 3H), 3.51 - 3.45 (m, 1H), 3.01 - 2.67 (m, 2H), 2.63 (s, 3H), 2.10 - 1.92 (m, 1H), 1.59 (d, J = 6.8 Hz, 6H), 15 1.45 -1.30 (m, 1 H); m/z (ESI) for (C22H26F2N6O3), 461.4 (M+H)+.
The examples in the below table were synthesized according to the methods used for the synthesis of methyl (3R,4R)-4-({5-fIuoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6yl]pyrimidin-2-yl}amino)-3-hydroxypiperidine-1-carboxylate (Example F1). The following 20 examples were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize. If necessary, séparation ofthe enantiomers was carried out understandard methods known in the art, such as chiral SFC or HPLC, to afford single enantiomers.
Example number | Structure/Name | LCMS | NMR |
F2 | N^C' hnAAhYF HO^ LA Il \ ,N L J N— ï A Μ'ΌΛο V ‘second eluting stereoisomer methyl (3R,4R)-4-({5-chloro-4[4-fluoro-1-(oxolan-3-yl)-1 Hbenzimidazol-6-yI]pyrimidin-2- | 491.1 [M+H]+ (ESI) | |1H NMR (400 MHz, DMSO-cfe) 5 8.47 — 8.39 (m, 2H), 8.087.90 (m, 1H), 7.57-7.36 (m, I2H), 5.41 -5.30 (m, 1H), 5.09 i(d, J =4.8 Hz, 1H), 4.19-3.77 (m, 7H), 3.59 (s, 3H), 3.51 3.39 (m, 1H), 3.02-2.64 (m, 2H), 2.62-2.52 (m, 1H), 2.29 - 2.18 (m, 1H), 2.02-1.87 (m, |
243
yl}amino)-3-hydroxypiperidine- 1-carboxylate | 1H), 1.43-1.29 (m, 1H);[a]D 20 =-28.8 (c=1.0, MeOH) | ||
Il J e - | 1H NMR (400 MHz, DMSO-d6) | ||
HN N^Yy | δ 8.45 - 8.40 (m, 2H), 8.05 - | ||
Tl \ ,N | 7.91 (m, 1H), 7.56 - 7.37 (m, | ||
ï M | 2H), 5.39-5.31 (m, 1H), 5.16 | ||
θΥ | 491.1 | -5.04 (m, 1H), 4.19-3.76 (m, | |
F3 | ‘first eluting stereoisomer | [M+H]+ | 7H), 3.59 (s, 3H), 3.51 - 3.39 |
methyl (3R,4R)-4-({5-chloro-4[4-fluoro-1-(oxolan-3-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-3-hydroxypiperidine1-carboxylate | (ESI) | (m, 1H), 3.00-2.64 (m, 2H), 2.62 - 2.52 (m, 1H), 2.29 - 2.19 (m, 1H), 2.05-1.87 (m, 1 H), 1.42 -1.29 (m, 1 H); [a]D 20 = -4.9 (c=1.0, MeOH) |
Example F4 (Scheme F-2): Préparation of (3R,4R)-4-({5-fIuoro-4-[4-fluoro-2-methyl-1(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amïno)-1-methylpiperidin-3-ol
Scheme F-2:
To a solution of paraformaldéhyde NaBH3CN
MeOH
58% yield
Example F4 (3R,4R)-4-({5-fluoro-4-[4-f]uoro-2-methyl-1 -(propan-2-yI)-1 H10 benzimidazol-6-yl]pyrimidin-2-yl}amino)piperidin-3-ol (Example A37) (Prepared as in Scheme A1, 50 mg, 0.12 mmol) in MeOH (3 mL) was added paraformaldéhyde (100 mg, 1.11 mmol) and NaBHsCN (100 mg, 1.59 mmol). The résultant solution was stirred at room température for 30 min. LCMS analysis showed consumption of starting material with formation of the desired product mass. -The solution was filtered and the filtrate was combined with a parallel reaction run in an identical fashion with 50 mg (3R,4R)-4-({5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H15 (150x20 mm, 5 pm particle size), which was eluted with 0-38% MeCN/H2O (0.225% formic acid) with a flow rate of 25 mL/min to provide (3R,4R)-4-({5-fluoro-4-[4-fluoro-2-methyI-1-(propan-2-yl)1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1-methylpiperidin-3-ol formic acid sait (Example F4) benzimidazol-6-yl]pyrimidin-2-yI}amino)-1-methylpiperidin-3-ol (Example A37) and concentrated. The residue was purified by préparative HPLC with an Agela Durashell C18 column
244 (60.2 mg, 58% yield) as a white solid. 1H NMR (400 MHz, DMSO-de) δ 8.42 (d, J = 4.1 Hz, 1H),
8.21-8.13 (m, 2H), 7.61 (d, J= 12.2 Hz, 1H), 7.10 (d, J= 6.3 Hz, 1 H), 5.22-4.57 (m, 2H), 3.65
- 3.52 (m, 2H), 2.99 - 2.88 (m, 1H), 2.81 - 2.72 (m, 1H), 2.63 (s, 3H), 2.24 (s, 3H), 2.08 - 1.85 (m, 3H), 1.64 - 1.42 (m, 7H); m/z (ESI) for (C2iH26F2N6O), 417.1 (M+H)+. 5 The examples in the below table were synthesized according to the methods used for the synthesis of (3R,4R)-4-({5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1 H-benzimidazol-6yi]pyrimidin-2-yl)amino)-1-methylpiperidin-3-ol (Example F4). The following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize. _
Example number | Structure/Name | LCMS | NMR |
F5 | N-YC' A HN N [|Ί HO^^k AA ri \ ,N L J n— n Mey( Me Me OH (3R,4R)-4-{[4-(1 -tert-butyl-4fluoro-1 H-benzimidazol-6-yl)-5chloropyrimidin-2-yl]amino}-1(2-hydroxyethyl)piperidin-3-ol formic acid sait | 463.3 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.51-8.35 (m, 3H), 8.15 (s, 1H), 7.52 (d, J=11.5 Hz, 1H), 4.06 - 3.90 (m, 2H), 3.82 (t, J = 5.6 Hz, 2H), 3.45 - 3.34 (m, 1H), 3.07-2.96 (m, 2H), 2.92 - 2.70 (m, 2H), 2.48 - 2.30 (m, 1 H), 1.87 -1.75 (m, 10H); one proton obscured by residual solvent peak |
F6 | Ν'^Α hnx^n'At<^<f HO^zk AA Il \ ,N L J N— N Me—/ Me Me A Me Me (3R,4R)-4-{[4-(1 -tert-butyl-4fiuoro-1 H-benzimidazol-6-yl)-5chIoropyrimidin-2-yl]amino}-1[2’ (dimethylamino)ethyl]piperidin3-ol formic acid sait | 490.3 [M+H]+ (ESI) | Ή NMR (400 MHz, CD3OD) δ 8.39 (s, 1H), 8.37-8.31 (m, 1H), 8.15 (s, 1H), 7.53 (d, J = 11.5 Hz, 1H), 3.^7-3.77 (m, 1H), 3.75-3.64 (m, 1H), 3.13 - 3.05 (m, 1H), 2.94-2.79 (m, 3H), 2.65 (t, J ='6.7 Hz, 2H), 2.55 (s, 6H), 2.27 - 2.07 (m, 3H), 1.82 (s, 9H), 1.68-1.54 (m, 1H) |
245
F7 | A HN N TT A N Me-/ Me Me ‘second eluting stereoisomer (3R,4R)-4-({5-chloro-4-[4fluoro-2-(hydroxymethyl)-1(propan-2-yi)-1 H-benzimidazol6-yl]pyrimidin-2-yl}amino)-1 (methanesulfonyl)piperidin-3-ol | 417.2 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) δβ.41-8.42 (m, 1H), 8.17 (s, 1 H), 7.60-7.63 (m, 1H), 7.067,07 (m, 1H), 4.85-4.79 (m, 2H), 3.60 - 3.50 (br m, 2H), 2.91-2.88 (m, 1H), 2.73-2.70 (m, 1H), 2.63 (s, 3H), 2.19 (s, 3H), 2.04 -1.75 (m, 3H), 1.591.62 (m, 6H), 1.51-1.40 (m,. 1H); [a]o20 = 15.4 (c=041, CHCI3) |
Example F8 (Scheme F-3): Préparation of (3/?,4R)-4-({5-chloro-4-[4-fluoro-2-methyI-1(oxetan-3-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1-(ethanesulfonyl)piperidin-3-ol
Scheme F-3:
EtSO2CI NaHCO3
EtOAc, H2O, 0 °C
8% yield
A mixture of (3R,4R)-4-({5-chloro-4-[4-fluoro-2-methyl-1-(oxetan-3-yl)-1H-benzimidazol6-yl]pyrimidin-2-yl}amino)piperidin-3-ol (F-1) (Prepared as in Scheme A-1, 70 mg, 0.152 mmol) and NaHCO3 (204 mg, 2.43 mmol) in EtOAc (1.0 mL) and H2O (1.0 mL) was cooled to 0 °C. A 10 solution of ethanesulfonyl chloride (20.8 mg, 0.162 mmol) in EtOAc (1.0 mL) was added dropwise over a period of 10 min. The réaction was stirred at 0 °C for 16 h. LMCS analysis |showed consumption of the starting material with formation of the desired product mass. The reaction layers were separated. The aqueous layer was extracted with EtOAc (3x10 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by 15 préparative HPLC with a DuraShell column (150x25 mm, 5 pm particle size), which was eluted with 28-48% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide (3R,4R)-4-({5chloro-4-[4-fluoro-2-methyl-1 -(oxetan-3-yl)-1 H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-1 (ethanesulfonyl)piperidin-3-ol (Example F8) (7 mg, 8% yield) as a white solid. 1H NMR (500 MHz, CD3OD) δ 8.61 ( br. s, 1H), 8.36 (s, 1H), 7.70-7.55 ( br. m, 1H), 5.81 -5.72 (m, 1H), 5.30- 5.25 20 (m, 2H), 5.22-517 (m, 2H), 3.96 - 3.90 (m, 1 H), 3.88-3.82 (m, 1 H), 3.73 - 3.66 (m, 2H), 3.11
246
-3.03 (m,2H), 3.02-2.95 (m, 1H), 2.83-2.77 (m, 1H), 2.63 (s, 3H), 2.26-2.17 (m, 1H), 1.68
- 1.58 (m, 1 H), 1.39 - 1.27 (m, 3H); m/z (ESI) for (C22H26CIFN6O4S), 525.3 (M+H)+.
The examples in the below table were synthesized according to the methods used for the synthesis of (3R,4R)-4-({5-chloro-4-[4-fIuoro-2-methyI-1-(oxetan-3-yI)-1H-benzimidazol-6yl]pyrimidin-2-yl}amino)-1-(ethanesulfonyl)piperidin-3-ol (Example F8). The following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize. If necessary, séparation of the enantiomers of was carried out under standard methods known in the art, such as chiral SFC or
HPLC, to afford single enantiomers.
Example number | Structure/Name | LCMS | NMR |
F9 | Ν^1 JL hn nY y LJ, Il ' //N ΜβΆ aoh °-S-° Me Me F^F (3R,4R)-4-({5-chloro-4-[4fluoro-2-(1 -hydroxyethyl)-1 (propan-2-yl)-1 H-benzimidazol6-yl]pyrimidin-2-yl}amino)-1(difluoromethanesulfonyl)piperi din-3-ol | 563.1 [M+HJ+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H), 8.06 (s, 1H), 7.51 (brd, J =11.5 Hz, 1H), 6.886.52 (m, 1H), 5.34 (td, J= 6.9, 14.0 Hz, 1H), 5.23 (q, J =6.8 Hz, 1H), 4.09-3.92 (m, 2H), 3.85 (brd, J= 13.7 Hz, 1H), 3.72 (dt, J = 4.7, 9.0 Hz, 1H), 3.29 - 3.21 (m, 1H), 3.08 (dd, J = 9.5, 12.8 Hz, 1H), 2.30 - 2.22 (m, 1H), 1.77-1.67 (m, 10H), 0.92 (brt, J =6.5 Hz, 1H); [afo^-e.S (c=0.1,MeOH) |
F10 | ïV 1 HN N ]|< ΗΟ^χ< LyL, Il ' //N Y Μβ^ O-S-O Me Me j F^F (3R,4R)-4-({5-chloro-4-[4fluoro-2-(1-hydroxyethyl)-1(propan-2-yl)-1 H-benzimidazol6-yl]pyrimidin-2-yl}amino)-1- | 584.9 [M+Na]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.38 (s, 1H), 8.06 (s, 1 H), 7.62 -7.41 (m, 1H), 6.90-6.48 (m, 1H), 5.40-5.31 (m, 1H), 5.24 (q, J =6.7 Hz, 1 H),4.06 - 3.92 (m, 2H), 3.86 (brd, J =13.2 Hz, 1 H), 3.72 (td, J = 4.6, 9.0 Hz, 1H), 3.31-3.21 (m, 1H), 3.15 - 2.95 (m, 1H), 2.34 - 2.15 (m, 1H), 1.77-1.70 (m,9H), |
247
(difluoromethanesulfonyl)piperi din-3-ol | 1.68-1.62(01,1^:(010^ = - 25.6(c=0.1, MeOH) | ||
F11 | N^YCI HO,, x^. keiJs r* i \ ,N k J n-4 V MeY >-..OH O-S-O Meue Me (3S,4R)-(re/)-4-[(5-chloro-4-{4- fluoro-2-[(1 R)-1 -hydroxyethyl]- 1 -(propan-2-yl)-1 H- benzimidazol-6-yl}pyrimidin-2yl)amino]-1(methanesulfonyl)piperidin-3-ol | 526.9 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.39 (s, 1H), 8.04 (s, 1H), 7.48 (d, J= 11.5 Hz, 1H), 5.40-5.29 (m, 1H), 5.23 (q, J =6.8 Hz, 1 H), 4.15 - 4.07 (m, 2H), 3.82 3.72 (m, 2H), 3.14 (br d, J = 11.8 Hz, 1H), 3.05 (dt, J =3.0, 12.2 Hz, 1H), 2.95 (s, 3H), 2.12 -2.00 (m, 1 H), 1.90 (brd, J = 9.5 Hz, 1H), 1.75-1.70 (m, 9H) |
F12 | xk J\X^XF HO,, χ-\ k^k r 1 \ ,N k J n-4 Y MeY >..·ΟΗ 0-S-O Mewe7 Me (3S,4R)-(re/)-4-[(5-chloro-4-{4- fluoro-2-[(1 R)-1-hydroxyethyl]- 1 -(propan-2-yl)-1 H- benzimidazol-6-yl}pyrimidin-2yl)amino]-1- (methanesulfonyl)piperidin-3-ol | 526.9 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.06 (s, 1H), 7.50 (d, J=11.5 Hz, 1H), 5.34 (m, J = 7.0, 13.9 Hz, 1H), 5.23 (m, J = 6.7 Hz, 1H), 4.00-3.91 (m, 1H), 3.87-3.81 (m, 1H), 3.783.66 (m, 2H), 2.95 (m, J = 2.5, 12.0 Hz, 1H), 2.90 (s, 3H), 2.76 (m, J= 9.5,11.5 Hz, 1H), 2.29 2.20 (m, 1H), 1.75-1.65 (m, 10H) |
F13 | xk HN N fl “'A Ύν k χ* N-4 V MeY Λ...ΟΗ - 0-S-O Me^e Me (3S,4S)-4-[(5-chloro-4-{4fIuoro-2-[(1 R)-1 -hydroxyethyl]1-(propan-2-yl)-1Hbenzimidazol-6-yl}pyrimidin-2yl)amino]-1(methanesulfonyl)piperidin-3-ol | 526.9 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1 H), 8.06 (s, 1 H), 7.50 (d, J = 11.6 Hz, 1H), 5.34 (m, J = 6.9,13.9 Hz, 1H), 5.23 (m, J = 6.6 Hz, 1H), 4.00-3.92 (m, 1H), 3.84 (m, J = 1.7, 4.6,11.6 Hz, 1H), 3.79-3.65 (m, 2H), 2.99-2.91 (m, 1H),2.90(s, 3H), 2.80 - 2.67 (m, 1H), 2.28 2.21 (m, 1H), 1.76-1.63 (m, 10H) |
248
F14 | A F HN N Ti A I1 MeA Xfe O=S=O Me Me (3S,4S)-4-({5-fluoro-4-[4-fluoro2-methy!-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-1- (methanesulfonyl)piperidin-3-oI | 481.2 [M+HJ+ (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.43 (d, J = 4.0 Hz, 1H), 8.12 (s, 1H), 7.62 (brd, J = 12.3 Hz, 1H), 7.22 (br d, J = 7.0 Hz, 1H), 5.22 (br d, J = 4.3 Hz, 1 H), 4.89 -4.73 (m, 1H), 3.77 (brs, 1H), 3.61 (brd, J = 10.8 Hz, 2H), 3.49 (brs, 1H), 2.91 (s, 3H), 2.89 - 2.82 (m, 1H), 2.71 - 2.64 (m, 1H), 2.63 (s, 3H), 2.09 (br s, 1H), 1.60 (d, J = 6.8 Hz, 6H), 1.52 (brs, 1H). |
1H NMR (700 MHz, DMSO-d6) | |||
n^A | 5 8.42 - 8.34 (m, 2H), 8.21 (br. | ||
JL HN | s., 1H), 7.65-7.54 (m, 1H), | ||
HO^/X LA Il \ ,N | 7.15 (d, J =7.7 Hz, 1H), 5.22- | ||
F15 | k > N— N Me-/ O=S=O MeZL Me | 481.1 [M+HJ+ | 5.07 (m, 1H), 3.77-3.66 (m, 1H), 3.62-3.51 (m, 2H), 3.48- |
(3R,4R)-4-{[4-(1 -fert-butyl-4fluoro-1 H-benzimidazol-6-yl)-5- | (ESI) | 3.39 (m, 1H), 2.84 (s, 3H), 2.80 (dt, J = 2.6, 11.7 Hz, 1H), 2.61 | |
fIuoropyrimidin-2-yl]amino}-1(methanesulfonyl)piperidin-3-ol | (t, J =10.1 Hz, 1H), 2.04 (d, J = 7.3 Hz, 1H), 1.69 (s, 9H), 1.531.42 (m, 1H) |
Example F16 (Scheme F-4): Préparation of 1-[(3R,4R)-4-({5-fluoro-4-[4-fIuoro-2-methyl-1(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-3-hydroxypiperidin-1-yl]ethan1-o|ne I
Scheme F-4:
Example A37
Example F16
To a stimng solution of (3R,4R)-4-({5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1Hbenzimidazol-6-yl]pyrimidin-2-yi}amino)piperidin-3-ol trifluoroacetate (Example A37) (300 mg,
249
0.581 mmol) and triethylamine (226 mg, 0.31 mL, 2.24 mmol) in DCM (5 mL) was added AC2O (152 mg, 0.14 mL, 1.49 mmol). The mixture was stirred at ambient température for 2 h before being diluted with water (10 mL) and extracted with DCM (3x10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated. The crude residue was purified by préparative HPLC with an Agela Durashell C18 column (150x25 mm, 5 pm particle size, 25 °C column température), which was eluted with 15-55% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide 1-[(3R,4R)-4-({5-fluoro-4-[4-fIuoro-2-methyI-1(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yI}amino)-3-hydroxypiperidin-1-yl]ethan-1-one (Example F16) (22.0 mg, 9% yield) as a white solid. 1H NMR (400 MHz, DMSO-de) δ 8.43 (br s, 10 1H), 8.13 (brs, 1H), 7.61 (brd, J = 12.0 Hz, 1H), 7.28 - 7.13 (m, 1H), 5.18 - 5.01 (m, 1H), 4.894.75 (m, 1H), 3.91 - 3.70 (m, 2H), 3.18 - 2.75 (m, 2H), 2.69 - 2.60 (m, 3H), 2.33 (br s, 1H), 2.01 (br d, J = 4.3 Hz, 4H), 1.59 (br d, J = 6.5 Hz, 7H), 1.36 (br d, J = 14.1 Hz, 1H); m/z (ESI+) for (C22H26F2N6O2), 445.4 (M+H)+.
Example F17 (Scheme F-5): Préparation of 1-[(3R,4R)-4-({5-fIuoro-4-[4-fluoro-2-methyl-1(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-3-hydroxypipéridin-1-yl]-2hydroxyethan-1-one
Scheme F-5:
To . (3R,4R)-4-({5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazoI-6yl]pyrimidin-2-yl}amino)piperidin-3-ol trifluoroacetate (Example A37) (50 mg, 0.12 mmol) and glycolic acid| (9.45 mg, 0.124 mmol) in DMF (4.0 mL) were added dJpEA (48.2 mg, 0.373 mmol) and HATU (70.9 mg, 0.186 mmol). The mixture was stirred at ambient température for 16 h. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The reaction mixture was washed with H2O (20 mL) and satôrated aqueous NaHCO3 (20 mL). The combined aqueous layers were extracted with EtOAc (20 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by préparative HPLC with a DuraShell column (150x25 mm, 5 pm particle size), which was eluted with 12-52% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide 1-[(3R,4R)-430 ({5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazoÎ-6-yl]pyrimidin-2-yl}amino)-3hydroxypiperidin-1-yl]-2-hydroxyethan-1-one (Example F17) (8 mg, 14% yield) as a white solid.
250 1H NMR (400 MHz, DMSO-d6) δ 8.44 (t, J = 4.0 Hz, 1H), 8.14 (brs, 1H), 7.62 (brd, J = 12.0 Hz, 1H), 7.32 - 7.21 (m, 1H), 5.15 (dd, J = 4.8, 9.3 Hz, 1H), 4.83 (hept, J = 6.9 Hz, 1H), 4.56 (t, J = 5.0 Hz, 1H), 4.33 (br d, J = 9.3 Hz, 1H), 4.17 - 4.04 (m, 2H), 4.04 - 3.81 (m, 2H), 3.73 - 3.40 (m, 2H), 3.10 - 2.95 (m, 1H), 2.63 (s, 3H), 2.09 - 1.97 (m, 1H), 1.60 (d, J = 7.0 Hz, 6H),1.48 - 1.33 5 (m, 1 H); m/z (ESI+) for (C22H26F2N6O3), 461.3 (M+H)+.
The examples in the below table were synthesized according to the methods used for the synthesis of 1-[(3R,4R)-4-({5-fiuoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6yl]pyrimidin-2-yl}amino)-3-hydroxypiperidin-1-yl]-2-hydroxyethan-1-one (Example F17). The 10 following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
251
Example number | Structure/Name | LCMS | NMR | |
F18 | N-YCI A hn nYV HCLxk AA Il \ ,N L J N—/ N Me-γ /-A0 _Me O-J [(3R,4R)-4-({5-chloro-4-[4- fluoro-1-(propan-2-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-3-hydroxypiperidin-1yl](oxetan-3-yl)methanone | 488.9 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-de) δ 8.52 (s, 1H), 8.43 (d, J = 4.8 Hz, 1H), 7.91 (brs, 1H), 7.427.40 (m, 2H), 5.24-5.11 (m, 1H), 4.88 - 4.77 (m, 1H), 4.76 4.58 (m, 4H), 4.41 - 3.95 (m, 4H), 3.93 - 3.83 (m, 1H), 3.10 2.84 (m, 1H), 2.67-2.56 (m, 1H), 1.95-1.93 (m, 1H), 1.57 (d, J =6.8 Hz, 6H), 1.34-1.32 (m, 1H) | |
F19 | n O HN^ HO^xk SA oA^o V Me [(3R,4R)-4-( fluoro-1-(prc benzimidazolyl}amino)-3-hy yl](3-mett yl)me | ^Cl N tX \An N— Me—γ Me [5-chloro-4-[4- >pan-2-yl)-1H6-yl]pyrimidin-2droxypiperidin-1iyloxetan-3thanone | 502.9 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-de) δ 8.54 (s, 1H), 8.44 (s, 1H), 7.91 (brs, 1H), 7.64-7.35 (m, 2H), 5.26 - 5.12 (m, 1H), 4.89 4.71 (m, 3H), 4.38-4.07 (m, 3H), 3.95 - 3.83 (m, 1H), 3.58 3.38 (m, 1H), 3.12-2.94 (m, 1H), 2.92 - 2.79 (m, 1H), 2.66 2.57 (m, 1H), 2.08-1.89 (m, 1H), 1.58 (s, 3H), 1.57-1.49 (m, 6H), 1.44-1.30 (m, 1H) I |
F20 | Nx HN HO^A. Me-Ao ÔH . (2R)-1-[(3R,4F [4-chloro-1-(p benzimidazol- | Αχ” N— Me—γ Me ?)-4-({5-chloro-4- ropan-2-yl)-1H- 6-yl]pyrimidin-2- | 515.1 [M+Na]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.48 - 8.36 (m, 1H), 8.04 (s, 1H), 7.67 (s, 1H), 7.55 (brs, 1H), 5.15 (brd, J = 30.2 Hz, 1H), 4.98-4½ (m, 2H), 4.51-3.80 (m, 5H), 3.18 -2.83 (m, 1H), 1.98 (s, 1H), 1.57 (d, J=6.7 Hz, 6H), 1.491.26 (m, 2H), 1.18 (dd, J = 9.2, 6.5 Hz, 3H) |
252
yl}amino)-3-hydroxypiperidin-1 yl]-2-hydroxypropan-1-one | |||
F21 | N-VCI A HN N q, ««.A IA Il \ N k J N— N Me—/ Me^AQ Me Me OH (2S)-1-[(3R,4R)-4-{[4-(1-tertbutyl-4-fluoro-1 H-benzimidazol6-yl)-5-chloropyrimidin-2yl]amino}-3-hydroxypiperidin-1yl]-2-hydroxypropan-1 -one | 490.9 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-cfe) δ 8.43 (s, 2H), 8.29- 7.90 (m, 1H), 7.72-7.12 (m, 2H), 5.13 (brs, 1H), 4.96 (brd, J = 6.7 Hz, 1H), 4.49-4.13 (m,2H), 4.09 - 3.84 (m, 2H), 3.50 - 3.46 (m, 1H), 3.17-2.76 (m, 2H), 2.08-1.92 (m, 1H), 1.74 (s, 9H), 1.51-1.27 (m, 1H), 1.19 (brt, J =7.5 Hz, 3H) |
F22 | JOA ΗΝ'^Άίι^ HO.^k nLA il \ /N TT Me—7^ [ΆΟ Me Me OH 1 -[(3R,4R)-4-{[4-(3-tert-butyl3H-imidazo[4,5-b]pyridin-5-yl)5-chloropyridin-2-yl]amino}-3hydroxypiperidin-1 -yl]-2hydroxyethan-1-one I | 459.0 [M+H]+ (ESI) | 1H NMR (500 MHz, DMSO-d6) δ 8.55 (s, 1H), 8.20-8.20 (m, 1H), 8.20-8.20 (m, 1H), 8.19 (d, J =8.2 Hz, 1H), 8.11 (d, J = 4.9 Hz, 1H), 7.54 (d, J =8:4 Hz, 1H), 6.98-6.90 (m, 1H), 6.82 (d, J =9.3 Hz, 1H), 5.20 (dd, J = 4.7,11.2 Hz, 1H), 4.55 (t, J = 5.2 Hz, 1H), 4.17-4.06 (m, 2H), 3.87 (brd, J =13.7 Hz, 1H), 3.68-3.58 (m, 1H), 3.19 (brt, J = 9.6 Hz, 1H), 3.12 -3.00 (m, 1H), 2.09-2.00 (m, 1H), 1.84-1.77 (m, 9H), 1.371.27 (m, 1 H) |
Example F23 (Scheme F-6): Préparation of 1-[(3/?,4/?)-4-({5-fIuoro-4-[4-fluoro-2-methyl-1(propan-2-yl)-1 W-benzimidazol-6-yl]pyrimidin-2-yl}amino)-3-hydroxypiperidin-1 -y l]-25 (methylamino)ethan-l-one .....
Scheme F-6:
To a solution of (F-2) (prepared as in Example F17, 160 mg, 0.279) in DCM (10.0 mL) and TFA (10.0 mL). The mixture was stirred at ambient température for 1 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The 5 reaction solution was concentrated to dryness. The residue was taken up in MeOH (5 mL) and treated with ΝΗ3Ή2Ο to adjust to pH -7-8. The solution was concentrated. The residue was purified by préparative HPLC with a DuraShell column (150x25 mm, 5 pm particle size), which was eluted with 22-42% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide 1[(3R,4R)-4-({5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-210 y|}amino)-3-hydroxypiperidin-1-yl]-2-(methylamino)ethan-1-one (Example F23) (35.2 mg, 27% yield) as a white solid. 1H NMR (400 MHz, DMSO-cfe) δ 8.43 (t, J = 4.1 Hz, 1H), 8.13 (br s, 1H), 7.61 (brd, J=12.1 Hz, 1H), 7.31-7.11 (m, 1H), 5.10 (brd, J = 4.5 Hz, 1H), 4.82 (td, J= 6.8,13.8 Hz, 1H), 4.11 - 3.65 (m, 3H), 3.60 - 3.38 (m, 2H), 3.26 - 2.98 (m, 3H), 2.70 - 2.53 (m, 4H), 2.27 (d, J = 1.3 Hz, 3H), 2.02 (br s, 1H), 1.59 (d, J = 6.8Hz, 6H), 1.45 - 1.29 (m, 1H); m/z (ESI+) for 15 (C23H29F2N7O2), 474.5 (M+H)+.
The examples in the below table were synthesized according to the methods used for the synthesis of 1-[(3R,4R)-4-({5-fluoro-4-[4-fluoro-2-methyl-1-(propan-2-yl)-1H-benzimidazol-6yl]pyrimidin-2-yl}amino)-3-hydroxypiperidin-1-yl]-2-(methylamino)ethan-1-one (Example F23).
The following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize. If necessary, séparation of the enantiomers was iarried out under standard methods known in the art, such as chiral SFC or HPLC, to afford single enantiomers.
Example number | Structure/Name j __________________________________________________________________________________i | LCMS | NMR |
254
F24 | N-yc' H0^< Tl \ ,N LJ N— N Me—/ Me ,, -NH Me 1 -[(3R,4R)-4-({5-chloro-4-[4fluoro-1-(propan-2-yl)-1 H- benzimidazol-6-yl]pyrimidin-2yl}amino)-3-hydroxypiperidin-1yl]-2-(methylamino)ethan-1-one | 476.2 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) 5 8.53 (s, 1H), 8.44 (d, J =5.3 Hz, 1 H), 7.90 (brs, 1H), 7.977.84 (m, 1H), 7.61-7.36 (m, 2H), 5.10 (brs, 1H), 4.82 (td, J = 6.7, 13.3 Hz, 1H), 4.35 (brd, J = 12.5 Hz, 1H), 4.04-3.80 (m, 2H), 3.75 (br d, J = 9.8 Hz, 1H), 3.51 (brs, 1H), 3.10-2.94 (m, 2H), 2.58 (brt, J = 11.3 Hz,1H), 2.28 (d, J =2.0 Hz, 3H), 1.90 (s, 1H), 1.56 (d, J = 6.7 Hz, 6H), 1.38 (brd, J = 17.2 Hz, 1H) |
F25 | N^<CI hcx^\ L^\ L J N— N Me-/ Ao Μθ Me „ zNH Me 1 -[(3R,4R)-4-{[4-(1 -tert-butyl-4fluoro-1 H-benzimidazol-6-yl)-5chloropyrimidin-2-yl]amino}-3hydroxypiperidin-1 -yl]-2(methylamino)ethan-l-one | 512.2 [M+Na]+ (ESI) | 1H NMR (400 MHz, D2O) 5 9.43 -9.31 (m, 1H), 8.43 (s, 1H), 8.31 (brs, 1H), 7.77 (brd, J = 10.8 Hz, 1H), 4.46-3.98 (m, 4H), 3.85 - 3.56 (m, 2H), 3.32 2.82 (m, 2H), 2.76 (d, J =3.0 Hz, 3H), 2.15-2.14 (m, 1H), 1.84 (s, 9H), 1.60-1.59 (m, 1H) |
F26 | nV' JL HN N ]|Y ho.â UA L J N— N Me-γ Me Me HN^ [(3R,4R)-4-{[4-(1-tert-butyl-4fluoro-1 H-benzimidazol-6-yl)-5chloropyrimidin-2-yl]amino}-3hydroxypiperidin-1-yl](3fIuoroazetidin-3-yl)methanone | 520.Ô [M+H]+ (ESI) | 1H NMR (500 MHz, CD3OD) 5 8.42-8.17 (m, 2H), 8.04 (s, 1H), 7.42 (d, J = 11.4 Hz, 1H), 4.40 - 3.88 (m, 4H), 3.84 3.45 (m, 4H), 3.15-2.67 (m, 2H), 2.09 (d, J =13.4 Hz, 1H), 1.72 (s, 9H), 1.50-1.36 (m, 1H) |
255
F27 | N^YC' JL „F hn nV y AA L J N— N Me—/ jA0 Me HN3 [(3R,4R)-4-({5-chloro-4-[4fluoro-1-(propan-2-yl)-1Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-3-hydroxypiperidin-1 yl](3-fluoroazetidin-3yl)methanone | 506.1 [M+H]+ (ESI) | 1H NMR (500 MHz, DMSO-de) 5 8.45 (s, 1H), 8.35 (s, 1H), 7.82 (br s, 1H), 7.55 - 7.04 (m, 2H), 5.13 (dd, J = 21.1, 4.8 Hz, 1H), 4.75 (p, J =6.7 Hz, 1H), 4.27 - 3.74 (m, 4H), 3.70 3.35 (m,4H), 3.09-2.62 (m, 2H), 1.96 (brs, J =33.6 Hz, 1H), 1.49 (d, J = 6.7 Hz, 6H), 1.43-1.23 (m, 1H) |
F28 | N^C' HnA^A'^A HO^^k AA Il T .N L J N-^ N Me—/ Z^Aq Me nh2 (1 -aminocyclopropyl)[(3R,4R)4-({5-chloro-4-[4-fluoro-1 (propan-2-yl)-1 H-benzimidazol6-yl]pyrimidin-2-yl}amino)-3hydroxypiperidin-1yl]methanone | 488.1 [M+H]+ (ESI) | 1H NMR (500 MHz, DMSO-d6) 5 8.52 (s, 1H), 8.43 (s, 1H), 7.90 (brs, 1H), 7.59-7.21 (m, 2H), 5.20 (br s, 1H), 4.82 (td, J = 6.7, 13.4 Hz, 1H), 4.25 (brd, J =10.2 Hz, 1H), 4.17-3.94 (m, 1H), 3.88 (brdd, J =3.2, 8.1 Hz, 1H), 3.49 (brd, J =3.4 Hz, 1H), 3.03 (brs, 1H), 2.372.19 (m, 2H), 1.97 (brs, 1H), 1.56 (d, J =6.6 Hz, 6H), 1.461.24 (m, 1H), 0.79 (brs, 2H), 0.71 - 0.53 (m, 2H) |
1 1 1 F29 I | N^CI A A^^^f HN^N'^V HO. A LA Il \ ,N L J N— N Me—/ f v nh2 (1-amino-3,3- difluorocyclobutyl)[(3R,4R)-4({5-chloro-4-[4-fluoro-1(propan-2-yl)-1 /7-benzimidazol6-yl]pyrimidin-2-yl}amino)-3- | 538.0 [M+H]+ (ESI) | 1H NMR (400 MHz, DMSO-d6) δ |δ.54 (s, IH), 8.44 (s, 1H), 7.91 (br s, 1 H), 7.56 - 7.32 (m, 2H), 5.18 (d, J =70.6 Hz, 1H), 4.83 (p, J= 6.8 Hz, 1H), 4.42 3.76 (m, 3H), 3.51 (d, J = 65.9 Hz, 1H), 3.25-2.92 (m, 3H), 2.64-2.55 (m, 3H), 2.48- 2.42 (m, 1H), 1.99 (s, 1H), 1.57 (d, J = 6.7 Hz, 6H), 1.52-1.30 (m, 1H) |
256
hydroxypiperidin-1yl]methanone | |||
F30 | N-YC' A-^Lx^xF HN N [|Y ΗΟ^χΑ L-Y Tl \ ,N k ,J N— N Me—/ F>/\Yo Me Me F v nh2 (1-amino-3,3difluorocyclobutyI)[(3R,4R)-4{[4-(1 -tert-butyl-4-fluoro-1 Hbenzimidazol-6-yl)-5- chloropyrimidin-2-yl]amino}-3hydroxypiperidin-1yl]methanone | 552.2 [M+H]+ (ESI) | 1H NMR (500 MHz, CD3OD) δ 8.27 (d, J =5.1 Hz, 2H), 8.04 (s, 1H), 7.42 (d, J = 11.4 Hz, 1 H), 4.01 -3.43 (m, 4H), 3.16 - 3.04 (m, 3H), 2.75 - 2.37 (m, 3H), 2.14-2.01 (m, 1H), 1.72 (s, 9H), 1.48 (s, 1H) |
F31 | A Y/^xF Hy N ΗΟ»^χ< *k/k Il \ ,N Me— Ao Me f3ct ''nh2 (3S)-3-amino-1 -[(3R,4R)-4-({5chloro-4-[4-fluoro-1-(propan-2yl)-1 H-benzimidazol-6yl]pyrimidin-2-yl}amino)-3hydroxypiperidin-1 -yl]-4,4,4trifluorobutan-1 -one | 544.0 [M+H]+ (ESI) | 1H NMR (500 MHz, DMSO-d6) 5 8.45 (s, 1H), 8.41-8.28 (m, 1H), 7.83 (brs, 1H), 7.65-7.26 (m, 2H), 5.03 (dd, J =4.7,12.5 Hz, 1H), 4.75 (td, J =6.7, 13.4 Hz, 1H), 4.40-3.28 (m, 5H), 3.12 - 2.98 (m, 1H), 2.55 - 2.45 (m, 2H), 1.89 (br s, 3H), 2.02 1.79 (m, 1H), 1.50 (s, 6H), 1.36 -1.^1 (m, 1H) |
F32 | i ΗΝ^/ΥΥ i ho*/\ YY I Il \ ,N k J N— N Me—/ AÂO Me Me A 3-amino-1-[(3R,4R)-44[4-(1- tert-butyl-4-fluoro-1 H- | 525.3 [M+HJ+ (ESI) | 1H NMR (400 MHz, DMSO-cfe) δ 8.38 (s, 1H), 8.08 (s, 1H), 7.69 (s, 1H), 7.12 (d, J= 11.4 Hz, 1H), 6.90-6.83 (m, 1H), 6.65 (s, 1H), 5.30 (brs, 1H), 4.19 - 4.01 (m, 2H), 3.99 - 3.80 (m, 2H), 3.46 (br s, 2H), 3.23 2.96 (m, 4H), 2.11 (brt, J = |
257
benzimidazol-6-yl)-5chloropyridin-2-yl]amino}-3hydroxypiperidin-1-yl]-2,2difluoropropan-1-one | 12.7 Hz, 1H), 1.72 (s, 9H), 1.39 -1.23 (m, 1H) |
Example F33 (Scheme F-7): Préparation of 2-[(3R,4R)-4-{[4-(3-tert-butyI-3H-imidazo[4,5b]pyridin-5-yl)-5-chIoropyridin-2-yl]amino}-3-hydroxypiperidin-1-yl]-N-methyIacetamide
Scheme F-7:
To a solution of (3R,4R)-4-{[4-(3-tert-butyl-3H-imidazo[4,5-b]pyridin-5-yl)-5-chloropyridin2-yl]amino}piperidin-3-ol (Prepared as in Example D3, 100 mg, 0.249 mmol) in EtOH (6.0 mL) was added 2-bromo-N-methylacetamide (56.7 mg, 0.374 mmol) and a solution of saturated aqueous NaHCO3 (3.0 mL). The mixture was stirred at 70 “C for 16 h. TLC analysis (1:3 MeOH/EtOAc) indicated consumption of the starting material. The mixture was diluted with H2O (10 mL) and extracted with EtOAc (20 mL). The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified by préparative HPLC with a DuraShell column (150x25 mm, 5 pm particle size), which was eluted with 21-41% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide 2-[(3R,4R)-4-{[4-(3-terf-butyl-3H-imidazo[4,5-b]pyridin-5yl)-5-chloropyridin-2-yl]amino}-3-hydroxypiperidin-1-yl]-A/-methylacetamide (Example F33) (45.5 mg, 39% yield) as a white solid. 1H NMR (500 MHz, DMSO-ds) δ 8.54 (s, 1H), 8.17 (d, J= 8.4 Hz, 1H), 8.07 (s, 1H), 7.72 (br i, J = 4.6 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 6.85 - 6.80 l(m, 2H), 4.91 (d, J = 5.6 Hz, 1 H), 3.60 - 3.49 (m, 2H), 2.91 (d, J = 2.0 Hz, 2H), 2.89 - 2.85 (m, 1 H), 2.68 (br d,
J =11.1 Hz, 1H), 2.62 (d, J = 4.7 Hz, 3H), 2.18 -2.09 (m, 1H), 2.06 - 1.98 (m, 2H), 1.80(s, 9H),
1.50 - 1.39 (m, 1 H); m/z (ESI+) for (C23H3oClN702), 472.2 (M+H)+. '
Example G1 (Scheme G-1): 1-[6-(5-chloro-2-{[(3R,4R)-3-hydroxy-1(methanesulfonyl)piperidin-4-yl]amino}pyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1H25 benzimïdazol-2-yl]ethan-1-one
Scheme G-1:
258
nh2
Example G1
Step 1: Synthesis of 1-[6-(2,5-dichloropyrimidin-4-yl)-4-fIuoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]ethan-1-one (G-2)
To a solution of 1-[6-(2,5-dichloropyrimidin-4-yI)-4-fluoro-1-(propan-2-yl)-1H5 benzimidazol-2-yl]ethan-1-ol (G-1) (Prepared as in Example A1, 500 mg, 1.35 mmol) in CHCI3 (10 mL) was added MnÛ2 (824 mg, 9.48 mmol). The mixture was stirred at 50 °C for 6 h. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The mixture was filtered and concentrated. The residue was purified by flash chromatography (Biotage, SiO2,25% EtOAc/petroleum ether) to provide 1-[6-(2,5-dichloropyrimidin-4-yl)-4-fluoro10 1-(propan-2-yl)-1/7-benzimidazol-2-yI]ethan-1-one (G-2) (480 mg, 97% yield) as a white solid. 1H NMR (400 MHz, CDCI3) δ 8.73 (s, 1H), 8.10 (d, J= 1.2 Hz, 1H), 7.64 (dd, J = 1.3, 10.9 Hz, 1H), 6.06 - 5.92 (m, 1H), 2.93 (s, 3H), 1.71 (d, J = 7.1 Hz, 6H); m/z (ESI+) for (C16H13CI2FN4O), 3|67.0 (M+H)+.
Step 2: Synthesis of 1-[6-(5-chloi-o-2-{[(3R,4R)-3-hydroxy-1-(methanesulfonyl)piperidin-4yl]amino}pyrimidin-4-yl)-4-fluoro-jl-(propan-2-yl)-1H-benzimidazoI-2-yl]ethan-1-one । (Example G1) . _ __________ _
To a solution of 1-[6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1Hbenzimidazol-2-yl]ethan-1-one (G-2) (100 mg, 0.272 mmol) in DMSO (5.0 mL) was added DIPEA (106 mg, 0.817 mmol) and (3R,4R)-4-amino-1-(methanesulfonyl)piperidin-3-ol (lnt-69). The mixture was stirred at 70 °C for 16 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The mixture was diluted with H2O (30 mL) and
259 extracted with EtOAc (2x30 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by préparative TLC (S1O2, 50% EtOAc/petroleum ether, Rf = 0.4) to provide 1-[6-(5-chloro-2-{[(3R,4R)-3-hydroxy-1-(methanesulfonyl)piperidin-4yl]amino}pyrimidin-4-yl)-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]ethan-1-one (Example 5 G1) (58.2 mg, 41% yield) as a white solid. 1H NMR (400 MHz, DMSO-cfe) δ 8.47 (s, 1H), 8.21 8.03 (m, 1H), 7.67 - 7.41 (m, 2H), 5.86 - 5.72 (m, 1H), 5.23 (d, J = 4.6 Hz, 1H), 3.88 - 3.75 (m, 1H), 3.68 - 3.56 (m, 2H), 3.53 - 3.44 (m, 1H), 2.90 (s, 3H), 2.87 - 2.81 (m, 1H), 2.79 (s, 3H), 2.66 - 2.60 (m, 1H), 2.14 -1.98 (m, 1H), 1.61 (d, J = 7.0 Hz, 6H), 1.57 -1.45 (m, 1H); m/z (ESI+) for (C22H26CIFN6O4S), 525.2 (M+H)+.
260
Example H1 (Scheme H-1): Préparation of 1,5-anhydro-3-({5-chIoro-4-[2-(chloromethyl)-4fIuoro-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amlno)-2,3-dideoxy-D-tbreopentitol ’
Scheme H-1:
APrNH2 Cs2CO3
THF
98% yield
no2 Na2S2°4
Me^NH EtOH, H2O, 80 °C Me A-16 46% yield
Me p-TSA, DHP THF, 90 ’C
PdCI2(dppf) KOAc, B2Pin2
1,4-dioxane, 80 °C
73% yield
73% yield
DIPEA DMSO, 120 C
56% yield
MsCI, TEA DCM
96% yield
261
Step 1: Synthesis of 5-bromo-3-fIuoro-2-nitro-A/-(propan-2-yI)aniline (A-16)
To a solution of 5-bromo-1,3-difluoro-2-nitrobenzene (A-15) (35.0 g, 147 mmol) in THF (700 mL) was added /-PrNH2 (8.7 g, 147 mmol) and CS2CO3 (57.5 g, 176 mmol). The mixture was stirred at room température for 16 h. LCMS analysis showed consumption ofthe starting material 5 with formation of the desired product mass. The reaction was diluted with H2O (300 mL) and extracted with EtOAc (3x300 mL). The combined organic layers were washed with brine, dried over Na2SÛ4, filtered, and concentrated to provide 5-bromo-3-fluoro-2-nitro-/V-(propan-2yl)aniline (A-16) (40.0 g, 98% yield) as a red solid. 1H NMR (400 MHz, DMSO-d6) δ 7.09 - 6.98 (m, 2H), 6.89 (dd, J = 1.9,11.1 Hz, 1H), 6.17 (s, 1H), 3.88 (brd, J =7.5 Hz, 1H), 1.19 (d, J = 6.4 10 Hz, 6H); m/z (ESI+) for (CgHioBrFN202), 276.7 (M+H)+.
Step 2: Synthesis of [6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]methanol (H1)
To a solution of 5-bromo-3-fIuoro-2-nitro-/V-(propan-2-yl)aniline (A-16) (40.0 g, 144 mmol) 15 in EtOH/H2O (4:1,700 mL) was added 1,4-dioxane-2,5-diol (20.8 g, 173 mmol) and Na2S2O4 (126 g, 722 mmol). The mixture was stirred at reflux for 80 °C for 16 h. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The mixture was diluted with H2O (100 mL) and extracted with EtOAc (3x300 mL). The combined organic layers were washed with saturated aqueous NaHCOs, dried over Na2SO4, filtered, and concentrated. 20 The crude residue was purified by flash chromatography (S1O2, 0-100% EtOAc/petroleum ether) to provide [6-bromo-4-fIuoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]methanol (H-1) (19.0 g, 46% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 7.81 (d, J = 1.5 Hz, 1H), 7.28 (dd, J = 1.5, 10.0 Hz, 1H), 5.72 (t, J = 5.8 Hz, 1H), 5.01 - 4.87 (m, 1H), 4.72 (d, J = 5.5 Hz, 2H), 1.56 (d, J = 6.8 Hz, 6H); m/z (ESI+) for (CiiHi2BrFN2O), 286.8 (M+H)+.
Step 3: Synthesis of 6-bromo-4-fluoro-2-{[(oxan-2-yl)oxy]methyl}-1-(propan-2-yl)-1Wbenzintadazole (lnt-20)I
To a solution of [6-bromo-4-fluoro-1-(propan-2-yl)-1H-benzimidazol-2-yl]methanol (H-1) (19.0 g, 66.2 mmol) in THF (250 mL)was added p-TSA (1.7 g, 6.62 mmol) and DHP (22.3 g, 265 II mmol)J The mixture was stirred at 90 °C for 4 h. LCMS analysis showed consumption of the i ‘.
starting material with formation of the desired product mass. The reaction was diluted with H2O (100 mL) and extracted with EtOAc (3x150 mL). The combined organic layers were dried over
Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (S1O2, ΟΙ 00% EtOAc/petroleum ether) to provide 6-bromo-4-fluoro-2-{[(oxan-2-yl)oxy]methyl}-1-(propan35 2-yl)-1H-benzimidazole (lnt-20) (18.0 g, 73% yield) as a pale yellow solid. 1H NMR (400 MHz,
DMSO-d6) δ 7.85 (d, J = 1.5 Hz, 1H), 7.31 (dd, J = 1.5, 10.1 Hz, 1H), 4.97 - 4.84 (m, 2H), 4.78 19876
262
4.68 (m, 2H), 3.83 - 3.71 (m, 1H), 3.57 - 3.46 (m, 1H), 1.72 - 1.63 (m, 2H), 1.57 (d, J = 6.8 Hz,
6H), 1.53-1.46 (m,4H); m/z (ESI+) for (C16H20BrFN2O2), 372.6 (M+H)+.
Step 4: Synthesis of 4-fIuoro-2-{[(oxan-2-yl)oxy]methyl}-1-(propan-2-yl)-6-(4,4,5,55 tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole (H-2)
To a suspension of 6-bromo-4-fluoro-2-{[(oxan-2-yl)oxy]methyl}-1-(propan-2-yl)-1Hbenzimidazole (H-2) (8.0 g, 21.6 mmol), B2Pin2 (6.6 g, 25.9 mmol), and KOAc (6.3 g, 64.6 mmol) in 1,4-dioxane (160 mL) was added PdCI2(dppf) (0.788 g, 1.08 mmol) under N2. The mixture was stirred at 80 eC under N2 for 16 h. LCMS analysis indicated consumption of the starting material 10 with formation of the desired product mass. The mixture was cooled to room température, filtered through celite, and concentrated to dryness. The residue was taken up in H2O (150 mL) and extracted with EtOAc (3x150 mL). The combined organics were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (360 g SiO2, 0-100% EtOAc/petroleum ether) to provide 4-fluoro-2-{[(oxan-2-yl)oxy]methyl}-1-(propan15 2-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazole (H-2) (9.4 g, 73% yield) as a yellow solution, m/z (ESI+) for (C22H32BFN2O4), 419.1 (M+H)+.
Step 5: Synthesis of 6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-2-{[(oxan-2-yl)oxy]methyl}-1(propan-2-yl)-1H-benzimidazole (H-3)
A mixture of 4-fluoro-2-{[(oxan-2-yl)oxy]methyl)-1-(propan-2-yl)-6-(4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl)-1H-benzimidazole (H-2) (6.0 g, 14.3 mmol), 2,4,5-trichIoropyrimidine (3.95 g, 21.5 mmol), and K2CO3 (3.96 g, 28.7 mmol) in 1,4-dioxane (90 mL) and H2O (30 mL) was degassed with N2 for 5 min. Pd(PPh3)4 (829 mg, 0.717 mmol) was added and the mixture was degassed for an additional 10 min. The reaction was stirred at 90 °C under N2 for 16 h. LCMS 25 analysis showed consumption of the starting material with formation of the desired product mass.
The reaction was cooled to room température, diluted with H2O (30 mL), and extracted with EtOAc (3x100 mL). Th^ combined organic layers were washed with brine, dri^d over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (40 g SiO2, 0-60% EtOAc/petroleum ether) to provide 6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-2-{[(oxan-230 yI)oxy]methyl}-1-(propan-2-yl)-1H-benzimidazole (H-3) (7.4 g, 99% yield) as a white solid. m/z (ESI+) for (C22H32BFN2O4), 461.0 (M+H)+. i
Step 6: Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-{[(oxan-2-yl)oxy]methyl}-1(propan-2-yl)-1H-benzïmidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol (H35 4)
263
To a solution of 6-(2,5-dichloropyrimidin-4-yl)-4-fluoro-2-{[(oxan-2-yl)oxy]methyl}-1(propan-2-yl)-1H-benzimidazole (H-3) (2.3 g, 19.8 mmol) in DMSO (150 mL) was added DIPEA (10.6 g, 82.4 mmol) and 3-amino-1,5-anhydro-2,3-dideoxy-D-f/7reo-pentitol (7.2 g, 16.5 mmol). The mixture was stirred at 120 °C for 16 h. LCMS analysis showed consumption of the starting 5 material with formation of the desired product mass. The reaction solution was diluted with H2O (200 mL) and extracted with EtOAc (3x200 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by flash chromatography (360 g SiO2l 0-10% MeOH/DCM) to provide 1,5-anhydro-3-({5-chloro-4-[4fluoro-2-{[(oxan-2-yl)oxy]methyl}-1-(propan-2-yl)-1/-/-benzimidazol-6-yl]pyrimidin-2-yl}amino)10 2,3-dideoxy-D-f/7reo-pentitol (H-4) (4.8 g, 56% yield) as a yellow solid. m/z (ESI+) for (C25H3iCIFN5O4), 520.1 (M+H)+.
Step 7: Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fiuoro-2-(hydroxymethyl)-1-(propan-2yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-t/ireo-pentitoi (H-5)
To a solution of 1,5-anhydro-3-({5-chloro-4-[4-fIuoro-2-{[(oxan-2-yl)oxy]methyl}-1(propan-2-yl)-1 H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-f/7neo-pentitol (H-4) (4.7 g, 9.2 mmol) in MeOH (40.0 mL) was added a solution of HCl (4 N in 1,4-dioxane, 10.0 mL) dropwise at 0 °C. The solution was stirred at 20 °C for 1 h. LCMS analysis showed consumption ofthe starting material with formation ofthe desired product mass. The reaction mixture was concentrated to dryness. The residue was purified by flash chromatography (80 g SiO2, 1:10 MeOH/DCM) to provide 1,5-anhydro-3-({5-chloro-4-[4-fIuoro-2-(hydroxymethyl)-1-(propan-2-yl)1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-f/7reo-pentitol (H-5) (3.2 g, 80% yield) as a yellow oil. 1H NMR (400 MHz, CD3OD) δ 1.77 - 1.78 (m, 1 H) 1.80 (dd, J = 6.90, 2.89 Hz, 5H) 2.06 - 2.16 (m, 1 H) 3.18 - 3.27 (m, 1 H) 3.44 - 3.54 (m, 1 H) 3.65 (s, 1 H) 3.99 (br dd, J=11.29, 5.02
Hz, 3 H) 5.07 (s, 2H) 5.21 (s, 2H) 7.92 (d, J = 11.04 Hz, 1 H) 8.36 (s, 1 H) 8.49 (s, 1 H); m/z (ESI+) for (C20H23CIFN5O3), 436.2 (M+H)+.
Step 8: Synthesis of 1,5-anhydro-3-({5-chloro-4-[2-(chloromethyl)-4-fluoro-1-(propan-2-yl)1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-f/jreo-pentitol (H-6)
To a solution of1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(hydroxymethyl)-1-(propan-2-yl)1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-f/)reo-pentitol (H-5) । (800 mg, 1.8 mmol) in DCM (10 mL) was added TEA (557 mg, 5.5 mmol). The mixture was cooled to 0 °C and treated with methanesulfonyl chloride (328 mg, 2.2 mmol)Tlropwise. The mixture was stirred at ambient température for 3 h. LCMS analysis showed consumption of the starting material.
Reaction was washed with H2O. The aqueous layer was extracted with DCM (3x10 mL). The combined organics were washed with brine, dried over Na2SO4, filtered, and concentrated to
264 provide 1,5-anhydro-3-({5-chIoro-4-[2-(chloromethyl)-4-fIuoro-1-(propan-2-yl)-1H-benzimidazol6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol (H-6) (800 mg, 96% yield), which was taken on without further purification, m/z (ESI+) for (C20H22CI2FN5O2), 454.1 (M+H)+.
265
Step 9: Synthesis of 1,5-anhydro-3-[(5-chloro-4-{4-fluoro-2-[(3-hydroxy-3-methylazetîdin1-yI)methyl]-1-(propan-2-yI)-1H-benzimidazol-6-yl}pyrimidin-2-yl)amino]-2,3-dideoxy-Dfhreo-pentitol (Example H1)
To a solution of 1,5-anhydro-3-({5-chloro-4-[2-(chloromethÿl)-4-fluoro-1-(prôpan-2-yl)-1H5 benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-fhreo-pentitol (H-6) (100 mg, 0.22 mmol) in MeCN (2.0 mL) was added 3-methylazetidin-3-ol (19.2 mg, 0.22 mmol), Nal (33.0 mg, 0.22 mmol) and DIPEA (142 mg, 1.1 mmol). The mixture was stirred under an atmosphère of N2 at 25 °C for 3 h. LCMS analysis showed consumption of the starting material with formation of the desired product mass. The reaction solution was washed with H2O (5 mL). The aqueous layer 10 was extracted with DCM (3x5 mL). The combined organic layers were washed with brine (10 mk), dried over Na2SO4, filtered, and concentrated. The crude residue was purified by préparative HPLC with a YMC Triart column (30x150 mm, 7 pm particle size), which was eluted with 30-50% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide 1,5-anhydro-3-[(5-chloro4-{4-fluoro-2-[(3-hydroxy-3-methylazetidin-1 -yl)methyl]-1 -(propan-2-yl)-1 H-benzimidazol-615 yl}pyrimidin-2-yl)amino]-2,3-dideoxy-D-t/?reo-pentitol (Example H1) (23.5 mg, 21% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.35 (s, 1H), 8.02 (s, 1H), 7.49 (d, J = 11.4 Hz, 1H), 5.16 (app p, J = 7.0 Hz, 1H), 4.03 - 3.87 (m, 5H), 3.61 (dt, J = 4.8, 9.4 Hz, 1H), 3.48 (dt, J = 2.2, 11.7 Hz, 1H), 3.30 - 3.27 (m, 2H), 3.24 - 3.19 (m, 1H), 3.18 - 3.14 (m, 2H), 2.19 - 2.08 (m, 1H), 1.68 (d, J = 6.8 Hz, 6H), 1.67 - 1.59 (m, 1 H), 1.46 (s, 3H); m/z (ESI+) for (C24H30CIFN6O3), 505.2 (M+H)+.
The examples in the below table were synthesized according to the methods used for the synthesis of 1,5-anhydro-3-({5-chloro-4-[2-(chloromethyl)-4-fluoro-1-(propan-2-yl)-1/7benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-f/7reo-pentitol (Example H1). The 25 following examples were synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Example number | Structure/Name | LCMS | NMR...... |
H2 | A HN N ]| | HO^>< JA Il ' //N N—\ Me O Me—/ \ - - . .....: \ - —N% | 463.1 [M+H]+ | 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H) 8.06 (s, 1H) 7.52 (d, J = 11.5Hz, 1H) 5.25-5.18 (m, 1 H) 3.88 -4.06 (m, 3H) |
-- | Me Me 1,5-anhydro-3-[(5-chloro-4-{2[(dimethylamino)methyl]-4fluoro-1 -(propan-2-yl)-1 H- | (ESI) | 3.80 (s, 2H) 3.63 (m, 1 H) 3.36 - 3.54(m, 1H) 3.16 - 3.29 (m, 1H) 2.31 (s, 6H) 2.03 - 2.20 (m, 1H) |
266
benzimidazol-6-yl)pyrimidin-2yl)amino]-2,3-dideoxy-D-f/jreopentitol | 1.69 (d, J =7.0 Hz, 6H)1.58- 1.67 (m,1H) | ||
H3 | A x\^F ΗΟ^χ\ AA Il ' //N k^x1 N—Y Λ ο Μθ^ Λ,/^οη Me v 1,5-anhydro-3-[(5-chloro-4-{4fluoro-2-[(3-hydroxyazetidin-1 yl)methyl]-1-(propan-2-yl)-1Hbenzimidazol-6-yI}pyrimidin-2yl)amino]-2,3-dideoxy-D-t/7reopentitol | 491.1 [M+HJ+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.35 (s, 1H), 8.02 (s, 1H), 7.49 (d, J=11.4 Hz, 1H), 5.16-5.06 (m, 1H), 4.35 (t, J =6.2 Hz, 1H), 4.01 - 3.89 (m, 5H), 3.66 3.57 (m, 3H), 3.48 (dt, J =2.1, 11.7 Ηζ, ΊΗ), 3.20 (dd, J = 9.7, 11.1 Hz, 1H), 3.11-3.05 (m, 2H), 2.18-2.09 (m, 1H), 1.68 (d, J = 7.0 Hz, 6H), 1.66-1.58 (m, 1H) |
H4 | Jk -JAxïî^F HN HC^xk AA Il ' Z/N k x* N-X . „ . O Me-γ V^Me Me V OH Me 1,5-anhydro-3-({5-chloro-4-[4fluoro-2-{[(2S,3R)-3-hydroxy2,3-dimethylazetidin-1- yl]methyl}-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl]pyrimidin-2yl}amino)-2,3-dideoxy-D-fbreopentitol | 519.3 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.35 (s, 1H), 8.03 (s, 1H), 7.50 (d, J = 11.6 Hz, 1H), 5.19-5.10 (m, 1 H), 4.04-3.89 (m, 5H), 3.61 (dt, J = 4.7, 9.4 Hz, 1H), 3.48 (dt, J = 2.3, 11.7 Hz, 1H), 3.25 - 3.17 (m, 3H), 2.97 (d, J = 6.7 Hz, 1H), 2.13 (td, J = 2.3, 13.2 Hz, 1H), 1.69 (dd, J = 6.9, 12.9 Hz, 7H), 1.28 (s, 3H), 0.88 (d, J =6.2 Hz, 3H) |
H5 | N-ycl HO^xk AA Il ' //N k J N-X O Me—γ \_NH Me Ά ^0 1,5-anhydro-3-({5-chloro-4-[4fluoro-2-{[(oxetan-3yl)amino]methyl}-1 -(propan-2- | ^491.2 „ [M+H]* (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H) 8.06 (s, 1H) 7.52 (d, J = 11.8 Hz, 1H) 5.08-5.16 (m, 1H) 4.80 (m, 2H) 4.46 (m, 2H) 4.11 (s, 2H) 3.90 - 4.08 (m, 4H) 3.63 (m, 1H) 3.50 (m, 1H) 3.19-3.26 (m, 1H) 2.13 (m, 1 H) 1.72 (d, J =6.7 Hz, 6H), 1.69-1.61 (m, 2H) |
267
y l)-1 H-benzimidazol-6yl]pyrimidin-2-yl}amino)-2,3dideoxy-D-fhreo-pentitol | - ... : - . - .... | ||
H6 | nV JL HN n HCk A. L-A Il 'A k A N-X Λ 0 Me^ VN/\_F Me v 1,5-anhydro-3-[(5-chloro-4-{4fluoro-2-[(3-fluoroazetidin-1 yl)methyl]-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl}pyrimidin-2yl)amino]-2,3-dideoxy-D-threopentitol | 493.2 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.35 (s, 1H), 8.03 (s, 1H), 7.49 (d, J = 11.5 Hz, 1H), 5.25-5.04 (m, 2H), 4.01 (s, 2H), 4.00 3.87 (m, 3H), 3.74 - 3.56 (m, 3H), 3.53 - 3.44 (m, 1H), 3.43 3.37 (m, 1H), 3.37-3.32 (m, 1H), 3.20 (dd, J = 9.7, 11.1 Hz, 1H), 2.18-2.09 (m, 1H), 1.68 (d, J =6.8 Hz, 6H), 1.66-1.58 (m, 1H) |
H7 | n^Y<ci hnAA^H ΠΑ Il ' A k A N-X Λ O Me—γ VN/\ 1,5-anhydro-3-[(4-{2-[(azetidin1 -yl)methyl]-4-fluoro-1 -(propan2-yl)-1 /7-benzimidazol-6-yl}-5chloropyrimidin-2-yl)amino]-2,3dideoxy-D-fhreo-pentitol | 475.2 [M+H]+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.35 (s, 1H), 8.03 (s, 1H), 7.49 (d, J = 11.4 Hz, 1H), 5.15-5.07 (m, 1H), 4.01-3.89 (m, 5H), 3.61 (brd, J =4.8 Hz, 1H), 3.52 -3.44 (m, 1H), 3.35 (t, J =7.0 Hz, 4H), 3.20 (dd, J =9.7,11.1 Hz, 1H), 2.16-2.08 (m, 3H), 1.69 (d, J =7.0 Hz, 6H), 1.671.60 (m, 1 H) |
Example H8 (Scheme H-2): 1,5-anhydro-3-({5-chloro-4-[4-fluoro-1-(propan-2-yl)-2{[(pr|opan-2-yl)amino]methyl}-1H-benzimidazol-6-yl]pyriijfiidin-2-yl}amino)-2,3-dideoxy-Dthreo-pentitol
Scheme H-2:
268
MnO2
MeOH, 60 “C ..
26% yield
IPrNH2, AcOH NaBH3CN MeCN
21% yield
Step 1: Synthesis of 1,5-anhydro-3-({5-chloro-4-[2-(dihydroxymethyi)-4-fluoro-1-(propan2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol (H-7)
A mixture (3R,4R)-4-({5-chloro-4-[4-fluoro-2-(hydroxymethyl)-1-(propan-2-yl)-1H5 benzimidazol-6-yl]pyrimidin-2-yl}amino)-1-(methanesulfonyl)piperidin-3-ol (H-5) (900mg, 2.1 mmol) and MnO2 (2.7 g, 31 mmol in MeOH (20.0 mL) was stirred at 60 eC for 16 h. LCMS analysis showed consumption of the starting material. The reaction was filtered and the filter cake was washed with MeOH (20 mL). The filtrate was concentrated to dryness. The residue was purified by flash chromatography (ISCO, 20 g SiO2, 1:10 MeOH/DCM) to provide 1,5-anhydro-3-({510 chloro-4-[2-(dihydroxymethyl)-4-fluoro-1 -(propan-2-yl)-1 H-benzimidazol-6-yl]pyrimidin-2yl}amino)-2,3-dideoxy-D-fhreo-pentitol (H-7) (162 mg, 26% yield) as a colorless oil. 1H NMR (400 MHz, CD3OD) δ 1.69 (t, J = 5.77 Hz, 7H) 2.00 - 2.23 (m, 1H) 3.18 - 3.26 (m, 1H) 3.50 (br d, J = 2.26 Hz, 1H) 3.63 (td, J = 9.29, 5.02 Hz, 1H) 3.98 (br. dd, J = 11.29, 4.52 Hz, 3H) 5.44 - 5.53 (m, 1H) 5.88 (s, 1 H) 7.53 (br d, J = 11.54 Hz, 1H) 8.07 (s, 1H) 8.37 (s, 1H); m/z (ESI+) for (C2oH23CIFN5f)4), 452.2 (M+H)+. |
Step 2: Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-1-(propan-2-yl)-2-{[(propan-2yl)amino]methyl}-1H-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-f/ireo- . pentitol (Example H8) I
To a solution 1,5-anhydro-3-({5-chloro-4-[2-(dihydroxymethyl)-4-fluoro-1-(propan-2-yl)1/7-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-threo-pentitol (H-7) (50mg, 0.11 mmol) and /-PrNH2 (12.7 mg, 0.215 mmol) in MeOH (5.0 mL) was added AcOH (6.4 mg, 0.107 mmol). After stirring for 2 h at ambient température NaBHsCN (13.5, 0.215 mmol) was added and the mixture was stirred for 16 h overnight. LCMS analysis showed consumption of the starting
269 material with formation of the desired product mass. The reaction was poured into a solution aqueous NazCOs (1.0 M, 5 mL) and extracted with DCM (3x5 mL). The combined organic layers were washed with brine (15 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by préparative HPLC with an Xtimate C18 column (250x80 mm, 10 pm particle size), which was eluted with 35-55% MeCN/H2O (+0.05% NH4OH) with a flow rate of 25 mL/min to provide 1,5-anhydro-3-({5-chloro-4-[4-fluoro-1 -(propan-2-yl)-2-{[(propan-2-yl)amino]methyl}-1 Hbenzimidazol-6-yl]pyrimidin-2-yi}amino)-2,3-dideoxy-D-f/jneo-pentitol (Example H8) (10.9 mg, 21% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H) 8.05 (s, 1H) 7.51 (d, J = 11.8 Hz, 1H) 5.05-5.17 (m, 1H) 4.15 (s, 2H) 3.90 - 4.03 (m, 3H) 3.64 (m, 1H)3.50(m, 1H)3.13
- 3.26 (m, 1H) 2.85 -2.95 (m, 1 H) 2.15 (m, 1H) 1.71 (d, J= 7.0 Hz, 6H) 1.66 (m, 1H) 1.16 (d, J =
6.2 Hz, 6H); m/z (ESI+) for (C23H30CIFN6O2), 477.1 (M+H)+.
The examples in the below table was synthesized according to the methods used for the synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-1 -(propan-2-yl)-2-{[(propan-2-yl)amino]methyl}15 1H-benzimidazol-6-yl]pyrimidin-2-yl)amino)-2,3-dideoxy-D-f/7reo-pentitol (Example H8). The following example was synthesized with non-critical changes or substitutions to the exemplified procedures that someone who is skilled in the art would be able to realize.
Example number | Structure/Name | LCMS | NMR |
H9 | HN N LY |L HCxX AA k J N-K N Me—γ ~VNH O=s=o U < Me /7 O (3R,4R)-4-({5-chloro-4-[4flLoro-2-{[(oxetan-3- yl)amino]methyl}-1 -(propan-2yl)-1H-benzimidazol-6yl]p^rimidin-2-yl}amino)-1(methanesulfonyl)piperidin-3-ol | 568.1 [M+H]+ (APCI) | 1H NMR (700 MHz, DMSO-d6) δ 8.43 (s, 1H), 8.09-7.68 (m, 1H), 7.44 (d, J =35 3 Hz, 1H), 5.01 (p, J = 6.8 Hz, 1H), 4.59 (t, J = 6.6 Hz, 2H), 4.35 - 4.26 (m, 2H), 4.00 (s, 2H), 3.92 (d, J = 11.1 Hz, 1H), 3(85 — 3.74 (m, 2H), 3.66 - 3.57 (m, 6H), 2.89 (s, 3H), 1.59 (d, J = 6.8 Hz, 6H) |
270
H10 | HO^A. AA Il ' //N k J N-X _ γ MeA NH O-S-O Me X- Me Me Me (3R,4R)-4-({5-chloro-4-[4fluoro-1 -(propan-2-yl)-2{[(propan-2-yl)amino]methyl}1 H-benzimidazol-6-yl]pyrimidin2-yl)amino)-1(methanesulfonyl)piperidin-3-ol | 553.9 [M+H]+ (APCI) | 1H NMR (600 MHz, DMSO-de) δ 7.96 (s, 1H), 7.62-7.39 (m, 1H), 7.09 - 6.82 (m, 2H), 4.88 - 4.67 (m, 1 H), 4.65-4.48 (m, 1H), 3.58 (s, 2H), 3.34 (d, J = 6.1 Hz, 1H), 3.15 (d, J =10.1 Hz, 1H), 2.46-2.37 (m, 4H), 2.31- 2.25 (m, 1H), 2.19 (t, J = 10.4 Hz, 1H), 1.63-1.55 (m, 1H), 1.41(br.s., 3H), 1.13 (d, J = 7.0 Hz, 6H), 1.10-1.01 (m, 1H), 0.56 (d, J =6.2 Hz, 6H) |
H11 | N-VCI A <A^î^/F HN N T| HO^/k AA Il ' //N k fi N-X O Me-y \_NH Me 1,5-anhydro-3-[(5-chloro-4-{2[(cyclopropylamino)methyl]-4fluoro-1 -(propan-2-yl)-1 Hbenzimidazol-6-yl)pyrimidin-2yl)amino]-2,3-dideoxy-D-f/7reopentitol | 475.3 [M+HJ+ (ESI) | 1H NMR (400 MHz, CD3OD) δ 8.37 (s, 1H), 8.05 (s, 1H), 7.51 (d, J = 11.54 Hz, 1H), 5.07 (dt, J = 13.93, 6.84 Hz, 1H), 4.19 (s, 2H), 3.90 - 4.03 (m, 3H), 3.63 (td, J = 9.41, 4.77 Hz, 1H), 3.50 (td, J =11.67, 2.01 Hz, 1H), 3.22 (dd, J =11.04, 9.79 Hz, 1H), 2.26 (dt, J = 6.71, 3.29 Hz, 1H), 2.12-2.18 (m, 1H), 1.69 (d, J = 7.03 Hz, 6H), 1.601.68 (m, 1H), 0.45-0.51 (m, 2H), 0.31 - 0.36 (m, 2H) |
Biological Assavs and Data | I
CDK4/Cyclin D1 mobilitv shift assay
The purpose CDK4/Cyclin D1 assay is to evaluate the inhibition (% inhibition, Kiapp and Ki 5 values) in the presence of small molécule inhibitors by using a fluorescence based microfluidic mobility shift assay. CDK4/Cyclîn D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFRPASPLRGPPK) (SEQ ID NO:1). The mobility shift assay electrophoretically séparâtes the fluorescently labeled peptides (substrate and phosphorylated product) following the kinase reaction. Both substrate 10 and product are measured and the ratio of these values is used to generate %Conversion of substrate to product by the LabChip EZ Reader. Typical reaction solutions contained 2% DMSO
271 (± inhibitor), 10 mM MgCI2, 1 mM DTT, 3.5 mM ATP, 0.005% TW-20, 3 μΜ 5-FAM-Dyrktide, 3 nM (active sites) activated CDK4/Cyclin D1 in 40 mM HEPES buffer at pH 7.5.
Inhibitor Ki déterminations for activated CDK4/Cyclin D1 (2007 E1/2008 +PO4) were initiated with the addition of ATP (50 pL final reaction volume), following a eighteen minute pre-incubation of enzyme and inhibitor at 22 °C in the reaction mix. The reaction was stopped after 195 minutes by the addition of 50 pL of 30 mM EDTA. Ki déterminations were made from a plot of the fractional velocity as a function of inhibitor concentration fit to the Morrison équation with the enzyme concentration as a variable.
CDK6/Cyclin D3 mobilitv shift assay
The purpose of the CDK6/Cyclin D3 assay is to evaluate the inhibition (% inhibition, Kiapp and Ki values) in the presence of small molécule inhibitors by using a fluorescence based microfluidic mobility shift assay. CDK6/Cyclin D3 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFRPASPLRGPPK) (SEQ ID NO:1). The mobility shift assay electrophoretically séparâtes the fluorescently labeled peptides (substrate and phosphorylated product) following the kinase reaction. Both substrate and product are measured and the ratio of these values is used to generate %conversion of substrate to product by the LabChip EZ Reader. Typical reaction solutions contained 2% DMSO (± inhibitor), 2% glycerol, 10 mM MgCI2,1 mM DTT, 3.5 mM ATP, 0.005% Tween 20 (TW-20), 3 pM 5-FAM-Dyrktide, 4 nM (active sites) activated CDK6/Cyclin D3 in 40 mM HEPES buffer at pH 7.5.
Inhibitor K déterminations for activated CDK6/Cyclin D3 (LJIC-2009G1/2010 +PO4) were initiated with the addition of ATP (50 pL final reaction volume), following a eighteen minute pre-incubation of enzyme and inhibitor at 22 °C in the reaction mix. The reaction was stopped after 95 minutes by the addition of 50 pL of 30 mM EDTA. Ki déterminations were made from a plot of the fractional velocity as a function of inhibitor concentration fit to the Morrison équation with the enzyme concentration as a variable. ,
For CDK4 and CDK6 mobility shift assays, see also Morrison, J. F. (1969) Kinetics of the réversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors, Biochimlca et blophysica acta 185, 269-286; and Murphy, D. J. (2004) Détermination of accurâte Kl values for tight-binding enzyme inhibitors: an in Jsilico study of experimental error and assay design, Analytical biochemistry 327, 61-67.
Phospho-Serine 795 Rb ELISA Assays
JEKO-1 or MV4-11 cells were seeded at 15,000 or 20,000 cells per well, respectively, in
100 pL growth media and allowed to incubate at 37°C with 5% CÔ2 overnight. The following day, compounds were serially diluted from a 10 mM top dose for an 11-point 3-fold dilution curve in
DMSO. Compounds were intermediately diluted 1:200 into growth media prior to diluting 1:5 on
272 cells for final concentration 10 μΜ to 0.1 nM in 0.1% DMSO on cells. JEKO-1 and MV4-11 cells were treated were treated overnight, at 37°C with 5% CO2. Cells were lysed in 100 pL/well CST lysis buffer on ice and transferred to pre-coated and blocked anti-phospho-Ser795 Rb ELISA plates for overnight incubation at 4°C. Plates were washed to remove residual, unbound cellular proteins and total Rb détection antibody added for 90 minutes at 37°C. Following wash to remove unbound total Rb antibody, the HRP tagged antibody was allowed to bind for 30 minutes at 37°C. Following wash to remove unbound HRP antibody, Glo Substrate Reagent was added and incubated protected from light for 5 to 10 minutes. Plates were read in luminescence mode and IC50 values calculated.
Biological Activity ...... .....
Biological activity data for représentative compounds of the invention are provided inTable 6. CDK4 and CDK6 in vitro Ki (nM) data are provided using calorimetric assays. CDK4 and CDK6 cell-based IC50 (nM) data are provided for CDK4 and CDK6 using phospho-Rb S795 ELISA assays in JEKO-1 and MV4-11 cells.
Example No. | CDK4D1 Ki (nM) | CDK4 pRB S795 ELISA JEKO-1 cells IC50 (nM) | CDK6_D3 Ki (nM) | CDK6 pRB S795 ELISA MV4-11 cells IC50 (nM) |
A01 | 0.1 | 25.3 | 2.3 | 76.5 |
A02 | 0.1 | 88.6 | 2.5 | 163.3 |
A03 | 4.0 | 17.3 | ||
A04 | 0.6 | 329.6 | 11.4 | 289.2 |
A05 | 3.3 | 225.1 | 50.8 | 541.4 |
A06 | 1.4 | 87.4 | 17.5 | 192.2 |
A07 | 1.8 | 182.1 | 28.0 | 520.4 |
A08 | 1.1 | 4.8 | ||
A09 | 0.1 | 16.8 | 1.4 | 57.6 |
A10 | 0.6 | 72.7 | 10.4 | 195.3 |
A11 | 0.3 | 122.7 | 3.0 | 143.9 |
A12 | 0.6 | 29.8 | 7.9 | 108.5 |
A13 | 1.7 | 72.2 | | 31.5 | 276.7 |
A14 | 0.5 | - 4.6 | ||
A15 | 0.3 | 2.4 | ||
A16 | 0.2 | 25.7 | 2.7 | 98.1 |
A17 | 0.1 | 9.9 i | 0.4 | 13.4 |
A18 | 0.2 | 25.0 ! | 2.3 | 77.2 |
A19 | 0.9 | 69.1 I | 14.6 | 318.4 |
A20 | 2.7 | 20.4 | ||
A21 | 7.3 | 135.6 | ||
A22 | 3.2 | 49.7 | ||
A23 | 0.5 | 26.5 | 11.6 | 84.1 |
A24 | 1.3 | 40.1 | 16.4 | 166.9 |
A25 | 0.0 | 13.3 | 1.3 | 30.6 |
A26 | 0.2 | 12.2 | 4.2 | 24.3 |
A27 | 1.0 | 75.6 | 15.7 | 269.2 |
273
A28 | 0.5 | 99.2 | 6.2 | 131.1 | ||
A29 | 0.6 | 68.6 | 5.1 | 95.7 | ||
A30 | 0.2 | 51.6 | 4.9 | 63.5 | ||
A31 | 0.5 | 23.5 | 7.1 | 87.0 | ||
A32 | 0.9 | 7.1 | ||||
A33 | 8.3 | 78.0 | ||||
A34 | 11.1 | 102.1 | ||||
A35 | 1.5 | 123.8 | 58.9 | 966.7 | ||
A36 | 0.2 | 19.6 | 3.7 | 43.9 | ||
A37 | 3.5 | 34.2 | ||||
A38 | 0.5 | 455.7 | 10.2 | 598.1 | ||
A39 | 1.3 | 12.3 | ||||
A40 | 0.3 | 85.5 | 3.5 | 346.5 | ||
A41 | 3.1 | 92.8 | 48.8 | 216.1 | ||
A42 | 6.0 | 54.7 | ||||
A43 | 4.8 | 44.0 | ||||
A44 | 4.9 | 76.5 | 113.9 | 408.0 | ||
A45 | 1.0 | 65.8 | 52.0 | 468.4 | ||
A46 | 2.3 | 40.5 | ||||
A47 | 1.0 | 382.7 | 24.6 | 370.3 | ||
A48 | 0.1 | 36.5 | 2.3 | 58.9 | ||
A49 | 0.7 | 76.0 | 14.3 | 219.2 | ||
A50 | 17.0 | 109.5 | ||||
A51 | 2.0 | 245.0 | 55.7 | 1528.4 | ||
A52 | 2.7 | 202.1 | 60.1 | 973.1 | ||
A53 | 0.6 | 67.3 | 16.7 | 208.3 | ||
A54 | 2.3 | 173.1 | 37.5 | 605.3 | ||
A55 | 3.2 | 197.8 | 64.9 | 283.5 | ||
A56 | 1.3 | 9.6 | ||||
A57 | 0.4 | 49.0 | 19.1 | 269.1 | ||
A58 | 0.6 | 33.1 | 17.6 | 203.0 | ||
A59 | 0.6 | 47.7 | 56.7 | 521.4 | ||
A60 | 1.6 | 65.2 | 33.6 | 190.3 | ||
A61 | 0.2 | 11.4 | 2.6 | 33.5 | ||
A62 | 0.5 | 27.5 | 8.0 | 66.6 | ||
A63 | 0.9 | 9.7 | ||||
A64 | 2.0 | 10.7 | ||||
A65 | 0.6 | 3.5 | ||||
A66 | 12.1 | 54.7 | ||||
A67 | 1.4 | 15.5 | ||||
A68 | 0.7 | ..... 48.7 | 14.3 | 234.9 | ||
A69 | 0.7 | 101.4 | 4.9 | 237.7 | ||
A70 | 26.2 | 124.2 | ||||
A71 | 0.8 | 94.9 | 11.4 | 286.9 | ||
A72 | 0.3 | 2.1 | ||||
A73 | 0.9 | 72.0 | 16.1 | 188.1 | ||
A74 | 0.2 | 26.5 . | . 6.2 | . 89.7 | ||
A75 | 0.3 | 33.2 | 5.0 | 102.8 | ||
A76 | 0.2 | 96.1 | 6.3 | 242.0 | ||
A77 | 0.3 | 61.1 | 4.9 | 126.4 | ||
A78 | 0.1 | 26.4 | 1.8 | 73.9 | ||
A79 | 1.8 | 598.0 | 17.6 | 1138.0 |
274
A80 | 0.5 | 72.9 | 14.7 | 216.7 |
A81 | ||||
A82 | 3.8 | 24.6 | ||
A83 | 4.1 | 394.8 | 88.5 | 1223.0 |
A84 | 6.0 | . · -- - - | - - 30.3 | |
A85 | 9.9 | 62.8 | ||
A86 | 4.7 | 23.5 | ||
A87 | 0.2 | 40.1 | 2.8 | 97.7 |
A88 | 4.5 | 7318.0 | 80.4 | 10000.0 |
A89 | 0.5 | 118.4 | 12.0 | 570.3 |
A90 | 0.2 | 1.1 | ||
A91 | 0.1 | 14.9 | 1.7 | 25.7 |
A92 | 0.1 | 23.8 | 0.9 | 42.9 |
A93 | 0.2 | 34.7 | 4.4 | 61.4 |
A94 | 0.6 | 38.5 | 13.9 | 144.9 |
B01 | 0.1 | 65.6 | 1.5 | 129.0 |
B02 | 7.3 | 27.1 | ||
C01 | 5.2 | 176.4 | 98.1 | 1379.5 |
C02 | 4.1 | 583.7 | 89.3 | 1350.0 |
D01 | 0.4 | 1.7 | ||
D02 | 1.0 | 9.3 | ||
D03 | 0.6 | 4.7 | ||
D04 | 0.6 | 68.2 | 12.5 | 172.0 |
D05 | 2.2 | 85.7 | 39.4 | 258.0 |
D06 | ||||
E01 | 0.1 | 17.0 | 1.4 | 37.9 |
F01 | 0.8 | 114.1 | 14.6 | 576.0 |
F02 | 4.3 | 39.9 | ||
F03 | 2.7 | 26.4 | ||
F04 | ||||
F05 | 2.1 | 247.9 | 25.8 | 478.2 |
F06 | 1.5 | 160.6 | 27.8 | 134.4 |
F07 | 15.3 | 125.4 | ||
F08 | 0.5 | 108.4 | 11.5 | 311.3 |
F09 | 0.6 | 5.5 | ||
F10 | 0.5 | 41.3 | 6.1 | 152.7 |
F11 | 5.4 | 821.1 | 79.9 | 2402.1 |
F12 | 50.0 | 109.5 | ||
F13 | 11.6 | .. . | 81.1 | . . _ |
F14 | 3.6 | 30.8 | ||
F15 | 0.0 | 34.4 | 1.0 | 39.8 |
F16 | 1.4 | 675.3 | 26.0 | 362.7 |
F17I | 0.5 | 83.2 | 8.3 । | 126.6 |
F18I | 0.9 | 31.7 | 10.1 I | |
F19 | 1.5 | 11.8 | ||
F20 | 2.0 | 155.1 | 24.3 | 787.5 |
F21 | 0.4 | 59.5 | 7.7 | 246.2 |
F22 | 0.5 | 61.3 | 9.1 | 171.1 |
F23 | 1.0 | 691.9 | 11.0 | 1318.1 |
F24 | 2.1 | 19.9 | ||
F25 | 1.2 | 455.3 | 19.3 | 455.2 |
F26 | 0.1 | 142.8 | 4.6 | 182.3 |
275 | ||||||
F27 | 0.5 | 60.8 | 5.1 | 188.0 | - . . - — | |
F28 | 2.2 | 190.5 | 22.3 | 745.2 | ||
F29 | 1.8 | 245.5 | 23.3 | 643.7 | ||
F30 | 0.5 | 66.1 | 12.5 | 377.1 | ||
F31 | 2.4 | - 23.0 | ||||
F32 | 0.9 | 171.6 | 12.8 | 628.3 | ||
F33 | 0.2 | 24.6 | 5.2 | 112.8 | ||
G01 | 0.4 | 5.9 | ||||
H01 | 2.4 | 137.1 | 127.0 | 857.6 | ||
H02 | 0.8 | 52.1 | 20.0 | 117.9 | ||
H03 | 1.8 | 155.4 | 66.9 | 422.9 | ||
H04 | 0.8 | 63.4 | 38.2 | 220.9 | ||
H05 | 4.5 | 249.0 | 93.3 | 1470.2 | ||
H06 - | 1.1 | 79.6 | 35.6 | 343.3 | ||
H07 | 1.4 | 48.3 | 43.0 | 409.1 | ||
H08 | 1.2 | 35.6 | 44.5 | 305.9 | ||
H09 | 0.9 | 205.1 | 18.6 | 230.3 | ||
H10 | 0.5 | 14.9 | 16.4 | 51.1 | ||
H11 | 0.7 | 43.4 | 22.1 | 295.1 |
Ail publications and patent applications cited in the spécification are herein incorporated by reference in their entirety. It will be apparent to those of ordinary skill in the art that certain changes and modifications may be made thereto without departing from the spirit or scope of 5 the appended claims.
Claims (10)
1. A compound of Formula (X):
or a pharmaceutically acceptable sait thereof, wherein: .... .......
R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
R2 is H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-C8 cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said C3-C8 cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20;
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3;
R7 and R8 are independently H, F, Cl, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy or C1-C2 fluoroalkoxy, where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 fluoroalkoxy is optionally substituted by R20;
R9 is H, OH, NH2, NHCH3 or N(CH3)2;
each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, C1-C2 alkoxy, C1-C2 fluoroalkoxy, CN or N R22R23;
each R21 is independently F, OH, CN, NR22R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2; I each R22 and R23 is independently H, C1-C2 alkyl or C1-C2 fluoroalkyl; or
R22 and R23 may be taken together with the nitrogen atom to whîch they are attached to form an azetidinyl ring, which is optionally substituted by F or OH; and | nisO, 1,2, 3 or 4. ' '
2. The compound of claim 1, having the Formula (X-A):
277
or a pharmaceutically acceptable sait thereof.
3. A compound of Formula (IX):
R11 (IX)
4. The compound of claim 3, having the Formula (IX-A):
x^ .R1 n r7
R11 (IX-A)
20 or a pharmaceutically acceptable sait thereof.
5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable sait thereof, wherein R1 is Cl.
5 R17 is C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R18 and R19 is independently H, C1-C4 alkyl or C1-C4 fluoroalkyl, where each said C1-C4 alkyl and C1-C4 fluoroalkyl is optionally substituted by R20;
each R20 is independently OH, Ci-C2 alkoxy, CrC2 fluoroalkoxy, CN or N R22R23;___
10 each R21 is independently F, OH, CN, NR22R23, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally further substituted by OH, NH2, NHCH3 or N(CH3)2;
each R22 and R23 is independently H, Ci-C2 alkyl or Ci-C2 fluoroalkyl; or
R22 and R23 may be taken together with the nitrogen atom to which they are attached to
15 form an azetidinyl ring, which is optionally substituted by F or OH; and n is 0,1, 2, 3 or 4.
5 or a pharmaceutically acceptable sait thereof, wherein:
R1 is H, F, Cl, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 alkyl and C1-C2 fluoroalkyl is optionally substituted by R20;
R2 is H, C1-C5 alkyl, C1-C5 fluoroalkyl, C3-Ce cycloalkyl or 3-6 membered heterocyclyl, where each said C1-C5 alkyl and C1-C5 fluoroalkyl is optionally substituted by R20 and each said 10 C3-Ce cycloalkyl and 3-6 membered heterocyclyl is optionally substituted by R21;
R4 is H, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy or C1-C4 fluoroalkoxy, where each said C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 alkoxy and C1-C4 fluoroalkoxy is optionally substituted by R20;
R6 is H, F, Cl, CN, CH3, CH2F, CHF2 or CF3;
15 R7 and R8 are independently (1, F, CI, CN, C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkox^ or
C1-C2 fluoroalkoxy, where each said C1-C2 alkyl, C1-C2 fluoroalkyl, C1-C2 alkoxy and C1-C2 fluoroalkoxy is optionally substituted by R20; ---------------- . --------------- ----R9 is H, OH, NH2, NHCH3 or N(CH3)2; !
each R10 is independently F, CN, C1-C2 alkyl or C1-C2 fluoroalkyl, where each said C1-C2 20 alkyl and C1-C2 fluoroalkyl is optionally substituted bÿ R20;
278
R11 is H, C1-C4 alkyl, G-C4 fluoroalkyl, SO2R14, SO2NR15R16, COR17, COOR17 or
CONR18R19;
R14 is C1-C4 alkyl or C1-C4 fluoroalkyl;
each R15 and R16 is independently H or CH3;
6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable sait 25 thereof, wherein R2 is C1-C5 alkyl, where said C1-C5 alkyl is optionally substituted by R20.
279 ^^^
7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable sait thereof, wherein R4 is C1-C4 alkyl, where said C1-C4 alkyl is optionally substituted by R20.
8. The compound of claim 7, or a pharmaceutically acceptable sait thereof, wherein R20 is OH.
5
9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable sait thereof, wherein R6 is F, R7 is H, and R8 is H.
10. 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1 -(propan-2-yl)-1 HbenzimidazoI-6-yi]pyrimidin-2-yl}amino)-2,3-dideoxy-D-f/7reo-pentitol, having the structure:
or a pharmaceutically acceptable sait thereof.
11. (3R,4R)-4-[(5-chloro-4-{4-fluoro-2-[(1 R)-1 -hydroxyethyl]-1 -(propan-2-yl)-1 H- benzimidazol-6-yl}pyrimidin-2-yl)amino]-1-(methanesulfonyl)piperidin-3-ol, having the structure:
15 or a pharmaceutically acceptable sait thereof.
112. A pharmaceutical composition comprising the compound of any one of claims 1 to 9, or a pharmaceutically acceptable sait thereof, and a j pharmaceutically acceptable carrier or excipient.
280
A pharmaceutical composition comprising the compound of claim 10, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient.
14. A pharmaceutical composition comprising the compound of claim 11, or a 5 pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient.
15. The compound of any one of claims 1 to 11, or a pharmaceutically acceptable sait thereof, for use in a method for the treatment of cancer in a subject in need thereof.
16. Use of the compound of any one of claims 1 to 11, or a pharmaceutically acceptable sait
10 thereof, in the manufacture of a médicament for the treatment of cancer in a subject in need thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/663,096 | 2018-04-26 | ||
US62/750,454 | 2018-10-25 | ||
US62/826,609 | 2019-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA19876A true OA19876A (en) | 2021-06-23 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019259653B2 (en) | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors | |
AU2017311645A1 (en) | Pyridopyrimdinone CDK2/4/6 inhibitors | |
JP7511097B1 (en) | HER2 mutation inhibitor | |
US11834453B2 (en) | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors | |
RU2790006C2 (en) | 2-aminopyridine or 2-aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | |
OA19876A (en) | 2-Amino-Pyridine or 2-Amino-Pyrimidine derivatives as cyclin dependent kinase inhibitors. | |
WO2020116662A1 (en) | Cycloalkane-1,3-diamine derivative | |
EA042105B1 (en) | 2-AMINO-PYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | |
KR20240102884A (en) | Her2 mutation inhibitors | |
JP2024089651A (en) | HER2 mutation inhibitor | |
OA20321A (en) | 3-carbonylamino-5-cyclopentyl-1H-pyrazole compounds having inhibitory activity on CDK2. | |
EA046965B1 (en) | 3-CARBONYLAMINO-5-CYCLOPENTYL-1H-PYRAZOLE COMPOUNDS WITH CDK2 INHIBITORY ACTIVITY | |
OA19219A (en) | Pyridopyrimdinone CDK2/4/6 inhibitors. |